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The incidence and prevalence of Inflammatory Bowel Disease (IBD) has rapidly increased
worldwide and now is a global disease with some of the highest rates observed in North America [1].
IBD is believed to arise from a shared interaction between genetic and environmental influences,
resulting in an imbalance between pro-inflammatory and anti-inflammatory signaling, however the
etiology of this imbalance and of IBD itself is incompletely understood [2]. Environmental risk factors
for both disease onset and risk for disease exacerbation are attractive to explore, as these may be
modifiable, and have the potential to represent a therapeutic opportunity with few adverse side effects.
Patients identify associations between diet and disease flare and the topic of diet and IBD is among the
frequently asked questions by patients to their gastroenterologist. However, guidelines for dietary
recommendations as primary therapy are lacking [3]. Additionally, IBD is associated with malnutrition,
sarcopenia, and micronutrient deficiencies, all of which can reduce quality of life, increase morbidity,
and contribute to symptoms [4,5]. The recently published literature assessing relationships between
diet, nutrition, and IBD has increased substantially in the past 2 years, reflecting the urgency to find
therapeutic solutions to meet patient needs and reduce disease related complications.
Specifically, epidemiologic data often implicate dietary lipids and fatty acids imbalance, in addition
to animal proteins, as increasing predisposition to IBD, while vitamin D and fiber intake may be
protective [6]. Some of these are dietary components are traditionally considered part of a healthy
diet, such as vegetables, fruits, dietary fibers, n-3 polyunsaturated fatty acids (n-3 PUFA), n-9 PUFA,
and vitamin D, while others, such as meats, n-6 PUFA, and refined sugars are often considered part
of the ‘unhealthy’ Western diet, but it is unclear to what extent any of these are specific for IBD.
Considerable evidence has emerged that diet targets innate and adaptive immunity in the intestinal
barrier and gut microbiome in addition to correcting ‘malnutrition’ inherent in IBD [7,8]. With the
tremendous amount of research in the gut microbiome in IBD, it is inevitable that interest in many
aspects of diet and nutrition in IBD will increase exponentially, as highlighted in this issue. However,
it is imperative that studying nutritional intervention in IBD evolves new paradigms and does not
simply follow drug development paths. Intervening in early disease and in IBD sufferers in remission
to prevent relapse is especially attractive.
This Special Issue of Nutrients, “Nutrition in Inflammatory Bowel Disease”, includes a collection
of 21 manuscripts that richly describe the vibrant and diverse state of nutrition research in IBD.
Close to half of the contributions are review articles that provide perspectives on mechanisms through
which diet could play an important role in the pathogenesis of IBD, while another important review
summarizes the state of randomized clinical trials in Ulcerative Colitis (UC), highlighting gaps and
areas for research [9]. The high number of review articles on the topic of dietary mechanisms and
IBD truly reflects the acute interest in this growing field. The stark lack of clinical trials exploring
dietary relationships and gut inflammation is also very revealing and is a further call to action for
IBD researchers.
Nutrients 2019, 11, 1740; doi:10.3390/nu11081740 www.mdpi.com/journal/nutrients1
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Eight original articles, ranging from in vitro to animal models and human clinical research,
explore various nutrition-focused themes that include probiotics, symbiotics, vitamin D, dietary intake
and composition, protein dosing, obesity, myopenia, and exclusive enteral nutrition on diverse IBD
outcomes [4,10–16].
Vidal-Lletjos et al. identified that moderately high protein dosing modulated mucosal healing,
however high the protein intake, had deleterious consequences in animal models [14]. These results are
undoubtedly of interest for developing nutrition prescriptions in the clinical setting and require further
study in human populations. Taylor et al. described suboptimal dietary intake and low adherence with
Mediterranean diet guidelines as not keeping with anti-inflammatory dietary patterns [4]. Shinde et al.
demonstrated that symbiotic supplementation ameliorated disease activity index and histological
scores in animal models, warranting human trials [12]. Of interest, Bryant et al. determined that, over 24
months of longitudinal follow-up, the body composition of patients with IBD changed, with gains
of fat mass but decreases in lean muscle mass [16]. The morbidity that may be associated with these
findings deserves further attention.
These valuable manuscripts contribute toward advancing knowledge about current dietary
intake and composition in patients with IBD, describe existing nutritional deficiencies including
myopenia, and provide a platform of nutritional supplements with biologic plausibility to be subjected
to further trials.
We believe this compendium is a useful summary of the nutrition progress in IBD. The need
for further nutrition intervention trials with diets that are mechanistically sensible and address the
industrialization of food remains as a loud unspoken statement.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Background: Rising rates of obesity have been reported in patients with inflammatory
bowel disease (IBD); however, prospective data is lacking. The aim of this study is to prospectively
evaluate body composition in adults with IBD over 24 months. Methods: Whole body dual
energy X-ray absorptiometry (DXA) data was performed at 0 months, 12 months, and 24 months.
Bone mineral density (BMD), fat mass index (FMI (kg)/height (m2)), appendicular skeletal muscle
index (ASMI (kg)/height (m2)), visceral adipose tissue and the visceral adipose height index
(VHI, VAT area (cm3)/height (m2)), and clinical and anthropometric assessments were performed
at each time point. Multivariable linear mixed effects regression analyses were performed.
Results: Initially, 154 participants were assessed at baseline (70% Crohn’s disease, 55% male,
median age 31 years), of whom 129 underwent repeated DXA at 12 months, and 110 underwent
repeated DXA at 24 months. Amongst those undergoing repeated DXA, their body mass index
(BMI) significantly increased over time, such that by 24 months, 62% of patients were overweight
or obese (annual change BMI β = 0.43, 95%CI = [0.18, 0.67], p = 0.0006). Gains in BMI related to
increases in both FMI and VHI (β = 0.33, 95%CI = [0.14, 0.53], p = 0.0007; β = 0.08, 95%CI = [0.02, 0.13],
p = 0.001; respectively), whereas ASMI decreased (β = −0.07, 95%CI = [−0.12, −0.01], p = 0.01) with
a concordant rise in rates of myopenia (OR = 3.1 95%CI = [1.2, 7.7]; p = 0.01). Rates of osteopenia and
osteoporosis were high (37%), but remained unchanged over time (p = 0.23). Conclusion: Increasing
rates of obesity in patients with IBD coincide with decreases in lean muscle mass over time, while high
rates of osteopenia remain stable. These previously undocumented issues warrant attention in routine
care to prevent avoidable morbidity.
Keywords: body composition; obesity; visceral adipose tissue; fat; osteoporosis; osteopenia;
sarcopenia; inflammatory bowel disease
Nutrients 2018, 10, 1192; doi:10.3390/nu10091192 www.mdpi.com/journal/nutrients4
Nutrients 2018, 10, 1192
1. Introduction
Body composition refers to proportions of bone, fat, and fat-free (lean) mass in the body and
may be abnormal in many patients with inflammatory bowel disease (IBD) [1]. Despite the potential
negative effects of disturbances in body composition on IBD-related outcomes, response to therapy,
cardiovascular disease, and quality of life (QoL), there is a paucity of prospective data on body
composition in patients with IBD [1,2].
Rates of obesity are rising in patients with IBD, as in the general population; 15–40% of adults
with IBD are obese, and 20–40% are overweight [3]. IBD may be an independent risk factor for obesity
that is driven by dysbiosis and aberrations in intestinal microbial metabolism [4,5]. Treatments used for
IBD, in particular corticosteroids and anti-tumor necrosis factor alpha therapies, may also play a role
in obesity [3]. On the other hand, adipose tissue is metabolically active, and could plausibly contribute
to a pro-inflammatory susceptibility to IBD [4,6]. However, existing data on the impact of obesity on
IBD susceptibility and disease course are conflicting. This is partly due to the use of the body mass
index (BMI) as a blunt instrument for measuring adiposity, which is unable to distinguish between
adiposity compartments with distinct metabolic profiles [3,6–10]. Visceral adipose tissue (VAT) is
increased in many patients with Crohn’s disease (CD) and has been associated with a complicated CD
phenotype [3,4,6,11–14]. There are no longitudinal prospective data on direct measures of adiposity in
patients with IBD.
There are emerging reports of high rates of both myopenia, which is defined as low lean mass,
and sarcopenia, which is defined as a low lean mass coupled with loss of strength, in patients with
IBD [1,15–17]. This matters, because low lean mass has been associated with an increased need for
surgery and poor surgical outcomes in IBD, as well as with osteopenia [18–20]. Lean mass deficits may
be difficult to detect in clinical practice, where BMI can be falsely reassuring [17,18]. Current data on
sarcopenia in IBD are limited by small sample sizes and retrospective study designs, as well as a lack
of an appropriate incorporation of a functional assessment [1].
A deficit in bone mineral density (BMD) (osteoporosis/osteopenia) is one of the most common
complications of IBD, and has been reported in 20% to 50% of patients [21–23]. Reduced BMD is associated
with an increased risk of pathological fractures and associated morbidity [22,24]. The pathogenesis of
metabolic bone disease in IBD is likely multifactorial; however, clinical data are lacking, and the influence
of IBD-related factors beyond conventional risk factors remains poorly explored [25,26].
Dual-energy X-ray absorptiometry (DXA) is in routine use in patients with IBD for the
measurement of BMD. Whole body DXA adds little in terms of time and radiation, yet gleans accurate
and regional body composition information and is considered a gold-standard tool for the evaluation
of body composition as compared to cross-sectional imaging [1,27].
Therefore, the aims of this study were:
1. To evaluate body composition in patients with IBD, with serial prospective measurements
over time;
2. To explore the influence of clinical factors on body composition in patients with IBD;
3. To explore whether standard anthropometric testing can detect aberrations in body composition.
2. Materials and Methods
2.1. Subjects
Consecutive patients with IBD (aged 18–50 years and pre-menopausal if female) managed by
a tertiary IBD service were invited to participate in a prospective study between April 2012 and
September 2013 (Figure 1). Those with significant medical or surgical comorbidity other than IBD,
current pregnancy, or steroid use other than that required for IBD, were excluded.
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Figure 1. CONSORT diagram—inflammatory bowel disease (IBD) cohort. Legend: DXA, dual energy
X-ray absorptiometry, BMD, bone mineral density.
2.2. Subject Data Collection
Prospective data were captured at 0 months, 12 months, and 24 months. At each study time-point
case note, an IBD database and medical prescription review was undertaken. Data capture included
demographics, Montreal classification at baseline, current IBD therapy, cumulative lifetime corticosteroid
use (equivalent to prednisolone ≥10 mg/day) and IBD-related surgery [28]. IBD disease activity was
assessed at each study time point using clinical indices and biomarkers of inflammation (C-reactive protein
(CRP) and faecal calprotectin (FC) using a CALPRO® ELISA test). CRP ≥ 5 mg/L and/or FC ≥ 100 μg/g
were considered consistent with active disease as a composite biomarker assessment.
Lifestyle factors were assessed at 0 months, 12 months, and 24 months. Average alcohol
consumption was dichotomised into <20 g/day versus ≥20 g/day. Habitual physical activity was
assessed using a validated self-administered Short International Physical Activity Questionnaire
(IPAQ), which approximates metabolic equivalents MET-minutes per week and allows stratification
into low, medium, and high activity groups [29].
2.3. Body Composition, Anthropometric Assessment, and Nutritional Assessment
Dual energy X-ray absorptiometry (DXA, General Electric Lunar Prodigy Vision bone densitometer
(system DF + 13727; Encore version 13.60, Madison WI, USA)) of the lumbar spine, total femur, and whole
body was used to evaluate BMD and body composition at 0 months, 12 months, and 24 months using
standard protocols [30].
Standard calculations of fat and muscle body components were made from DXA data. Appendicular
skeletal muscle (ASM) mass, which is considered functionally relevant lean mass, was calculated as
the sum of the lean mass of the arms and legs (kg) [31]. The ASM index (ASMI) is the ASM mass in
kg divided by the height in metres, squared [32]. Fat mass (FM) is the sum of the body fat mass (kg).
The fat mass index (FMI) is calculated as FM in kg divided by height in metres, squared [32]. VAT was
measured using CoreScan® analysis software, which correlates well with CT scan measurements [33].
VAT was measured in terms of volume (cm3), mass (grams), visceral adipose tissue/height index
(VHI, VAT volume (cm3)/height in metres, squared), and VAT: subcutaneous adipose tissue (SAT)
ratio. Height (m), weight (kg), waist circumference (cm), and hip circumference (cm) were measured at
the time of the DXA and the waist–hip ratio (WHR) was calculated.
World Health Organisation (WHO) standard categories for BMI were used: <18.5 kg/m2
(underweight), 18.5–24.9 kg/m2 (normal weight), 25–29.9 kg/m2 (overweight), ≥30 kg/m2 (obese) [34].
Data from the Australian Bureau of Statistics National Health Survey 2014–2015 provided numerical
comparisons with age and sex-matched Australian population for BMI and waist circumference [35].
Population-based, age and gender-matched normative data and standard deviation (SD) values from
the National Health and Nutritional Examination Survey (NHANES) were used to calculate the
6
Nutrients 2018, 10, 1192
z-scores for ASMI and the fat mass index (FMI) [17,32]. WHO population-based, age and sex-matched
normative data of the lumbar spine and femur BMD were used to calculate BMD t-scores and
z-scores [36]. The lowest BMD t-score at either site was used to stratify patients as normal (>−1),
osteopenic (≤−1 >−2.5), or osteoporotic (≤−2.5).
Isometric handgrip strength was measured using a Jamar® Digital Hand Dynamometer,
representing a robust surrogate measure of whole body strength [31]. Grip strength z-scores were
calculated from population-based age and sex-matched normative data derived from healthy adult
controls [17].
Myopenia was defined as an ASMI ≥1 SD below the age and gender-matched ASMI mean [31].
Sarcopenia was defined using combined anatomical and functional criteria, as both ASMI and grip
strength >1 SD below the age and gender-matched means [31].
Nutritional assessment was performed at each study time point using clinical and laboratory
criteria, including albumin, vitamin D (automated chemiluminescent assay), calcium, haemoglobin,
iron studies, vitamin B12, and folate. Low vitamin D was defined as serum 25(OH) vitamin D level
<50 nmol/L.
2.4. Management during Prospective Study Period
The routine IBD care of enrolled subjects within the tertiary IBD service was consistent with
international guidelines (Figure 1) [37,38]. The protocolised management of bone health and nutrition
was undertaken during the study period. Oral vitamin D supplementation was recommended to
those with low levels (<50 nmol/L). All of the patients were advised to follow a calcium-rich diet and
engage in regular exercise. Patients who were found to be osteopenic (or at risk of osteopenia with
current corticosteroid use) were advised to take calcium supplementation (1000 mg/day) and oral
vitamin D supplementation (≥1000 IU/day). Patients found to be osteoporotic were referred to the
Endocrinology service for consideration of bisphosphonate therapy.
2.5. Ethical Considerations
The study was approved by the Royal Adelaide Hospital Research Ethics Committee (#120304).
Whole-body DXA does not confer significant additional radiation to standard BMD assessment.
Radiation safety reported that the total radiation dose per DXA study visit was 2.56 μSv.
2.6. Statistical Methods
Continuous outcomes are presented using means, standard deviations, medians, and interquartile
ranges (IQR), with categorical outcomes as counts and percentages, unless otherwise stated. The lack
of existing prospective data on body composition in IBD did not allow a formal power calculation.
The enrolment of 150 patients was considered sufficient to provide adequate power for multivariable
analysis, allowing for a dropout rate of 30% over the 24 months.
Change over time. Changes in disease activity, treatment, nutrition, and anthropometric and
body composition variables in individual patients who underwent repeated measures testing over
the 24-month study period were assessed using either linear or logistic mixed effects models,
where appropriate. The β coefficient describes the change in the body composition variable per
unit of time in the study (12 months). In all of the models, time since baseline assessment (years) was
the linear fixed effect, with random intercepts per individual. Compound symmetric and unstructured
variance–covariance were assumed for the linear and logistic models respectively. In all of the
models, residuals and random effect estimates were examined to ensure that the model distributional
assumptions appeared satisfied. As a consequence, VHI was log transformed. Missing data values
were not included in the analysis.
Assessment of factors associated with body composition. Linear mixed-effects models were
constructed to explore prospective clinical associations with serial assessments of BMI, FMI, VHI,
ASMI, and BMD (lumbar spine t-score) at 0 months, 12 months, and 24 months. Univariable models
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were constructed, followed by full multivariable models. We report β coefficients that describe the
change in the dependent variable per unit change in a covariate. Missing data were imputed with
cohort means. Significance was set at the 5% alpha level (two-sided). Analyses were performed on R
software v3.4.3 (R Studio, Boston, MA 02210, USA) using the nlme and lme4 packages.
3. Results
3.1. Subject Characteristics
Overall, 197 patients with IBD were assessed for eligibility during the study enrolment period
(April 2012–September 2013), 43 of whom were excluded (Figure 1). Initially, 154 patients were enrolled
in the study at baseline, of whom 129 (84%) completed the 12-month and 110 (71%) completed the
24-month study assessment. Cross-sectional analysis of the cohort at baseline has been previously
published (Supplementary Table S1) [17]. Only those patients who underwent repeated measures
(n = 129) were included in the primary analysis (Table 1).
In brief, 95 (74%) patients had CD, and 34 (26%) had ulcerative colitis (UC) (Table 1). The median
age of the cohort was 31 years (IQR 25–40), with a median IBD disease duration of 7.7 years (IQR
4.5–12.3). The cohort was predominantly Caucasian (n = 121, 94%). Active disease, defined by
composite biomarker assessment, was present in 65 patients (50%) at baseline. Prior to enrolment, 38/95
(40%) patients with CD and 1/34 (1%) patient with UC had undergone abdominal surgery. At baseline,
53 (41%) of patients were prescribed biologic therapy, the use of which increased over the study period
(59 (54%) patients were prescribed biologic therapy at 24 months, p = 0.004). Oral corticosteroid therapy
was currently prescribed for 38 (29%) patients, which significantly decreased over time (p < 0.0001).
Vitamin D levels were low in 52 (40%) of the patients at baseline, 50/52 (96%) of whom were prescribed
replacement therapy. Accordingly, there was a significant increase in vitamin D levels over the study
period (p = 0.01).
3.2. Baseline Body Composition
A detailed cross-sectional analysis of the body composition of this cohort at baseline (n = 137,
as enrolled until July 2013) has been previously published [17].
In brief, of those who underwent repeated measures testing (n = 129), the mean BMI at baseline
was 26.5 ± 5.1; with 33 (26%) patients classified as overweight and 30 (23%) patients classified as obese
(Table 2). Myopenia was evident in 24 (19%) patients, and functional sarcopenia was evident in 12 (9%)
patients. Low BMD was prevalent at baseline; with 45 (35%) patients classified as osteopenic and 3
(2%) patients classified as osteoporotic (48 (37%), with either osteopenia or osteoporosis).
3.3. Changes in Body Composition over 24 Months
Anthropometrics. BMI increased over the study period (annual change β = 0.43, 95%CI = [0.18,
0.67], p = 0.0006), as did the proportion of patients categorised as overweight and obese (at 24 months
31% overweight and 31% obese) (Table 2, Figure 2). Waist circumference increased over time (β = 1.4,
95%CI = [0.4, 2.3], p = 0.003), although no significant change in WHR was observed. Mean BMI,
waist circumference, and the proportions of people characterised as overweight or obese, were each
numerically higher in the IBD cohort compared to the Australian population stratified by age and
gender (Supplementary Table S2).
8
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Figure 2. BMI and measures of adiposity in patients with IBD over 24 months. Figure Legend:
(A) Body mass index (BMI) categories according to World Health Organisation criteria; (B) Fat mass
index (kg/height m2). Mean and standard deviation presented; (C) Visceral adipose tissue (VAT)
height index (VAT volume cm3 /height m2). Mean and standard deviation presented. * p < 0.05,
denoting statistical significance.
Adiposity. FMI increased significantly over the study period (β = 0.33, 95%CI = [0.14, 0.53],
p = 0.0007), with a concordant increase in FMI z-score (β = 0.08, 95%CI = [0.02, 0.14], p = 0.006).
(Table 2, Figures 2 and 3) Similarly, VAT volume increased (β = 0.08, 95%CI = [0.02, 0.14], p = 0.01),
which resulted in an increase in VHI (β = 0.08, 95%CI = [0.02, 0.13], p = 0.01), but not VAT:SAT
(β = 0.027, 95%CI = [−0.032, 0.087], p = 0.36) (Table 2).
Figure 3. Changes in bone, muscle, and fat in patients with IBD over 24 months. Figure Legend: Summary
of mean z-scores for fat mass index (FMI), appendicular skeletal muscle mass index (ASMI), and bone
mineral density (BMD), at the femur and lumbar spine. ** p < 0.01, denoting statistical significance.
Muscle. ASMI decreased significantly over the study period (ASMIβ=−0.07, 95%CI = [−0.12, −0.01],
p = 0.01; ASMI z-score β = −0.07, 95%CI = [−0.11, −0.02], p = 0.002) (Table 2). There was a significant
increase in myopenia over the study period (19%, 19%, and 24% at 0 months, 12 months, and 24 months,
respectively; OR = 3.1 95%CI = [1.2, 7.7]; p = 0.01) (Figure 4). There was a trend towards an increase in the
proportion of patients classified as sarcopenic; however, this did not reach statistical significance (OR = 2.4,
95%CI = [1.0, 6.0]; p = 0.05).
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Figure 4. Myopenia, sarcopenia, and metabolic bone disease in patients with IBD over 24 months.
Figure Legend: (A) Sarcopenia defined as BOTH appendicular skeletal muscle index (ASMI) and
grip strength <1 standard deviation below gender and age-matched mean. Myopenia defined as
appendicular skeletal muscle index (ASMI) <1 standard deviation below gender and age-matched
mean; (B) osteopenia and osteoporosis according to World Health Organisation criteria. Osteopenia
defined as bone mineral density (BMD) 1–2.5 standard deviations and osteoporosis as ≥2.5 standard
deviations below the young adult mean. * p < 0.05, denoting statistical significance; ns, non-significant
p value > 0.05.
Bone. Femur BMD t-score increased significantly over the study period, but there was no
change in lumbar spine BMD t-score (β = 0.041, 95%CI = [0.016, 0.066], p = 0.001; β = 0.013,
95%CI = [−0.022, 0.048], p = 0.47, respectively). No difference in BMD z-scores at either site was
detected over time (Table 2). Overall, there was no significant change in the proportion of patients
classified with osteopenia 37/110 (34%) or osteoporosis 3/110 (3%) (p = 0.23), despite the proactive
management of bone health over the study period (Figure 4).
3.4. Clinical Associations with Serial BMI Measurements
BMI was positively associated with vitamin D levels (β = 0.006, 95%CI = [0.00, 0.0.11], p = 0.03). FMI,
ASMI, and grip strength were also positively associated with BMI over time (β = 1.0, 95%CI = [1.0, 1.1],
p < 0.0001; β = 1.3, 95%CI = [1.1, 1.5], p < 0.0001; β = 0.028, 95%CI = [0.008, 0.049], p = 0.006, respectively)
(Table 3).
3.5. Clinical Associations with Serial FM and VAT Measurements
Older age was positively associated with VHI (β = 0.040, 95%CI = [0.023, 0.057], p < 0.0001)
(Supplementary Tables S3 and S4). Male gender was positively associated with VHI, but negatively
associated with FMI (β = 0.67, 95%CI = [0.39, 0.95], p < 0.0001; β = −2.2, 95%CI = [−2.8, −1.6],
p < 0.0001, respectively). Serum vitamin D was negatively associated with FMI (β = −0.007,
95%CI = [−0.013, −0.001], p = 0.02, p = 0.02).
Anthropometric measures (BMI and waist circumference) were associated with a higher FMI
(β = 0.52, 95%CI = [0.45, 0.59], p < 0.0001; β = 0.07, 95%CI = [0.04, 0.10], p < 0.0001, respectively) and
VHI (β = 0.08, 95%CI = [0.06, 0.11], p < 0.0001; β = 0.015, 95%CI = [0.005, 0.026], p = 0.003 respectively).
In contrast, grip strength was negatively associated with FMI (β = −0.044, 95%CI = [−0.066, −0.021],
p < 0.0001).
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3.6. Clinical Associations with Serial ASMI Measurements
Male gender was associated with a higher ASMI (β= 1.2, 95%CI = [0.9, 1.4], p < 0.0001) (Supplementary
Table S5). FC was negatively associated with ASMI (β = −0.00043, 95%CI = [−0.00067, −0.00018],
p = 0.0004), whereas anthropometric measures, BMI, and grip strength were positively associated with
ASMI (β = 0.13, 95%CI = [0.11, 0.15], p < 0.0001; β = 0.020, 95%CI = [0.011, 0.028], p < 0.0001, respectively).
3.7. Clinical Associations with Serial BMD Measurements
IBD disease duration was negatively associated with lumbar spine t-score (β = 0.0031,
95%CI = [−0.0057, −0.0005], p = 0.01), as was grip strength (β = 0.009, 95%CI = [0.002, 0.017], p = 0.01)
(Supplementary Table S6). Both biologic therapy and corticosteroids (cumulative use) were associated
with increase lumbar spine t-scores (β = 0.08, 95%CI = [0.01, 0.16], p = 0.02; β = 0.10, 95%CI = [0.01, 0.18],
p = 0.02; respectively). Neither IBD phenotype nor vitamin D level was associated with changes in the lumbar
spine t-score.
4. Discussion
This prospective study has demonstrated persistent and progressive disturbances in body
composition in people with IBD over a relatively short time frame. The most striking finding was
a significant increase in the proportion of patients classified as overweight and obese, driven by
gains in adiposity. Conversely, muscle mass decreased, with a concordant rise in rates of myopenia.
Despite the proactive management of bone health, rates of osteopenia remained high and unchanged.
Abnormal body composition may go frequently unrecognised in clinical practice using BMI alone,
leaving patients with IBD at risk of potentially avoidable morbidity.
After 24 months of follow-up, 62% of patients with IBD were overweight or obese despite a
median age of just 33 years, which is numerically higher than age and gender- matched Australian
population data [35]. Earlier studies of obesity in IBD have failed to take into account direct measures
of adiposity [3,10]. This study demonstrates that gains in BMI were associated with significant
increases in both overall FM and VAT. VAT is a strong independent predictor of incident cardiovascular
disease after adjustment for clinical risk factors, including BMI [39,40]. Similar to to other chronic
inflammatory conditions, there is emerging evidence to suggest that patients with IBD are at increased
risk of cardiovascular disease, which is now recognised as a prime cause of morbidity in this young
demographic [2,41].
How can a link between IBD and obesity be explained? In contrast to retrospective reports,
we found no association between measures of adiposity and IBD phenotype, inflammatory burden,
or medications over time [3,6–10]. The lack of correlation between obesity and IBD therapy, in particular
cumulative corticosteroid use is surprising, yet may be in part accounted for by the significant decrease
in rates of corticosteroid use over the study period. Interestingly, serum vitamin D levels were
negatively associated with FMI, which may be related to the sequestration of vitamin D in adipose
tissue, coupled with lifestyle factors associated with obesity (less outdoor activity) [42]. The majority
of patients were classified as either inactive or minimally active, which is likely reflective of the
burden of chronic illness in this cohort, yet this was not shown to be associated with BMI. It is
possible that dysbiosis in IBD, which is characterised by reduced microbial diversity and an altered
microbial metabolic profile, is a predisposing factor to obesity [43–45], but this is speculation despite
gut metabolomic associations with post-prandial glucose [43–46].
While adiposity increased, muscle mass (ASMI) decreased. FC, as a measure of luminal inflammation
in IBD, was negatively associated with ASMI, which is consistent with the known catabolic effects of
chronic inflammation [18,20,47]. Lean mass is important in patients with IBD, and has been shown to
have a bearing on response to therapy, surgical outcomes, and quality of life [15,18,20,48,49]. Grip strength
proved to be a simple anthropometric test that was independently and positively associated with ASMI,
while also negatively associated with FMI.
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IBD disease duration was shown to be negatively associated with BMD; however, inflammation was not
associated with BMD over time, which is consistent with existing data showing a minimal impact of
IBD-related inflammation on longitudinal bone loss [21,23,25,26,50]. Likewise, vitamin D levels were
not associated with BMD, which is similar to other studies showing an uncertain benefit of vitamin D
supplementation on BMD in IBD patients [21,23,25,26,50]. Biologic therapy was found to be positively
associated with BMD over time, which is in line with current data [50,51]. The positive association
between corticosteroid use and BMD is surprising, and may be a spurious result due to multiple
comparisons. Nevertheless, rates of osteopenia remained high in this cohort, despite not only protocolised
management of bone health, but also a warm climate and readily accessible dairy products.
The limitations of this study are the relatively small sample size, which may have limited
statistical power. The study was neither structured nor powered to evaluate the influence of body
composition on hospitalisation or surgery over time, nor could it evaluate the impact of these factors
on body composition. It did not account for dietary intake, nor were other factors associated with
cardiometabolic risk measured (cholesterol, family history, blood pressure). Although a control group
was not included, the findings were compared to population-based data [35]. The predominantly
Caucasian cohort, which was derived from a single tertiary IBD referral centre, may also limit the
generalisability of the findings. On the other hand, it is the first prospective study that has incorporated
serial measures of body composition in IBD. Furthermore, DXA, in routine use for measuring BMD,
is an affordable tool for monitoring body composition, adding little to the time or radiation of the
test [21,33].
This study illustrates the rising rates of obesity in patents with IBD over time, driven by gains
in fat mass, while lean mass decreases and metabolic bone disease remains unchanged. Apart from
raising concerns about the cardiometabolic risk profile of patients with IBD, it is important that
clinicians recognise that an increase in BMI may obscure a decrease in muscle mass (myopenia).
The study provides a rationale for measuring body composition, as well as a means to do so with DXA,
and supports recommendations for the use of grip strength as a discriminatory anthropometric test in
clinical practice.
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Abstract: The primary objective of this study was to explore the macro- and micro-nutrient intakes
and dietary patterns of patients with Crohn’s disease (CD). Secondary objectives were to (a) compare
the micronutrient intakes of CD patients with a representative sample of individuals, (b) describe the
macro- and micronutrient intakes of male and female CD patients, and (c) describe Mediterranean diet
scores (P-MDS) of male and female CD patients in remission that were recruited from an inflammatory
bowel disease (IBD) clinic in Calgary, AB. Consecutive patients with ileal and/or colonic CD in
endoscopic remission were recruited for participation in this cross-sectional study. Sixty-seven
patients were enrolled with a mean age of 45, and a Body Mass Index (BMI) ≥ 25. Compared with
the representative sample, patients with CD had similar energy, protein, carbohydrate, and total fat
intake. However, polyunsaturated fats (PUFA), omega-6 and 3, and monounsaturated fats (MUFA)
were lower in CD patients and dietary fiber intake was higher (p < 0.05). Vitamins C, D, thiamin,
niacin, magnesium, phosphorus, zinc, and potassium were all significantly lower in all CD patients
when compared to the representative sample (p < 0.05). Few patients with CD met the P-MDS criteria
and overall scores were low (mean 4.5, Standard Deviation (SD) = 1.1 in males and 4.7, SD = 1.8 in
females). The CD patients in this study had suboptimal dietary intakes and patterns and these data
may be used to inform future dietary interventions in this population to improve intake.
Keywords: Crohn’s disease; dietary intake; malnutrition; Mediterranean diet
1. Introduction
There is a compelling argument for environmental factors such as diet to play a role in the course
of inflammatory bowel disease (IBD) [1]. Given the mounting evidence for the role of diet and gut
microbial composition and function in IBD development and exacerbation, a richer understanding of
the role of diet in disease pathogenesis is warranted. Perturbations related to dietary intake are thought
to relate to the consumption of a dietary pattern that negatively alters gut microbiota composition [2,3],
leading to functional changes in short chain fatty acid (SCFA) profiles affecting the inflammation
process [4] and stimulating an inappropriate immune activation of the gut mucosa.
There are limited published data describing the dietary patterns and macro- and micronutrient
intakes in patients with Crohn’s disease (CD); in particular, the differences between males and females.
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Nearly 50% of CD patients perceive diet to be an initiating factor in their disease, and over half
of patients have reported diet exacerbates disease severity [5]. In IBD, deficiencies of micro- and
macronutrients are observed and arise through multifactorial etiologies including disruptions in
digestion, malabsorption, and disease activity, resulting in increased energy and nutrient requirements,
anorexia, consumption of a nondiversified diet with food avoidance due to symptoms, and cachexia
arising as a consequence of pro-inflammatory cytokines [6]. The reported prevalence of malnutrition is
variable (12–85%) [7–9] and depends on disease activity and the definitions used to define malnutrition.
Nutrient deficiencies usually develop over time and are linked to duration of illness. Macronutrient
deficiencies leading to protein-energy malnutrition are less common in the biologic era, however,
they are still of significant prevalence in patients admitted to hospital. Overt malnutrition may lead
to complications such as frequent infections, poor immunity, and increased hospitalizations [10].
Micronutrient deficiencies occur for multiple reasons including chronic blood loss leading to iron
deficiency; chronic diarrhea resulting in hypomagnesemia or zinc deficiency; malabsorption leading to
B12, folate, and vitamin D deficiencies; and other deficiencies such as antioxidants [11,12]. No previous
study has reported the prevalence of macro- and micronutrient deficiencies in Canadian CD patients
compared to a representative population.
While single nutrients may play a role in the natural history of IBD [13,14], single nutrients are
rarely consumed in isolation. Specific to IBD, epidemiological studies have described associations of
increased risk of IBD and high dietary intake of refined sugar, grains, calories, animal fat from meat
and dairy, and regular intake of processed foods, while a diet high in fruit, vegetables, and dietary fiber
decreases risk [15,16]. A recent meta-analysis showed an inverse association between the intake of
vegetables and fruit and CD, respectively (pooled odds ratio for the highest versus lowest consumption
of fruit = 0.57; 95% Confidence Interval (CI) 0.44–0.74) [17]. Patients consuming a pro-inflammatory
diet (e.g., high in animal protein, low in fruit and vegetables) have demonstrated a higher risk of
ulcerative colitis [18]. Recently, the association between food intake and course of disease in patients
with IBD was explored using fecal calprotectin and a protective role of legumes and potato, with a
detrimental influence of meat in maintaining clinical remission in IBD was identified [19].
There is a large body of evidence showing Mediterranean dietary patterns regulate inflammation
in chronic disease [20–22]. A Mediterranean dietary pattern is high in extra-virgin olive oil, vegetables,
fruit, legumes, nuts, and seeds with a moderate consumption of fish, poultry, and milk products
and is low in processed foods, baked goods, and red and processed meat. This dietary pattern is
high in monounsaturated fats (MUFA), omega-3 polyunsaturated fats (PUFA), fermentable fibers
and polyphenols, and adherence to a Mediterranean dietary pattern is associated with lower levels
of inflammation biomarkers. A Mediterranean dietary pattern has shown positive effects in chronic
disease [23], although it may impact men and women differently [24], and has been understudied
in IBD.
The primary objective of this study was to examine the macro- and micro-nutrient intakes and
dietary patterns of patients with CD to inform future dietary interventions. Secondary objectives
were to (a) compare micronutrient intakes of CD patients to a representative sample of individuals,
(b) describe macro- and micronutrient intakes of male and female CD patients, and (c) describe the
Mediterranean diet scores (P-MDS) of male and female CD patients in a Canadian ambulatory care
gastroenterology clinical setting.
2. Methods
2.1. Study Design and Recruitment
A single center cross-sectional study was undertaken at the University of Calgary, Foothills
Medical Center, in Calgary, AB, Canada. Eligible patients were recruited consecutively from
ambulatory gastrointestinal clinics at this site.
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2.2. Eligibility Criteria
To be eligible for the study, patients were required to: (a) be ≥18 years of age; (b) have a
documented diagnosis of ileal and/or colonic CD based on clinical, radiological and endoscopic
criteria; (c) be in clinical and endoscopic remission, defined by a Harvey Bradshaw Index (HBI) <5
with evidence of mucosal healing by endoscopy defined by no large ulcers, inflammation, or strictures,
within three months of recruitment; (d) been in steroid-free remission for three months prior to study
entry; (e) achieved induction of remission either through anti-tumor necrosis factor (anti-TNF) agents
or corticosteroids; and (f) provide informed consent. Patients were excluded if: (a) HBI >5, (b) had
evidence of active endoscopic mucosal disease, (c) used corticosteroids within the preceding three
months, (d) had >1 bowel resection, (d) presence of ostomy, (e) used laxatives in the past 3 months,
(f) used prebiotic fiber supplements in the past three months, (f) used probiotic supplements in the
past three months, and (g) used antibiotics in the past six months.
2.3. Ethics and Consent
The study protocol was approved by the University of Calgary Conjoint Health Research Ethics
Board REB15-1805. All participants provided informed written consent prior to participating in
the study.
2.4. Data Collection
Patient characteristics, medications, and symptoms were extracted from the patients’ medical
record and confirmed with the patient during their first study visit. The following data were collected:
age, sex, HBI, recent endoscopic findings, current medication, previous IBD surgery, last use of
antibiotics and/or probiotics, corticosteroids, and laxative use.
Dietary intake was collected using prospective 3-day weighed food records. Eligible patients met
with the study coordinator to receive training on how to record an accurate 3-day weighed food record.
Patients were instructed to document all food and drinks consumed and preparation method on two
representative weekdays, and one weekend day. The food records were then reviewed by the study
dietitian (RD) with the patient to identify any missing food or drink items.
Three-day dietary intake data were subsequently entered and analyzed using ESHA Food
Analysis Software (Version 11.3 X, ESHA Food Processor Nutrition Analysis Software, Salem OR,
USA) [25]. Intake data was reviewed for acceptable ranges of macro- and micronutrients. Adherence
to a Mediterranean diet was measured using an adapted 13-item PREDIMED Mediterranean Diet
Score (P-MDS) [26]; points were not given for red wine consumption considering the impact alcohol
consumption may have on symptoms related to IBD. Each item in the P-MDS received a score of 0 or 1,
and items were evenly weighted. Total P-MDS scores ranged from 0–13.
Macro- and micronutrient intakes of CD patients were compared to population usual nutrient
intakes from the Canadian Community Health Survey (CCHS; Cycle 2.2) [27]. A complete
description of the sampling frame is provided in the following documentation by Statistics
Canada (www.statcan.ca/cgi-bin/imdb/p2SV.pl?FunctioN=getSurvey&SDDS=5049&lang=en&db=
IMDB&dbg=f&adm=8&dis=2#b3). The sampling strategy was designed to provide a representative
sample based on age, sex, geography, and socioeconomic status [28]. The CCHS used interviews to
collect 24-h recall data with a subsample of respondents completing a second recall. To transfer daily
intake into usual intake, a measurement error model was used to reduce the effect of within-individual
variance and measure between-individual variance [27]. Data were compared for the following
parameters: (a) total energy intake in kilocalories (kcal); (b) protein, carbohydrate, fiber, total fat,
and PUFA including omega-6 and 3, MUFA and saturated fat (SFA) as proportions of total energy
intake; and (c) select micronutrients (vitamins and minerals) reported as a percentage of daily
recommended intakes (DRI) and mean daily/usual intakes.
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2.5. Statistical Analysis
Statistical analysis was carried out using SPSS (IBM Corp. Version 24.0, Armonk, NY, USA).
Data were expressed as means with standard deviation (SD) or standard errors (SE) where it facilitated
a comparison with normative population data. Median and interquartile ranges (IQR) were presented
for P-MDS due to the variability of the data. Comparisons were done using independent sample t-tests
to identify mean differences between males and females and between CD patients’ and population
usual intakes. Chi-squared tests were conducted to identify gender differences in P-MDS for categorical
variables and independent sample t-tests were used for mean P-MDS scores. Statistical significance
was established at p < 0.05.
3. Results
3.1. Demographic and Health
Eighty-seven patients were originally recruited to participate, but complete dietary data were
only completed by sixty-seven patients. These 67 patients had a mean age of 45, and a mean BMI
characterized as overweight (Table 1). Most patients (female = 88%, male = 73%) were receiving
anti-TNF maintenance therapy. Patients who were not receiving anti-TNF therapies were not on other
IBD specific therapies including dietary therapies. Less than half of the study participants received
immunomodulators. Close to one quarter of patients had one previous small bowel resection, none had
colonic resections, and no patients had an ileostomy.
Table 1. Patient demographics and health information.
Female N = 34 Male N = 33
Age in years (mean, SD) 44.7 (14.4) 49.7 (12.7)
BMI (kg/m2; mean, SD) 27.8 (6.1) 26.7 (3.9)
Anti-TNF n, (%) 30 (88.2%) 24 (72.7%)
IMM n, (%) 15 (44.1%) 14 (42.4%)
Previous bowel surgery n, (%) 7 (20.6%) 11 (33.3%)
Abbreviations: SD: Standard Deviation, BMI: body mass index, Anti-TNF: Anti-tumor necrosis factor, IMM:
Receiving immunomodulators.
3.2. Macronutrient Intake
Compared with the representative sample, male and female patients with CD had similar energy,
protein, carbohydrate, and total fat intake (Table 2). However, fat intake from PUFA, omega-6, omega-3
in females only, and MUFA were significantly lower in patients with CD when compared to the
representative sample of Albertans (Table 2). Dietary fiber intake was significantly higher in patients
with CD when compared to the representative sample.
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3.3. Vitamin Intake
Vitamin comparisons are all listed in Table 3. Compared to the representative sample, vitamins
C, D, thiamin, and niacin were significantly lower in male and female patients with CD, whereas a
lower intake of riboflavin and pyridoxine was observed only in female patients with CD, and lower
folate intake was noted only in males with CD. Males compared to female patients with CD had a
significantly lower intake of vitamin K, and higher thiamin, niacin, pyridoxine, and biotin intakes.
Compared to the DRIs, both male and female patients had inadequate intakes of vitamins A, D, E,
pantothenic acid, biotin, folate, and choline, although there was a high level of variation around the
mean scores. Representative sample data for some vitamins (E, K, pantothenic acid, biotin, and choline)
and minerals (chromium, copper, manganese, and selenium) were not available for comparison.
3.4. Mineral Intake
Compared to the representative sample, intakes of magnesium, phosphorus, zinc, and potassium
was lower for both male and female CD patients, whereas sodium intake was higher in female patients
(Table 4). Compared to male patients with CD, female patients had lower intakes of iron, phosphorus,
and sodium. Both male and female patients with CD did not meet the DRI adequacy for calcium,
chromium, magnesium, zinc, or potassium.
3.5. P-MDS Adherence
Few patients with CD met the P-MDS criteria for olive oil, vegetable, legume intake or
consumption of sofrito sauce (made from olive oil, onions, garlic, and tomatoes, and is similar to
spaghetti sauce; Table 5). One quarter of male patients and one fifth of female patients met the P-MDS
criteria for fruit servings, while 36% of males and 24% of females met the P-MDS criteria for nuts.
Fish and/or shellfish intake had a median intake of 0 per week and 21% of males and 32% of females
ate more than three or more servings a week. Over 70% of patients met the serving recommendations
for limiting butter, sugar sweetened beverages, and red or processed meat, and approximately half
of the patients limited baked goods and sweets to less than three times a week. Although patients
reported limiting red meat according to the P-MDS criteria (<6 oz or 175 g/day), few chose poultry
over red meat on a regular basis.
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4. Discussion
The present study is a description of the dietary patterns and food intake at one time point
at a single center, in adult patients in remission with CD. To our knowledge, this was the first
study to report on P-MDS in an adult cohort of patients with CD, and to examine the population
data and gender differences in nutrient intakes. Major study findings identified significantly
different (a) micronutrient intakes between CD patients and a representative sample of individuals;
(b) micronutrient intakes between male and female CD patients; and (c) dietary patterns compared to
the P-MDS recommendations.
Few published studies have identified dietary predictors of relapse. One such study in 103 CD
and ulcerative colitis (UC) patients used a cross-sectional design to evaluate the association between
food intake and course of disease; half with active disease [19]. Intake of legumes and potato were
inversely associated with the risk of active disease, defined as fecal calprotectin >150, with close to
80% of the highest quartile consumers of legumes at a lower risk of active disease (adjusted Odds
Ratio (OR) 0.21, 95% CI 0.57–0.81). Similarly, patients consuming the highest intake of meat coincided
with a higher risk of active disease (unadjusted OR 3.6). In the Tasson study [19], significant effects
for fruits and vegetables on disease relapse were not identified. The duration of active inflammation
before data collection prevented the authors from inferring the causality of diet determinants of relapse.
It is compelling to observe that in our current study, only three individuals consumed three or more
servings of legumes, and 30% of male patients demonstrated meat overconsumption.
Similar to our study, significant micronutrient deficits were observed including suboptimal intakes
of vitamins A, E, C, folate, and zinc. Vitamins C and E are antioxidants, and supplementation has
previously been shown to result in a reduction of oxidative stress [32]. Zinc plays a pivotal role in
wound repair, tissue regeneration, and the immune system; zinc deficiency in IBD has been associated
with an increased risk of hospitalizations, surgeries, and disease related complications. Normalization
of zinc was associated with improvement of these adverse clinical outcomes [33]. Limited dietary
diversity including the avoidance of food groups may offer one possible explanation for the deficiency
in micronutrient intake. Optimizing dietary diversity through focused nutrition counseling may lead
toward an improvement in micronutrient intake.
Compared to the representative sample, dietary MUFA intake from foods like olive and canola oils,
avocado, and nuts were low in patients with CD. One recently published study showed that dietary
lipid and overall energy intake in a mixed IBD sample was higher than that of the healthy control
subjects, however, no differences were observed in protein and carbohydrate intake [34]. Dietary lipid
composition, unfortunately, was not reported in this study, rendering the proportion of MUFA and
PUFA unknown. An older study in patients stratified by disease severity using the CD Activity Index
threshold of 150, showed the mean energy and macronutrient intakes were close to the recommended
levels in both patients with active disease and in remission, and reported MUFA intakes of 12% [35];
the MUFA intakes in our CD patients were significantly lower than this. In rheumatoid arthritis, a high
intake of MUFAs, was recently demonstrated to be an independent predictor of remission [36].
Gender differences in micronutrient intakes were observed although there was a large degree
of variability in the sample. Females consumed less thiamin compared to males, however, they still
met 80% of the DRI. Given the adequacy of intake, the clinical relevance of this finding is likely not
significant. Males only consumed half of the recommended potassium intake, and had lower intakes
than females. Both males and females had low intakes of biotin compared to DRI recommendations;
however, females were significantly lower than males at 25%. The consequence and etiology for
these findings are not readily apparent, although likely result from the extremely low intakes of
legumes, fruit and vegetables, and nuts and seeds. Although both males and females exceeded the DRI
recommendation for sodium, males had a significantly greater intake, possibly a surrogate for a greater
intake of processed foods. Both males and females exceeded DRIs for sodium in the representative
sample, however, to a lesser extent than our sample of patients with CD. While the dietary intake
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of sodium is under-reported in IBD, there are signs that show a diet enriched in sodium chloride
enhances inflammatory cytokine production and exacerbates colitis in animal models [37].
The dietary composition in our patient sample differed from the P-MDS criteria. Olive oil was
seldom used as the primary culinary fat of choice, and few patients in our sample met the P-MDS
criteria for intake of vegetables or legumes and fruit including fruit juice, and median intakes were 50%
below the recommended three or more fruit servings a day. For fruit and vegetable intake, the P-MDS
criteria are similar to the North American dietary recommendations. Thirty percent of males exceeded
the recommendations for red or processed meats per P-MDS criteria. Over 80% of patients reported
inadequate intake of fish and nuts.
Data evaluating the relationship between Mediterranean diets (MD) and disease characteristics
(severity and relapse) in IBD are limited. Drawing from the cardiovascular literature, the incidence
of major cardiovascular events was lower among participants assigned to an energy-unrestricted
MD, and MD supplemented with extra-virgin olive oil or nuts when compared to those assigned to a
reduced-fat diet [23]. A subsequent study identified significant reductions in plasma concentrations of
high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor in patients following
a MD supplemented with extra-virgin olive oil or nuts compared to a low fat diet, identifying
anti-inflammatory signals to explain the observed clinical findings [38]. Recently, Arpon et al. identified
that specific components of the MD, particularly nuts and extra virgin olive oil, were able to induce
methylation changes in several peripheral white blood cells, showing a role for specific fatty acids on
epigenetic modulation [39]. To our knowledge, studies assessing the gut microbiome composition in
long term MD consumers compared to habitual diet in humans have not yet been completed. However,
a very recent study identified significant microbiome differences in non-human primates consuming
MD when compared to a Western diet [40].
The results of our study provoke further curiosity into the relationships between dietary patterns,
nutrition adequacy, and disease pathogenesis in IBD. Protective mechanistic roles for MD patterns in
IBD are plausible, mediated through anti-oxidant effects, microbiome changes, and anti-inflammatory
effects. Interventional studies are required to test the efficacy of MD patterns on disease severity.
Promising effects on disease activity have been observed with elimination diets such as the specific
carbohydrate diet [41] and the autoimmune protocol diet [42], among other test diets in the recent
literature, highlighting the growing interest in undertaking intervention studies in this population
of patients.
The P-MDS was useful in identifying low intakes of foods rich in the deficient micronutrients
like olive oil, legumes, nuts, and fruits and vegetables. In patients with suboptimal intakes of these
foods, early referral to effective nutrition intervention programs and/or supplementation should
be considered. At the present time, in our center, patients are not routinely referred for dietary
assessment and counseling, nor do they receive nutrition risk screening. Gastroenterologists and nurse
practitioners providing care to patients with IBD at our site generally refrain from offering diet-focused
therapies as a solution for disease management in the absence of overt malnutrition. We recognize
that the lack of dietary focus as therapy may differ from other centers. We also recognize that patients
with IBD assessed at our center are interested in dietary therapies, although the source for nutrition
education is not readily apparent. Patients with IBD had a higher dietary fiber intake compared to the
representative sample, and 70% met the serving recommendations to limit butter, sugar sweetened
beverages, and processed meat.
There are study limitations that should be noted. This study was conducted at a single Canadian
center with a small sample, and therefore, the generalizability of the study findings may be limited.
While there are limitations to the use of the 3-day food record to capture dietary intake such as biased
estimates of intake due to underreporting or changes in normal dietary patterns, this validated tool
has been used extensively to measure food intake in a variety of populations. Deficient dietary intake
may not be synonymous with deficient total body stores of micronutrients. The current study design
was unable to infer a relationship between intake and body stores. In addition, the representative
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sample data did not report on several micronutrients, so comparisons between patients with IBD and
this population were not possible for all micronutrients. This study was underpowered to detect a
medium difference between males and females and produced point estimates with a large degree of
variability; therefore, results should be interpreted with caution. In addition, multiple analyses were
conducted, increasing the risk of type 1 error; however, due to the exploratory nature of this study and
limited sample size, a statistical correction was not made and results should be interpreted with this in
mind. Additional studies with larger numbers are recommended to confirm this study’s conclusions.
Studies such as this one are necessary to identify the need for dietary intervention and offers
potential dietary targets for intervention in patients with CD in an ambulatory care setting. Future
directions include a further description of dietary patterns in patients with CD and dietary intervention
studies to test the feasibility, acceptability, compliance, and efficacy of a MD pattern on disease related
outcomes. Dietary intervention studies may be regarded as complex interventions, and should be
developed based on established frameworks that may include a needs assessment of the population,
rationale for intervention development, and pilot studies to inform the details of a subsequent robust
clinical trial [43].
5. Conclusions
Differences in dietary quality and micronutrient intakes were observed between a representative
population and male and female patients with CD. Compared with a MD pattern shown to have
anti-inflammatory properties, patients with CD reported food choices that promote a more restricted
nutrient intake. These results suggest patients with CD should be screened for nutrient deficiencies
and inadequacy of dietary patterns. Using a simple tool such as the P-MDS may be a practical and
effective way to identify pro-inflammatory dietary patterns at an individual level. These data may
be used to inform future dietary interventions in this population to optimize dietary intake. Further
investigation into the efficacy of nutrition interventions to improve MD quality and the effect this has
on clinical outcomes and nutrient deficiency is warranted.
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Abstract: Exclusive Enteral Nutrition (EEN) is the first-line treatment in children with Crohn’s disease
(CD) for induction of remission. However, the mode of action remains conjectural. The aim of this
study was to investigate whether the effect of EEN is paralleled by changes in the mucosal cytokine
profiles (MCP). Twelve children with new onset inflammatory bowel disease (IBD) received induction
treatment with a polymeric EEN. We assessed clinical, endoscopic and histologic scoring before and
after EEN. Twelve colonic cytokines were analyzed by Polymerase Chain Reaction (PCR) in six of
the IBD patients at onset and after EEN as well as in six non-IBD control children at the diagnostic
colonoscopy. Twelve children completed 6 weeks of EEN, except from one child who completed
4 weeks. At the control colonoscopy, 83% were in complete clinical remission. Changes were found
in the MCPs of individual patients after EEN. In particular, children with IBD showed significantly
higher values of Interleukin (IL)-12β (p = 0.008) and IL-23α (p = 0.02) compared to non-IBD controls
at the diagnostic colonoscopy. Furthermore, an overall change in proinflammatory cytokines was
noted in the IBD-group after treatment. Further studies are warranted to understand the role of EEN
in MCP.
Keywords: exclusive enteral nutrition; children; IBD; remission; mucosal cytokines
1. Introduction
Crohn’s disease (CD) and Ulcerative Colitis (UC), the major entities of pediatric IBD, are chronic
inflammatory conditions of the gastrointestinal tract. Childhood IBD is characterized by more severe
symptoms and wider disease extension at diagnosis compared to adults [1]. Abdominal pain, nausea
and bloody diarrhea are common symptoms in both children and adults while growth retardation is
frequently seen in pediatric patients [2]. EEN is the first-line treatment for remission induction of CD
in pediatric patients. The clinical remission rate is 73–80% and it effectively induces mucosal healing
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(MH) at a rate that is superior to corticosteroids [3–7]. EEN consists of high energy liquid formulas,
which are either elemental, semi-elemental or polymeric based. EEN is recommended to all children
with luminal disease, including those with colonic involvement [3].
The immunological effects driven by EEN that contribute to mucosal healing (MH) are not yet
fully understood [7]. The intestine hosts a majority of the body’s immune cells (70–80%) [8] and the
interactions between a disrupted microbial composition, an impaired intestinal mucosal barrier and
the mucosal immune system are considered to play an important role in the IBD development and
its chronicity [7]. Some studies suggest that a deficiency of host immunity also contributes to the
pathogenesis of IBD [9]. The cytokines, small immune-regulating messenger proteins, play a crucial
part in the inflammatory response by regulating cell differentiation, producing proinflammatory
cytokines and recruiting white blood cells from the bone marrow [10]. There are only a few studies
that show that EEN seems to affect the expression of cytokines in the mucosa [11–13].
The aim of this study was to investigate the clinical effect of EEN as induction therapy and
whether the effect of EEN is paralleled by changes in the mucosal cytokine profiles (MCP).
2. Materials and Methods
We conducted a prospective cohort study of children with new onset symptoms of possible IBD
between August 2013 and September 2016. The inclusion criterion was previously healthy children up
to 18 years of age with signs of IBD and the exclusion criterion was any use of immunosuppressive
drugs within 6 months prior to inclusion. Thirteen children who fulfilled the ECCO/ESPGHAN
consensus criteria for pediatric CD (14) entered the EEN study but one patient immediately left the
study after the diagnostic endoscopy. One child received concomitant medication with mesalazine
(53 mg/kg/day). Six patients who did not receive any IBD diagnosis were included as non-IBD
controls. Demographic data are presented in Table 1.
Table 1. Demography and Paris classification of 13 IBD patients at inclusion.
Sex (Girls/Boys) 6/7
Age in years, median (IQR) range 12.5 (10.5–14.5) 7.8–16.4
Symptom duration in months, median (IQR) range 6 (3.1–11.1) 1.5–12








2.1. Examinations and Tests
The patients were investigated according to the ECCO/ESPGHAN guidelines for pediatric IBD
with initial laboratory investigations: peripheral blood count, liver enzymes, albumin, erythrocyte
sedimentation rate (ESR), iron status, C-reactive protein (CRP), fecal calprotectin and stool cultures
to exclude infectious etiology. In line with the guidelines, all patients were investigated with
upper endoscopy and ileocolonoscopy under general anesthesia with multiple mucosal biopsies
for histopathological evaluation [14]. For the study, four mucosal biopsies were obtained from the
most inflamed site in the ileum or colon. The endoscopies were documented by a still picture system
integrated in the computerized medical record program (Picsara, Mawell, Solna, Sweden). A control
upper and lower endoscopy with biopsy harvesting at the same site as the diagnostic endoscopy was
performed shortly after completion of EEN remission treatment in children with CD. No CC was
performed in the six non-IBD controls. The body weight of study patients was obtained before and
after the EEN treatment.
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2.2. Clinical Assessment of Disease Activity and Disease Extension
We used the validated disease activity scoring PCDAI (Pediatric CD Activity Index) with
<10 points for remission, 10–27.5 for mild disease, >27.5–37.5 moderate disease and >37.5–100 for
severe disease. A PCDAI decrease of >12.5 points was regarded as a clinically significant response to
treatment [15]. PCDAI score was assessed at inclusion and at CC. Disease extension was assessed by
Paris classification [16].
2.3. Endoscopic Scoring
Simple Endoscopic Score for Crohn’s disease (SES-CD) was used to assess the mucosal
inflammation in the CD patients [17] and was evaluated either by the endoscopist or by the investigator
from the charts (the endoscopy history and endoscopy imaging). SES-CD describes the presence and
size of ulcers, extent of the ulcerated surface, extent of the affected surface and the presence and type
of narrowing scored with 0–3 points in rectum, sigmoid and left colon, transverse colon, right colon
and ileum. Remission is equal to 0–2 points, mild disease to 3–6 points, moderate to 7–15 points and
severe disease to ≥16 points.
2.4. Histopathology Scoring
The mucosal biopsies were reviewed by the validated histological Geboes scoring [18]. Grades < 3
were regarded as the absence of IBD inflammation, while grades ≥3 were regarded as the presence of
IBD inflammation of varying degrees (3:1–3:7) with the following subgroups: a = basal plasmacytosis,
b = lymphoid nodules, c = Paneth cell hyperplasia, d = eosinophils in the lamina propria, e = histiocytic
cell proliferation, f = giant cells, g = granuloma, h = vasculitis and i = dysplasia.
2.5. Exclusive Enteral Nutrition (EEN)
Fortimel Energy®, a polymeric formula, was prescribed to meet a daily energy intake estimated at
120% of recommended daily allowance (RDA). Fortimel Energy® contains 625 kJ, 5.8 g of fat and 5.9 g
of protein/100 mL (Nutricia Advanced Medical Nutrition, Solna, Sweden). The EEN treatment was
introduced by a daily step-wise increase by 25% of full daily intake for three days, which was followed
by six weeks of EEN and rounded off by a step-wise decrease by 25% of full daily intake for 3 days.
The children were allowed to drink clear beverages, eat a few popsicles and a few hard mints per day
during the EEN treatment. Patients were allowed additional formula at their own discretion for daily
satiation. At de-escalation, the patients were advised to avoid large amounts of dairy products, spicy
food and large amount of legumes. The children and caregivers had one introductory session with a
dietitian. Thereafter, the dietitian had weekly phone calls to monitor intake and motivate the patients
and caregivers to complete the whole EEN treatment period. Scheduled clinical assessments were
arranged after two weeks of EEN.
2.6. Cytokine-Selection
A panel of cytokines that are known to participate in chronic intestinal inflammation were selected
for testing. We investigated Colony Stimulating Factor(CSF)-2, Interferon(IFN)-γ, Tumor Necrosis
Factor(TNF)-α, Interleukin(IL)-1β, IL-4, IL-6, IL-10, IL-12β, IL-22, IL-23α, IL-36γ, Tumor Growth
factor(TGF)-β1 and a control gene ABL. The amount of messenger-RNA (m-RNA) in the different
proinflammatory mediators was compared to the signal from the ABL-gene and the result is presented
as the cytokine/ABL ratio. We used TaqMan® Gene Expression Assays, applied biosystems (Thermo
Fischer Scientific®, Waltham, MA, USA)
2.7. RNA Extraction and Gene Expression by Quantitative Real-Time PCR
Biopsies for MCP were put into the RNA-later (Invitrogen, Waltham, MA USA) and kept at
+6 ◦C for 24 h and then frozen (−20 ◦C) until analysis. Total RNA was isolated by utilizing the
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Fibrous tissue kit (Qiagen, Hilden, Germany) with slight modification. Defrosted and minced biopsies
(3 mm) were homogenized with a pestle motor (WVR®, Radnor, PA, USA) for 30–60 s in 350 μL of
RLT-buffer and 350 μL of 70% ethanol was added. The homogenates were loaded into spin columns
and centrifuged before the columns were washed with 350 μL of RW1-buffer. Samples in the columns
were treated by DNase I and washed with 350 μL of RW1-buffer, with the remainder handled according
to the manufacturer protocol. cDNA was obtained by reverse transcription. Quantitative real-time
PCR (qPCR) was performed using the 7500 Fast Real Time PCR System (Applied Biosystems, Foster
City, CA, USA) for quantification. Probes were obtained from Applied Biosystems, TaqMan® MGB
probes, FAM™ dye-labeled: IL-1β (Hs00174097_m1), IL-4 (Hs00174122_m1), IL-6 (Hs00985639_m1),
IL-10 (Hs00961622_m1), IL-12β (Hs001011518_m1), IL-22 (Hs01574154_m1), IL-23 (Hs00900828_g1),
IL-36γ (Hs00219742_m1), TGF-β1 (Hs00998133_m1), TNF-α (Hs01113624_g1), IFN-γ (Hs00989291_m1),
GM-CSF-2 (Hs00929873_m1) and ABL1 (Hs01104728_m1) according to the manufacturer protocol.
Fold increases of mRNA transcripts were calculated as follows: ΔCt = Ct (gene of interest)−Ct (ABL1),
ΔΔCt = ΔCt sample− average ΔCt control group and fold difference = 2−ΔΔCt. For technical reasons,
CMCP was not analyzed in all children with IBD both at diagnosis and at CC. No active selection
was performed.
2.8. Ethical Approval
The study was approved by the local Ethics Committee in Stockholm, Sweden (No. 2010/1252-31/1).
Informed written consents were obtained from legal guardians for patients and also from all patients
over 15 years of age before any study-related procedures were initiated in accordance with the
Helsinki II Declaration.
2.9. Statistics
The comparisons between clinical chemistry values, SES-CD and disease activity index (PCDAI)
before and after treatment were conducted with paired sample t-tests (parametric data) or Wilcoxon
paired t-tests (non-parametric data) depending on the normal distribution (tested with Shapiro–Wilks
test). Paired comparisons between cytokines before and after treatment were conducted with Wilcoxon
paired t-tests while the comparisons between groups were conducted with Mann–Whitney U test
after control of normality with Shapiro–Wilks test. All analyses were performed with the IBM SPSS
Statistics Data Editor, version 23® (Armonk, NY, USA). Statistical significance was set at p < 0.05.
3. Results
Thirteen children were included with a CD diagnosis according to the ECCO/ESPGHAN
guidelines. One CD patient left the study after the first colonoscopy due to social circumstances.
Out of 12 patients who completed EEN treatment, two patients were re-diagnosed with UC and one
with IBD-unclassified (IBD-U) at the time of histopathological review after study completion (Table 1
for Paris classification at inclusion).
3.1. EEN Treatment
Eleven children completed six weeks of EEN and one CD patient completed only four weeks of
EEN due to a lack of motivation, but fulfilled participation in all other aspects of the study. All patients
accepted the prescribed EEN by oral intake without the use of nasogastric tube.
3.2. Clinical Activity Scoring
Clinical scoring of the children diagnosed with CD was measured by PCDAI, which was also
used for the children who had their diagnoses changed to UC (n = 2) or IBD-U (n = 1). At inclusion,
six children were considered to have mild disease (PCDAI 10–27.5) and seven patients showed
moderate to severe disease (PCDAI > 27.5). There was a significant decrease in PCDAI at CC (p = 0.02).
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The median PCDAI was 26.5 (IQR 20.0–36.6, range 20–40) at inclusion and 5 (IQR 0-5, range 0–15)
after EEN treatment. Ten of twelve patients (83%) showed clinical remission (PCDAI < 10) after EEN
induction treatment.
3.3. Laboratory Values
ESR, CRP, hemoglobin, plasma-albumin and F-calprotectin were monitored in all patients. There
were significant decreases in ESR (p = 0.005), CRP (p = 0.016) and f-calprotectin (p = 0.033) and
significant increases in hemoglobin (p = 0.001) and p-albumin (p = 0.003) after EEN treatment (Table 2).
Table 2. Laboratory values and weight in 12 patients at inclusion and at control colonoscopy.
Value At Inclusion Median (IQR) Range After EEN Treatment Median (IQR) Range
Weight (kg) 37.9 (31.5–52.6) 27.5–59.7 40.5 (32.8–55.4) 29.8–59.1
ESR (mm/h) 28 (17.3–27.5) 8–53 9 (8–11) 2–21
CRP (mg/L) 14 (2–49.3) 1–86 2.5 (1–8.3) 1–20
Albumin (g/L) 33 (25–36) 24–41 36.3 (33.5–40.5) 31–44
Hemoglobin (g/L) 113 (101–119.5) 83–142 129 (121–135) 116–144
F-calprotectin (mg/kg) 2640 (1191–3169) 580–6360 620 (198–1556) 5–2256
3.4. Anthropometric Data
There was a significant gain in weight (p = 0.003) after EEN treatment (Table 2).
3.5. Endoscopic Healing
All patients were examined with a control upper and lower endoscopy at a median of 13 days
(range 1–45 days) after completion of EEN. A significant decrease (p = 0.008) was seen in SES-CD after
EEN (median SES-CD 9.5, IQR 4.5–14.3, range 4–28 at inclusion compared to median 3.5, IQR 1–10,
range 0–16 at CC).
3.6. Clinical Outcome of the Two UC Patients
One UC patient showed a reduction in PCDAI (23 to 5 points) and ESR (28 to 11 mm/h) and an
increased hemoglobin value (110 to 116 g/L). However, no considerable effect was seen in SES-CD,
CRP and F-calprotectin. The other UC patient showed a decrease in PCDAI (40 to 15 points), ESR
(53 to 2 mm/h), CRP (47 to 11 mg/L), F-calprotectin (3169 to 1430 mg/kg) and SES-CD (21 to 16 points)
and a raise in albumin (28 to 31 g/L) and Hb (83 to 128 g/L).
3.7. Mucosal Healing
The histopathological scoring using the Geboes score showed an improvement in ten patients,
worsening in one patient and resolution of inflammation in one patient after EEN treatment
(Tables A1 and A2).
3.8. Adverse Events
Two patients reported initial mild abdominal pain related to the intake of nutritional drinks.
The treatment was tolerated without any additional side effects in all 12 patients.
3.9. Mucosal Cytokine Profile
In six of twelve EEN-treated children, the cytokine profile in biopsies were analyzed both
at diagnosis and at CC. In the remaining seven patients, mucosal cytokines in biopsies were
analyzed either at diagnosis or at CC, but could not be analyzed both at diagnosis and CC due
to technical circumstances.
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3.9.1. Cytokine Profiles in Six Patients Pre- and Post EEN
No significant differences were found in any cytokine profile in six patients (five with CD and
one with IBD-U) who completed six weeks of EEN. Furthermore, there were no associations in the
cytokine profile in relation to gender, age or disease extension. In individual patients, both reductions
and increases in the cytokine expression were seen. With regards to the key proinflammatory cytokine
IL-12β, only one patient demonstrated a decrease while four patients showed an increase after EEN
(one sample missing). In addition, the antiinflammatory IL-10 decreased in three patients and increased
in three patients, while two patients had a reduction of the regulatory TGF-β1, one patient had no
change and three patients showed increased expression after EEN treatment. The regulatory cytokine
CSF-2 was downregulated in four out of five patients after EEN treatment (Table 3 and Figure 1).
Table A3 for real-time PCR values per patient pre- and post-EEN.
Table 3. MCP in biopsies from six children at IBD onset and after treatment harvested from colon
(in some patients, it was not possible to analyze all MCPs).












TGF-β1 2 1 3
Figure 1. Six cytokine profiles in mucosal biopsies according to mRNA levels measured by q-PCR
at disease onset and after EEN treatment. (A). IFN-γ at onset and after EEN treatment. (B). CSF-2
at onset and after EEN treatment. (C). TNF-α at onset and after EEN treatment. (D). IL-10 at onset
and after EEN treatment. (E). IL-12β at onset and after EEN treatment. (F). IL-23α at onset and after
EEN treatment.
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3.9.2. Cytokine Comparison between IBD Patients and Non-IBD Controls
When 12 MCPs in eight IBD-patients were compared to six non-IBD patients at inclusion,
significantly higher values of IL-12β (p = 0.007) and IL-23α (p = 0.025) were measured in the IBD
patients compared to non-IBD controls.
4. Discussion
In the present study, we aimed to investigate the effect of EEN treatment on symptoms,
biochemistry, endoscopy, histopathology and mucosal cytokine profile in children with new onset IBD.
We found a significant reduction of PCDAI, CRP, ESR and F-calprotectin; a significant increase
in hemoglobin and albumin levels; and a significant gain in weight between the baseline and after
completion of the EEN treatment. Mucosal healing (MH), measured by SES-CD, was seen in the
majority of the patients at CC compared to diagnosis. Our results are consistent with other reports,
which have showed that EEN is effective for clinical and biochemical remission in up to 80% in children
with newly diagnosed CD [19,20].
Interestingly, in the two patients with a subsequent change of diagnosis from CD to UC, EEN also
had an antiinflammatory effect. To the best of our knowledge, the literature on the evaluation of EEN
in UC is limited [21,22].
MCP
In this pilot study, no significant differences in MCP were found after EEN treatment in children
with IBD. However, we found significant higher levels of baseline IL-12β and IL-23α in the IBD-patients
compared to non-IBD controls. These cytokines are known to play an important role in the pathogenesis
of CD [23].
Our intention was to investigate the effects of EEN on the mucosal cytokine profile in addition
to its clinical effects. It is likely that MCP mirrors the inflammatory activity more adequately than
cytokines analyzed in peripheral blood [24]. Even though the reduced expression of proinflammatory
cytokines was seen after EEN treatment, no consistent effect of EEN variations was identified. This
is probably due to individual variations and a limited number of patients, which is an important
limitation of the study.
The expression of TGF-β1, CSF-2 and IL-10, which are known as regulatory cytokines,
demonstrated conflicting changes in the patient group after treatment. There are only a few reports
published on mucosal cytokines after EEN. Yamamoto et al. investigated IL-1β, IL-1 receptor antagonist
(IL-1ra), IL-6, IL-8 and TNF-α with enzyme-linked immunosorbent assay (ELISA) before and after four
weeks of elemental diet in 28 adult patients. After treatment, a reduction in the mucosal expression of
IL-1β, IL-1ra, IL-6, IL-8 and TNF-α was noticed. Furthermore, when they compared IBD patients to
healthy controls, significantly higher levels of all cytokines were observed in the IBD patients [12].
Fell et al. investigated clinical efficacy and mucosal healing after eight weeks of CT3211
(a polymeric nutritional diet) in 29 children with active CD. In addition, IL-1β, IL-8, IL-10, TGF-β1 and
IFN-γ were analyzed with PCR in ileal- and colonic biopsies from 18 children [11]. Complete clinical
remission was seen in 79% of the patients. Furthermore, macroscopic and histological healing was
associated with a significant downregulation of mucosal proinflammatory cytokines in ileum or/and
colon. Elevated mucosal cytokines were observed in CD patients before EEN treatment compared to
non-IBD controls and ileal TGF-β1 increased during treatment.
Thus, the reports on MCP and EEN show contradictory results and one explanation may be the
diversity in methodology, but also in the types and length of EEN treatment. The individual expression
of the mucosal cytokines may also reflect the diversity in patients and their immunological status
since CD probably comprises several pathogenic mechanisms that differ between patients [25,26].
Nevertheless, earlier reports show aberrant gene expression in patients with CD, which involves
cytokine expression. In 2006, Carr et al. found a strong association between an aberrant gene-expression
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of the proinflammatory cytokine IL23R and CD while Waschke et al. connected various single
nucleotide polymorphisms in the TNF receptors to different CD phenotypes [27–29]. In our report,
the expression of regulatory IL-10, TGF-β1 and CSF-2 was shown to decrease and increase in individual
patients after EEN treatment. This may reflect the temporal aspect, i.e., the same cytokine may be
protective during acute inflammation but harmful and perpetuate the chronic inflammation [30]. Thus,
cytokines may exert variable functions during different immunological conditions [31–33].
5. Conclusions
Complete remission after 6 weeks of EEN was achieved in a majority of children with new onset
IBD. We found a higher level of expression of IL-12β and IL-23α in these children compared to controls
at inclusion. There were individual changes in the mucosal cytokine profiles after EEN-treatment
but there were no consistent trends. Further understanding of the role of both antiinflammatory
and regulatory cytokines as well as the aspects of temporal changes in the cytokine expression from
diagnosis to remission requires larger studies.
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Appendix A
Table A1. Geboes scoring: Grades < 3 were regarded as absence of IBD inflammation, while grades
≥ 3 were regarded as presence of IBD inflammation of varying degree (3:1–3:7) with the following
subgroups: a = basal plasmacytosis, b = lymphoid nodules, c = Paneth cell hyperplasia, d = eosinophils
in the lamina propria, e = histiocytic cell proliferation, f = giant cells, g = granuloma, h = vasculitis and
i = dysplasia. The table shows 11 segments (segment 1 = ileum, segment 11 = rectum) before and after
EEN treatment.
Segm. 1 Segm. 2 Segm. 3 Segm. 4 Segm. 5 Segm. 6 Segm. 7 Segm. 8 Segm. 9 Segm. 10 Segm. 11
Patient
Endoscopy1|Endoscopy2
Pat 1 CD mult.g|g <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3
Pat 2 UC <3| 3:3 5|3:7 3:7|3:7 3:3|3:3 3:3|3:7 5|3:7 5|3:3 4|3:7 3:7|3:7 <3|3:7
Pat 3 CD <3|<3 <3+g|<3 5+b|<3+e <3|mult.g <3|<3+e <3|<3+e <3|<3 <3|<3+g <3|<3 <3|<3 <3|<3
Pat 4 CD 3:3+b+g|3:1 3:3+b+g|3:1 3:3+b+g|3:1 <3|<3 <3|<3 <3|<3 <3|<3 3:3|<3 <3|<3 <3|<3 <3|<3
Pat 5 CD <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3
Pat 6 CD 3:3+e|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 <3|<3 4+g|<3
Pat 7 UC <3|<3 3:7|3:3 3:7+e|3:3 3:7|3:3 3:7|3:3 3:3|3:3 3:7|3:7 3:7|3:3 4+e|3:7 3:7+c|3:3 3:7|3:3
Pat 8 CD infl.polyp|3:7 <3|<3+g <3+g|<3 <3+e|3:3 <3+g|3:3 3:2|<3 3:2+g|3:1 <3|<3 <3+g|<3 <3+g|<3 <3+g|<3
Pat 9 I-BDU <3|<3 <3|<3 <3|<3 3:2|<3 <3|<3 <3|<3 3:1|<3 3:1|<3 3:1|<3 <3|<3 <3|<3
Pat 10 CD <3+g|<3+g <3+g|<3+g <3|<3+g <3|<3 <3+g|<3 <3|<3 <3|<3+g <3+g|<3 <3|<3 <3+g|<3 <3+g|<3
Pat 11 <3|<3 <3|<3 3:4|<3 3:7+e|<3 3:7+e|<3 4+e|<3 4|<3:4 4|<3 4|3:4 3:7+e|<3 4|<3
Pat 12 5+e|3:2 3:3|3:2 3:3|3:2 <3|<3 <3|3:7 <3|3:7 <3|<3 <3|<3 <3|<3 <3|<3 3:7|<3
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Table A2. Geboes results summarized (every patient, 11 segments) as improvement, no change,
aggravated inflammation or no inflammation after EEN.
Patient Improvement No Change Aggravated Inflammation No Inflammation
1 1 10
2 4 4 3
3 2 4 5
4 4 7
5 11
6 2 1 8
7 8 3
8 7 2 1 1
9 4 7
10 4 5 2
11 9 2
12 4 2 5
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Abstract: Mucosal healing after an inflammatory flare is associated with lasting clinical remission.
The aim of the present work was to evaluate the impact of the amount of dietary protein on epithelial
repair after an acute inflammatory episode. C57BL/6 DSS-treated mice received isocaloric diets
with different levels of dietary protein: 14% (P14), 30% (P30) and 53% (P53) for 3 (day 10), 6 (day 13)
and 21 (day 28) days after the time of colitis maximal intensity. While the P53 diet worsened the
DSS- induced inflammation both in intensity and duration, the P30 diet, when compared to the P14
diet, showed a beneficial effect during the epithelial repair process by accelerating inflammation
resolution, reducing colonic permeability and increasing epithelial repair together with epithelial
hyperproliferation. Dietary protein intake also impacted mucosa-adherent microbiota composition
after inflammation since P30 fed mice showed increased colonization of butyrate-producing genera
throughout the resolution phase. This study revealed that in our colitis model, the amount of protein
in the diet modulated mucosal healing, with beneficial effects of a moderately high-protein diet,
while very high-protein diet displayed deleterious effects on this process.
Keywords: dietary protein level; colitis; epithelial repair; mucosa-adherent microbiota
1. Introduction
In recent years, mucosal healing (MH) has become a therapeutic goal for the prevention of
the complications of inflammatory bowel diseases (IBD) [1–4]. MH relies on concomitant cellular
events that provide epithelial repair to restore the tissue integrity and the physiological functions
of the colon such as barrier function and water absorption [4,5], these events being presumably
protein and energy consuming processes. In addition, the nutritional status is known to be impaired
during and after an intestinal inflammatory episode due in particular to the catabolic action of the
pro-inflammatory cytokines [6]. Although there is some evidence that the daily protein needs of
IBD patients may differ from those of healthy controls, further experimental and clinical data are
required to fully validate this concept. The European Society for Clinical Nutrition and Metabolism
recommends to increase the protein intake in active IBD to 1.2–1.5 g/kg body weight/day in adults
and to maintain a similar level as it is recommended for the general population during remission
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(about 1 g/kg body weight/day) [7]. However, the beneficial effects of increasing dietary protein
level have been barely studied. Notwithstanding, majoring dietary protein intake may impact the
colonic mucosa in the healthy gut as recently reviewed [8] by altering colonocyte biology [9,10] and
colonic luminal environment [11–14]. Furthermore, we showed that a high protein (HP, 53% of total
energy provided by protein) intake exacerbated acute colonic inflammation when simultaneously
given with colitis induction [15]. Interestingly, the same study showed that this protein level in the diet
was rather beneficial after the acute episode of colitis as it enhanced colonic epithelium restoration in
surviving animals, thus indicating a potential effect of the dietary protein level on colonic crypt repair
after acute inflammation [15]. Actually, supplementation with some AA, alone or in combination,
improved parameters related to mucosal healing in colitis model such as epithelial regeneration and
colonic barrier function (for review, see Reference [16]). Moreover, published data suggest that the
availability of some amino acids, such as threonine or cysteine, is limiting under conditions of colonic
inflammation [17,18] and that dietary supplementation of protein or amino acids is needed to promote
favorably epithelial repair. However, AA supplementation may also exert deleterious impact as it
has been recently shown with threonine during colitis [19]. To date, the positive effect of any AA
supplementation on colitis has never been demonstrated in clinical studies.
We then hypothesized that increasing dietary protein intake might influence colon epithelial
repair by a direct effect of additional AA blood supply or via microbiota-derived effects. The present
study thus aims to evaluate the impact of different level of dietary proteins (normoproteic (14% of
the total energy provided by protein, P14)), moderately HP diet (30%, P30) and an elevated HP diet
(53%, P53) on some relevant barrier function parameters after the acute inflammatory episode in the
DSS-mouse model of colitis.
2. Materials and Methods
2.1. Animals and Diets
Seven-week-old C57BL/6 male mice were obtained from ENVIGO, France (144, weight 18–23 g).
Animals were housed in a 12:12-h light-dark circle at 23 ◦C and controlled humidity (55 ± 10%) and
acclimated for one week with free access to standard mouse chow and tap water. Each mouse was
maintained in an individual cage with a grid and was allowed to acclimate to the P14 diet after three
days of a standard mouse chow/fresh P14 diet (Table 1). The study was performed according to the
European directive for the use and care of laboratory animals (2010/63/UE) and received the agreement
of the local animal ethics committee and of the ministerial committee for animal experimentation
(registration number: APAFIS#3987-2016012214388658).
Table 1. Composition of the experimental diets.
P14 P30 P53
Weight content (g/kg)
Acid casein (Armor Protéines®, ref. #139860) 112 232 424
Whey protein (Armor Protéines®, Protarmor 80, ref. #139805) 28 58 96
Corn starch 622.4 493.2 287
Sucrose 100.3 79.5 45.7
Cellulose 50 50 50
Soybean oil 40 40 40
Mineral Mixture (AIN 93-M) 35 35 35
Vitamin Mixture (AIN 93-V) 10 10 10
Choline 2.3 2.3 2.3
Energy content (%)
Protein 14 30 55
Carbohydrate 76 60 35
Fat 10 10 10
Energy density (kJ/g) 14.5 14.5 14.5
47
Nutrients 2019, 11, 514
2.2. Experimental Design
Three types of experimental isocaloric diets (14.5 kJ/g) were used in this study: a normoproteic
diet (P14, 140 g/kg milk protein), a moderately HP diet (P30, 300 g/kg of milk protein) and an elevated
HP diet (P53, 530 g/kg of milk protein) isocellulose diet with similar energy content (Table 1). Healthy
controls (non-treated mice at day 0, n = 12) received fresh tap water. DSS-treated mice (n = 132) were
given 3.5% (wt/vol) DSS (36,000–50,000 MW, MP Biomedicals Illkirch-Graffenstaden, France) in the
drinking water for 5 days, from day 1 to day 5 (fresh DSS solution being prepared every two days)
to induce an acute colitis episode (Figure 1). At day 7, corresponding to the maximal intensity of
colon inflammation, mice were divided into three groups with the same mean body weight (BW) and
were fed either the P14, the P30 or the P53 diet during 3, 6 or 21 days. Food and drink were given ad
libitum and measured daily. Disease activity was scored based on stool consistency, rectal bleeding
and percentage of body weight loss, as previously described [15]. For each parameter, a score of 0
to 3 was attributed: loss of weight (0, none; 1, 0%–10%; 2, 10%–20%; 3, >20%), stool consistency (0,
normal pellets; 1, slightly loose feces; 2, loose feces; 3, watery diarrhea) and visible fecal blood (0,
negative; 1, slightly bloody; 2, bloody; 3, blood in the whole colon). Mice were euthanized to evaluate
the impact of diet on epithelial repair kinetics at days 10 (n = 12), 13 (n = 12) and 28 (n = 16) per diet
group (Figure 1). Body fat and lean body mass of mice belonging to day 28 group, were measured
every nine days with dual-energy x-ray absorptiometry (DEXA) using a PIXImus imager (GE Lunar
PIXImus, GE Healthcare, Fitchburg, WI, USA). Mice were euthanized if they lost more than 20% BW,
as per approved animal protocol guidelines, to meet the end point criteria.
Figure 1. Schematic representation of the experimental design. Mice received either P14 (14% of
proteins), P30 (30% of proteins) or P53 (53% of proteins) diet from D7 to D28. Mice were euthanized (E)
at day 0, 7, and during the resolution phase at days 10, 13 and 28.
2.3. Intestinal Permeability Assessment
Firstly, epithelial barrier integrity was assessed in vivo with the 4 kDa paracellular marker
fluorescein isothiocyanate (FITC)-labeled dextran (FD4, Sigma-Aldrich, St Quentin Fallavier, France)
at days 9, 12 and 18. Food was withdrawn for 4h before gavage (600 mg/kg BW of FD4) and plasma
was collected from the tail 4 h later (n = 8/diet group). Fluorescence intensity of each sample was later
used to calculate permeability using standard curves generated by serial dilution of FD4. Secondly,
at euthanasia, the proximal colon section was mounted in EasyMount Ussing chambers (Physiologic
Instrument Inc, San Diego, CA, USA), within 15 min from dissection as previously described [13].
Paracellular permeability was assessed by measuring the mucosal-to-serosal flux of FD4 at a final
concentration of 0.25 mg/mL, and fluorescence units (FU) were measured 90 min later with the
Infinite® 200 Pro spectrofluorimeter (TECAN, Männedorf, Switzerland). Tissue viability was assessed
at the end of each recording by adding the cholinergic drug carbachol (10−4 M) on the serosal side.
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2.4. Tissue Collection
Mice were euthanized by an intracardiac puncture after sedation by isoflurane. Plasma was
frozen and kept at −80 ◦C for later measurement of cytokines and lipopolysaccharide binding protein
(LBP) concentrations. Colon was resected, measured, weighted and the proximal colon section
mounted in Ussing chamber. Proximal colon mucosa was scraped for latter mucosa-adherent bacterial
DNA extraction procedure. Colon samples were harvested for RNA analysis, myeloperoxidase (MPO)
activity and protein expression assays, immediately frozen in liquid nitrogen and stored at −80 ◦C after
resection. Histological analysis was performed with distal colon fixed in 4% buffered formaldehyde.
2.4.1. Determination of Local and Systemic Inflammatory Markers
Colon inflammation was assayed with MPO assay measurement as described in Reference [20]
and colonic IL-1β and IL-6 concentrations were measured by Luminex technology in total colon protein
lysate by using Bio-Plex kits (Bio-Rad, Marnes-La- Coquette, France). Plasma concentration of LBP was
determined with a commercial solid-phase sandwich ELISA (PikoKine ELISA Kit Mouse, Set EK1274;
Boechout, Belgium).
2.4.2. Histological Analysis
Histological and re-epithelization scores on hematoxylin-and-eosin (HE) stained colonic sections
were calculated as previously described (Vidal-Lletjós, et al., submitted) after blind microscopic
assessment performed by the histological platform Histalim (Montpellier, France). Quantitative
evaluation of well-oriented crypts and cell numeration in periodic acid-schiff (PAS) stained 4-μm
transversal colon sections was determined using the image analysis software Pannoramic Viewer
v. 1.15.4 (3DHISTECH, Budapest, Hungary). Paraffin-embedded distal colon samples were cut
into 4 μm-thick sections, mounted on positively charged slides and dried. Immunohistochemical
stainings of Ki67 and Caspase 3 were performed on the Discovery XT Automated IHC stainer using
either Ventana DAB MAP detection kit (Ventana Medical Systems, Tucson, AZ, USA) or the Ventana
CHROMO MAP detection kit (Ventana Medical Systems, Tucson, AZ, USA). Following deparaffination
with Discovery wash solution (Ventana), antigen retrieval was performed using a Tris-based buffer
solution. Later, endogen peroxidase was blocked and slides rinsed before incubation with primary
antibodies either rabbit anti-ki67 (NB600-1252 Novusbio, Centennial, CO, USA) diluted at 1/100
or rabbit anti-Casp3 (9661, Cell Signaling, Danvers, MA, USA) diluted at 1/250. For Ki67 staining,
signal enhancement was performed using Goat anti-Rabbit biotinylated secondary antibody (Vector
laboratory, Burlingame, CA, USA) and DAB MAP detection kit. An anti-rabbit HRP (Ventana Medical
Systems, Tucson, AZ, USA) secondary antibody and the CHROMO MAP detection kit (Ventana Medical
Systems, Tucson, AZ, USA) was used for the caspase 3 staining. Slides were then counterstained with
hematoxylin and rinsed. Slides were manually dehydrated and coverslipped. Ki67 labelling index
was calculated as the percentage of Ki67 positive cells relative to the total number of cells within the
same crypts.
2.4.3. RNA Isolation and Quantitative Real-Time PCR
Total RNA was extracted after tissue homogenization in TRIzol® Reagent (Invitrogen, Cergy
Pontoise, France). Purification was performed with the RNeasy Mini Kit (Qiagen, Courtaboeuf,
France) and a DNase step (Qiagen, Courtaboeuf, France). After cDNA synthesis from mRNA using
a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Fisher Scientific, Illkirch,
France), quantitative real-time polymerase chain reaction (qRT-PCR) was performed (primer sequences
available on demand) with the Fast SYBR Green MasterMix (Applied Biosystems, Fisher Scientific,
Illkirch, France) and StepOne Real-Time PCR system (Applied Biosystems, Fisher Scientific, Illkirch,
France). Gene expression level was normalized relative to the normalizing gene HPRT and normalized
to day 7 group with 2−ΔΔCt calculation.
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2.4.4. Western-Blot Analysis
Frozen colonic tissue was homogenized in a lysis buffer [15], and 25 μg of total protein lysates were
loaded onto 4%–12% Criterion XT gel (Bio-Rad, Marnes-La-Coquette, France) before electrophoresis in
MOPS buffer (Bio-Rad, Marnes-La-Coquette, France). After transfer onto nitrocellulose membrane
and incubation in blocking solution (TBS pH 7.5, 0.05% Tween 20, and 5% (wt/vol) non-fat dry
milk), membranes were incubated overnight (4 ◦C) with rabbit ZO-1 antibody (1/250, 617300,
Invitrogen, Cergy Pontoise, France) or with mouse claudin-1 antibody (1/250, 374900, Thermo-Fisher
Scientific, Bedford, MA, USA) diluted in blocking solution. After three washes, blots were incubated
for 2 h at room temperature with an anti-rabbit or anti-mouse HRP-linked secondary antibody.
Revealing was performed using enhanced chemiluminescence (ECL system, Pierce Biotechnology,
Courtabœuf, France), and bands were quantified by densitometry using the FluorChem FC2 device
and the AlphaView software (Cell Biosciences, Santa Clara, CA, USA). GAPDH expression (Ab9484,
mouse monoclonal antibody, Abcam, Cambridge, UK) was used to ensure consistent protein loading
and transferring.
2.4.5. Evaluation of Adherent Mucosal Microbiota Composition
From the scrapped adherent-mucosa, bacterial DNA extracts were obtained by using the
PowerFecal DNA Isolation kit (MoBio Laboratories, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Specific regions of the bacterial 16S rDNA gene were amplified using
real-time qPCR. Eubacteria were quantified by real-time qPCR using specific primers (HAD-1:
5′-TGGCTCAGGACGAACGCTGGCGGC-3′ and HAD-2: 5′-CCTACTGCTGCCTCCCGTAGGAGT-3′),
annealing at 59 ◦C for total bacteria. In addition, the V3-V4 region amplification of the 16S rDNA
gene was performed and sent to the GenoToul platform (Castanet-Tolosan, France) for MiSeq Illumina
sequencing using the MiSeq kit V2 2 × 250 bp. Data quality check and analysis were performed using
the INRA-Migale server, as previously published [21]. In parallel, sulphate-reducing bacteria group
were quantified by real-time qPCR using specific primers targeting Dissimilatory Sulfite Reductase
A (DSR-1F: 5′-ACSCACTGGAAGCACGGCGG-3′ and DSR-R: 5′-GTGGMRCCGTGCAKRTTGG-3′),
Fast SYBR Green MasterMix (Applied Biosystems, Fisher Scientific, Illkirch, France) and StepOne
Real-Time PCR system (Applied Biosystems, Fisher Scientific, Illkirch, France).
2.5. Statistical Analysis
All statistical analysis were performed with R software version 1.0.143 (Boston, MA, USA).
For follow-up data, a mixed-model was used with mice as random effect while diet and time repeated
factor were used as fixed effects. From day 7, the mean of values for each diet were compared using
Bonferonni post-hoc tests. For parameters measured at euthanasia, Anova with diet as a fixed effect
was used and the means were compared using Bonferonni post-hoc tests. For all statistical tests,
the level of significance was set to p < 0.05. Principal component analysis (PCA) was performed on
family-level taxonomy to assess the influence of diet on the mucosa-adherent microbiota composition
at days 10, 13 and 28 as well as all times combined. The analysis of similarity (Anosim) test was
used to assess the correlation between the ecological distance (based on family composition) and diet
groups where an R-value of 0 indicates the highest dissimilarity possible and 1 indicates the highest
similarity possible.
3. Results
3.1. Dietary Protein Level Influences Colon Inflammation and Body Weight Recovery
High protein diets, which were introduced the day of the maximal inflammatory score (at day
7), did not influence mortality, which was similar between the three groups (12.5% per diet) from
day 3 to day 14. After an average of 14% BW loss, mild to severe diarrhoea and rectal bleeding,
disease activity index (DAI) started to decline after day 8 for P14 and P30 diets (Figure 2A), while a
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two-day delay was observed for P53 mice. In this latter group of animals, the DAI was systematically
two-point higher from day 9 to day 19 when compared to the other two diets (Figure 2A) due mainly
to higher stool consistency score. This was confirmed by the area under the curve (AUC) values,
even though P14 and P30 were not different between them (P14: 72.6 and P30: 71.03 AUC of DAI
measured between 0 and 28 days, NS), both were statistically different from P53 (45.8 AUC of DAI for
28 days, vs P14 and P30, p < 0.01). In addition, P30 mice recovered their fat mass more rapidly than
with the two other diets (P14: 33.9, P30: 49.2 and P53: 23.0 AUC of fat percentage evolution between
days 7 and 26, p < 0.001) (Figure 2B). These differences were not related to the global energy intake
level, since diet intake per day was similar whatever the diet (data not shown). P14 and P30 fed-mice
presented a similar level of inflammation based on colon MPO activity (Figure 2C) and IL-6 and IL-1β
concentrations (Figure 2D) but these inflammatory biomarkers were higher in P53-fed mice. Colonic
MPO activity was indeed significantly increased at day 28 for P53 mice compared to P30 (Figure 2C),
as well as the pro-inflammatory cytokines at day 10 and at day 28 for IL-1β (Figure 2D). However, the
overall histological score (based on crypt damage, ulceration and erosion, goblet cell depletion and
cell infiltration) which showed high inter-individual variability, was not different between groups
whatever the time (Figure 3A). Although the histological score was significantly reduced for all the
groups when compared to day 7 (9.3 ± 1.4, p < 0.05), some histological abnormalities persisted for all
dietary groups at day 28.
Figure 2. Effects of dietary protein intake level on inflammatory parameters at after 3 (D10), 6 (D13)
or 21 days (D28) of dietary intervention with P14, P30 or P53 diet. (A): Disease activity index scoring
evolution during time. #: p < 0.05 DSS P53 vs P14 and P30 at the same time point. (B): Evolution of fat
mass (percentage vs baseline). ‡: p < 0.05 DSS P53 vs P30 at the same time point. (C): Colonic MPO
activity. (D): Colonic concentrations of the pro-inflammatory cytokines IL-6 and IL-1β. Values are
means ± SEM (n = 9–12). Means that are significantly different (p < 0.05) according to the post-hoc test
have different letters (a or b or c or d). *: p < 0.05; ***: p < 0.001; NS: non-significant difference.
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Figure 3. Effects of dietary protein intake on colon histomorphology after 3 (D10), 6 (D13) or 21 days
(D28) of dietary intervention with P14, P30 or P53 diet. (A): Histological score. (B): Colon crypt length.
(C): Cell numeration. (D). Representative illustrations of longitudinal colonic sections immunostained
with an anti-Ki67 antibody. (E): Percentage of proliferation (Ki67-positive cells/total number of cells
per crypt) at day 10. Values are means ± SEM (n = 9–12). Means that are significantly different (p < 0.05)
according to the post-hoc test have different letters (a or b or c or d). *: p < 0.05; **: p < 0.01; ***: p < 0.001;
NS: non-significant difference.
3.2. P30 Diet Enhances Epithelial Repair Features
P30 mice showed a significant thickening of the colonic wall at day 10 (colon weight/length
ratio: 0.037 ± 0.002) when compared to day 7 (P30: 0.025 ± 0.002, p = 0.0059) and to P14 diet (P14:
0.030 ± 0.002, p = 0.0142). P30-fed mice were indeed the only group which recovered initial colonic
length at day 28 (day 0: 6.50 ± 0.17 cm vs day 28 P30: 5.98 ± 0.16 cm, NS) contrastingly to other dietary
protein groups (5.70 ± 0.20 cm). This increase in colon weight and length corresponded to a higher
crypt height and a higher number of nuclei per crypt in P30 mice than in the P14 group at day 10
(Figure 3B,C). The percentage of Ki67 positive cells was greater in the colonic tissue of P30 mice (vs
P14, p = 0.0467), as illustrated in Figure 3D although 30% of the mucosa surface on average was devoid
of crypts in all groups at day 10, and the number of caspase 3 positive cells was significantly reduced
in P30 mice when compared to the other two diets (P30: 0.21 ± 0.07 vs P14: 0.70 ± 0.26 and P53:
0.98 ± 0.26 positive cells per crypt, p < 0.05). These epithelial morphometric changes coincided with
increased gene expression of the epithelial repair factor Tgf-ß1 in P30-fed mice (Table 2). Interestingly,
the gene encoding Gpx2, which protects intestinal tissue against oxidative damage, displayed an
increased expression in P30 mice at day 10 (P30: 1.21 ± 0.21 vs P14: 0.78 ± 0.06 and P53: 0.51 ± 0.12,
p < 0.05). In addition, the genes encoding Tff3, colonic Saa (Serum Amyloid A) and Il-15 were also
higher compared to P14 at day 13 (Table 2).
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3.3. P30 Diet Improves Dss-Induced Barrier Function Alterations
Interestingly, FD4 challenge showed an intestinal permeability reduction for animals receiving
a P30 diet at days 9 and 12 compared to the P14 group (Figure 4A) and this was confirmed at the
colon level where FD4 flux measured in a Ussing chamber was decreased in P30 mice (7119 ± 507 FU)
when compared to P14 (9945 ± 303 FU) at day 10 (p = 0.014). This reduction of DSS-induced colon
permeability was associated with lower LBP plasmatic concentrations at days 13 and 28 compared
to P14 and P53 groups (Figure 4B). In addition, the gene expression of the tight-junction proteins
Cldn1 and Ocln was differentially modulated by dietary protein intake. Indeed, Cldn1 gene expression
was increased by P30 at days 10 and 13 while Ocln increased at days 13 and 28 (Table 2). This result
of Cldn1 expression has been confirmed by western blotting (Figure 4A), where Claudin-1 protein
level was higher in P30 colon at day 13. Moreover, ZO-1 was more expressed at day 13 in P30 mice,
when compared to the other two groups, although no significant difference at the gene expression level
was detected (Tjp1, Table 2) and inter-individual variability was seen (Figure 4C). In addition, the level
of dietary protein intake modulated colonic gene expression of several mucins. Indeed, both HP diets
increased mRNA expression of the transmembrane mucin Muc3 at day 13 and the main gel-forming
mucin Muc2 at day 28 (which was also increased at day 13 by the P53 diet only). In contrast, neither
Muc1 nor Muc4 were affected by the diet (Table 2).
 
Figure 4. Effects of dietary protein intake level on barrier function after dietary intervention with
P14, P30 or P53 diet. (A): Evolution of plasmatic FD4 concentration. (B): Plasmatic concentration of
LPS-binding protein (LBP). (C): Western-blot analysis of the tight junction proteins Zona Occludens-1
and Claudin-1, was performed in colonic homogenates of day 13 mice. GAPDH was used as loading
control. Images are representative of four Western blots. Means that are significantly different (p < 0.05)
according to the post-hoc test have different letters (a or b or c). Values are means ± SEM (n = 10–12).
*: p < 0.05; **: p < 0.01; ***: p < 0.001; NS: non-significant difference.
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3.4. DSS-Induced Dysbiosis is not Alleviated by Diet, but P30 Diet Increases the Proportions of
Butyrate-Producing Bacteria
DSS-induced dysbiosis was not resolved within 28 days, whatever the diet (Table 3). Diversity
and richness were still lower than at day 0 (6.46 ± 0.07 and 794 ± 55.2 for Shannon and Chao indexes,
respectively) and similar to day 7 (4.75 ± 0.32 and 633 ± 43.7, for Shannon and Chao, respectively).
Only the Simpson index was significantly less decreased in P30 group at day 10 when compared to the
two other diets. In addition, the number of observed OTUs at day 13 was significantly decreased in
P53 mice compared to P30 (Table 3).
The overall microbiota composition at the phylum level for each dietary group is shown in
Figure 5A and the data describing microbial composition similarities based on family were compared
between the diet groups with PCA with the three diet groups as classifying variables (Figure 5B–D).
At day 10, mucosa-adherent microbial samples clustered by diet groups, as evidenced by their
significant ecological distance (R = 0.32, p < 0.001) (Figure 5B). P53 group was mostly explained
by Clostridiales (Firmicutes), Enterobacteriaceae (Proteobacteria), Rikenellaceae and Porphyromonaceae
(Bacteroidetes) versus Eubacteriaceae (Firmicutes) and Bifidobacteriaceae (Actinobacteria) for P30 group
(Figure 5B). Haemophilus (Proteobacteria) and Alloprevotella (Bacteroidetes) proportions were statistically
increased in P53 mice at day 10 while Desulfovibrio (Proteobacteria), an H2S producer, showed a higher
abundance at day 10 for P30 and P14 diets (vs P53, p < 0.05) (Table 3). However, the quantification of
total sulphato-reducing bacteria did not indicate differences at any time for any diet (data not shown).
Interestingly, the Bacteroides genus relative percentage was reduced in the P30 group (vs P14 and P53,
p < 0.001) while caecal SCFA concentrations were higher (Table 3).
 
Figure 5. Effects of dietary protein intake on mucosa-associated microbiota composition after 3 (D10),
6 (D13) or 21 days (D28) of dietary intervention with P14, P30 or P53 diet. (A). Relative abundance
percentages of bacterial phyla in mucosa-adherent microbiota a: vs P14, p < 0.05 at the same time. Due
to low relative proportions, Tenericutes is not visible in the figure. (B–D): Principal coordinate analysis
on family relative abundances of mucosa-adherent microbiota at day 10 (B), day 13 (C) and day 28 (D).
55





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2019, 11, 514
Although Firmicutes phylum proportions remained stable and similar to day 0 (Figure 5) whatever
the time and the diet, Clostridium_XIVa and Faecalibacterium proportions were higher in P30 group
than in P53 at day 13 (p = 0.005) (Table 3). In contrast to day 10, Bacteroidetes relative abundance was
higher with both P30 and P53 diets owing to increased proportions of Bacteroides genus. Moreover,
Haemophilus had increased proportions in the P53 group when compared to the P14 group at day 13, as
well as Enterorhabdus (Actinobacteria) (Table 3).
At day 28, the impact of dietary protein intake on mucosal-adherent composition was less marked
between groups (Figure 5D) especially between P14 and P30 groups (Table 3). However, Actinobacteria,
which proportions stayed low before day 28 (day 0–day 13: 0.1%) (Figure 5A), were two-fold higher in
P30 (P30: 3.1% vs P14: 1.4%, p = 0.014) and in the P53 group, the proportion of Bifidobacteriaceae being
increased in that latter group (p = 0.021, P14: 0.60 ± 0.28%, P30: 1.70 ± 0.83% and P53: 0.93 ± 0.36%).
In addition, the protein intake modulated microbiota activities since total caecal SCFA concentrations
increased in both HP groups at day 28. Although Deferribacteres proportion was reduced for the three
diets when compared to days 10 and 13, reaching day 0 level (3.7 ± 1.0%, NS vs day 28 whatever the
diet), no other major differences at the phylum level were recorded. Interestingly, Lachnospiraceae
family (Firmicutes) relative proportion at day 28 was greater than the one at day 7 (day 7: 13.48 ± 2.91%
vs day 28: 24.22 ± 1.82%, p = 0.0184). Moreover, higher proportions of Faecalibacterium (Clostridiaceae)
(vs P53) and Roseburia (vs P53 and P14) in P30 group were observed at day 28 (Table 3). Contrastingly,
P53 microbiota composition showed again noticeable taxonomic differences compared to P14 and
P30 mice, with increased abundance of the genera Porphyromonas, Ethanoligenens and Haemophilus
contrasting with a decreased abundance of Bacteroides (Table 3).
4. Discussion
The present study showed that the level of dietary protein intake differentially modulated mucosal
healing after an acute colon inflammatory episode. While the P53 diet worsened both the intensity
and duration of the inflammation induced by DSS treatment, the P30 diet, when compared to P14 diet,
accelerated epithelial repair by favoring the restoration of colon barrier architecture and function.
P30 diet indeed induced crypt hyperproliferation associated with increased gene expression of
the repairing factors Tgf-ß1 and Tff3, both factors being known to contribute to the integrity of mucosal
surface continuity but in an independent manner [22]. In addition, Saa, which was over-expressed
in P30 mice compared to the two other diets, was recently described as a protective factor against
colon epithelium acute injury [23]. Altogether, the increased expression of genes encoding these
promoting repair factors as well as tight-junction proteins (Claudin-1 and Zona-Occludens 1), likely
contributed to the restoration of colon barrier integrity, as evidenced by lower permeability and
bacterial translocation-related marker (LBP) in the systemic flow. Additionally, an increased mRNA
level of Gpx2, which upregulation is associated with inflammation resolution [24], suggests a lower
inflammation-induced oxidative stress in P30 animals. Furthermore, the P30-mediated positive effects
on epithelial repair might be related to a modulation of the mucosa-adherent microbiota composition
and activities within the first days of colitis resolution. Indeed, the higher relative abundance of
bacteria belonging to Lachnospiraceae, Eubacteriaceae and Bifidobacteriaceae families, together with higher
concentrations of SCFAs, the major end products of microbiota metabolic activity, may partly explain
the beneficial impact of P30 diet on colon mucosa. Interestingly, the P30 diet also longitudinally
increased the proportion of Faecalibacterium, a commensal butyrate producer, detected in healthy
subjects, whose abundance is reduced in IBD patients and is positively correlated with the maintenance
of clinical remission [25,26]. Butyrate is well known to be a major fuel for colonic epithelial cells,
to exert pluripotent effects on the colon such as the regulation of cell growth and differentiation [27],
and to present anti-inflammatory properties [28]. Butyrate deficiency in its concentrations and/or in
its transport and metabolism has been indeed observed in the inflamed mucosa [29].
Although minor differences in mucosa-adherent bacterial composition were noticed between the
animals fed with P14 or P30 diets in the week following the acute colitis episode (with the notable
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exception regarding the Bacteroides proportion), bacterial populations were severely modulated in P53
mice compared to the two other diets. Indeed, P53 diet consumption in DSS-treated mice decreased
the proportions of butyrate-producing bacteria from Clostridium XIVa, Faecalibacterium and Roseburia
genera in the mucosa-adherent microbiota. P53 diet-fed mice were also characterized by an increased
representation of families and genera previously reported in IBD patients during flares [30,31] such
as Alloprevotella, Ethanoligenens, Klebsiella, Porphyromonas and Haemophilus. In parallel, Desulfovibrio,
an H2S producer, was reduced in P53 diet-fed mice as recently reported in the faecal microbiota
recovered from UC patients [31], whereas the quantification of sulphato-reducing bacteria was not
different between diets. This latter result is somewhat unexpected since an increased protein content
in the diet is associated with a higher faecal H2S concentration [32]. However, substrate availability,
microbiote composition and metabolic activity are major parameters for fixing the production of
bacterial metabolites [13], and other AA-derived bacterial metabolites that are known to exert
deleterious effects on intestinal epithelial cells when present in excess, such as ammonium, p-cresol
or hydrogen sulphide [9,33–35], that might have been over-produced in P53-fed mice. Our study
is in accordance with Llewellyn et al. study that shows that the level of dietary proteins has an
impact on colitis severity that is associated with changes in microbiota composition [36]. In this study,
the authors have shown that a high-protein diet (41%) enhanced disease progression when compared
to a low-protein diet (6%). However, comparison between this study and ours should take into account
the important experimental designs differences, which were the quantity and quality of proteins in the
diets. Indeed, we used a mix of milk proteins containing both whey and caseins (20:80) to mimic cow
milk composition, while Llewellyn et al. used casein as the only protein source. Furthermore, diets were
provided one week prior to the DSS administration, whereas we started to give our different diets
after colitis induction at day 7. Other studies, outside the scope of the present work, are necessary for
determining more precisely the changes in the luminal environment in each experimental conditions.
Such changes may partly explain that P53-fed mice showed a higher inflammation state but a level of
epithelial crypt repair similar to P30-fed mice. Consequently, in addition to the quantity, the source of
dietary proteins may modulate the IBD course [37,38] although association between protein intake
and IBD risk has not been found in all studies [39,40], highlighting the urgent need for human studies
to decipher the role of quantity and source of dietary proteins in IBD.
Furthermore, the reduction of carbohydrate supply in the diet may also influence colon healing.
Indeed, P30 diet proportions might be more suitable to cover the requirements of macronutrients
(both carbohydrates and proteins) to sustain the metabolic activity of cells [41] and synthesis
of macromolecules involved in epithelial repair and restoration of barrier integrity. Additional
experiments, such as the measurement of colon mucosal cell bioenergetics and protein synthesis
during acute inflammation and following mucosal healing, would help to decipher these points.
5. Conclusions
Our results fit with the view that an optimized epithelium repair after an acute inflammatory
episode can be obtained through the supply of an appropriate amount of dietary protein. It indeed
depends upon a balance between the AA originating from dietary and endogenous proteins, which are
available from the blood supply for mucosal healing, and the gut microbial activity towards undigested
protein that enters the colon. Our study showed that a moderately high dietary protein intake during
a post-inflammatory phase appears beneficial to speed up the restoration of the intestinal mucosa
integrity when compared to a normoproteic diet, by affecting several key parameters associated
with inflammation and healing during and after the inflammatory flare in the DSS model of colitis.
In contrast, a further increase in the dietary protein amount appears counter-productive for such a
process. As such, our experimental study is in accordance with the need for an increased protein intake
during active IBD [7] but suggests that a threshold protein intake value should be not exceeded to
avoid deleterious effects on the patients’ inflamed mucosa.
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Abstract: Under physiological conditions, the small intestine represents a barrier against harmful
antigens and pathogens. Maintaining of the intestinal barrier depends largely on cell–cell interactions
(adherent-junctions) and cell–matrix interactions (tight-junctions). Inflammatory bowel disease is
characterized by chronic inflammation, which induces a destructuring of the architecture junctional
epithelial proteins with consequent rupture of the intestinal barrier. Recently, a peptide identified by
Bubalus bubalis milk-derived products (MBCP) has been able to reduce oxidative stress in intestinal
epithelial cells and erythrocytes. Our aim was to evaluate the therapeutic potential of MBCP in
inflammatory bowel disease (IBD). We studied the effect of MBCP on (i) inflamed human intestinal
Caco2 cells and (ii) dinitrobenzene sulfonic acid (DNBS) mice model of colitis. We have shown
that MBCP, at non-cytotoxic concentrations, both in vitro and in vivo induced the adherent epithelial
junctions organization, modulated the nuclear factor (NF)-κB pathway and reduced the intestinal
permeability. Furthermore, the MBCP reverted the atropine and tubocurarine injury effects on
adherent-junctions. The data obtained showed that MBCP possesses anti-inflammatory effects both
in vitro and in vivo. These results could have an important impact on the therapeutic potential of
MBCP in helping to restore the intestinal epithelium integrity damaged by inflammation.
Keywords: intestinal inflammation; inflammatory bowel disease; epithelial adherens junctions;
bioactive peptides
1. Introduction
Inflammatory bowel disease (IBD) is a term used to describe conditions that are characterized
by chronic inflammation of the gastrointestinal tract. Crohn’s disease and ulcerative colitis are the
principal types of inflammatory bowel disease. Worldwide, the prevalence and incidence of IBD is
increasing mainly in newly industrialized countries whose societies have become more Westernized [1].
Although the etiology of IBD is still unknown, it arises as a result of the interaction of environmental
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or genetic factors and the immune responses [2]. IBD treatment involves the use of anti-inflammatory
drugs (such as 5-aminosalicylic acid), corticosteroids, monoclonal antibodies [anti-tumor necrosis
factor (TNF)-α antibodies] and vascular adhesion molecules [2,3] (anti-integrin antibodies). However,
these drugs are not curative therapies and are mainly used as induction and maintenance therapy.
Moreover, for most of these drugs, a high inter-individual variability in a positive response has been
reported [3]. Therefore, it is essential to find clinical efficacious alternatives for the treatment of
inflammatory bowel disease (IBD). Recently, intestinal permeability has been recognized as a new
target for IBD prevention and therapy [4,5]. In physiological conditions, the intestinal epithelium
selectively absorbs nutrients and represents an efficient barrier to noxious antigens and pathogens.
Disruption of the intestinal barrier has been considered a major factor in several inflammatory
intestinal diseases [6]. The architecture and function of the intestinal epithelium requires close
coordination between enterocyte proliferation and apoptosis, both highly dependent on cell–cell and
cell–matrix interactions. Enterocytes are joined to each other by tight junctions and adherens junctions.
The main molecular component of the adherens junctions is E-cadherin, a transmembrane protein
with five extracellular domains that interdigitate with those of an adjacent cell in a calcium-dependent
homophilic manner to form a continuous linear “zipper” structure [7,8]. E-cadherin exerts functional
adhesion activity when it is connected to the actin cytoskeleton by the cytoplasmic complex α-,
β-, or γ-catenin in a mutually exclusive manner [7,8]. It is well established that, in IBD patients,
these junctional complexes undergo a disruption leading to a breaking of the intestinal barrier [9].
Moreover, mucosal biopsies from patients with IBD have increased levels of cytokines, able to regulate
intercellular permeability, such as interferon-gamma (IFN-γ) and tumor necrosis factor (TNF-α), have
been observed [10].
Buffalo (Bubalus bubalis) milk is a source of many bioactive peptides that have been demonstrated
to play a relevant role in preventing various disorders [11–14]. These bioactive peptides are mainly
released during gastrointestinal digestion of milk and milk-products. Recently, novel peptides have
been identified from buffalo milk-derived products (MBCP) that are able to reduce H2O2-induced
oxidative stress in intestinal epithelial cells and in erythrocytes [15,16]. Among these, MBCP,
a peptide isolated from the buffalo milk after in vitro digestion of Mozzarella di Bufala Campana
DOP, has demonstrated possession of a good stability to brush border exopeptidases and a high
bioavailability [16]. In this paper, we evaluated the therapeutic potential of MBCP in IBD. For this
purpose, we investigated the effect of MBCP on (i) adjacent junctions conformation and permeability
under inflammatory conditions in an intestinal epithelial cell line, Caco-2 cells and (ii) intestinal
inflammation and the associated changes in motility in mice.
2. Material and Methods
2.1. Peptide Synthesis
MBCP was synthetised using the solid-phase method and purified via HPLC after deprotection,
as previously described [16]. MBCP was dissolved in water for in vitro and in vivo experiments.
2.2. Drugs and Reagents
2,4,6-dinitrobenzenesulfonic acid (DNBS), croton oil, fluorescein isothiocyanate (FITC)-conjugated
dextran (molecular mass 3–5 kDa), betamethasone, atropine, tubocurarine and neutral red (NR)
solution were purchased from Sigma (Milan, Italy). TNF-α was obtained from R&D Systems, Space
Import-Export SRL (Milano, Italy). All reagents for cell cultures were obtained from Sigma, Bio-Rad
Laboratories (Milan, Italy) and Microtech Srl (Naples, Italy). All chemicals and reagents employed in
this study were of analytical grade.
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2.3. Cell Culture
Caco-2 cells (American Type Culture Collection, Rockville, MD, USA), a human colorectal
adenocarcinoma epithelial cell line, were grown at 37 ◦C in a 5% CO2 atmosphere in h-glucose
Minimum essential medium MEM containing 1% non-essential amino acids and supplemented with
10% de-complemented fetal bovine serum (FBS), 100 U·mL−1 penicillin, 100 mg·mL−1 streptomycin,
1% L-glutamine and 1% sodium pyruvate. The growth of the cells was measured by counting the cells
with a Coulter counter (Nexcelom, Lawrence, MA, USA, Cellometer Auto1000). All experiments were
performed in triplicate.
2.4. Animals
Male adult ICR mice, weighing 20–25 g for upper gastrointestinal transit experiments and 25–30 g
for colitis experiments, were purchased from Charles River Laboratories (Calco, Lecco, Italy) and
housed in polycarbonate cages under controlled temperature (23 ± 2 ◦C), constant humidity (60%)
and a 12 h light/dark cycle. The animals were acclimatized to their environment at least 1 week under
the above reported standard conditions with free access to tap water. Mice were fed ad libitum with a
standard rodent diet, except for the 24 h immediately before the intracolonic administration of DNBS
or the oral administration of the charcoal meal and for 2-h before the oral gavage of croton oil or
MBCP. Mice were randomly allocated to different experimental groups and outcome assessments
were performed in single-blind. All experiments were approved by the Institutional Animal Ethics
Committee for the use of experimental animals and conformed to guidelines for the safe use and care
of experimental animals in accordance with the Italian D.L. no. 116 of 27 January 1992 and associated
guidelines in the European Communities Council (86/609/ECC and 2010/63/UE).
2.5. Cytotoxicity Studies
We evaluated the effect of MBCP on Caco-2 cell viability by using a microplate colorimetric assay
that measures the ability of viable cells to incorporate and bind the neutral red (NR), a weak cationic
dye, in lysosomes. Cells were plated at the appropriate density to obtain a model of undifferentiated
and differentiated cells; then, 5 × 103 and 20 × 103 cells per well in 96-well plates for undifferentiated
and differentiated cells, respectively. After 24 hours, cells were exposed to various concentrations of
MBCP (9–375 μM) for 48-h. Then, cells were incubated with NR dye solution (50 μg/mL) for 3-h at
37 ◦C, and finally washed with phosphate buffered saline (PBS) and lysed with 1% acetic acid. The
absorbance was read at 540 nm (iMarkTM microplate reader, Bio-Rad, Milano, Italy).
2.6. Alkaline Phosphatase (ALP) Activity
ALP activity was used as marker of the degree of differentiation of human Caco-2 cells. Attached
and floating cells were washed and lysed with 0.25% sodium deoxycholate. ALP activity was
determined using Sigma Diagnostics ALP reagent (no. 245). Total cellular protein content of the
samples was determined in a microassay procedure using the Coomassie protein assay reagent kit
(Pierce). ALP activity was calculated as nmol/min/mg of protein.
2.7. Western Blotting
For cell extract preparation, the cells were washed twice with ice-cold PBS/bovine serum albumin
(BSA), scraped and centrifuged for 30 min at 4 ◦C in 1 mL of lysis buffer (1% Triton, 0.5% sodium
deoxycholate, 0.1 M NaCl, 1mM Ethylenediamine tetra-acetic acid (EDTA), pH 7.5, 10 mM Na2HPO4,
pH 7.4, 10 mM Phenylmethyl sulfonyl fluoride, 25 mM benzamidin, 1 mM leupeptin, 0.025 units/mL
aprotinin). Colon tissue were lysed in a specific buffer (1% NP-40, 0.1% SDS, 100 mM sodium
ortovanadate, 0.5% sodium deoxycholate in RIPA buffer) in the presence of protease inhibitors
(4 mg/mL of leupeptin, aprotinin, pepstatin A, chymostatin, PMSF and 5 mg/mL of chymotrypsin-like
proteases (TPCK)). The homogenates were sonicated twice by three strokes (20 Hz for 20 s each); after
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centrifugation for 30 min at 10,000× g, the supernatants were stored at 80 ◦C. Equal amounts of cell
and tissues proteins were separated by SDS-PAGE, electrotransferred to nitrocellulose and reacted with
the different antibodies. Blots were then developed using enhanced chemoluminescence detection
reagents (SuperSignal West Pico, Pierce) and exposed to X-ray film. All films were scanned by using
Quantity One software (BioRad laboratories, Hercules, CA, USA).
2.8. Immunostaining and Confocal Microscopy
After 24-h and 48-h of incubation with TNF-α (10 μM), TNF-α plus MBCP (18 μM) or TNF-α
plus betamethasone (10 μM), Caco-2 cells were fixed for 20 min with a 3% (w/v) paraformaldehyde
solution and permeabilized for 10 min with 0.1% (w/v) Triton X-100 in PBS at room temperature.
To prevent nonspecific interactions of antibodies, cells were treated for 2 h in 5% BSA in PBS. In another
set of experiments, Caco-2 cells were treated with the acetylcholine receptor antagonists atropine
(10 μM) and tubocurarine (10 μM) for 6-h. Immunostaining was carried out by incubation with
anti-E-cadherin, anti-actin and anti-β-catenin antibodies (1:500, Alexa Fluor®, BD PharmingenTM).
The slides were mounted on microscope slides by Mowiol. The analyses were performed with a
Zeiss LSM 510 microscope equipped with a plan-apochromat objective X 63 (NA 1.4) in oil immersion.
The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI).
2.9. Permeability Assay on Caco-2 Cells
To evaluate cell permeability, Caco-2 cells were seeded into a transwell filters with a pore diameter
of 8 μm in 24-well plates at a density of 2.0 × 105 cells/insert. Further cultivation in the same medium as
above allowed the cells to spontaneously differentiate and polarize into the epithelial monolayer within
21 days. The basolateral compartment contained 1.5 mL of culture medium while apical compartment
contained 0.2 mL. After seeding, the cells were treated with 0.07 μM of MBCP. The culture medium was
replaced 3 times/wk. After 21 days, the filters containing the cell monolayers (with or without MBCP)
were treated for 2 h with TNF-α (10 μM) and then with a mannitol-lactulose solution (0.05 mmol/L,
0.25 mol/L, 0.2 mL). After 3 hours, the basolateral solution was collected and both mannitol and
lactulose concentration were measured by liquid chromatography-mass spectrometry (LC-MS).
2.10. Induction of Experimental Colitis
Colitis was induced in the anesthetized mice by the intracolonic administration of
2,4,6-dinitrobenzene sulfonic acid (DNBS) as previously described [17]. Briefly, DNBS (150 mg/kg),
dissolved in 50% ethanol (150 μL/mouse), was administrated into the distal colon using a polyethylene
catheter (1 mm in diameter) via the rectum (4.5 cm from the anus). Three days after the DNBS
administration, all mice were euthanized by asphyxiation with CO2, the mice abdomen was opened
by a midline incision and the colon removed, isolated from surrounding tissues, length measured,
opened along the antimesenteric border, rinsed and weighed and then fixed in 10% formaldehyde for
histopathological analysis. MBCP was administrated by oral gavage (10–100 mg/kg) once a day for
3 consecutive days starting 24 h after DNBS administration. Animals were euthanized 2 hours after
the last administration of MBCP.
2.11. Haematoxylin-Eosin Staining
Paraffin-embedded colon tissues were cut into 5-mm sections. The sections were dewaxed
in xylene for 10 min and dehydrated in gradient alcohol. The sections were then stained with
haematoxylin for 8 min and eosin for 5 min. After dehydration, the sections were sealed and examined
under a light microscope (Leica DM 2500). Photographs were taken using the Leica DFC320 R2 digital
camera [18].
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2.12. Immuno-Fluorescence Microscopy
The fixed slides of colon tissue, were dewaxed, rehydrated and processed. Briefly, antigen retrieval
was performed by pressure-cooking slides for 3 min in 0.01 M citrate buffer (pH 6.0). To prevent
nonspecific interactions of antibodies, the slides were treated for 2 h in 5% BSA in PBS. Immunostaining
was carried out by incubation, overnight at 4 ◦C, with anti-E-cadherin and anti-β-Catenin antibodies
(1:100, Alexa Fluor®, BD PharmingenTM). The slides were mounted on microscope slides by Mowiol
+ DAPI for nuclear staining, and then observed under the optical microscope (Leica DM 5000 B +
CTR 5000).
2.13. Intestinal Permeability Measurement
The effect of MBCP, at a dose of 100 mg/kg, was also tested on intestinal permeability, using
the FITC-Dextran method.Briefly, 2 days after the induction of colitis, mice were gavaged with
600 mg/kg of FITC–conjugated dextran (molecular mass 3–5 kDa). After 24 h, blood was collected
by cardiac puncture, and the FITC-derived fluorescence was immediately analyzed in the serum
by a microplate reader (GloMax Explorer System, Promega; excitation wavelengths 485 ± 14 nm,
emission wavelengths 520 ± 25 nm). Serial-diluted FITC dextran was used to generate a standard
curve. Intestinal permeability was expressed as the concentrations of FITC (μM) detected in the serum.
2.14. Induction of Intestinal Hypermotility and Upper Gastrointestinal Transit in Mice
Upper gastrointestinal transit was measured in both physiological and pathological conditions.
The hypermotility was induced by the inflammatory agent croton oil (CO) as previously described [19].
Briefly, two doses of CO (20 μL/mouse) were given for two consecutive days by oral gavage and
the upper gastrointestinal transit was measured 4 days after the first administration of CO [20] (i.e.,
when the maximal inflammatory response associated to the intestinal hypermotility was reported).
Mice were deprived of food overnight and then the upper gastrointestinal transit was evaluated by
identifying the leading front of an intragastrically administered charcoal meal marker (10% charcoal
suspension in 5% gum Arabic, 10 mL/kg) in the small intestine as previously described [19]. Twenty
minutes after charcoal administration, mice were euthanized and the small intestine was isolated by
cutting at the pyloric and ileocaecal junctions. The distance traveled by the marker was measured and
expressed as a percentage of the total length of the small intestine from pylorus to caecum. MBCP was
administrated by oral gavage (5–50 mg/kg) 30 min prior to charcoal administration.
2.15. Statistical Analysis
Data are expressed as the mean ± S.E.M. or S.D. of n experiments. Statistical significance was
assessed using the Student’s t-test for comparing a single treatment mean with a control mean, and a
one-way ANOVA followed by a Tukey multiple comparisons test for the analysis of multiple treatment
means. Values of p < 0.05 were considered significant. The IC50 (concentration that produced 50%
inhibition of cell viability) values were calculated using sigmoidal dose response curve-fitting models
(Graphpad Prism Software, version 5.03, Inc. Avendia de la Playa La Jolla, CA, USA).
3. Results
3.1. In Vitro Study
3.1.1. MBCP Induces Cytotoxic Effects in Caco-2 Cells at Very High Concentrations
In order to characterize a safety profile of MBCP, we evaluated its effect on the cell viability of
pre- (undifferentiated exponentially growing) and post-confluent (differentiated) Caco-2 cells. MBCP
(9–375 μM), induced in undifferentiated and differentiated Caco-2 cells, a concentration-dependent
cell viability inhibition at 48 h with an IC50 of 65 μM (Figure 1). Therefore, to characterize the
anti-inflammatory effects of MBCP on Caco-2 cells, subsequent experiments were performed using a
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MBCP concentration that did not induce significant cytotoxic effect in both pre and post-confluent
cells (i.e., 18 μM).
Figure 1. MBCP reduces cell viability in Caco-2 cells. Cell viability was evaluated by the Neutral Red
assay in pre and post-confluent Caco-2 cells. Cells were incubated with increasing concentration of
MBCP (9–375 μM) for 48 h. Each point represents the mean ± SD of three independent experiments.
3.1.2. MBCP Stimulates Differentiation in Growing Caco-2 Cells
The effect of MBCP on cell differentiation was evaluated by measuring the activity of alkaline
phosphatase, with the enzyme frequently used as a marker of colon cells differentiation [21].
A treatment of undifferentiated Caco-2 cells with MBCP (18 μM for 48 h) induced a significantly
increase (p < 0.05) of alkaline phosphatase activity (APA) of about 14% compared to the untreated
Caco-2 cells (control). The APA value was in the Caco-2 cells of 8.6 ± 0.4 (nmol/min/mg protein),
while, in MBCP treated Caco-2 cells, it was 10 ± 0.7 (mean ± SD, n = 3, * p < 0.05)
3.1.3. MBCP Modulates Adherent Junctions Formation in Control and TNF-α-Stimulated Caco-2 Cells
In order to investigate the role of MBCP on adherent junctions (AJs) formation, we studied the
cellular organization of E-cadherin and actin in pre-confluent Caco-2 cells by confocal miscroscopy.
Caco-2 cells, after 24 h from seeding, showed a strong cytoplasmic localization of both E-cadherin and
actin proteins (Figure 2A–C) that was ameliorated by MBCP treatment (Figure 2D–F). At 48 h, the
E-cadherin-actin complex presented a not homogeneous membranous localization in untreated Caco-2
cells (Figure 2G–I). MBCP treatment induced a strong cell–cell contact membranous localization of
E-cadherin-Actin complex (Figure 2M–O).
To assess whether MBCP could counteract the AJ-destructuration induced by the
pro-inflammatory mediator TNF-α, we examined the β-catenin organization in TNF-α-stimulated
cells. Caco-2 cells treated with TNF-α (10 μM, for 48-h) showed a cytoplasmic compartment β-catenin
localization (Figure 3D–F) compared to untreated cells (CTR) (Figure 3A–C). A treatment of Caco-2
cell with MBCP (18 μM) induced an enhancement of both E-cadherin and β-catenin localization
at AJs (Figure 2G–I) compared to TNF-α alone. Since corticosteroids are the effective first-line
treatment in cytokine-induced inflammation, we treated the Caco-2 cells (stimulated with TNF-α) with
betamethasone. Betamethasone (10 μM) treatment induced a membranous E-cadherin and β-catenin
organization, although a β-catenin cytoplasmic immunoreactivity persisted (Figure 3L–N). In our
experimental conditions (Caco-2 cells treated or not with TNF-α), MBCP accelerated and induced an
organization of adjacent junctions in the cells, without changes the E-cadherin, actin and β-catenin
protein expression evaluated by Western blot analysis (data not shown).
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Figure 2. MBCP accelerates the formation of adherens junctions. Confocal microscopy images of
Caco-2 cells (A–C,G–I) and MBCP treated Caco-2 cells (panel (D–F,M–O). Cells were treated for 24-h
and 48-h with MBCP at 18 μM concentration. The merged image is on the right (green, actin; red,
E-cadherin; blue, dapi).
Figure 3. MBCP ameliorates the adherens junctions destructured by TNF-α. Confocal microscopy
images of untreated Caco-2 cells (panel (A–C), Caco-2 cells treated for 48 h with TNF-α (10 μM, (D–F)),
TNFα 10μM plus MBCP (18 μM, (G–I)) or with TNF-α (10 μM) plus betamethasone (L–N). On the
right, merged image (green, β-catenin; red, E-cadherin; blue, dapi).
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3.1.4. MBCP Counteracts the TNF-α Inflammatory Effect by Modulating the NF-κB Pathway
It is well known that TNF-α causes the activation of transcription factors, including NF-κB.
NF-κB regulates host inflammatory, immune responses and also stimulates the expression of inducible
cyclooxygenase enzymes (COX-2) that contribute to the pathogenesis of the inflammatory process.
Therefore, we evaluated, by Western blot analysis, the effects of MBCP on NF-κB, pNF-κB, COX-2 and
5-Lipoxygenases (LOX) expression in TNF-α treated Caco-2 cells. A treatment with TNF-α induced an
increase of 5-LOX, p-NF-κB and COX-2 expression. MBCP (18 μM) was able to reduce the expression
of p-NF-κB, 5-LOX and COX-2 expression increased by TNF-α (Figure 4). Moreover, MBCP (18 μM)
reduced the basal expression of NF-κB in untreated Caco-2 cells. Betamethasone (10 μM), used as
a positive control, significantly reduced 5-LOX expression, but not the NF-κB, p-NF-κB and COX-2
expression, increased by TNF-α.
Figure 4. MBCP ameliorates the adherens junctions destructured by atropine and tubocurarine.
Confocal microscopy images of untreated Caco-2 cells (A) or Caco-2 cells treated for six hours with
MBCP (18 μM, (B)), tubocurarine (10 μM, (C)), Tubocurarine plus MBCP (D), atropine (10 μM, (E)) and
atropine plus MBCP (F). The color green represents β-catenin.
3.1.5. MBCP Reduces Atropine and Tubocurarine-Induced Adherens Junctions Disorganization
Several studies reported that the stimulation of the acetylcholine receptors (AChR) enhances
epithelial barrier formation [22,23] and ameliorates TNF-α induced barrier dysfunction in intestinal
epithelial cells [24]. According to literature, treatment of Caco-2 cells with the AChR antagonists
atropine (10 μM) or tubocurarine (10 μM) induced an disorganization of adherents junctions (Figure 5).
MBCP (18 μM) attenuated both atropine and tubocurarine AChR antagonist effects on Caco-2 cells
adherens junctions, indicating that MBCP treatment could affect the AChR pathway (Figure 5).
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Figure 5. MBCP reduces the expression of 5-LOX, COX-2, p-NF-κB and NF-κB. (A) Western blot
analysis of Caco-2 cells alone or treated with MBCP or betamethasone. Bands associated with the
expression of 5-LOX, COX-2, p-NF-κB, NF-κB, and house-keeping γ-tubulin, after 48 h of treatment
with MBCP (18 μM) and betamethasone (10 μM). The expression of the house-keeping protein γ-tubulin
was used as loading control. (B) The expression levels of the above proteins are reported as a percentage
with respect to the level of the protein in untreated cells, used as control. Bars show the mean ± SD of
three different determinations. # p < 0.05, ## p < 0.01 and ### p < 0.001 vs. control; * p < 0.05, ** p < 0.01
and *** p < 0.001 vs. TNF-α alone.
3.1.6. MBCP Inhibits the TNF-α-Increased Caco-2 Permeability
The intestinal epithelial cell line Caco-2 has been used extensively as a model of the human
epithelium, as it can be grown in the Transwell system as a differentiated cell monolayer that has
selective paracellular permeability to ions and solutes. We used both mannitol and lactulose, intestinal
permeability probes, to evaluate the permeability changes in Caco-2 stimulated with TNF-α. Treatment
of the Caco-2 cell (see Section 2.9) with TNF-α (10 μM) increased the concentration of mannitol in the
basolateral solution by about twofold compared to the control cells (cells without TNF-α treatment).
[Control of mannitol concentration (mmol/L): 0.01 ± 0.004; TNF-α 0.023 ± 0.005 *; mean ± SD;
* p < 0.05]. The mannitol concentration in the basolateral side of the Caco-2 cells pretreated with MBCP
and then incubated with TNF-α (0.009 ± 0.003 mmol/L, mean ± SD; n = 3, * p < 0.05) was decreased
twofold compared to the TNF-α treated Caco-2 cells. The MBCP induced any change of the lactulose
permeability in the same inflammatory cell condition.
3.2. In Vivo Study
3.2.1. MBCP Reduces the Inflammation in the DNBS Model of Colitis
The DNBS murine model of colitis was used to assess the in vivo intestinal anti-inflammatory
effects of MBCP. DNBS administration (150 mg/kg) caused inflammatory damage, as indicated by the
approximately twofold increase in colon weight/colon length ratio (mg/cm), a simple and reliable
marker of inflammation and damage (Figure 6A). MBCP (10–100 mg/kg, by oral gavage), administered
for three consecutive days after the inflammatory insult, significantly and in a dose-dependent manner,
reduced the effect of DNBS on colon weight/colon length ratio. The effect was significant starting from
30 mg/kg dose (Figure 6A). The anti-inflammatory effect MBCP was further confirmed by histological
analysis. As shown in Figure 6B, DNBS caused a severe inflammatory cellular infiltration and complete
destruction of the colon epithelium, compared to control mice (Figure 6B). Our data showed that oral
MBCP (100 mg/kg) reduced the colonic damage induced by DNBS (Figure 6B).
Considering that the peptide inhibited the phosphorylation of NF-κB in vitro, we investigated if
this pathway was involved in the in vivo anti-inflammatory effect of MBCP. As shown in Figure 6C,
the phosphorylation of IκBα and active NF-κB expression were increased in the colons of mice treated
with DNBS. MBCP (100 mg/kg) was able to significantly reduce these changes induced by DNBS.
These results demonstrated that MBCP suppressed NF-κB activation both in the experimental model
of colitis and in TNFα-stimulated Caco-2 cells.
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Figure 6. MBCP reduces colon weight/colon length ratio in DNBS-induced colitis in mice. (A) MBCP
(10–100 mg/kg, by oral gavage) was administered once a day starting 24 h after the induction of colitis
by DNBS (150 mg/kg). Colons were collected three days after DNBS. (B) representative hematoxylin
& eosin stained colon cross-sections of mice treated with vehicle (control), DNBS and DNBS plus
MBCP (100 mg/kg by oral gavage). Colons were collected three days after the induction of colitis
by DNBS. Original magnification 10× and 20× (A). (C) Western blot analysis of p-NF-κB, NF-κB,
and house-keeping γ-tubulin expression in normal mice colon and after the induction of colitis by
DNBS.All data are represented as mean ± SEM of seven mice for each experimental group. Statistical
significance was calculated using one-way ANOVA test. # p < 0.001 vs. control, * p < 0.05 and ** p < 0.01
vs. DNBS alone.
3.2.2. MBCP Reduces the Intestinal Permeability in Vivo
The intestinal permeability was increased of the intracolonic administration of DNBS, as revealed
by the high concentration of FITC-conjugated dextran in the serum (see Supplementary Files Figure S1).
While MBCP (100 mg/kg), given by oral gavage for three consecutive days, synergistically (p < 0.01)
partially counteracted the DNBS-induced increase in intestinal permeability (see Supplementary
Files Figure S1). Moreover, immunofluorescence analysis showed that DNBS administration caused
a destructuration of the colonic AJs associated with an increase of the citoplasmatic expression of
E-cadherin and β-catenin. MBCP (100 mg/kg) counteracted the effect of DNBS on AJs, (Figure 7), thus
confirming the in vitro results on TNF-α-stimulated Caco-2 cells.
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Figure 7. MBCP induces the organization of colonic AJs in DNBS-induced colitis in mice.
Immunofluorescence analysis showing the expression of E-cadherin (red) and β-catenin (green) in
control (A–C), DNBS (D–F) and DNBS plus MBCP (G–I) (100 mg/kg) mice. Original magnification
20×. A magnified portion of the immunofluorescence was shown at higher magnification in the inset
of panel (C,F,I). The DNBS-induced colitis in mice was treated for three consecutive days after the
inflammatory insults with MBCP (100 mg/kg, by oral gavage).
3.2.3. MBCP Counteracts the Accelerated Upper Gastrointestinal Transit Induced by Croton Oil
The administration of the flogogen agent croton oil (CO) induced an accelerated upper
gastrointestinal transit (GT) 4 days after its first administration. The physiological GT percentage in
the mice (control) was of 49.8 ± 1.4; whereas GT significantly increased up to values of 65.50 ± 6.26*
(mean ± SEM; * p < 0.05) in CO treated mice. MBCP (5–50 mg/kg), given by oral gavage 30 min before
the administration of the charcoal, in a dose dependent manner restored the intestinal motility to
physiological conditions (% of GT MBCP 5 mg/kg: 59.43 ± 2.75; MBCP 10 mg/kg: 56.14 ± 3.63; MBCP
50 mg/kg: 39.87 ± 6.38 **; ** p < 0.01). MBCP, at the high dose (50 mg/kg), did not modify the upper
gastrointestinal transit in control mice (% of GT: control 55 ± 3.53; MBCP 48.60 ± 4.38 (mean ± SEM)).
4. Discussion
In mammals, the enterocytes are renewed continuously every 4–8 days through an organized
series of events involving proliferation, differentiation and programmed cell death. The proliferation
to differentiation transition (PDT) is a critical step in the continual renewal of a normal intestinal
epithelium [25]. A useful in vitro model to study the effects of food ingredients on the gut epithelial
layer is based on the use of Caco-2 cells for their functional similarity to colonic enterocytes [26].
Indeed, Caco-2 cells express tight junctions, microvilli, enzymes and transporters functionally similar
to colonic enterocyte [26]. Moreover, this cell line has the ability to elicit a pro-inflammatory reaction in
response to stimulants like TNF-α, a known mediator of gastrointestinal mucosal barrier injury [5,27].
In this study, we have shown that a peptide (MBCP) obtained from gastrointestinal digestion of
Mozzarella of Bufala Campana DOP is able to modulate the differentiation and permeability in Caco-2
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cells stimulated with TNF-α and to attenuate inflammation and hypermotility in murine models of
intestinal inflammation.
4.1. MBPC Modulates the Differentiation and Permeability in Caco-2 Cells
Proliferating Caco-2 cells spontaneously initiate the differentiation process when they have
reached confluence. The differentiation program starts when specific biochemical events induce
the cell–cell contact, through the E-Cadherin/actin/β-Catenin complex [28]. Here, we have found
that MBCP, at a non-cytotoxic concentration (i.e., 18 μM), induced an increase of intestinal alkaline
phosphatase activity in undifferentiated Caco2 cells. Intestinal alkaline phosphatase is a well-known
cell differentiation marker and its activity has been inversely correlated with an increased risk of
intestinal inflammation development [29]. Moreover, we also found that MBCP treatment, already after
24 h, induced the differentiation program accelerating the E-cadherin-actin membranous organization,
thus suggesting a beneficial effect on the AJ. This result is further supported by the experiments with
TNF-α. According to previous studies [30], we have shown that Caco-2 treatment with TNF-α induced
molecular alterations of the E-cadherin organization and consequently a passage of mannitol through
the Caco-2 monolayer. MBCP treatment was able to restore the cell–cell junctions, counteracting
the breakdown of E-cadherin-β-catenin complex and reducing the increase of mannitol permeability
inducted by TNF-α.
According to previous studies, we found that un-stimulated Caco-2 cells over-expressed COX-2
and NF-κB and TNF-α-stimulated Caco-2 cells increased 5-LOX expression. NF-κB transcription
factor is a master regulator of the inflammatory response and it is essential for the homeostasis of the
immune system. NF-κB regulates the transcription of genes, such as LOX and COX-2, which control
inflammation [31]. Our results demonstrated that MBCP reduced the phosphorylation of NF-κB as
well as COX-2 and 5-LOX expression in TNF-α stimulated cells.
Many mechanisms are responsible for the regulation and stability of adherens junction proteins,
one of these possibilities could be the AChR activation. Furthermore, previous studies indicate that
cholinergic agonists interfere with NF-κB pathways preventing IkBα breakdown and p65 nuclear
translocation [24,32]. Moreover, cholinergic agonists could prevent gut barrier failure after severe burn
injury maintaining intestinal barrier integrity. McGilligan has showed that nicotine decrease Caco-2
permeability by regulating the expression of TJ proteins [33]. Therefore, we measured changes in
localization of β-catenin to determine whether modulation of this protein correlates with the adherens
junctions disorganization induced by cholinergic antagonists like atropine and tubocurarine. Confocal
microscopy analysis confirmed that both atropine and tubocurarine treatment induced a cytoplasmic
accumulation of β-catenin in Caco-2 cells. These detrimental effects induced by cholinergic antagonists
were counteracted by MBCP treatment.
4.2. MBPC Ameliorates Murine Colitis
The ability of MBCP to restore cell–cell contacts as well as to exert an anti-inflammatory actions
was subsequently evaluated in vivo by using the mice model of DNBS-induced colitis. According
to previous studies [34,35] intracolonic administration of DNBS induced intestinal inflammation
associated to an increase of epithelial permeability. Oral MBCP administration was able to reduce
intestinal inflammation as demonstrated by the reduction of colon weight colon length ratio (a simple
and reliable marker of inflammation and damage), histological alterations, IκBα phosphorylation and
of NF-κB activation associated with DNBS administration.
Intestinal permeability plays a crucial role in the development of IBD as well as in the IBD ongoing
bowel symptoms [5,36]. Moreover, inflammation reduces barrier integrity and affects the normal
intestinal permeability [4]. Studies on Caco-2 cells have shown that MBCP restored tight junctions
altered by TNF-α. Tight junctions are multi-protein complexes that maintain the intestinal barrier while
regulating permeability [9]. Therefore, we investigated the effect of MBPC on intestinal permeability
in vivo. We adopted an immunofluorescent method through which an orally-administered marker
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(i.e., FITC-conjugated dextran) can be detected in the blood if permeability is impaired. As expected,
intestinal permeability increased after DNBS administration and, more importantly, MBCP restored
the impaired permeability.
4.3. MBPC Normalizes Inflammation-Induced Murine Intestinal Hypermotility
It is clinically well established that inflammation in the gut causes debilitating symptoms due to
motility disturbances [37]. To investigate the effect of MBCP on intestinal motility, we administered
mice croton oil, which is a flogogen agent able to induce hypermotility as a consequence of intestinal
inflammation. By using this experimental model, we have shown that MBPC did not affect motility
in healthy mice, but normalized the exaggerated intestinal transit caused by the inflammatory insult.
The lack of effect of MBPC in control mice is clinically relevant in the light of the observation that
constipation is a very common side effect associated with drugs clinically used to reduce intestinal
motility [38,39].
5. Conclusions
In conclusion, the data obtained in our study shown that MBCP, a peptide isolated from the
buffalo milk after in vitro digestion of Mozzarella di Bufala Campana DOP, exerts anti-inflammatory
effects both in vitro and in vivo. This anti-inflammatory effect could be related to its beneficial effects
on adherens junctions mainly during an inflammatory process. These results could have an important
impact on the therapeutic potential of MBCP in helping to restore the intestinal epithelium integrity
damaged by inflammation, thereby reducing the risk of colorectal cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/3/610/s1,
Figure S1: MBCP reduces intestinal permeability in DNBS-induced colitis in mice.
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Abstract: Inflammatory bowel diseases (IBD) are a chronic inflammatory disorders with increasing
global incidence. Synbiotic, which is a two-point approach carrying probiotic and prebiotic
components in mitigating inflammation in IBD, is thought to be a pragmatic approach owing to the
synergistic outcomes. In this study, the impacts of dietary supplementation with probiotic Bacillus
coagulans MTCC5856 spores (B. coagulans) and prebiotic whole plant sugar cane fibre (PSCF) was
assessed using a murine model of IBD. Eight-week-old C57BL/6 mice were fed a normal chow
diet supplemented with either B. coagulans, PSCF or its synbiotic combination. After seven days of
supplementation, colitis was induced with dextran sulfate sodium (DSS) in drinking water for seven
days during the continuation of the supplemented diets. Synbiotic supplementation ameliorated
disease activity index and histological score (−72%, 7.38, respectively), more effectively than either
B. coagulans (−47%, 10.1) and PSCF (−53%, 13.0) alone. Synbiotic supplementation also significantly
(p < 0.0001) prevented the expression of tight junction proteins and modulated the altered serum IL-1β
(−40%), IL-10 (+26%), and C-reactive protein (CRP) (−39%) levels. Synbiotic supplementations also
raised the short-chain fatty acids (SCFA) profile more extensively compared to the unsupplemented
DSS-control. The synbiotic health outcome effect of the probiotic and prebiotic combinations may
be associated with a synergistic direct immune-regulating efficacy of the components, their ability
to protect epithelial integrity, stimulation of probiotic spores by the prebiotic fibre, and/or with
stimulation of greater levels of fermentation of fibres releasing SCFAs that mediate the reduction in
colonic inflammation. Our model findings suggest synbiotic supplementation should be tested in
clinical trials.
Keywords: synbiotic; prebiotic; probiotic; IBD; Bacillus spores; dietary fibre; sugar cane fibre;
ulcerative colitis
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the
gastrointestinal tract that comprises two partially overlapping but distinct clinical entities: Crohn’s
disease (CD) that involves the entire gastrointestinal tract and ulcerative colitis (UC) that is limited
to colon and rectum [1]. The incidence of CD and UC has become a global disease with accelerating
incidence in countries adopting a Westernised diet, highlighting the urgent need for research into
prevention and management of this complex and costly pathology [2]. Although the aetiology and
pathogenesis of IBD still remains unclear, emerging evidence supports the involvement of a recurrent
tripartite pathophysiological circuit encompassing gut dysbiosis, altered epithelial integrity and
defective immune responses [1]. Therefore, preventive and therapeutic approaches that impede or
break this inflammatory circuit by resolving one or more of the pathophysiological circuit components
are highly sought.
Dietary interventions are increasingly perceived as both preventive and corrective strategies to
normalise the dysfunctional microbiome, altered immune and barrier integrity functions to normality
in IBD [3–5]. In this regard, probiotic and prebiotic dietary fibres (DF) are thought to be useful in
mitigating the inflammatory circuit thereby resolving or preventing the severity of IBD. Both bioactive
ingredients can improve inflammatory parameters in the gut by modifying microbiota composition and
metabolites, regulating secretion of immunomodulatory molecules and protecting the colonic epithelial
barrier [1,6–8]. Synbiotics, being a combination of probiotic and prebiotic ingredients that positively
interact, potentially offer prophylactic and therapeutic effects that could function synergistically to
confer health benefits to the host.
DFs have shown particular promise in attenuating colonic inflammation in humans [9].
Meanwhile, the underlying mechanisms are likely to be multifactorial: they include dilution of toxins
via stool bulking and the production of metabolites, particularly short-chain fatty acids (SCFA),
as a result of microbial fermentation is frequently cited as a major potential contributor to the
protective effect [10]. DFs consist of edible plant parts that resist digestion and absorption in the
small intestine and undergo complete or partial fermentation in the colon. It is an extremely complex
group of substances, including non-starch polysaccharides, resistant starch, cellulose and hemicellulose,
oligosaccharides, pectins, gums, lignin, and waxes [11]. Much work on DFs, however, has examined
various purified ingredients that represent limited chemical complexity, contrasting to those that
naturally occur in fruits and vegetables [12]. Nevertheless, the biochemical complexity of DFs is
recently being more appreciated to be a vital factor influencing the gut microbial complexity [12–14].
This highlights the prudence of application of prebiotic fibres that are representative of whole plant
vegetables and fruits, prepared to retain fibre biochemical complexity. In this context, a process to
produce sugar cane fibre by wet diffusion to remove most of the sucrose from cut cane, which is then
dried and ground into a flour, has been reported to preserve the cell wall components and retain other
intrinsic nutritional biologically active components [15,16]. Such fibre, in addition to retaining other
micronutrients and polyphenols, also contains both soluble and insoluble benefits as well as rapid- and
poor-fermentable fibres and at ratios that more accurately represent natural whole plant foods. In a
recent study, such sugar cane fibre has been shown to impart positive effects on human gut microbiota
in vitro [17]. The high content of total dietary fibre (87%) was accounted for with respect to its positive
effect in this study. The relative similarity of this sugar cane fibre product to that in other whole plant
foods indicates its potential as a convenient supplementary source of dietary fibre that could alter
microbial ecology and have a positive influence for IBD attenuation.
Bacillus coagulans is a GRAS (generally recognised as safe) affirmed probiotic that can ferment a
variety of plant substrates rich in insoluble cell wall components [18,19] more efficiently than most
members of gut microbiota [20,21]. It is also known to be capable of modulating the innate immune
system by binding and interacting with the gastrointestinal tract epithelium [22,23]. This makes it
a suitable probiotic for its synbiotic combination with prebiotic whole plant sugar cane fibre (PSCF)
rich in insoluble cell wall fractions. Probiotic Bacillus coagulans MTCC (Microbial Type Culture
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Collection) 5856 spores in addition to exhibiting excellent immunomodulatory effects in vitro, have
shown significant survival during simulated gastric transit with substantial adhesion capacity to
human colonic epithelial cells [22]. Based on the aforementioned findings, we hypothesised that
preconditioning with probiotic B. coagulans MTCC 5856 spores, prebiotic PSCF and its synbiotic
combination might repress the onset and/or severity of DSS-induced colitis in mice. This study
aimed to evaluate the efficacy of probiotic B. coagulans spores and PSCF, both alone and in
combination as synbiotic to ameliorate the onset of experimental colitis in mice and further examine
its underlying mechanisms.
2. Materials and Methods
2.1. Probiotic Bacteria and Prebiotic Dietary Fibre
LactoSpore® (Sabinsa Corporation, East Windsor, NJ, USA) containing the probiotic strain Bacillus
coagulans MTCC 5856 (6 × 109 spores/gm) was produced by Sami Labs Limited (Bangalore, India) and
supplied by Sabinsa Corporation (Australia). Kfibre™, prebiotic whole plant sugar cane fibre (PSCF)
was supplied by KFSU Pty Ltd., Queensland, Australia.
2.2. Animals
Fifty C57BL/6J (seven week old) mice of both sexes of average weight 19g were obtained from the
University of Tasmania animal breeding facility and housed in a temperature-controlled environment
with a 12-h day/night light cycle. Individual body weights were assessed daily including over an initial
acclimation period of seven days. All mice had ad libitum access to radiation-sterilised rodent feed
pellets (Barastoc Rat and Mouse, Ridley AgProducts, Melbourne, Victoria, Australia) and autoclaved
tap water for drinking during experiments. All animal experiments were approved by the Animal
Ethics Committee of the University of Tasmania (ethics approval number: A0015840) and conducted
in accordance with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes
(8th Edition, 2013). All efforts were made to minimize animals’ suffering and to reduce the number of
animals used.
2.3. Study Design and Treatments
Following one week of acclimation, mice at eight weeks of age were randomly allocated into
the following five groups (n = 10 per group): (1) Healthy control (HC), (2) DSS-control, (3) probiotic
B. coagulans MTCC 5856 spores (B. coagulans), (4) whole plant prebiotic sugar cane fibre (PSCF)
supplement, and (5) synbiotic combined supplement. Mice in HC and DSS-control groups received
4 g chow mash (standard chow pellet blended with water). The B. coagulans group received 4 g
chow mash supplemented with probiotic B. coagulans MTCC 5856 spores (2 × 109 CFU/day/mouse).
The PSCF group received 4g chow mash supplemented with Kfibre™ (200 mg/day/mouse). Synbiotic
treatment group mice received 4 g chow, each supplemented with B. coagulans MTCC 5856 spores
(2 × 109 CFU/ day/mouse) and Kfibre (200 mg/day/mouse). The chow mash was prepared fresh
each day. The mice were single-caged throughout the experiment to measure the defined daily intake
of respective treatments from prepared chow mash. The mice were fed these treatments for 14 days.
Colitis was induced during the last seven days of the experimental period as previously described [24],
by administering 2% dextran sulfate sodium (DSS; MP Biomedicals, colitis grade average molecular
weight: 36,000–50,000) in the drinking water of all groups except for the non-colitic DSS-control mice
which received normal drinking water. Mice were sacrificed on day 15 by CO2 asphyxiation.
2.4. Clinical Scoring and Histological Analysis
A Disease Activity Index (DAI) was determined daily in all mice by scoring for body weight,
hemocult reactivity or presence of gross blood and stool consistency during the week of DSS induction,
as detailed in [25]. Stool was collected from individual mice and tested for the presence of blood using
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Hemoccult II slides (Beckman Coulter Inc., Brea, CA, USA). Briefly, the following parameters were used
for calculation: (a) body weight loss (score 0 = 0%, score 1 = 1–5%, score 2 = 6–10%, score 3 = 11–15%); (b)
stool consistency (score 0 = normal, score 1 = soft but still formed, score 2 = very soft/loose stool, score
3 = diarrhoea/watery stool); and (c) blood in stool (score 0 = negative hemoccult, score 1 = positive
hemoccult, score 2 = Blood traces in stool visible, score 3 = rectal bleeding). DAI was determined
by combining the scores from these three categories. Body weights were measured for each animal
throughout the experiments and expressed as percent weight loss to the weight immediately before
DSS treatment. Fecal samples were collected and stored at −80 ◦C on day 14 for metabolite analysis.
After sacrificing the mice, the colons were removed from the caecum to the anus following the
method of Perera et al. [26]. The length of the colons from the ileocaecal junction to the rectum were
recorded. The colon was subsequently opened along its longitudinal axis and the luminal (mucosal)
contents were removed using sterilised 200 μL pipette tips prior to weighing the organ. The length and
weight of colon and spleen were documented. Spleen weight, colon length, and colon weight/body
weight ratio were calculated as macroscopic markers of inflammation. The mucosal and cecal contents
were collected for metabolite profiling and stored at −80 ◦C. The colon was bisected longitudinally,
and one half was prepared using the Swiss roll technique [27] whereas the remaining colonic tissue was
dissected out, segregated into proximal colon (PC) and distal colon (DC) and snap-frozen for molecular
analyses. Swiss rolls underwent 24 h fixation in 10% (v/v) neutral-buffered formalin. Swiss rolls were
subsequently transferred to 70% ethanol prior to progressive dehydration, clearing and infiltration
with HistoPrep paraffin wax (Fisher Scientific, Philadelphia, PA, USA). Swiss rolls were then embedded
in wax and 5 μm sections were cut using a rotary microtome. Sections were stained with haematoxylin
and eosin (H and E; HD Scientific, Sydney, Australia). Slides stained with H and E (n = 8 per
group) graded blindly for the severity of tissue damage at distal and proximal regions as described
previously [28,29]. Briefly, frequency of distribution of inflammation graded 0-3, crypt architectural
distortion and ulceration graded 0–5, tissue damage graded 0-3, inflammatory infiltrate graded 0–3,
goblet cell loss graded 0–3, mucosal thickening (oedema) were graded 0–3. All images were captured
on a Leica DM500 microscope using a Leica ICC50 W camera (Leica Microsys-tems, Wetzlar, Germany).
2.5. Alcian Blue Staining
DSS-induced alterations in goblet cells and subsequent depletion in synthesis and secretion of
mucin glycoprotein (MUC2) was analysed by Alcian blue staining (ab150662 Alcian Blue, pH 2.5
(Mucin Stain), Abcam, Australia) following the manufacturer’s instructions. Briefly, paraffin-embedded
colon sections (n = 4/group) were stained with Alcian blue, staining the acidic sulphated mucin blue
and the counterstained with Safranin O, staining the nuclei red following the method previously
described [30]. Computer-assisted image analysis was performed with a Leica DM500 microscope
(Leica Microsystems, Wet-zlar, Germany) and Leica ICC50 W camera (Leica Microsys-tems, Wetzlar,
Germany). The staining intensity (IOD) was assessed using Image Pro Plus 7.0 (Media Cybernetics,
Inc., Rockville, MD, USA) and used for comparison among groups [31].
2.6. Immunohistochemical Detection of Tight Junction Proteins
Immunohistochemical detection of epithelial tight junction (TJ) proteins was performed using
a Rabbit specific HRP/DAB (ABC) Detection IHC kit (ab64261, Abcam, Australia) following the
manufacturer’s instruction and as previously described [32]. Following removal of paraffin and
rehydration, the tissue sections were exposed to heat-induced epitope retrieval (4 min at 121 ◦C)
in a sodium citrate buffer, pH 6 in a Decloaking chamber (Biocare Medical, Pachico, CA, USA).
After washing the slides in 1× phosphate buffered saline (PBS) 2 mins/wash, endogenous peroxidase
activity was blocked by incubating the slides with hydrogen peroxide block for 10 min. Next, the slides
were washed with PBS (2 × 2 min) washes and protein block was then applied for 30 min at room
temperature to block non-specific background staining. Following PBS (1 × 2 min) wash, colon sections
were then incubated with primary antibodies: anti-ZO-1 (NBP1-85046, Novus Biologicals, Australia,
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1:400); anti-occludin (NBP1-87402, Novus, 1:600); anti-claudin-1 (NBP1-77036, Novus, 1 μg/mL)
overnight at 4 ◦C. Sections were then washed with PBS (4 × 2 min) and biotinylated goat anti-rabbit
IgG was applied and incubated for 10 min at room temperature. At the end of incubation, the slides
were washed in PBS (4 × 2 min) and streptavidin peroxidase was applied to the sections and further
incubated for 10 at room temperature. The slides were then thoroughly rinsed with PBS (4 × 2 min)
before sections were covered with 3,3′-diaminobenzidine (DAB) chromogen and substrate solution for
10 min. Tissue sections were subsequently counterstained with hematoxylin, dehydrated, and mounted
with DPX media (Sigma-Aldrich, Sydney, Australia).
Computer-assisted image analysis was performed with a Leica DM500 microscope
(Leica Microsystems, Wet-zlar, Germany), Leica ICC50 W camera (Leica Microsys-tems, Wetzlar,
Germany), and Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) software. The
expression of tight junction proteins (TJPs): ZO-1, occludin and claudin-1 was blindly assessed by
choosing random five fields on each slide (n = 4/group). Barrier TJ protein expressions and staining
intensity in colonic epithelium was expressed as the percentage expression of a respective TJ protein.
2.7. Myeloperoxidase Activity
The extent of the inflammatory cell invasion in the colon was examined by the assessment
of myeloperoxidase (MPO) activity [24]. Weighed and snap frozen PC and DC specimens (n = 3)
were analysed for MPO activity using a Myeloperoxidase Activity Assay kit (ab105136, colorimetric,
Abcam®, Cambridge, UK). Briefly, frozen tissue after washing in cold PBS, was resuspended in
MPO assay buffer, before homogenisation with 10–15 passes using an Omni TH tissue homogeniser
(Omni International, US) with 10–15 passes. The homogenate was then centrifuged at 13,000× g (10
min) and the supernatant assayed for MPO activity as per the manufacturer’s instructions. The values
are expressed as MPO activity units/g tissue.
2.8. Tissue Explant Culture and Cytokine Measurements
PC and DC colon tissues of mice from each group were cut, weighed and washed with cold
PBS before transferring to a 12 well plate containing 0.5 mL/well of RPMI1640 culture medium
(In Vitro Technologies Pty Ltd, Melbourne, Australia) supplemented with 10% v/v fetal calf serum
(Gibco, Life Technologies Pty Ltd, Melbourne, Australia), penicillin (100 mU/L), and streptomycin
(100 mg/L) (Sigma-Aldrich Pty Ltd, Sydney, Australia) as described previously [26]. After 24 h of
incubation, supernatant was collected from each well, centrifuged and stored at −80 ◦C until further
analysis. Serum was collected from blood drawn by cardiac puncture at the end of the study for
cytokine analysis.
The cytokine levels in colon tissue (n = 3) and serum (n = 3) were determined by immunoassay
using a Bio-Plex Pro Mouse cytokine 23-plex kit (Bio-Rad #M60009RDPD, Bio-Rad Laboratories,
Gladesville, NSW, Australia) following the manufacturer’s instructions and concentrations analysed
using a Bio-Plex 200 instrument (Bio-Rad) and Bioplex Manager software, version 6 (Bio-Rad
Laboratories) respectively. For tissues, the cytokine levels were normalized by dividing the cytokine
results (pg/mL) by the measured biopsy weight (g). The most significantly altered cytokines are
presented as pg/g of tissue.
2.9. iNOS Activity
The expression of inducible isoform of nitric oxide synthase (iNOS) in colonic epithelial cells in
response to pro-inflammatory stimuli [33] was determined in PC and DC specimens using a Nitic Oxide
Synthase Activity Assay kit (ab211084, Fluorometric, Abcam®, Cambridge, UK). Snap frozen proximal
and distal colonic tissues (n = 3) were washed in in cold PBS and resuspended in 200 μL NOS assay
buffer then homogenised by 10–15 passes of an Omni TH tissue homogeniser (Omni International,
Tulsa, OK, USA). The homogenate was then centrifuged at 10,000× g (10 min, 4 ◦C) and the supernatant
then underwent iNOS activity assay activity assay as per the manufacturer’s instructions. The amount
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of protein in the lysate was determined using DC™ Protein Assay (Bio-Rad Laboratories, Australia).
The results are expressed as iNOS activity mU/mg.
2.10. Serum C-Reactive Protein Analysis
The levels of C-reactive protein (CRP) in serum from respective groups (n = 3 samples/group)
were analysed using Mouse C-Reactive Protein/CRP Quantikine Elisa kit (MCRP00, R and D Systems,
Australia) following the manufacturer’s instructions. The results are expressed as μg/mL.
2.11. Volatile SCFA Analysis
Cecal, mucosal and fecal samples (n = 5 per group) were prepared and derivatized following
the protocol developed by Furuhashi et al. [34] with some modifications. Briefly, cecal, mucosal and
fecal samples of 100–150 mg fresh weight (stored at −80 ◦C) were weighed to ± 0.1 mg accuracy.
These samples were added to a sterile 1.5 mL bead-beating tube (NAVY Rino Lysis tubes, Next Advance,
Troy, NY, USA). A 1.0 mL aliquot isobutanol (10% MilliQ water), (LC-MS grade, Merck, Castle Hill,
NSW, Australia) was added to each sample, followed by two 30 s, 4000 rpm homogenization pulses
sandwiched between a 20-s pause interval (Precellys Evolution Homogenizer, Bertin Instruments,
Montigny-le-Bretonneux, France). The samples were subsequently centrifuged at 16,000× g for 6 min.
The supernatant (675 μL) was transferred to a clean round bottomed 2 mL centrifuge tube (Eppendorf
South Pacific Pty. Ltd., Macquarie Park, NSW, Australia) and NaOH (20 mM, 125 μL, Merck Pty Ltd.,
Castle Hill, NSW, Australia) and chloroform (400 μL, LC-MS grade, Merck Pty Ltd.,) were added.
The samples were briefly vortexed and centrifuged at 16,000·g for 3 min. The aqueous phase (upper layer,
400 μL) was transferred to a new clean round bottomed 2 mL centrifuge tube (Eppendorf South Pacific
Pty. Ltd., Macquarie Park, NSW, Australia) containing a boiling chip (Sigma Aldrich, Castle Hill, NSW,
Australia). Pyridine (100μL), isobutanol (80 μL) (both LC-MS grade, Sigma Aldrich, Castle Hill, NSW,
Australia), and MilliQ (Millipore Corporation) water (70 μL) were added and the samples were subjected
to gentle hand vortexing (swirling action) followed by the addition of 50 μL isobutyl chloroformate (98%
purity, Sigma Aldrich, Castle Hill, NSW, Australia). The tube was kept opened to release any generated
gases and was allowed to stand for about one minute. Hexane (150 μL, LC-MS grade, Sigma Aldrich,
Castle Hill, NSW, Australia) was then added to each tube, which was then capped and vortexed prior to
centrifugation at 15,700× g for 4 min. The upper phase (100 μL) was subsequently transferred to clean gas
chromatography (GC) autosampler vial fitted with silanized low volume glass inserts; Malathion (1 μL,
equivalent to 2.5 μg dry weight) was added as an internal standard.
The GC-MS analysis was performed on an Agilent 6890B GC oven coupled to a 5977B mass
spectrometer (MS) detector (Agilent Technologies, Mulgrave, VIC, Australia) fitted with an MPS
autosampler (Gerstel GmbH & Co.KG, Mülheim an der Ruhr, Germany). The GC oven was fitted
with two 15 m HP-5MS columns (0.25 mm ID and 0.25μm film thickness; 19091S-431 UI (Ultra Inert),
Agilent Technologies, VIC, Australia) coupled to each other through a purged ultimate union (PUU)
for the use of post-run backflushing. The sample (1.0 μL) was introduced via a multimode inlet
(MMI) operated in split mode (1:20). The column was maintained at 40 ◦C for 5 min, followed by
an increase to 250 ◦C at a rate of 10 ◦C/min. This was followed by a second increment to 310 ◦C at
a rate of 60 ◦C/min. The column was held at 310 ◦C for 1 min. The mass spectrometer was kept in
extractor ion mode (EI mode) at 70 eV. The GC-MS ion source temperature and transfer line were
kept at 250 ◦C and 280 ◦C, respectively. Detector voltage was kept at 1054 V. The MS detector was
turned off for the first 3 min and, at 4.0–4.8 min and 12.5–13.2-min time windows until the excess
derivatization reagent (chloroformate/hexane solvents) were eluted from the column. This ensured
that the source filament was not saturated and damaged. The scan range was kept in the range of
m/z 35–350 (35–350 Daltons). Data acquisition and spectral analysis were performed as described in
a previous study [35] and qualitative identification of metabolites was performed according to the
Metabolomics Standard Initiative (MSI) chemical analysis workgroup [36] using standard GC-MS
reference metabolite libraries (NIST 17, and an in-house CF-based metabolomics library developed
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after Smart et al. [37] with the use of Kovats retention indices based on a reference n-alkane standard
(C8-C40 Alkanes Calibration Standard, Sigma-Aldrich, Castle Hill, NSW, Australia).
2.12. Metabolic Phenotyping Analysis
Untargeted metabolomic profiling of cecal, mucosal and fecal samples (n = 5 per group) were
performed using GC-MS analysis as described previously [35].
2.13. Statistical Analysis
The samples in the study were randomly chosen for all the analysis to avoid bias. All data are
presented as means ± standard error of the mean (SEM). The statistical analysis was performed with
the use of GraphPad Prism Software (Version 7.0, San Diego, CA, USA) The data were evaluated using
One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to determine statistical
differences between the groups against the DSS-control samples. For the analysis of DAI and body
weight changes during the experimental period, two-way ANOVA followed by Tukey’s post-hoc test
was used, setting treatment and the time as the variables. A p-value of < 0.05 was considered significant.
3. Results
3.1. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on DAI and Macroscopic Inflammatory
Markers in DSS-Induced Mice
In comparison with the HC group, the administration of probiotic, prebiotic and synbiotic
treatments in the respective groups did not show any sign of toxicity, which was evaluated by body
weight increase, food intake and general appearance of the animals. DAI (cumulative score for body
weight change, stool consistency and blood in feces) was evaluated to determine the efficacy of the
treatments in reducing the severity of disease symptoms in DSS-induced colitis (Figure 1A). Compared
with the DSS-control group that showed severe colitis symptoms, pre-conditioning with B. coagulans,
PSCF and synbiotic combination significantly reduced the DAI levels as early as day2 until the end
of experiment. At the end of the experiment, DAI of DSS-control group was significantly high (5.8 ±
0.5) (p ≤ 0.0001) compared with that of B. coagulans (3.1 ± 0.6, 47% reduction), PSCF (2.7 ± 0.5,
53% reduction), and synbiotic (1.6 ± 0.2, 72% reduction) groups. DSS induction in DSS-control mice
resulted in significant body weight loss until the end of experiment (−4.13 ± 1.4%). In contrast,
mice maintained healthy body weight gain with Bacillus (2.84 ± 1.7%), PSCF (4.25 ± 1.0%), and
synbiotic (4.7 ± 0.7%) treatments. Interestingly, PSCF was the more effective in reducing DAI starting
from day 2 of DSS and in remediating the body weight loss as early as day 5 owing mainly to the































Figure 1. Effect of B. coagulans spores, PSCF and synbiotic in DSS-induced colitis model. (A) Disease
Activity Index (DAI), (B) % body weight change. Statistical significance among groups evaluated
by two-way repeated-measures analysis of variance (ANOVA) followed by Tukey’s test. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control group and data expressed as mean ± SEM (n =10
per group). Colon weight/body weight ratio (C), Spleen weight (D), Colon length (E) and Macroscopic
appearance of colon (F). Data expressed as mean ± SEM (n =10 per group), evaluated by one-way
ANOVA followed by Tukey’s Test. ns-non-significant, HC-Healthy control, PSCF-Prebiotic sugar
cane fibre.
The macroscopic evaluation of colonic segments determined the beneficial effects of all three
treatments used in our study as evidenced by substantial reduction in colon weight/body weight
ratio (B. coagulans, 7.68 ± 0.2; PSCF, 9.24 ± 0.3 and synbiotic, 8.74 ± 0.3 mg/g) compared with
DSS-control group (11.12 ± 0.3 mg/gm) (Figure 1C). Intestinal inflammation is associated with
spleen enlargement [24] and, as expected, relative spleen weight of untreated DSS-control mice was
significantly higher (0.076 ± 0.004 g) than that of HC mice (0.054 ± 0.003 g). PSCF (0.062 ± 0.003 g)
and synbiotic (0.063 ± 0.002 g) were equally significantly effective in reducing spleen weight while
B. coagulans did not affect the relative spleen weight (Figure 1D). In contrast to shortening of colon
length (Figure 1E,F) in DSS-control group (6.75 ± 0.3 cm), synbiotic treatment proved effective in
reducing this outcome by maintaining the colon length (8.12 ± 0.2 cm), significantly equal (p = 0.99) to
that of HC group (8.01 ± 0.2 cm). These markers are considered to be directly correlated to the severity
of colonic damage in this experimental model of colitis [24].
84
Nutrients 2019, 11, 818
3.2. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on Histological Alterations in
DSS-Induced Mice
Histological (H and E staining) examination of proximal colon (PC) and distal colon (DC) sections
of DSS-induced mice showed altered erosion or destruction of epithelium, crypt distortion, depletion
of goblet cells, submucosal oedema, and inflammatory cellular infiltration in the colon, mostly affecting
the DC (Figure 2A). HC mice showed no signs of histological colon damage with score 0, while DSS
induction in DSS-control mice resulted in a cumulative damage score of 10.5 ± 0.8 for the PC and
17.4 ± 0.5 for the DC (Figure 2B). Supplementation of DSS-induced mice with B. coagulans, PSCF and
synbiotic induced protection and repair of the colonic mucosa. B. coagulans and synbiotic in particular
were more effective in retention of colonic structure, protection of crypts and goblet cells and rescued
infiltration of inflammatory cells, which resulted in a significant overall reduction of cumulative
histological score of DC (10.1 ± 1.2 and 7.38 ± 0.7 respectively). Relatively, PSCF also provided partial
significant protection with histological score of 13.0 ± 1.0. In contrast, PCSF had no effect in PC
(10.1 ± 0.5) with only B. coagulans and synbiotic treatments being significantly successful in reducing
damage to the PC with histological scores of 9.5 ± 0.7 and 7.8 ± 0.3 respectively. Unlike DSS-control
group, there was reduced polymorphic inflammatory infiltrate in the lamina propria and submucosa
in probiotic, prebiotic and synbiotic supplemented group. This observation corroborates with the
significantly reduced MPO activity in the colon (Figure 2C) of all three treatments compared with the
DSS-control group. The attenuation of colonic inflammation in pre-conditioned mice (B. coagulans,
PSCF and synbiotic) is probably due to the anti-inflammatory properties of the functional dietary
ingredients tested in this study.
3.3. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on Goblet Cells and Colonic Tight
Junction Barrier
Histological examination of distal colon from DSS mice showed a depletion of goblet cells
when compared to HC and pre-conditioned mice. This suggested beneficial effects of probiotic and
prebiotic ingredients on the intestinal epithelium potentially through stimulating mucus secretion
by goblet cells. Specific staining with Alcian blue was therefore carried out to assess the mucus
production following the administration of probiotic, prebiotic and synbiotic treatments. As depicted
in Figure 3, in comparison with DSS-control group, there was a higher level of mucus staining with
Alcian blue in supplemented mice samples. This implied that there has been an induction of higher
levels of mucus secretion in the DSS-challenged mice that received B. coagulans spores, symbiotic,
and PSCF supplementaions. Unlike the DSS-controlled samples where, goblet cells were almost entirely
destroyed, the mice supplemented with synbiotic and B. coagulans showed protection of the goblet
cells. PSCF also partially protected the goblet cells with mucus staining compared with DSS-control.
Immunohistochemical analysis was then performed to evaluate the assembly of the TJs and the
integrity of the intestinal barrier. The presence of the TJ proteins-ZO-1, occludin, and claudin-1 on
the tissue sections were analysed (Figure 4). In HC, ZO-1 (Figure 4A) staining was more intense in
the apical tight junction complex both at the surface and in the crypts. In addition to showing their
presence at the crypt surface, occludin (Figure 4B), and claudin-1 (Figure 4C) proteins stained more
strongly at the basolateral membrane of crypts. As previously reported [38,39] such signals were weak
or totally absent on the epithelium of DSS-control sections resulting in very low percentage TJ protein
expressions. Basolateral and partial apical staining of ZO-1, occludin and claudin-1 was maintained
with B. coagulans and synbiotic supplementation in DSS-treated animals. While PSCF was able to
partially maintain ZO-1 and claudin-1 staining, such an effect was less evident for occludin. Synbiotic
treatment was most effective in preserving the TJ protein expressions in DSS-induced mice further
confirming its beneficial effects on the intestinal integrity.
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Figure 2. Effect of B. coagulans spores, PSCF and synbiotic treatments on DSS-induced colon injury and
inflammation. (A) Histological images of proximal and distal colonic tissues stained with hematoxylin
and eosin at 20× for each experimental group. (B) Histological score calculated after microscopic
analyses of proximal and distal sections of the colon. (C) Myeloperoxidase (MPO) activity in colonic
tissues was determined by colorimetric assay. Results expressed as mean ± SEM (n = 8 per group),
evaluated by one-way ANOVA followed by Tukey’s test (*p < 0.05, **p < 0.01, ****p < 0.0001).
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Figure 3. Effect of B. coagulans spores, PSCF and synbiotic on goblet cells. The paraffin embedded
sections were stained with Alcian Blue to detect changes in goblet cells and in production of mucus in
distal colonic tissue in each experimental group (40×) and staining intensity (IOD) of respective group
is illustrated in the graph. Results expressed as mean ± SEM (n = 4 per group), evaluated by one-way
ANOVA followed by Tukey’s test (*p < 0.05, ***p < 0.001).
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Figure 4. Effects of B. coagulans spores, PSCF and synbiotic on expression of epithelial tight junction
proteins. Immunohistochemical detection of (A) ZO-1, (B) Occludin and (C) claudin-1 and its respective
percentage of expression in colon at 40×. Data expressed as mean ± SEM (n = 4 per group) and
statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control group.
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3.4. Immunomodulatory Effects of B. Coagulans, PSCF, and Synbiotic Supplementation on Immune Markers in
DSS-Induced Mice
The cytokine analysis of the colonic segments and serum measured the intestinal
immunomodulatory and anti-inflammatory effects of B. coagulans, PSCF and their synbiotic
combination. A beneficial impact of ameliorating the altered immune response induced by DSS
intake was noted. Overall, probiotic, prebiotic, and synbiotic treatments remarkably reduced the
pro-inflammatory cytokine secretions of IL-1α, IL-1β, IL-6, IL-12, TNF-α, and IFN-γ in proximal
and distal colon segments compared with that of the DSS-colitic segments (Figure 5), while no
significant effect of supplementations was noted on other cytokine levels (Supplementary Figure
S1). B. coagulans and synbiotic treatments were equally effective in maintaining the levels of these
altered cytokines relative to that of non-colitic mice while PSCF did not show significant effective
reduction of IL-12 cytokine levels (Figure 5D). Synbiotic treatment was statistically more potent in
suppressing the elevated levels of IL-1α (−90.29%) and IL-12 (−67.42%) compared with B. coagulans
(−85.94%, −52.20%, respectively) in the DC. No positive effect was observed in the PC segment for
IL-6 and TNF-α levels by PSCF treatment. However, the excellent immunomodulatory effect in the
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Figure 5. Effect of B. coagulans spores, PSCF and synbiotic on immune markers in colon tissues and
blood serum. Protein levels of cytokines including (A) IL-1α, (B) IL-1β, (C) IL-6, (D) IL-12, (E) TNF-α,
(F) IFN-γ in proximal and distal colon explants as well as cytokine levels of (G) IL-1β, (H) IL-10, and (I)
IL-12 in blood serum were analysed by Bio-plex. iNOS activity in colon tissues (J) measured by NOS
activity assay and CRP levels in serum (K) by ELISA. Statistical significance among groups evaluated
by one-way ANOVA followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs.
DSS-colitic group and data expressed as mean ± SEM (n = 3 per group).
Similar immunomodulatory effects were found on the serum cytokines Il-1β, IL-12, and IL-10
(Figure 5G–I), while no significant effect was observed for other serum cytokines (Supplementary
Figure S1). All three treatments substantially restored the IL-12 levels to values similar to HC mice,
while synbiotic treatment was significantly more efficacious in reducing pro-inflammatory IL-1β
levels in serum. Moreover, B. coagulans and synbiotic treatments increased the anti-inflammatory
IL-10 levels in serum (181.2 ± 8.70, 184.7 ± 3.81 pg/mL respectively) compared with the DSS-colitic
group (143.8 ± 12.80 pg/mL) (Figure 3H). iNOS activity which is known to be high in colitis in
response to pro-inflammatory stimuli [33], was significantly suppressed in both colon segments by all
treatments (Figure 5J) compared with DSS-colitic levels. Serum CRP level was significantly higher in
the DSS-control group (14.58 ± 0.45 μg/mL) in comparison with HC animals (9.32 ± 0.45 μg/mL).
Bacillus, PSCF and synbiotic remarkably normalised the CRP levels (9.67 ± 0.34, 9.95 ± 0.65, 8.83 ± 0.59
μg/mL, respectively) to that of the HC group. These results confirmed the notable anti-inflammatory
efficacy of probiotic Bacillus spores, prebiotic PSCF and synbiotic treatments used in our study.
3.5. Effects of B. coagulans, PSCF and Synbiotic Supplementation on Altered Fecal Metabolic Profile in
DSS-Induced Mice
Fecal metabolites were analysed using GC-MS to gain an overview of changes induced by
B. coagulans, PSCF and synbiotic supplementation in DSS-treated mice. A total of 61 metabolites of
different functional groups such as sugars, amino acids, volatile fatty acids, and biogenic amines
were detected. A supervised partial least squares-discriminant analysis (PLS-DA) was performed
to evaluate metabolic phenotyping of each experimental group as shown in Figure 6A. The samples
from HC and DSS-control clusters were clearly divergent indicating marked distinction in metabolic
patterns between the two groups. While, clusters of supplemented mice samples overlapped with
that of HC and DSS-control, clear demarcation of the synbiotic and B. coagulans cluster was noted,
with PSCF showing only partial divergence relative to that of DSS-control. This indicates substantial
efficacy of B. coagulans to metabolise PSCF that, in turn, induced significant biochemical changes
potentially owing to their synergistic effects as evidenced from synbiotic samples. Combination of
PLS-DA (R2Y = 0.810 (p = 0.01), Q2 = 0.710), VIP scores (Figure 6B) and significance analysis for
microarrays (SAM) enabled us to identify potential biomarkers. The results showed 61 metabolites
with 40 statistically significant compounds contributing to the clustering, with their SAM scores fold
changes and International Chemical Identifiers (InChI) and standard InChI hashes (InChIKey IDs)
listed in Table S1. Key metabolic markers making a significant contribution were identified by VIP
analysis as displayed in Figure 6B. Among these identified metabolites, noticeable differences between
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DSS-control, and HC samples were noted particularly for succinic acid, stearic acid, and glycerol.
Synbiotic supplementation was beneficial in minimising the metabolite alterations induced by DSS
(Figure 6B and Table S1).











Figure 6. Effect of B. coagulans spores, PSCF and synbiotic on metabolic modulations in DSS-induced
colitic mice. (A) 2D-PLS-DA plot showing spatial division among groups that received different
supplementations, DSS-control mice that received no supplementation and HC. (B) Key compounds
separating the groups based on variable importance projection (VIP) score plot in PLS-DA analysis.
(BC-B. coagulans, Syn-synbiotic).
3.6. Effects of B. Coagulans, PSCF and Synbiotic Supplementation SCFA Levels in DSS-Induced Mice
As shown in Figure 7, supplementation of DSS-induced mice with B. coagulans, PSCF, and synbiotic
treatments induced substantial modulations in the SCFA concentrations and their effects varied across
cecal, luminal and fecal contents. Overall, the highest concentration of SCFA were noted in cecal
contents compared to mucosal and fecal contents. There were no significant differences between
the concentration of acetate and propionate in DSS-control and HC mice. PSCF however, induced
a significant increase in the acetate levels in cecal and mucosal samples while, Synbiotic treatment
was most significant in elevating acetate concentrations in mucosal-associated samples. All three
supplementations were significantly effective in improving the propionate concentrations in cecal and
mucosal contents while, only synbiotic supplementation increased propionate levels in fecal samples.
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Figure 7. Effects of B. coagulans spores, PSCF and synbiotic in modulating SCFA concentrations in
cecal, mucosal-associated and fecal contents in DSS-induced colitis. Cecal- acetate (a), proionate (d),
butyrate (g), valerate (j), succinate (m); mucosal-associated acetate (b), proionate (e), butyrate (h),
valerate (k), succinate (n) and fecal- acetate (c), propionate (f), butyrate (i), valerate (l), succinate
(o). -Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-colitic group and data expressed as mean ± SEM
(n = 5 per group). ns-non-significant
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Butyrate levels were significantly decreased by DSS administration (2.05 ± 0.6 μg/g) compared
with that of HC mice (7.91 ± 1.1 μg/g) in the cecum. The decrease in butyrate induced by DSS was
maintained at control levels with all three supplements in the cecum with PSCF (13.2 ± 2.4 μg/g)
being significantly more effective than B. coagulans (11 ± 0.9 μg/g) and synbiotic (10.4 ± 1.0 μg/g).
Similarly, in fecal content, PSCF significantly improved butyrate (13.6 ± 1.6 μg/g compared with
3.72 ± 0.1 μg/g for DSS-colitic followed by synbiotic (8.15 ± 0.6 μg/g) while B. coagulans (6.69 ± 0.1
μg/g) had no effect. Synbiotic supplementation resulted in marked increase in mucosal-assocaited
valerate while, PSCF caused elevation in its concentration in fecal content. Similarly, synbiotic was
more efficient in reducing elevated succinate levels.
4. Discussion
Dietary strategies involving probiotic and prebiotic fibre components that function by modulating
immune responses, colonic epithelial integrity and microbial composition and related metabolites are
being widely investigated for the prevention or reduction of severity of IBD [40,41]. The present study
clearly supported the premise that conditioning of the gut with synbiotic supplementation containing
compatible probiotic and prebiotic fibre can be greatly beneficial to reducing the symptoms and severity
of DSS-induced acute colitis in mice. The observations confirmed substantial anti-inflammatory
efficacy by synbiotic supplementation containing B. coagulans and PSCF. This was evidenced by the
improvement of clinical symptoms, macroscopic, histological, biochemical, metabolic and immune
parameters in the DSS-induced colitic mice model.
The addition of 2% (w/v) DSS to drinking water for seven days without ameliorating treatments
resulted in a progressive rise in DAI (Figure 1A), owing to both body weight loss (Figure 1B) and
excretion of diarrheic/bleeding feces. However, the supplementation of DSS-induced mice with
B. coagulans, PSCF, and their synbiotic combination significantly attenuated the severity of the DSS
damage and improved DAI and macroscopic markers of inflammation (Figure 1C–F). The ability of
PSCF to show early effect on DAI and body weight could be related to its high content of insoluble
hemicellulose. This fraction has a large water-holding capacity thus, could appropriately contribute
to regulating the fecal water content in colitic mice [42,43]. The anti-diarrheal effect of B. coagulans
have been previously confirmed [44]. The increased beneficial effects of synbiotic supplementation
in reducing the disease severity could be related to the synergistic actions between the probiotic and
prebiotic components.
A potentiated synbiotic effect relative to that of B. coagulans and PSCF individually was also
evident from the histology of the colon compared with DSS-control mice (Figure 2A,B). Synbiotic
supplementation showed substantial protection to the colonic epithelial architecture by mitigating
crypt disruption, loss of goblet cells, submucosal edema and epithelial structure damage induced by
DSS. Synbiotic supplementation also induced suppression of infiltration of activated neutrophils as
evidenced by significant reduction in MPO activity in DSS-induced mice (Figure 2C). The infiltration
of activated neutrophils is one of the most prominent histological features observed in IBD and is
directly proportional to the MPO activity. Superoxide anions and other reactive species produced
by neutrophils leads to tissue necrosis and mucosal dysfunction in IBD [39]. The reduction in MPO
activity suggests that synbiotic supplementation imparted an anti-inflammatory effect, in addition to
histological protection.
Disruption of intestinal epithelial TJs and impaired epithelial barrier function is a central event
in the pathogenesis of IBD and may lead to persistent aberrant immune reactions, thus accelerating
gut inflammation and the inflammatory circuit [45]. Synbiotic treatment in our study was the most
effective followed by B. coagulans and PSCF in protecting the expression level of TJ proteins (ZO-1,
occludin and claudin-1) in DSS-induced mice (Figure 4). TJs create a semi-permeable barrier against
paracellular penetration of harmful substances from the gut lumen [45]. Bacillus subtilis intake has
been recently confirmed to upregulate the expressions of TJ proteins for improved barrier function
in colitic mice [46] and corroborates with our results. Moreover, synbiotic and B. coagulans protected
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the goblet cells and mucin production more effectively than PSCF alone (Figure 3). This indicates the
possible ability of these B. coagulans MTCC 5856 spores to benefit goblet cell structure and function
and needs further investigation to determine the mechanism of this effect. Some Bacillus species have
been shown to upregulate mucin glycoproteins and protect colonic mucus layer integrity and goblet
cell function [47]. Although we could not confirm if synbiotic supplementation had a stimulating
effect on TJ proteins and/or localisation or, instead if it avoided TJ degradation by DSS, we observed
that synbiotic supplementation significantly maintained the TJ patterns similar to that of animals
in HC. This is indicative that synbiotic supplementation significantly preserved the integrity of the
epithelium. The synergy between B. coagulans and PSCF could have imparted excellent protection
and/or maintenance of epithelial integrity on DSS-induced mice, thus supporting its application in
IBD to reinforce intestinal barrier integrity.
Alterations in the barrier integrity in IBD also leads to aberrant immune responses resulting in
an inflammation cascade and tissue damage [48]. Although B. coagulans and PSCF supplementations
alone were able to modulate the tested cytokines (IL-1α, IL-1β, IL-6, IL-12, TNF-α, and IFN-γ), a more
profound anti-inflammatory effect was observed with synbiotic supplementation in both the colon and
serum (Figure 5A–I). A spike in the levels of IL-1β, IL-6, and TNF-α have been implicated in human
IBD pathogenesis [49]. Such pro-inflammatory cytokines are secreted at high levels by activated lamina
propria antigen presenting cells in response to inflammation. Pro-inflammatory cytokines such as IL-6,
TNF-α, and IL-1β are being targeted by therapeutic approaches to curb the aberrant inflammatory
response in IBD due to their roles in the pathogenesis of the disease [50–52]. TNF-α is reported to exert
its pro-inflammatory effect through elevated production of IL-6 and IL-1β [53]. This is in line with
the present study, where DSS-induction caused elevated secretions of these cytokines in DSS-control
group relative to that of HC (Figure 5). Upregulation of pro-inflammatory cytokine levels has also
been reported to upregulate iNOS expression and secretion of nitric oxide that causes tissue damage in
IBD [54]. The anti-inflammatory effects of synbiotic, B. coagulans and PSCF in suppressing the levels
of these pro-inflammatory cytokines as well as reducing iNOS activity in colonic tissues, indicates
their immunomodulatory potentials. B. coagulans MTCC 5856 spores in our previous study showed
excellent immunomodulatory effect in vitro [22]. Marked reduction in pro-inflammatory cytokines in
the colon of DSS-induced mice in the current study further supports its excellent immunomodulatory
efficacy in IBD application.
Synbiotic supplementation was the most effective in demonstrating noticeable anti-inflammatory
effect by significantly reducing the serum levels of pro-inflammatory IL-1β and IL-12 while
concurrently elevating anti-inflammatory IL-10 in the serum. IL-10 plays a prominent role in
counterbalancing Th1 and Th17 immune activity in IBD towards a Th2 response by downregulating
antigen presentation and subsequent release of proinflammatory cytokines thereby attenuating
mucosal inflammation [53]. IL-10 has been reported to play a role in maintaining intestinal
barrier integrity possibly owing to effects on zonulin pathway [55]. The ability of B. coagulans
spores to elicit IL-10 levels in inflammatory condition has been determined in vitro and in human
subjects. Thus, the anti-inflammatory efficacy of synbiotic supplementation could be related to major
immune-regulating capability of B. coagulans MTCC 5856 spores, thereby supporting its application
in synbiotic therapies for IBD. Furthermore, synbiotic treatment also reduced the increased CRP
levels in the serum of DSS-induced mice. In the inflammatory state, circulating IL-6 promotes CRP
production in the liver and its release into the bloodstream [56]. Elevated levels of CRP has been
implicated in human IBD patients [57]. The reduction in overall pro-inflammatory mediators by
synbiotic supplementation may be due to either direct immune-regulating effect of the B. coagulans and
PSCF on cytokine secretion or it could be owing to their indirect effect on the protection of intestinal
barrier integrity. In either case this leads to reduction in luminal antigens and full activation of the
innate immune system.
DNA extracted from cecal, fecal and mucosal-associated contents from DSS-induced mice in
the present study, failed amplification before 16s rRNA sequencing owing to the presence of DSS
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in the samples that inhibited the PCR amplification as known earlier [58]. The microbiota profiling
of DSS samples could therefore not be performed and is the limitation of the study. The levels
of microbiota-derived untargeted metabolites and SCFAs were therefore alternatively analysed as
signatures of the gut microbiota that contribute to modulating the immune activity of the intestinal
mucosa [59,60]. The untreated DSS-control mice exhibited distinct fecal metabolic phenotype relative
to that of HC. This was reflective of clinical and animal IBD studies that confirmed significant
differences in metabolic profiles between healthy and IBD patients [61–63]. The metabolic analysis
of supplemented mice in our study resulted in considerable normalization of metabolic profile
indicating the positive effects of synergistic combination of B. coagulans and PSCF that induced
marked improvement in metabolic pattern. Notably for mice supplemented with PSCF there was
not much distinction from the DSS-control group was observed but the synbiotic combination with
B. coagulans resulted in an improved metabolic pattern. This marked synergism could be associated
with the acceleration of fermentation of insoluble plant cellular materials, such as hemicellulose in
PSCF, by the supplemented B. coagulans [18]. The resulting higher levels of fermentation metabolites
would thus, in turn, influence other beneficial microbial metabolic activities. This further supports
the application of compatible synbiotic components to generate maximum benefits through increased
SCFA production.
Increased levels of microbiota-derived SCFAs are inversely associated with dysbiosis in IBD [64].
Of particular interest are higher levels of acetate, propionate and butyrate, which results from
fermentation of indigestible carbohydrates from fibre-rich diets. The effects of SCFAs have been
studied to in animal models of colitis [42] and clinical UC [65]. Each type of SCFA is likely to contribute
to host health [66]. In this study we determined the SCFA profile along the gastro-intestinal tract,
analyzing samples across cecal, mucosal-associated, and fecal contents. The concentration of SCFAs
varied along the length of the gut, with most abundant levels in the cecum and PC, while it declined
towards the DC [66]. In line with a recent study [67], cecum showed the highest levels of all the
SCFAs tested in our study irrespective of the supplementation. Cecum is considered the major site
for fermentation in the rodent gut and contains the largest pool of microbiota. It therefore generates
the most SCFAs. However, some recent studies have also reported changes in the microbiota and
associated amounts of metabolites in along different regions of gastro-intestinal (GI) tract [67–69].
Therefore, the overall GI profile is of importance when associating the gut microbiome and metabolites
with health outcomes.
All three supplementations caused a substantial increase in concentrations of measured SCFAs
compares with that of DSS-control group. However, the potentiated effect of synbiotic supplementation
is evidenced by induction of SCFA production along the entire length of the colon compared to
B. coagulans supplementation alone where the additional SCFA production capacity was absent past
the cecum. This effect highlights the advantage of using a compatible prebiotic fibre as synbiotic
companion with a particular probiotic that can metabolize it. The high total dietary fibre content of
PSCF (87%) [17] would contribute to this effect. PSCF supplementation resulted in increased butyrate
levels line with an in-vitro study with human gut microbiota utilizing sugar cane fibre [17]. The effect
of additional SCFA production in cecum by B. coagulans would not extend to the proximal or distal
parts of the colon. In the current study, the elicited extra SCFAs with synbiotic supplementation from
cecum to the fecal pellets indicated the ability of B. coagulans to utilize the PSCF to also generate SCFAs
after the cecum. The ability of B. coagulans to metabolize a variety of plant fibers for fermentation,
including cranberry fibre [70] and fenugreek seeds [71], to produce SCFAs and hemicellulose [18] for
lactic acid production has been previously determined.
PSCF supplementation also resulted in increased butyrate levels, correlating with results of an
in-vitro study with human gut microbiota utilizing sugar cane fibre [17]. This ability of synbiotic
supplementation for eliciting butyrate levels along the entire length of colon could contribute to the
beneficial effect observed in the current study. Butyrate is the preferred energy source for colonocytes
and has the ability to regulate cytokines thus showing protection against inflammation in UC and
95
Nutrients 2019, 11, 818
colorectal cancer [66]. Butyrate has been demonstrated in in vitro [72,73] and in vivo [74] studies
to increase epithelial integrity and mucus secretion, consistent with the immunohistological and
mucus staining analysis in the present study. The substantial increase in butyrate levels in the
cecum by B. coagulans supplementation may be due to ability to support the growth and activity of
butyrate producers probably via cross-feeding of the lactic acid production. B. coagulans are known
to be efficient at producing lactic acid through fermentation of various plant substrates, including
hemicellulose [18,19]. Lactic acid is reported to be utilized by strictly anaerobic butyrate-producing
bacteria of clostridial clusters XIVa for the production of high concentrations of butyric acid [75]. Thus,
the synbiotic approach with probiotic bacteria and prebiotic fibre that directly or indirectly influence
butyrate production may help to restore intestinal barrier integrity in diseased state. This effect was
evidenced by the significant reduction in DSS-induced colonic epithelial damage (Figure 2) by synbiotic
supplementation in our study.
Acetate and propionate have also been studied to benefit epithelial integrity via binding with
certain metabolite-sensing G-protein-coupled receptors (such as GPR43, GPR109A) and modulating
immune response [76–78]. Valerate that has been determined to stimulate intestinal growth and
attenuate inflammatory pathogenesis in colitis and cancer to metabolic disorders [79] was increased
by synbiotic supplementation. Besides its positive effect in colon, SCFAs have also been exhibited
to mediate improved host metabolism and modulate the activity of the enteric nervous system [66],
thus providing benefits beyond GI tract. The high levels of immuno-modulatory effects observed
in the present study could also possibly be correlated to high SCFA levels induced by synbiotic
supplementation owing to the synergistic combination. SCFAs by engaging with engage with GPRs
are known to induce immune-modulation leading to a direct local and systemic anti-inflammatory
effects [76,80]. This further supports the application of synergistic synbiotic combinations to achieve
maximum benefits in resolving the inflammatory circuit in IBD.
5. Conclusions
This is a detailed study highlighting the site-specific inflammatory and SCFA changes in a mice
model of IBD as a result of synbiotic supplementation of the normal diet with prebiotic whole plant fibre
and probiotic spores. The synbiotic pre-supplementation resulted in a substantial anti-inflammatory
effect, reducing disease severity, colonic damage, and inflammatory mediators while modulating the
metabolite and SCFA profiles of DSS-induced gut damage. The research has clearly demonstrated that
the supplementation of whole plant PSCF and B. coagulans spores produced a synergistic combination
that protected mice against acute damage induced by DSS in mice. The results underscore the
significant efficacy of synbiotic applications to increase the beneficial and preventive effects on the host
by targeting different mechanistic approaches to resolve inflammation cycle. However, the differences
in the evolved biology of humans compared to mice requires caution in translation of the results
to impacts on human disease [81]. While mice models do allow the changes in gut microbiota, as a
result of pre- and probiotic combinations to be studied in a controlled experiment direct human trials
will be needed. The delineation of the synergistic biological actions of probiotic B. coagulans spores
and prebiotic PSCF in mouse model of IBD provides support for investigating their therapeutic and
preventive effects in human IBD. However, the ability to reduce the severity of DSS-induced colitis
was demonstrated using pre-supplementation. Human trials should be aimed at proactive prevention
or after partial control of inflammatory disease, such as in association with drug treatment.
Patents: The information from this study has been filed as a provisional patent application in
Australia titled “Preparation for the Treatment of Inflammatory Bowel Disease using a Whole Plant
Fibre Extract from Sugar Cane” with application number 2018902145 and a filing date of 15 June 2018.
Information relating to novelty of synergy between probiotic Bacillus coagulans and prebiotic whole
plant sugar cane fibre in imparting health benefits is the subject of the patented claim.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/4/818/s1,
Figure S1: Effect of B. coagulans spores, PSCF and synbiotic on immune markers in colon tissues and blood serum,
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Table S1: Most significant compounds identified by OPLS-DA and SAM analysis in HC, DSS-control, B. coagulans
(BC), PSCF and synbiotic groups.
Author Contributions: Conceptualization: T.S., R.E., and R.S.; data curation: T.S.; formal analysis: T.S., A.P.P., R.V.,
S.S., and B.S.; funding acquisition: R.E. and R.S.; investigation: T.S.; methodology: T.S., S.V.G., A.V.K., and D.J.B.;
resources: S.V.G., A.V.K., D.J.B., R.E., and R.S.; supervision: R.E. and R.S.; validation: R.S.; visualization: T.S.;
writing—original draft: T.S.; writing—review and editing: T.S., S.V.G., A.V.K., D.J.B., R.E., and R.S.
Funding: This work was supported by industry grant from KFSU Ltd. (RT111031) allocated to R.S. and R.E.
Acknowledgments: The support from Tasmanian Government for Tasmania Graduate Research Scholarship for
the PhD study of T.S. is gratefully acknowledged.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Vindigni, S.M.; Zisman, T.L.; Suskind, D.L.; Damman, C.J. The intestinal microbiome, barrier function,
and immune system in inflammatory bowel disease: A tripartite pathophysiological circuit with implications
for new therapeutic directions. Ther. Adv. Gastroenterol. 2016, 9, 606–625. [CrossRef]
2. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.;
Wu, J.C.; Chan, F.K. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:
A systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [CrossRef]
3. Hou, J.K.; Lee, D.; Lewis, J. Diet and inflammatory bowel disease: Review of patient-targeted
recommendations. Clin. Gastroenterol. Hepatol. 2014, 12, 1592–1600. [CrossRef]
4. Palumbo, V.; Romeo, M.; Marino Gammazza, A.; Carini, F.; Damiani, P.; Damiano, G.; Buscemi, S.;
Lo Monte, A.; Gerges Geagea, A.; Jurjus, A. The long-term effects of probiotics in the therapy of ulcerative
colitis: A clinical study. Biomed. Pap. 2016, 160, 372–377. [CrossRef]
5. Abruzzo, A.; Damiano, G.; Altomare, R.; Palumbo, V.; Tomasello, G.; Buscemi, S.; Lo Monte, G.; Maione, C.;
Buscemi, G.; Lo Monte, A. The influence of some dietary components on intestinal microbiota. Prog. Nutr.
2016, 18, 205–212.
6. Steed, H.; Macfarlane, G.T.; Blackett, K.L.; Bahrami, B.; Reynolds, N.; Walsh, S.V.; Cummings, J.H.;
Macfarlane, S. Clinical trial: The microbiological and immunological effects of synbiotic consumption—A
randomized double-blind placebo-controlled study in active crohn’s disease. Aliment. Pharmacol. Ther. 2010,
32, 872–883. [CrossRef]
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Abstract: The biogeography of inflammation in ulcerative colitis (UC) suggests a proximal to distal
concentration gradient of a toxin. Hydrogen sulfide (H2S) has long been considered one such toxin
candidate, and dietary sulfur along with the abundance of sulfate reducing bacteria (SRB) were
considered the primary determinants of H2S production and clinical course of UC. The metabolic
milieu in the lumen of the colon, however, is the result of a multitude of factors beyond dietary sulfur
intake and SRB abundance. Here we present an updated formulation of the H2S toxin hypothesis
for UC pathogenesis, which strives to incorporate the interdependency of diet composition and the
metabolic activity of the entire colon microbial community. Specifically, we suggest that the increasing
severity of inflammation along the proximal-to-distal axis in UC is due to the dilution of beneficial
factors, concentration of toxic factors, and changing detoxification capacity of the host, all of which
are intimately linked to the nutrient flow from the diet.
Keywords: colon; high-sulfur foods; inflammation; metagenomics; microbiota; sulfur reducing
1. Introduction
Inflammatory bowel disease (IBD), which includes both Crohn’s disease and ulcerative colitis
(UC), is estimated to affect ~3 million individuals in the U.S. alone and continues to increase in incidence
and prevalence worldwide [1]. Epidemiological evidence implicates industrialization, an increasingly
western lifestyle, and associated changes in the microbiome with the development of IBD [2–4]. Diet is
a major determinant of intestinal microbiota composition and activity [4,5]; therefore, it is a focus of
intense interest for the mechanistic understanding of IBD pathogenesis.
The risk of IBD development increases in immigrant children from developing countries [6]
and substantial changes in the intestinal microbiome, including loss of diversity and displacement
of Prevotella by Bacteroides strains, which can be observed following immigration from developing
countries to the United States [7]. These findings lend strong support to the notion that changes in the
gut microbiota, driven in part by diet, contribute to the pathogenesis of UC. Although attempts to
identify consistent, specific ‘trigger’ foods that predict the development of UC have been unsuccessful,
there appears to be an overall trend for an association between an animal-based diet and UC
development and activity, while a plant-based diet may be protective against UC [8]. Conceptually,
the epidemiological data that demonstrates an increasing prevalence of IBD with westernization lend
support to this notion as westernization generally results in a transition from a plant-based to an
animal-based diet [9].
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The unique distribution of gut inflammation seen with UC, typically greatest in the rectum
and extending continuously towards the proximal colon, supports the notion that a directionally
concentrated toxic substance(s) may be involved in its pathogenesis. While the nature of this compound
remains unknown, several lines of evidence, both observational and mechanistic, implicate hydrogen
sulfide (H2S) as a possible candidate. The H2S toxin hypothesis, however, is complicated by the fact
that H2S at low levels can be anti-inflammatory [10]. Consequently, the H2S toxin hypothesis may be
better viewed in a concentration dependent manner where each individual host likely has a varied
tolerance to a specific concentration of H2S above which intestinal damage occurs [11].
To date, attempts to examine the role of diet in the H2S toxin hypothesis have focused primarily
on the intake of sulfur-containing foods, without regard for the overall diet composition [12–15]. It is
important to consider, however, that outside of a laboratory setting diets are far more complex than
can be captured by the measurement of a single or a few nutrients. Therefore, rather than focus on
the specific intake of a single dietary component (e.g., sulfur) in the pathogenesis of UC, an emphasis
should be placed on overall diet patterns (e.g., animal- vs plant-based diet). This approach has been
the focus of a number of recent reviews [16,17], and preliminary data suggest that these types of
compositional dietary changes may be beneficial in IBD [18].
The high protein content of animal-based diets provides a greater amount of sulfur that becomes
available to distal gut microbiota [19]. Additionally, the higher fat content of a typical animal-based diet
may lead to an increase in taurine conjugation to bile acids and a corresponding increase in the quantity
of sulfur in the colonic lumen through an endogenous source [20]. Importantly, an animal-based diet
pattern will also tend to be low in fiber, which may drive a metabolic shift of microbiota away from
carbohydrate and towards protein fermentation and increased mucin degradation (Figure 1) [21,22].
Figure 1. Contributions of an animal-based diet to hydrogen sulfide production. Legend: An
animal-based diet results in a greater amount of dietary sulfur available to distal gut microbiota, both
directly through sulfur-containing amino acids and indirectly through an increase in taurine conjugated
bile acids and mucin degradation.
A complimentary hypothesis to explain the directional biogeography of UC may be the dilution
of beneficial microbial metabolites along the luminal flow in the intestine. One such set of products
is the short-chain fatty acids (SCFA), which are generated as a result of complex polysaccharide
fermentation and play essential roles in colon physiology and mucosal homeostasis. Thus, butyrate (a
SCFA), in addition to being a preferred energy source for the colonocytes [23,24], also promotes the
presence of regulatory T cells in the colon [25,26], strengthens the gut barrier function [27], decreases
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epithelial oxygenation [28,29], and inhibits excessive colonic stem cell proliferation [30]. Furthermore,
the chemical milieu established by microbial metabolites impact the overall microbial community
structure through feedback loops affecting the relative abundances of different microbial trophic groups.
Lower pH, driven by higher concentrations of SCFA, favors the growth of methanogens over that of
sulfate reducing bacteria (SRB) [31], whereas H2S may increase the oxygenation in colonocytes by
inhibiting β-oxidation [32] and lead to the inhibition of obligate anaerobes that produce SCFA.
Therefore, the updated understanding of the H2S toxin hypothesis for UC pathogenesis presented
here strives to account for the activity of the entire microbial community rather than individual
microbial subgroups working in isolation (e.g., Desulfovibrio) and appreciates the interdependency of
diet composition on both the structure and function of the microbial community. In many respects, this
is a synecological approach to study of the relationship between gut microbiota and the development
of UC.
1.1. Toxic Effects of Hydrogen Sulfide
Although H2S is generated by the host and is increasingly recognized to have a multitude of
important beneficial physiologic functions [33], it becomes a potent toxin once its concentration exceeds
the detoxifying capacity in the tissue. Specifically, higher amounts of H2S generated in the intestine
have the potential to disrupt the gut barrier function, which may be an early and critical initiating
event in triggering the onset of UC and the perpetuation of its activity [34]. Traditionally, the H2S toxin
hypothesis has focused on the potential injurious effects of sulfide gas on the cellular metabolism of
colonocytes, mainly the inhibition of cytochrome c oxidase activity in mitochondria, which induces
oxidative stress in a fashion similar to cyanide [35]. Roediger and colleagues demonstrated that H2S
inhibits β-oxidation of butyrate by colonocytes, their preferred energy source [36]. Notably, UC mucosa
has lower rates of butyrate uptake and oxidation relative to healthy controls [37]. In summary,
oxidative stress and energy starvation caused by excessive H2S concentrations may lead to colonocyte
death, penetration of the epithelial barrier by the intestinal microbes and their direct interaction with
the mucosal immune system. Resulting inflammation leads to further disruption of the gut barrier,
decreased butyrate oxidation [37], and decreased mucosal sulfide detoxification and the subsequent
perpetuation of inflammation [38].
In recent years, considerable attention has also been focused on mucus integrity in UC. The mucus
layer of the colon consists of an outer (loose) and an inner (dense) layer, the latter being largely
impenetrable to the resident intestinal microbiota [39,40]. The inner mucus layer in UC patients and
in some animal models of IBD is more penetrable to bacteria relative to healthy controls [41]. Mucin
glycoproteins form the major building blocks of mucus. The dominant mucin secreted by the goblet
cells in the colon is MUC2, which contains cysteine-rich domains that mediate its multimerization
through disulfide bonds. H2S can directly break the sulfide bonds in the mucus and disrupt the MUC2
network leading to a loss of mucus viscosity and greater permeability [42].
1.2. Pre-Clinical Models
Some of the strongest support for the H2S toxin hypothesis in the literature comes from pre-clinical
models. The most commonly used animal model of IBD uses dextran sodium sulfate (DSS) to induce
damage to the epithelium [43]. This allows for bacterial translocation from the lumen of the intestine
resulting in inflammation [43]. This model is renowned for its simplicity and consistency in producing
epithelial damage similar to that seen in IBD and also lends support to a role of sulfur in the pathogenesis
of UC in humans.
In IL-10 knockout mice, a common murine model of IBD, a diet high in saturated fat increases the
presence of taurine-conjugated bile acids, leading to an expansion of the sulphite-reducing pathobiont
Bilophila wadsworthia and a greater severity of inflammation [20]. High fat diets also promote intestinal
inflammation in rats as well as adenoma formation in the presence of a mutagen [44]. A high protein
diet in a similar model increases SRB abundance and sulfide production and decreases the abundance
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of bacterial taxa associated with SCFA production and the amount of butyrate in stool [45]. Similarly, a
high protein diet has been associated with post-weaning diarrhea in piglets [46]. Taken together, a
high protein and saturated fat diet (characteristic of a western, animal-based diet) seems to result in an
increased capacity for H2S production, decreased capacity for butyrate production, and a potential to
cause intestinal inflammation.
1.3. Clinical Observations
Mesalamine, a first-line agent in treatment of mild-to-moderate ulcerative colitis, inhibits sulfide
production in a dose-dependent manner when added to a fecal slurry in vitro [47]. Furthermore,
UC patients taking mesalamine have reduced fecal sulfide relative to patients who do not [47]. It is
noteworthy that mesalamine and butyrate are both peroxisome proliferator activated receptor gamma
(PPAR-γ) agonists [48,49]. Stimulation of PPAR-γ promotes β oxidation of fatty acids and epithelial
hypoxia in the colon, which favors obligate anaerobes and lowers the abundance of Proteobacteria [50].
Interestingly, some antibiotics (e.g., aminoglycosides) which target Proteobacteria (including SRB)
have short-term benefits in UC patients [13,51].
Few studies have attempted to link dietary interventions targeting the updated H2S toxin
hypothesis (i.e., transition from a western-style diet) with UC. The available handful of reports is
limited to small case series or individual case studies (Table 1) [52–56]. These low dietary sulfur
interventions generally emphasize transitions to a plant-based, semi-vegetarian diet. While all these
experiences describe positive outcomes, conclusions are limited given the small patient numbers.
The earliest case series conducted by Roediger et al. included only four patients and relied on symptom
and histological criteria [52]. These patients sustained improvement in the activity of UC over 18
months of follow-up, while being maintained on the low sulfur diet. Chiba et al. reported a decreased
relapse rate of UC relative to historical expectations among 60 patients instructed to follow a plant-based
diet and followed for up to five years [56].
Table 1. Summary of reports detailing dietary interventions in the treatment of ulcerative colitis (UC)
targeting the updated H2S hypothesis.
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2. Sources of Sulfur in the Colon
2.1. Dietary Intake
While sulfur is ubiquitous in the food supply [57], and the fifth most abundant element on earth,
its dietary linkage is not well characterized. For example, the USDA Food Composition Database
does not include sulfur as a searchable nutrient. The sulfur content of food can be estimated using the
sulfur-containing amino acids (methionine and cysteine) as surrogates, but this fails to account for
sulfur-containing food modifiers or additives, such as sulfiting agents (e.g., potassium bisulfate, sodium
bisulfate), sulfuric acid, or carrageenan [58]. Therefore, the most robust method of estimating dietary
sulfur intake, including an estimate for inorganic sulfur, is through a 24–48 hour urine collection [59,60].
Because the primary dietary sources of sulfur are the sulfur-containing amino acids, in practice,
quantification of sulfur-containing amino acid content has been used to create low- and high-sulfur
diets [52,61].
Dietary input and small intestinal absorption are considered the main determinants of sulfur
delivery to the colon [19]. The small intestine has an efficient but saturable dietary sulfate absorptive
capacity of ~5–7 mmol/day [62]. Once dietary sulfate intake exceeds ~5–7 mmol/day the amount
reaching the colon increases linearly with intake. Therefore, the amount of dietary sulfur that reaches
the colon, particularly with increasing levels, can be generally assumed to parallel dietary intake.
A number of additional factors, however, such as food preparation (e.g., cooked versus uncooked,
cooking temperature and method, ground versus whole), meal consumption habits (e.g., chewing),
and transit time have been shown to influence small intestinal absorption of sulfur-containing molecules
and the total amount of sulfur reaching the colon [63–67].
2.2. Endogenous Sources
The main endogenous sources of sulfur are taurine-conjugated bile acids and mucin. Taurine is a
sulfur-containing amino acid that is synthesized in the liver from methionine and cysteine. Diet can
influence the rate of taurine conjugation and subsequent presence of taurine conjugated bile acids in
the colon [68]. Although the majority of bile acids are re-absorbed in the distal small intestine into the
enterohepatic circulation, a small percentage will spill into the colon [69]. Deconjugation of bile acids
is an early step in secondary bile metabolism and is mediated by gut microbiota.
Intestinal mucins are glycoproteins that form a mucus barrier along the epithelial surface of
the gastrointestinal tract. The primary intestinal mucin MUC2 contains cysteine amino acids as
core components of its structure [39,70]. Glycosylation of mucin proteins makes up a substantial
portion of their size and provides protection of the peptide backbone and the gel-forming capacity [70].
The glycosylation pattern of mucin varies along the intestinal tract with increasing sulfation moving
distally through the small intestine and into the colon [71,72]. The colonic mucus barrier is
predominately composed of sulfomucins with a trend toward slightly diminished sulfation moving
distally (100% sulfation in the right colon and 86% in the rectum) [73]. The normal sulfation pattern is
altered in UC and is associated with the concentration of SRB [73].
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2.3. H2S Measurement
The ideal experimental system to test the role of H2S in UC pathogenesis would be able to measure
its intraluminal concentration at different segments in the intestine. Unfortunately, technology to do
that does not yet exist; therefore, studies that measure H2S have focused on ex-vivo determination of
its production from fecal samples. Fecal concentrations of hydrogen sulfide, however, are notoriously
difficult due to the volatility of the gas, low intestinal concentrations, and instrumentation issues.
Historically, the majority of work assessing stool sulfide concentrations in UC relied on colorimetric
assays [62,74,75]. This method requires ‘trapping’ H2S in fresh fecal samples for measurement and is
associated with a number of inherent limitations [76,77]. Ion-exchange chromatography has also been
used to measure H2S in feces [78].
H2S gas measurements, done using gas chromatography (GC) with sulfur chemiluminescence
detection, are considered the reference standard for H2S measurement [79]. These measures, however,
cannot be obtained in real time and require in vitro incubation of the fecal sample. Only one study of UC
has used GC as the measurement method and found that H2S production was elevated substantially
in UC compared to controls over a 24 hour period [80]. Although this method does not capture the
H2S content of fresh fecal samples, in vitro incubation may reflect in vivo H2S production capacity of
the microbiota, providing a functional measure of the microbiota metabolic capacity. Furthermore,
this method allows for interrogation of the capacity of various dietary components to affect H2S
production (e.g., more H2S production with cysteine or mucin vs sulfate) [80,81].
3. Colonic Microbiota and H2S Production
3.1. Sulfate-Reducing Bacteria
Microbial production of H2S is generally thought to be carried out by a limited number of bacteria
and archael species. Sulfate-reducing bacteria (SRB) and the dissimilatory sulfur cycle, a form of
anaerobic respiration that uses sulfate as the terminal electron acceptor, have been the primary focus
of the H2S toxin hypothesis in UC [14]. This pathway generates H2S as an end-product of sulfate
reduction. The pathway consists of three enzymatic steps involving ATP sulfurylase, adenosine
5’-phosphosulfate reductase, and sulfite reductase [82]. The final step in the pathway, sulfite reduction,
is considered the rate limiting step. The genus Desulfovibrio is regarded as the most abundant SRB in
humans [83]. Despite the focus on Desulfovibrio spp. as the primary producer of H2S in the human gut,
the number of microbial groups known to be capable of dissimilatory sulfate reduction continues to
expand [82,84]. Many of these microbes can also reduce sulfite, dithionite, thiosulfate, elemental sulfur,
and several thionates. The three sulfite reductase genes which catalyze the production of hydrogen
sulfide are dissimilatory sulfite reductase (dsr), anaerobic sulfite reductase (asr), and cytochrome c
sulfite reductase (mccA) [82].
In humans, the measurement of key enzymes involved in the sulfate reduction pathway is a more
specific method for measurement of SRB than measurement of bacterial genera such as Desulfovibrio [85].
This approach identified a unique capacity of SRB genera in UC to generate H2S and induce epithelial
apoptosis, compared with healthy controls [74,86]. Recent multiomics data in colon cancer lends
additional support to the importance of accounting for the functional capacity of microbes (e.g., via
measurement of key enzymes) in addition to their community composition [87].
Despite their importance and usefulness, there is a dearth of literature that relies on the
quantification of sulfite reductase genes to characterize SRBs in large UC cohorts. Use of this
technique in healthy subjects demonstrated that an animal-based diet increases sulfite reductase gene
expression [5]. Recent work by Jia et al. used a semi-nested PCR method to detect dsrB DNA, but failed
to find a difference in abundance between healthy and UC cohorts (n = 18 and n = 14, respectively) [88].
The agar shake dilution method, which measures SRB growth over a specified incubation period,
has often been employed to measure SRB in individuals with UC. Studies done using this methodology
found elevated SRB abundance in individuals with UC compared to those without [47,74,89].
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3.2. Cysteine Degraders
Although sulfate intake and quantity of SRB has been the primary focus of the H2S toxin hypothesis,
there is a growing appreciation for the contribution of protein intake to H2S production. The efficiency
of protein degradation is greatest in the distal colon and at neutral to alkaline pH, which suggests
a possible relationship with the pathogenesis of UC [90]. A cross-over diet study conducted by
Magee and colleagues demonstrated that dietary protein intake positively correlates with fecal sulfide
concentrations in healthy individuals [78].
A recent in vitro study that profiled gas production from incubated fecal samples implicated
cysteine specifically as a primary driver of H2S production—conversely, the effect of sulfate was
small [81]. Cysteine degradation to H2S is catalyzed by enzymes with cysteine desulfhydrase
activity. Although the enzymes with cysteine desulfhydrase activity are well characterized in
humans [91], identifying enzymes with this activity in microorganisms has proven far more challenging.
Escherichia coli possess several enzymes with cysteine desulfhydrase activity, including O-acetylserine
sulfhydrylase-A, O-acetylserine sulfhydrylase-B, MalY, tryptophanase and cystathionine β-lyase [92].
Because cysteine likely makes a substantial contribution to H2S production in the colonic lumen,
there is a critical need to detail cysteine desulfhydrase activity within the colonic microbiome.
Prevention of excessive cysteine degradation to H2S may underlie the possible protective role
of appendectomy for appendicitis in UC [93]. Although the mechanism underlying the purported
beneficial effect of appendectomy in UC has yet to be elucidated, one possibility is related to the
potential role of the appendix as a reservoir for gut microbes [93]. Specifically, the appendix contains
Fusobacterium spp. in its healthy state [94] and appendicitis is associated with an abundance of this
bacteria [95]. Fusobacterium spp. contain a number of proteins necessary to metabolize L-cysteine
to H2S [96,97]. Therefore, removal of the appendix, and subsequently a source of H2S production,
may contribute to its possible therapeutic role in the prevention of UC.
3.3. Interplay Between Functional Microbial Groups
A number of physicochemical factors shape the composition and functional output of microbial
communities, which need to be integrated in order to fully account for the inter-individual differences.
One such factor is the availability of hydrogen (H2), which is essential as a substrate for anaerobic
respiration in the colonic lumen. The groups of bacteria that rely on and compete for H2 for anaerobic
respiration are acetogens, methanogens, and SRB (Figure 2) [98]. H2 production results from microbial
fermentation of carbohydrates in the lumen of the intestine. Therefore, the balance between H2
production and consumption is often referred to as the ‘hydrogen economy’ [99]. An imbalance of H2
consumption and production may result in a metabolic environment that consumes NADH for H2
production at the expense of butyrate production [100]. In the context of the H2S toxin hypothesis,
it is important to consider possible imbalances in H2 consumption (e.g., altered SRB concentration)
or production (e.g., low dietary intake of fermentable carbohydrate) that could create a metabolic
environment leading to UC—namely, excessive H2S production [80], mucin degradation [22,41],
and diminished butyrate production [5].
Other physical (e.g., intestinal transit time) and chemical factors (e.g., pH and oxygen tension),
also contribute to the microbial community structure in the colon by favoring some groups of microbes
over others. Accelerated colon motility is likely to benefit fast-growing microorganisms and disfavor
slow growing microorganisms, and constipation is associated with higher carriage of methanogenic
archaea and increased methane production [101]. Fermentation of digestible carbohydrate results in
the production of SCFA and a drop in luminal pH in the colon relative to the small intestine [102–104].
Increased dietary fiber also results in faster intestinal transit [105]. Indeed, the colon pH is lowest
proximally and increases distally, which is likely driven by the decreasing availability of digestible
carbohydrate [102]. Mildly acidic pH, characteristic of the proximal colon, is inhibitory to the growth
of SRB, but favors the growth of methanogens and some butyrate producers [30,106,107]. In contrast,
sulfate reduction and H2S production are optimal at an alkaline pH [108].
108
Nutrients 2019, 11, 931
Figure 2. Bacterial competition for hydrogen for anaerobic respiration in the lumen of the intestine.
Legend: Acetogens, methanogens, and sulfate reducing bacteria are the microbial groups that compete
for H2 in anaerobic respiration in the lumen of the colon. The availability of hydrogen can shape the
composition and functional output of microbial communities.
3.4. H2S Clearance
Clearance of hydrogen sulfide in the gut can be viewed as the final component of the H2S toxin
hypothesis. Due to its potential deleterious effects, H2S is highly regulated in the cell. As H2S is freely
permeable across membranes, luminal concentration in the colon would be expected to correlate with
intracellular concentrations [10]. Recent work in animal models demonstrates the relationship between
luminal H2S and intracellular regulation [109]. Although a small amount of H2S present in the lumen
of the colon is able to be cleared through flatus [110], the primary pathway for H2S clearance is via
intracellular sulfide oxidation. Interestingly, this pathway may be facilitated by cyanide, which has
been proposed by Levitt and colleagues to explain the well-documented beneficial role of smoking in
UC [111].
Colonic mucosa possesses a very efficient system for H2S detoxification, and defects in these
pathways are hypothesized to contribute to pathogenesis of colitis [111,112]. In earlier work,
thiol methyltransferase and rhodanese were thought to have a major role in the detoxification
of intestinal H2S [113]. However, the investigators found conflicting results when using these enzymes
to estimate the H2S detoxification capacity in UC [38,114]. Around the time this work was being
conducted, however, a more detailed and comprehensive understanding of H2S detoxification was
being developed that implicates sulfide quinone oxidoreductase (SQR) as the rate-limiting enzyme in
sulfur oxidation [115,116].
The SQR enzyme is located within the inner mitochondrial membrane [117]. The reaction of H2S
with SQR results in oxidation of H2S to a small-molecule persulfide and reduction of coenzyme Q
(CoQ), which links H2S oxidation with complex III of the electron transport chain [117]. The sulfur
transfer from H2S to a small molecule acceptor occurs via a cysteine intermediate within the SQR
enzyme. Therefore, the availability of a small molecule acceptor is believed to be the rate-limiting step
in the SQR reaction [118]. The antioxidant glutathione (GSH) is also believed to be the primary acceptor
in a physiological setting, but sulfite has also been proposed as an alternative acceptor [118]. If GSH is
utilized as the acceptor, the result is formation of glutathione persulfide (GSSH), which is then utilized
by persulfide dioxygenase (ETHE1) or rhodanese to form sulfite or thiosulfate, respectively [117,119].
If sulfite is used as the acceptor, thiosulfate is produced, and rhodanese instead converts thiosulfate to
GSSH, which is then converted to sulfite by ETHE1 [117,119]. In a steady state, GSH has been estimated
to be favored ~5:1 over sulfite [118], but elevated intracellular sulfite concentrations or depletion of
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GSH have been suggested to inhibit SQR [116,118,119]. Furthermore, although H2S oxidation appears
to be a robust pathway for intracellular control of H2S levels, an excess of H2S may paradoxically result
in feedback inhibition of SQR from the electron transport chain as a result of its deleterious effect on
cytochrome c oxidase activity [119].
The H2S detoxification capacity and expression of enzymes involved in the H2S detoxification
pathway (SQR, ETHE1, and thiosulfate sulfurtransferase) have been shown to follow a general trend
of highest in the proximal colon to lowest in the rectum [120]. This expression pattern lends further
support to the H2S toxin hypothesis as the progression of UC progresses from the lowest to the highest
H2S detoxification capacity and enzyme expression (Figure 3). In addition, GSH synthesis has been
demonstrated to be impaired in IBD [121].
Figure 3. Overview of metabolic milieu and influence of diet in the pathogenesis of ulcerative colitis.
Legend: The distribution of inflammation seen with ulcerative colitis is typically greatest in the
rectum and extends continuously towards the proximal colon with varying severity. This pattern of
inflammation parallels decreasing expression of the host H2S detoxifying enzymes, rising pH, and
decreasing concentrations of short-chain fatty acids (SCFA). A plant-based diet promotes greater
production of SCFA, but not H2S. SCFA production decreases in an animal-based diet, while H2S
production increases; however, there is a sufficient capacity for H2S detoxification to prevent epithelial
cell damage. Nonetheless, a decreased capacity for H2S detoxification results in inflammation, which
in turn further exacerbates the gradients of SCFA and H2S concentrations along the proximal-to-distal
colon axis.
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4. Dietary Factors Influencing Colonic H2S Production
4.1. Protein
Dietary protein has been shown to be a robust driver of in vitro and in vivo H2S production [78,81].
Furthermore, the efficiency of protein degradation is inverse to that of carbohydrate fermentation (and
SCFA production) and parallels that of UC pathogenesis (highest in the distal colon and decreasing
proximally) [90]. Dietary protein is efficiently absorbed in the small intestine, but the amount reaching
the colon is thought to be positively correlated with the amount consumed [90].
In both human and animal studies, a high protein diet results in fecal microbiota changes that
increase H2S production and decrease SCFA production [5,45]. Increases in SRB and Bacteroidetes sp.
observed in UC also occur in a high protein diet [5,45,122] and observed decreases in specific butyrate
producing species within a high protein diet (F. Prausnitzii, Akkermansia, and Ruminococcus) mirror
those seen in UC [45,122–124].
Sulfur-containing amino acids are the primary source of dietary sulfur. Because of limited
information on the sulfur content of food, outside of a metabolic unit, a ‘high’ or ‘low’ sulfur diet
is defined according to cysteine and methionine concentration [52]. Therefore, a ‘low sulfur’ diet is
actually a ‘sulfur-containing amino acid-controlled diet’, rather than a true ‘sulfur-controlled diet’ [52].
In general, a sulfur-containing amino acid-controlled diet results in a shift from a more traditional
western diet (high in animal protein and fat, and low in fiber) to more of a plant-based diet (high in fiber,
low in animal protein and fat). Recently published diet composition data from a small sulfur-containing
amino acid diet intervention study (n = 4) conducted in the U.S. suggests that a typical U.S. diet is
already high in sulfur-containing amino acids; a transition from a baseline diet to a ‘high sulfur’ diet
results in minor diet composition changes, while a transition from a baseline to a ‘low sulfur’ diet
results in a substantial transition from an animal-based to a plant-based diet (resulting in increased
fiber, and decreased protein and fat intake) [61].
As described above, H2S production capacity is often characterized by quantifying SRB, but
cysteine desulfhydrase activity provides another route of H2S production for the colonic microbiota
that is often left unassessed. In fact, in vitro modeling using healthy human feces suggests that the
contribution of cysteine to H2S production is substantially more than that from sulfate [81].
4.2. Carbohydrate and Fiber
High carbohydrate availability in the colon, as noted above, promotes microbial groups able to
utilize carbohydrate substrates, but also affects other aspects of microbial metabolism and especially
impacts protein degradation. The addition of fermentable fiber to healthy human feces in an in vitro
setting drastically reduces H2S production from any source (e.g., cysteine, sulfate) [81]. Lower pH
associated with microbial carbohydrate fermentation also leads to inhibition of dissimilatory aromatic
amino acid metabolism [125]. Interestingly, stool pH is lower in vegan and vegetarian individuals
relative to omnivores, consistent with greater abundance of carbohydrates in the proximal colon,
faster colon transit, and higher delivery of SCFA to the distal colon [126]. This finding underscores
the importance of overall diet composition when considering the relative proportions of different
end-products of microbial metabolism.
4.3. Dietary Fat
Although there is little data supporting a direct role of dietary fat in the H2S toxin hypothesis,
animal fat was shown in a murine model to result in increased production of taurine-conjugated bile
acids and a bloom of the sulfite-reducer Bilophila wadsworthia in the colonic microenvironment [127].
A high fat diet in mice is associated with lesser production of SCFA and greater production of H2S,
even when the protein content of high fat chow is lower relative to regular chow [128]. It is obvious that
a relative contribution of macronutrients to H2S production is difficult to isolate in a single comparison,
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given that an increase in one will correspondingly necessitate reduction in at least one other to maintain
the same caloric intake.
4.4. Endogenous Sulfur
The most significant source of endogenous sulfur (both as sulfate and cysteine) is intestinal mucin.
The mucous layer of the colon is composed of two layers [40], the microbiota is abundant in the
outer loose mucous layer, while the inner dense mucous layer—largely devoid of bacteria—maintains
a barrier between the colonic microbiota and colonocytes [39,40]. The composition of the colon
microbiota has been shown to influence mucin secretion, breakdown, structure, and the glycosylation
pattern [22,42,129–131]. Conversely, mucin glycosylation patterns have been shown to influence the
colonic microbiota [132]. Therefore, the H2S toxin hypothesis must consider these complex relationships
between the mucin, microbiota, and diet. A characteristically high sulfur diet (high in animal protein
and fat, and low in fiber) leads to nutrient deprivation for the microbiota and results in increased
mucin desulfating sulfatase activity and mucin degradation [5,22,131,133]. This pattern is remarkably
similar to that seen in UC [134–136]. The phenotypic changes resulting in increased mucin breakdown
(e.g., low fiber) and H2S production (e.g., high protein/sulfur intake) [5,22,45,78] may produce H2S
concentrations that overwhelm the detoxification capacity of colonocytes and contribute to H2S toxicity.
4.5. Miscellaneous Dietary Factors
Finally, it is also important to consider factors that may correlate with sulfur content in the diet but
are not related to sulfur metabolism. An increased intake of heme, present in its highest concentrations
in red meat, can have cytotoxic effects on colonocytes [42]. Consumption of processed foods expose
individuals to additives such as phosphates, nitrates, and emulsifiers, which have been shown to
influence the composition of microbiota, mucin layer thickness, and intestinal inflammation [137–140].
Even specific cooking methods may alter the potential of diet to impact the intestinal microbiome and
microbiota-host interactions. Both enzymatic and non-enzymatic mechanisms of protein modification
may also influence intestinal H2S production. Thus, glycation of dietary protein can to shift the colonic
microbiota towards greater abundance of SRB and lesser production of butyrate [64]. Conversely, there
are likely undiscovered or underappreciated components of a plant-based diet that may be protective
in UC [141].
4.6. Inflammatory Factors
Onset of inflammation triggers a number of positive feedback loops that amplify the detrimental
effects of H2S on the homeostasis of colonic mucosa. Increased synthesis of inducible nitric
oxide synthetase (iNOS) results in increased release of nitrate, which contributes to dysbiosis by
encouraging the expansion of facultative anaerobic Proteobacteria [28]. Nitric oxide also impairs H2S
detoxification [109], thus lowering the threshold concentration where H2S becomes toxic to epithelial
cells. Epithelial injury results in crypt hyperplasia and loss of epithelial hypoxia, which are detrimental
to butyrate-producing obligate anaerobes. In animal models and human studies, SCFA (and specifically
butyrate) production is inhibited in the presence of inflammation [122–124,142]. Inflammation is
also correlated with a lower BcoAT gene content of fecal microbiota, consistent with lower butyrate
production capacity [143]. Collectively, these changes hasten the collapse of the gut barrier to intestinal
microbes and inhibit regulatory immune circuits, such as regulatory T cells, which further augment
the inflammatory response.
4.7. Interventions Targeting the Colon Microbiota
The underlying mechanisms that make up the H2S toxin hypothesis are supported by
changes produced with fermentable fiber supplementation in individuals with UC (increased
butyrate production) [144] and findings from a recent fecal microbial transplantation (FMT) trial
that demonstrated a correlation between sustained remission and increased butyrate production,
112
Nutrients 2019, 11, 931
while increased abundances of Bacteroidetes and Proteobacteria correlated with no response or
relapse [122]. Notably, members of the Bacteroidetes phylum contain mucin desulfating sulfatase
enzymes [122,145,146]. The FMT in UC findings have also been recently expanded upon by Wei et al.
who demonstrated a role for fiber in maintaining the gut microbiota composition in individuals with
UC following FMT [147].
The role of carbohydrate, and more specifically fermentable carbohydrate, intake within the H2S
toxin hypothesis may be its overall impact on protein degradation by colonic bacteria. These findings
are supported by a diet study in healthy volunteers [148], where administration of metronidazole
effectively reduced SRB counts, but fecal concentration of H2S remained unchanged. In contrast,
consumption of fermentable fiber (oligofructose) resulted in a decrease in fecal H2S, concomitant
increase in SCFA concentrations, but failure to influence SRB counts. The impact of fiber on microbial
H2S production is further supported by recent data demonstrating a decrease in SRB with a high brassica
diet (sulfur-containing vegetables) [149]. Although brassica vegetables are technically considered to be
high sulfate foods, they also have a high fiber content. These findings underscore the beneficial role for
the latter within the H2S toxin hypothesis and support a clinical approach focusing on plant versus
animal-based diets rather than high- and low-sulfur diets.
It is important to consider that while short-term changes in diet can affect activities of different
microbial groups in the intestine, they do not change the overall individual-specific taxonomic
composition of microbiota [61,150]. Short-term low carbohydrate, high protein diets are among the
most popular approaches used to achieve weight loss. Such diets do result in decreases in relative
abundance of some butyrate producing bacteria, as well as altered fecal metabolite profiles, including
lower content of SCFA and fiber-derived antioxidant phenolic acids [151]. It is possible that such
dietary changes can even trigger the onset of UC, which may be reversed with increasing plant-derived
dietary components [54,56]. However, long-term diets low in microbiota-accessible carbohydrates
can lead to complete extinctions of microbial taxa [152]. Therefore, it is possible that most consistent
benefits of dietary therapies will also require transplantation of relevant microbiota, optimized in
capacity for the individual patients.
5. Conclusions
There is an intriguing body of literature supporting a relationship between dietary sulfur intake
and the H2S toxin hypothesis in the development of UC. To date, the focus of the H2S toxin hypothesis
in UC has primarily been focused on the abundance and activity of SRB (e.g., Desulfovibrio) and
dietary sulfur intake. However, this provides only a partial window on the total activity of the
microbiota that is relevant to UC pathogenesis. An updated approach to the H2S hypothesis has to
incorporate interactions between different microbial groups as well as multiple components of the
diet. A compelling case does exist that a typical western diet, which tends to be high in protein and
low in fermentable fiber, may promote the accumulation of harmful products such as H2S and even
increase their toxicity, and is also associated with a lower production of beneficial products such as
butyrate. Patients are intensely interested in adjunctive dietary therapies for UC. Multiple technological
developments that allow compositional and functional measurements of entire microbial communities
should facilitate the development and testing of novel microbiota-targeting interventions that include
the dietary management of IBD.
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Abstract: Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the
gastrointestinal tract. The rising incidence of IBD has been associated with urbanization and shifts
toward a Westernized diet. The intestinal microbiome has been a focus of disease pathogenesis
and also therapeutic intervention. Dietary therapy for IBD has been well-studied with exclusive
enteral nutrition, a formula-based diet with the exclusion of foods. In addition, interest in food-based
exclusion diets has been increasing, with patients and families leading the charge. Challenges with
dietary therapy for IBD include the lack of understanding of a detailed mechanistic pathway to
explain the impact of diet on IBD pathogenesis and the difficult nature of designing and implementing
dietary clinical trials. Epidemiological studies have demonstrated associations and intervention
studies have demonstrated efficacy, but specific dietary targets remain as hypotheses at present.
Current IBD therapy focuses on suppression of the immune system, yet the incomplete efficacy of
present drugs suggests that other therapies must be developed and employed. Dietary interventions,
with known ability to modulate the intestinal microbiome, are a unique opportunity to improve
outcomes in IBD. Dietary intervention trials are challenging, and capturing both broad dietary
patterns as well as exposure to individual food compounds is important. With increasing patient
interest and preliminary research in dietary therapy indicating efficacy, it is imperative to further
advance the science of utilizing diet in IBD, as well as to support patients by proactively addressing
diet within their care plan.
Keywords: inflammatory bowel disease; Crohn; ulcerative colitis; diet; nutrition; exclusive
enteral nutrition
1. Background
Nutritional interventions play a central role in the treatment and management of inflammatory
bowel disease (IBD). While malnutrition is a common presentation in IBD, nutritional interventions
have not only focused on correcting nutrient deficiencies but also on improving disease activity and
symptoms. In addition to other societies, the North American Society for Pediatric Gastroenterology
Hepatology and Nutrition has issued clinical guidelines emphasizing the importance of nutritional
interventions in pediatric IBD. These guidelines focus on the use of exclusive enteral nutrition (EEN),
a formula-based therapy, in pediatric Crohn’s disease [1–3]. Since the publication of these guidelines,
further research has expanded the concept of food-based nutritional intervention in patients with
IBD. Recent research has shown the impact of diet on all three components of the IBD paradigm: the
intestinal microbiome, mucosal integrity, and the immune system. With known influence on disease
pathogenesis and perpetuation, diet in IBD is developing into a powerful, state-of-the-art treatment
for IBD.
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The history of nutritional therapy for IBD began with initial observations in hospitalized adults
with severe Crohn’s disease who improved on EEN [4,5]. Since the initial report of EEN in IBD in the
late 1970s, there have been over 200 publications on EEN with multiple meta-analyses showing that
the use of EEN in children with Crohn’s disease is as effective as corticosteroids at inducing remission
of active inflammation [6,7]. In adults with Crohn’s disease, EEN has shown conflicting results. A 2018
Cochrane Database Systematic Review comparing EEN versus steroids showed greater efficacy of
steroids [8]. It is unclear whether the perceived difference between efficacy in pediatric and adult
EEN studies is related to compliance with therapy, greater duration of disease, or prior exposures to
immunosuppressive drugs. Two studies in adults with newly diagnosed Crohn’s disease showed
similar efficacy with EEN involving a nasogastric tube option [9,10].
Immunosuppressive therapies are not effective at treating IBD for all patients and carry risk.
The foods we eat have been hypothesized to play a role in pathogenesis as well as exacerbation of
inflammation for many years. With basic science research showing the effect of dietary exposures on
the intestinal microbiome as well as mucosal integrity, renewed interest has emerged on the ability of
diet to treat the inflammatory burden characterizing patients with IBD. Despite the complexities and
difficulty in doing clinical nutrition research, epidemiologic research has identified dietary components
that are protective and risk factors for the development of IBD [11,12]. In addition, many diets have
been reported to be efficacious in small case series, including the specific carbohydrate diet (SCD),
IBD anti-inflammatory diet (IBD-AID), Crohn’s disease exclusion diet (CDED), and semi-vegetarian
diet [13]. The SCD developed by Dr. Sydney Haas, a pediatrician, in the 1930s to treat patients with
celiac disease has been one of the better studies of exclusion diets used in IBD [14]. It was popularized
in the late 20th century by Elaine Gottschall, whose daughter’s ulcerative colitis was successfully
treated with the SCD by Dr. Haas [15]. The SCD and other exclusion diets have risen in popularity
among patients, and research efforts are underway attempting to keep pace with patient demand.
2. IBD Pathogenesis
The pathogenesis of IBD, while not completely elucidated, is thought to be multifactorial with
interplay between genetics, the environment, and the immune system. The major environmental
factors associated with IBD include shifts in diet, antibiotics, other medications, air pollution, infections,
major life stressors, and smoking [12,16]. Diet is an environmental exposure that has changed over
time, is modifiable, and has increasingly become a component of the treatment paradigm for IBD.
A look at the epidemiologic patterns of IBD, with highest prevalence in Northern Europe and North
America and rapidly increasing incidence in more-industrialized countries, has led to the theory that a
Westernized lifestyle, and in particular diet, is linked to the rising incidence of IBD [17].
Understanding the role of dietary therapy in IBD requires an appreciation of the intestinal
microbiome and intestinal mucosal integrity or barrier function. The intestinal microbiota consists
of thousands of bacterial species with a gene pool 150 times larger than the human genome,
with tremendous functional diversity [18]. The intestinal mucosal barrier consists of epithelial
cells connected by tight junctions, antimicrobial factors, and overlying inner and outer mucus layers
that limit the interaction between the microbiome and immune system [19]. In IBD, the homeostasis
between the microbiome, intestinal barrier, and immune system is disrupted resulting in dysbiosis,
increased barrier permeability, and inflammation [20].
The intestinal microbiome is highly adaptable and responsive to environmental factors. From the
time of birth, environmental factors such as mode of delivery (vaginal versus caesarean section) and
feeding method (breast feeding versus formula feeding) influence the microbiome [21,22]. Dietary
patterns have a profound effect on the gut microbiome, and Wu et al., demonstrated that a high fat and
animal protein diet compared to a high carbohydrate diet was associated with significant differences
in the intestinal microbiome [23]. Numerous studies have highlighted differences in the microbiome
between individuals with IBD and healthy individuals, with an overall trend towards loss of diversity
of the microbiota in IBD [24–27]. A decrease in certain Clostridium clusters is a consistent finding
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among studies [20,25]. These species stimulate regulator T cells, resulting in immune tolerance and
reduced gastrointestinal inflammation [20,28]. Conversely, members of the family Enterobacteriaceae
are consistently elevated in IBD [20]. These include the well-known intestinal pathogens Campylobacter
spp., Salmonella spp., and Escherichia coli. Whether these patterns are a cause or consequence of
intestinal inflammation remains debatable. In the healthy state, the microbiota comes into contact with
epithelial cells and the immune system in a highly controlled manner [29]. In IBD, the mucosal barrier
is compromised, resulting in translocation of the intestinal microbiota and resultant immune system
activation and inflammatory response [30].
3. Scientific Basis of Dietary Therapy for IBD
Many studies have evaluated the ability of diet to modulate intestinal microbiota and influence
epithelial barrier function. Low fiber diets have been linked to IBD with a posited mechanism of
reduction in short-chain fatty acid production by commensal bacteria whose preferred energy source is
fiber [31]. Butyrate, a short-chain fatty acid, is essential for colonic health and the major energy source
for colonocytes [32]. In addition to supporting intestinal barrier function, short-chain fatty acids also
promote immune tolerance by promoting development of T-regulatory cells [33,34]. Food additives are
commonly consumed by patients with IBD, and specific dietary emulsifiers (carboxymethylcellulose and
polysorbate 80) have been shown to induce low grade inflammation and metabolic syndrome in wild
type mice and promote colitis in genetically predisposed IL-10 knockout mice [35,36]. The emulsifiers
perturbed the host microbiota, resulting in increased inflammatory potential with a rise in the number
of mucolytic bacteria, and erosion of the protective mucous layer. At present, efforts are underway to
better evaluate the frequency of exposure to food additives and the effect of these compounds on the
intestinal system.
A summary of clinical trials and data reporting on the outcomes of dietary therapies in IBD are
well described in greater detail elsewhere [3,37–39]. Importantly, many of these trials are smaller in
size, deemed to produce a lower grade of evidence, and limited by the lack of long-term outcome
data. In a recently published Cochrane review, Limketkai et al. analyzed 18 randomized controlled
trials, comprising 1878 participants, published between 1965 and 2018 [37]. The intervention diets
involved complete exclusion or significant limitation of one or more food groups. Diets included low
refined carbohydrates; low microparticles; low calcium; low red and processed meat; low disaccharides,
grain, saturated fats, red, and processed meat; symptoms-guided diets; highly-restricted organic diet;
milk-free; Alberta-based anti-inflammatory diet; and Carrageenan-free diet. The different studies
looked at various outcomes, including induction of remission, clinical relapse, surrogate biomarkers
of inflammation, endoscopic improvement, health-related quality of life, and the need for surgery.
This review concluded that no firm conclusions could be reached about the effect of these dietary
interventions on IBD.
Though these included studies may be superior in that they are randomized controlled studies,
additional studies on EEN and broader restrictions diets have shown clearer impact on IBD [40–42].
A key distinction from the randomized trials is the more profound nature of dietary intervention with
EEN and many restrictions diets. Though not all controlled studies, the findings in these numerous,
heterogeneous studies suggest the impact of dietary interventions on inflammation and clinical
outcomes. Together with strong patient desire for dietary guidance and the opportunity for greater
efficacy with conventional immunosuppression, larger more definitive studies are needed.
The most rigorously studied dietary interventions in IBD is exclusive enteral nutrition (EEN),
a formula-based therapy for Crohn’s disease. Numerous studies in children and adolescents
have demonstrated the ability of EEN to induce remission of active Crohn’s disease in 80–85%
of patients [43,44]. EEN is equivalent to corticosteroid therapy in inducing clinical remission and
superior at achieving endoscopic mucosal healing [43,45]. EEN is a first-line therapy for pediatric
Crohn’s disease in many parts of the world, and the treatment protocol typically involves administration
of formula to provide 100% of caloric needs and exclusion of food for 6–8 weeks [1].
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The exact mechanism by which EEN exerts its effect is unknown. Hypothesized mechanisms
(Table 1) include limiting antigen exposure, antigenic monotony, enhancing nutritional status and
nutrient delivery, altering the microbiome and immune response, and avoidance of deleterious
compounds [3,5,20,46]. As EEN and exclusion diets are extremely different interventions, it is likely
that the mechanism by which they impact disease is likewise different. Despite disease activity
improvement, studies looking at fecal metagenomics in children with Crohn’s disease have found
that EEN seems to decrease gut microbiota diversity and promote a more “dysbiotic” state when
compared to healthy controls [47]. Microbial functional capacity also decreased with EEN as did genes
encoding proteins involved in B-complex vitamin biosynthesis [47]. In studies evaluating changes to
the intestinal microbiome in patients with IBD treated with conventional medical therapies, dysbiosis
improved with therapy [48]. Clearly therefore, the relationship between the beneficial effects of EEN
and alterations in the gut microbiota needs further characterization and may result from alterations in
beneficial or harmful metabolites produced by the bacteria.
Table 1. Hypothesized Mechanisms of Action for Diet Therapy in Inflammatory Bowel Disease (IBD).
Category of Mechanism Hypothesized Mechanism EEN Exclusion Diets
Mechanical/physical
Liquid nutrition x
Alteration of gut motility x x
Gut rest x
Nutritional status
Improved nutrient delivery x
Improved caloric delivery x
Epithelial barrier
Decreased permeability x x
Restitution of intestinal barrier x x
Improved delivery of fiber (SCFA * production) x
Immune system
Limited antigen exposure x
Antigenic monotony x
Direct anti-inflammatory effect x x
Alteration in bile acids x x
Microbiome
Shift of gut microbiome x x
Stabilize gut microbiome x x
Specific avoidances Avoidance of food additives x
Avoidance of deleterious food substances x x
Anti-inflammatory effect Provide beneficial substance x x
Increased antioxidant consumption x
* SCFA: short-chain fatty acid.
EEN established the ability of diet to drive Crohn’s disease into remission, but EEN is difficult
to sustain as long-term maintenance therapy and is not effective for ulcerative colitis. Exclusion
diets, though, are practical as long-term therapy and have been found to be useful in both Crohn’s
disease and ulcerative colitis. One of the most studied exclusion diets is the specific carbohydrate
diet (SCD). This diet removes all grains, sweeteners (except for honey), processed food, and all milk
products except for hard cheeses and yogurt fermented longer than 24 h. Both clinical and laboratory
improvement have been reported in pediatric and adult patients with IBD [49–52]. One study over 12
weeks in children and adolescents used capsule endoscopy and demonstrated mucosal healing [53].
Therapy with the SCD has been shown to result in significant changes in microbial composition [49].
The SCD has been the best-studied food-based diet for IBD, and one survey with 417 respondents
found patients reported significant improvement in symptoms, but that only 17% of patients partnered
with a healthcare professional in the implementation of the SCD [50].
The Crohn’s disease exclusion diet (CDED) is based on the hypothesis that components of the
Western diet promote a pro-inflammatory microbiome and may disrupt the mucosal barrier. The diet
focuses on excluding gluten, dairy, gluten-free baked goods, animal fat, emulsifiers, and all canned
125
Nutrients 2019, 11, 947
or processed foods. A prospective cohort of pediatric and adult participants with mild to moderate
Crohn’s disease treated with partial enteral nutrition (formula providing approximately 50% of daily
calories) and the CDED showed success in achieving induction of clinical remission [41]. The IBD
anti-inflammatory diet (IBD-AID) is derived from the SCD. It is a whole foods-based diet that restricts
the intake of complex carbohydrates such as refined sugar, gluten-based grains, and certain starches
from the diet, but also incorporates ingestion of prebiotics and probiotics. The diet also incorporates
phases of food textures. In a small retrospective case series of patients with IBD on the IBD-AID for at
least 4 weeks, all demonstrated improvement in clinical symptoms [54].
In a study of a semi-vegetarian diet in patients with remission of Crohn’s disease induced by either
medical therapy or surgery, patients maintained a greater rate of clinical remission over 2 years [55].
The CD-TREAT diet hypothesizes that a whole-food diet based on the composition of ModulenTM,
a commonly utilized formula for EEN in Europe, can emulate the efficacy of EEN [56]. In the component
of the study evaluating healthy adults, similar microbiome and metabolome changes were seen with
both the CD-TREAT diet and EEN. In the part of the study evaluating five children with active Crohn’s
disease, the CD-TREAT diet resulted in a significant decline in fecal calprotectin, though this surrogate
marker of intestinal inflammation remained elevated at both 4 and 8 weeks.
The worsening of dysbiosis and decrease in butyrate production demonstrated with EEN therapy
is seemingly counterintuitive, as is the lack of any fiber content in the formulas commonly utilized
for EEN [57,58]. It may be the case that EEN acts via a unique mechanism of action to impact
inflammation in IBD in comparison to the action of restrictions diets. As the gut microbiome can
both drive inflammation and respond to underlying inflammation, further elucidation of the complex
interaction between diet, microbiome, and host will help guide future therapy. With the paradoxical
findings seen in EEN versus whole food restriction diets, changes occurring while transitioning from
one diet to another may provide unique insights into mechanisms.
Epidemiologic studies have demonstrated greater risk of developing IBD with increased intake
of total fat, polyunsaturated fatty acids, omega-6 fatty acids, and meat, while fruits, vegetables,
and fiber intake have been shown to have protective effects [11]. Greater meat intake has been
associated with both increased risk of ulcerative colitis relapse in adults and decreased rate of achieving
remission of Crohn’s disease in children on partial enteral nutrition therapy [59,60]. Conversely the
only existing randomized study on red meat showed no association between red meat or processed
meat consumption and risk of Crohn’s disease relapse, as measured by self-reported symptoms [61].
A limitation of these studies evaluating individual dietary components is the potential for confounding
factors due to numerous associations between individual foods consumed [62].
While some dietary interventions have demonstrated impacts on inflammation, other interventions,
such as the low FODMAP diet, have been demonstrated to impact functional gastrointestinal symptoms
in patients with IBD [63–65]. A variety of exclusion diets have shown efficacy at treating inflammation
in small case series reports, but additional studies are needed to better substantiate these findings.
While these studies suggest that specific food components may be deleterious, it may be the complex
interactions of food components within the food matrix with the intestinal microbiome that trigger and
perpetuate the cycle of inflammation in IBD. At present, the mechanism by which dietary interventions
impact inflammation in IBD remains unknown. Studies involving the microbiome, metabolome,
and proteome are beginning to shed insight, and will help guide the movement to more targeted
dietary therapeutic approaches in the future. The mechanism of action for dietary therapies requires
further study in both clinical and preclinical models.
4. Contrasting Pharmacological and Dietary Therapy
The goals of IBD therapy include resolution of symptoms, mucosal healing, improved quality of
life, nutritional restitution, and minimizing adverse effects associated with therapy. For both nutritional
therapy and conventional medical therapy, disease remission is often a singular focus, but the broader
goals of the patient are important in the discussions about therapy. Primary outcomes in dietary
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and drug trials for IBD, though, should be the same, with a focus on evaluation of objective markers
of inflammation, including labs, imaging, endoscopic findings, and surrogate markers of intestinal
inflammation. An ongoing challenge for dietary trials is the ability to fund trials that are not sponsored
by corporations with a financial incentive to drive development of a new therapeutic.
EEN in pediatric Crohn’s disease has been demonstrated to lead to high rates of remission
(85%) and superior mucosal healing when compared to treatment with corticosteroids [40,43,66].
Immunosuppressive therapy for IBD with monoclonal antibody anti-TNF-alpha drugs (e.g., infliximab
or adalimumab), with or without concomitant immunomodulatory drugs are widely viewed as one
of the most efficacious approaches to inducing clinical remission. A randomized-controlled trial in
adults with newly diagnosed Crohn’s disease demonstrated steroid-free remission at week 26 for 56.8%
of patients on infliximab plus azathioprine, and 44.4% for those on infliximab alone [67]. A trial of
infliximab in children demonstrated clinical remission at week 10 in 58.9% of participants, and 55.8%
at week 54 [68]. In the ACT1 and ACT2 trials of infliximab in adult ulcerative colitis, clinical remission
at week 8, 30, and 54 was never above 40% [69]. Similarly, a pediatric trial of infliximab in ulcerative
colitis showed week 54 remission in less than 40% of study participants [70]. These data suggest that
medications, though effective, do not induce remission in all patients with IBD, and room exists to
further optimize therapy with newer medical therapies, and dietary interventions.
Like drugs, dietary therapy is not effective for all patients, and future personalization of dietary
therapy is an opportunity. Dietary therapy can be utilized as stand-alone monotherapy, or diet can
also be utilized concomitant with immunosuppressive drugs. A study in Japan evaluating the utility
of partial enteral nutrition therapy (greater than 900 kcal/day from enteral nutrition with formula)
with infliximab demonstrated a significant decrease in disease recurrence over the course of nearly
2 years [71]. Patients commonly employ dietary modifications to address symptoms but also attempt to
control inflammation with diet [72]. Implementation of dietary changes is often guided by individual
research and anecdotal experience, and the majority of patients are not guided by their medical team
to involve diet as part of their IBD therapy plan [13]. At present the push to study and employ dietary
measures is strongly driven by patients, while many medical practitioners remain skeptical and poorly
informed about dietary interventions. As an example, despite overwhelming evidence for the use of
EEN in pediatric CD, U.S. physicians still use EEN to a much lesser extent than their European and
Canadian colleagues [73].
That patients and families will employ dietary therapy despite the rigor this involves suggests
that tangible benefits exist. Given that therapies may be intensive for weeks to months (e.g., EEN),
or require changes to dietary patterns long-term, the presence of family and community support can
be key in the success of the patient’s ability to adhere to the treatment. There has been limited data
published on the patient experience while on EEN; however, a study of 29 families of patients with CD
who chose EEN as induction therapy showed 59% of patients would repeat EEN if needed. However,
72% of parents would be more interested in a solid food based exclusion diet option [74].
There is generally a lesser degree of concern regarding the safety of nutritional therapy when
compared to immunosuppressive drug therapies (Table 2). However, potential side effects can include
nutritional inadequacy, psychosocial impact, and a potential for loss to medical follow-up. Psychosocial
impact in the setting of nutritional therapy was evaluated by the measure of quality of life (QOL) in
children and adolescents in a trial over 8 weeks with anti-TNF therapy, partial enteral nutrition, and
exclusive enteral nutrition therapy [60]. This study demonstrated that children with Crohn’s disease
who achieved clinical remission on any of the three intervention arms had a significant increase in the
quality of life measured by the IMPACT-III questionnaire, a validated disease-specific measure of QOL
in pediatric IBD. This study evaluated sub-domains of QOL and found that body image-associated
QOL was superior in the EEN group compared to the anti-TNF therapy group. Exclusion diets
can be isolating and difficult to maintain, and certain patients may not be a good fit for dietary
therapy. For those who demonstrate interest in dietary therapy, close monitoring, support of their
family and friends, and partnership with the broader medical team (including physician, dietitian,
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and psychologist) helps with maintaining compliance and ensuring appropriateness of an ongoing
dietary approach to IBD.
Table 2. Comparison of Dietary Therapy and Drug Therapy.
Dietary Therapy Drug Therapy
Driven by patient/family interest ++
Ability to personalize ++ +
Directly impacts quality of life * ++
Importance of family support ++ +
Challenges with compliance ++ +
Challenges with study design ++
Risk of nutrient deficiency ++
Works in combination with other therapies ++ ++
Physician-driven ++
Targets known pathway ++
Greater risk of infection ++
Greater risk of cancers ++
Insurance coverage ++
Partnership with large industry to study ** ++
* Independent of disease activity. ** Formula companies have supported the design and implementation of some
studies on EEN, but the majority of dietary trials do not have corporate backing.
Since dietary therapies can be employed without physician prescription, there is potential for
loss of medical follow-up. Without partnership with the medical team, dietary therapy may result
in inadequate nutritional intake and a lack of appropriate objective evaluation of clinical, laboratory,
and mucosal remission. When considering potential side effects of nutritional therapy, medical
professionals must acknowledge that many patients are on dietary therapy as treatment for their IBD
without formal medical guidance [50]. At a minimum, the medical team should engage patients in
discussion about their dietary patterns, understand the basics of commonly utilized IBD exclusion
diets, and partner with patients to closely monitor nutritional status and disease activity. Medical
therapies require formal prescription from a healthcare professional and insurance provides coverage,
or at least provides coverage of alternative medications. At present, dietary therapy for IBD is not
broadly reimbursed by insurance. Further data on efficacy of exclusion diets is needed, but even for
established therapy like EEN for Crohn’s disease, insurance companies do not provide reimbursement
in the United States.
Despite the many challenges around utilizing dietary therapy for IBD, dietary interventions
are eagerly sought and employed by patients. The desire to avoid or lessen the degree of
immunosuppression or supplement existing medical therapies are common drivers. Given the
burden associated with dietary modification when considering cost, time for food preparation,
and dietary restriction, it is important to recognize that nutritional therapy may not be an appealing
option for many patients. For these reasons, not all patients and families will have equitable access to
or interest in nutritional therapies. No studies have yet shown the variation in average costs between
the different dietary interventions.
5. Vision for the Future of Diet and IBD
Dietary trials present challenges, but the ability to use nutrition to treat disease is a unique
opportunity. It has long been accepted that dietary exposures are associated with risk of developing
IBD, but diet as therapy has not been fully integrated into the broader paradigm of IBD therapy
(Table 3). Diet represents a fundamental aspect of daily living and has infinite variability; diet is
a potential target for profound intervention. Dietary intervention with EEN or even a shift in fat
and fiber consumption results in a tangible shift in the intestinal microbiome [23,47,75]. Efforts have
been placed into the development of therapeutic approaches to selectively modulate the intestinal
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microbiome, including prebiotics, probiotics, antibiotics, and fecal transplantation, but persistent
shaping of the microbiome requires ongoing maintenance of these therapies [76]. Dietary therapies
that reshape patterns of food consumption may alter exposures to deleterious substances such as
select food additives, directly influence the intestinal microbiome, and also have a direct impact on the
functioning of the host immune system [3].
Table 3. Dietary Therapy for IBD: Now and the Future.
Current Accepted Place of Dietary Therapy
EEN in pediatric Crohn’s disease
Dietary therapies for symptom control
Nutritional therapy to support malnutrition
Major Areas Requiring Research
Impact of dietary therapies with/without concomitant immunosuppression
Impact of dietary therapies long-term
Mechanism of action for dietary therapies
Exclusion diets—dietary components of importance
Cost-benefit analysis of dietary interventions
Targeted dietary approaches to selectively modulate microbiome
Many individuals institute dietary changes based on varied sources of information and also as a
reaction to the onset of IBD symptoms [13,77]. Recommendations are of variable validity, and better
data on the role of diet in the setting of active IBD is needed. The data on EEN therapy has led to
the utilization of this as standard therapy for induction of remission in pediatric Crohn’s disease.
The limitation of EEN is the difficulty in sustaining the intervention. Food-based IBD trials can involve
exclusion, supplementation, or dramatic changes in dietary pattern [62]. Thus far, it appears unlikely
that focused exclusion or supplementation have a role in IBD therapy, but more profound changes
in dietary pattern have shown promise. Though individual dietary components may be deleterious
(such as refined sugars, high fat, and specific food additives), it may be the case that the effect of
these components are balanced or attenuated by other components (e.g., fiber, antioxidants, bioactive
molecules). As such, we suggest that future dietary trials in IBD should consider the global dietary
pattern, while also considering the role of individual dietary components. At present, published trials
for exclusion diets in IBD often include a description of the general principles of the diet, but do not
further characterize the variability within the proposed intervention and the impact this has on clinical
outcomes. Challenges to consider in food-based dietary trials in IBD include issues with participant
compliance, the measurement of compliance, and variability within a particular dietary intervention.
Though randomized controlled trials are the gold standard for the generation of evidence to drive
clinical practice, innovative study design such as n-of-1 studies, and data from larger cohort studies,
together with preclinical data, will also help to better substantiate the existing literature supporting
dietary therapies in IBD. The paradigm of relying only on data from controlled trials is challenging in
the setting of dietary interventions requiring profound changes to habitual diet, the need to maintain
compliance, and the cost of implementing such trials.
As diet can be a primary or adjunctive therapy, the magnitude of effect considered as significant
may be different for dietary trials as compared to drug trials. For example, if a dietary intervention
results in lack of endoscopic mucosal healing but significantly decreases inflammatory burden as
measured by biochemical markers, this may suggest that the intervention has a promising role as an
adjunct to conventional immunosuppressive therapy. As the mechanism by which dietary therapy
impacts IBD involves gut luminal exposures, the microbiome, and triggering of the mucosal immune
system, diet has the potential to be utilized alongside medications to improve outcomes and durability,
and minimize risks associated with immunosuppression. Drugs are not commonly brought to market
with known partial efficacy, and they are not tested as frequently as adjuncts to existing therapies,
but this is different for dietary therapy. Dietary trials demonstrating complete remission or even some
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response to therapy may have utility, as the cost and side-effect profile of dietary therapy is generally
favorable for dietary therapy.
For novel pharmacologic therapeutics, often the initial identification and targeting of a specific
molecular pathway guides drug development. The mechanism by which diet impacts IBD has yet
to be fully elucidated [38,78]. Though the microbiome and specific deleterious substances have been
identified, as of yet no definitive molecular pathway target exists for dietary therapy. At present,
basic scientific research is ongoing to better elucidate mechanisms of action for both EEN and
exclusion diets on treatment of active IBD, but empiric clinical trials are being pushed forward as
well. Unlike drugs, with guidance, diet can be modulated within the bounds of safety, balance, and
nutritionally-adequacy. Empiric dietary changes guided by experience may have value, but systematic
evaluation of dietary interventions with trials is needed to produce the data to demonstrate efficacy
beyond anecdote. Publication bias in favor of positive studies and poorly designed clinical studies are
a limitation to the existing data for dietary therapy in IBD and need to be better addressed moving
forward. A variety of exclusion diets have been proposed as therapy for IBD, and with systematic
evaluation these trials will inform pre-clinical research, which in turn will help guide future trials.
Close partnership between the patient, gastroenterologist, and dietitian is necessary when utilizing
dietary therapy to treat IBD. The discussion about the concept of integrating dietary therapy, goals of
therapy, concerns, and a close monitoring plan should begin early. In some situations, diet will be used
as monotherapy and it is of particular importance that close follow-up and monitoring of objective
markers of inflammation occur, so as to prevent disease progression, select nutrient deficiencies,
or global malnutrition. For physicians, the most common IBD treatment paradigms have dismissed the
role of diet. A partnership with acknowledgement of the need for further clinical trial data, inherent
uncertainty of efficacy for all IBD therapies, and the potential for benefit with dietary interventions
will help guide progress towards better understanding of the utility of dietary therapy for individuals
with IBD.
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Abstract: Inflammatory bowel disease (IBD) is an emerging health problem associated with the
dysregulation of the intestinal immune system and microbiome. Probiotics are able to reduce
inflammatory responses in intestinal epithelial cells (IECs). However, entire signaling pathways
and the interaction between different probiotics have not been well-documented. This study was
designed to investigate the anti-inflammatory effects and mechanisms of single and combined
probiotics. HT-29 cells were induced by lipopolysaccharide (LPS) and tumor necrosis factor (TNF)-α,
treated with Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis or their combination and
analyzed for inflammation-related molecules. Both L. acidophilus and B. animalis subsp. lactis reduced
interleukin (IL)-8 secretion and the expressions of phosphorylated p65 nuclear factor-kappa B (p-p65
NF-κB), phosphorylated p38 mitogen-activated protein kinase (p-p38 MAPK), vascular cell adhesion
molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2), while they increased toll-like receptor 2
(TLR2) expression. L. acidophilus did not decrease intercellular adhesion molecule-1 (ICAM-1) but
enhanced the inhibitory efficacy of B. animalis subsp. lactis. Combined probiotics showed the best
anti-inflammatory activity. These results suggest that L. acidophilus and B. animalis subsp. lactis
may exert a potent anti-inflammatory effect through modulating TLR2-mediated NF-κB and MAPK
signaling pathways in inflammatory IECs. Both strains, especially their combination, may be novel
adjuvants for IBD therapy.
Keywords: intestinal epithelial cells; inflammation; probiotics; Lactobacillus acidophilus; Bifidobacterium
animalis subsp. lactis
1. Introduction
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD),
is traditionally a common chronic gastrointestinal disease in several Western countries. The highest
reported prevalence rates of IBD are in Europe (505/100,000 for UC in Norway and 322/100,000 for CD
in Germany) and North America (286/100,000 for UC in the USA and 319/100,000 for CD in Canada) [1].
The overall prevalence of IBD has exceeded 0.3% in North America and many European countries [1].
However, IBD has become a global disease with accelerating incidence in newly industrialized
countries in Asia, Africa and South America [1]. According to a recent study of Yen et al. [2], both the
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incidence and prevalence of IBD increased continuously in Taiwan from 2001 to 2015. Improved
hygiene, civilization and Westernization may be possible causes [2]. Several studies suggest that IBD
is an emerging health problem in the world [1–3]. The reason for the global increase in this initially
Western-prevalent disease is still unknown, but it may be closely associated with environmental and
social changes, such as the adoption of Western lifestyle and diet [1,2]. The rise of IBD in adults and
children has been observed in Western developed countries, while gut microbiota and dietary fiber-rich
diet of rural African individuals may protect them from the threat of IBD [4].
The etiology of IBD is thought to relate to a complex interaction of genetic and environmental factors,
including the dysregulation of the enteric immune system and alterations in the intestinal microbiome [5].
Patients with IBD have typical dysbiosis characterized by an increase in pro-inflammatory bacteria,
a decrease in anti-inflammatory bacteria and a reduction in bacterial diversity compared to the
healthy population [5]. A reduced diversity of the gut microbiota in IBD patients is largely due to
a low abundance of probiotics belonging to the Lactobacillus and Bifidobacterium genera [6]. IBD is
characterized by mucosal and systemic inflammatory responses to the gut microbiome, which is the
outcome of a lack of mucosal immune tolerance [6]. It is well-known that chronic inflammation is
related to carcinogenesis and thus long-standing IBD is considered as a risk factor of colorectal cancer
(CRC), especially colitis-associated colorectal cancer (CAC). In recent years, high incidence rates of
CRC have been observed in Taiwan and other countries where the rates were historically low [7].
This increasing trend of CRC is similar to that of IBD in many countries. Both CRC and IBD are now
global health issues that cannot be ignored.
The mucosal tissue of the intestine contains the largest part of the immune system in humans. It is
estimated that 70% of immune cells are present in the gut [8]. Intestinal epithelial cells (IECs) provide a
physical and chemical barrier between the intestinal lumen and the lamina propria [8]. They represent
the first contact point for bacteria within the gut and thus prevent microbial penetration and induce
communication for immune recognition of intestinal bacteria [9]. The activation of the pro-inflammatory
genes in IECs in response to challenges by bacterial products such as lipopolysaccharide (LPS) or
pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α is associated with acute and chronic
intestinal inflammation [10]. However, bacterial ligands may not directly alter the inflammation of IECs,
although bacterial cell wall components, such as LPS and lipoteichoic acid (LTA), contribute to toll-like
receptor (TLR)-mediated inflammation [11]. Ligands from pathogenic bacteria efficiently activate
monocytes and macrophages through the secretion of pro-inflammatory cytokines such as TNF-α,
interleukin (IL)-1β, IL-6 and IL-8 [11]. In contrast, ligands from probiotic bacteria only minimally
induce TNF-α production [11]. These studies suggest that it is reasonable to simulate the inflammatory
environment of the intestine using a combination of bacterial ligands and pro-inflammatory cytokines.
Probiotics have beneficial effects on the host through their ability to modulate the mucosal immune
system. They have been shown to both augment/modulate homeostatic immune defenses and to
ameliorate infection, inflammation and allergy by modulating gut function [12]. Treatment with
probiotics has been considered to be potentially effective and safe in patients with IBD. It has been
reported that individual probiotic species have variable potential to stimulate the mucosal immune
system [13]. Probiotics differentially modulate IECs’ responses via the activation or suppression of
distinct signaling pathways, such as TLR, nuclear factor-kappa B (NF-κB) and mitogen-activated
protein kinase (MAPK) signaling pathways, in a strain-dependent manner, including strains of the
same species [12,14].
The majority of probiotic microorganisms belong to the genera Lactobacillus and Bifidobacterium,
and most Lactobacillus and Bifidobacterium species belong to probiotics [15]. Lactobacillus and
Bifidobacterium species have been shown to reduce inflammatory responses, including NF-κB activation
and IL-8 production, in inflammatory IECs, rodent colitis models and patients with IBD [9,16].
However, not all probiotics exert constant anti-inflammatory effects in experimental models of
intestinal inflammation. For example, L. acidophilus, B. lactis and L. casei have an anti-inflammatory
activity in the 2,4,6-trinitrobenzene sulfonic acid (TNBS) model of rat colitis but each probiotic shows
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its own anti-inflammatory profile [17]. It would be interesting to compare different probiotics in the
same experimental model, in order to establish the best profile in a given setting and to further apply
this new concept for IBD therapy [17]. A recent meta-analysis study demonstrated that results from
clinical trials of probiotics on IBD were inconsistent [5]. Among all trials included in this meta-analysis,
some showed an improvement in the maintenance or induction of remission by probiotics, while others
failed to show any benefit [5]. This could be due to the species or strains of probiotics used, or the
methodological differences among studies. Some studies found that probiotics may be as effective as
5-aminosalicylates (5-ASAs), a common drug for the treatment of IBD, in preventing relapse of quiescent
UC but other studies showed that there was no benefit of probiotics over placebo in inducing remission
of active UC [5]. However, when only trials of VSL#3—a mixed preparation of probiotics—were
considered, there appeared to be a benefit. VSL#3 may be effective in inducing remission in patients
with active UC [5]. These findings suggest that combination of probiotics seems to be more effective in
anti-inflammation than single strains. However, the detailed anti-inflammatory mechanism of each
probiotic and their interactions are still unclear.
Although some strains of probiotics belonging to the Lactobacillus and Bifidobacterium genera have
been shown to possess anti-inflammatory and immunomodulatory activities, their entire signaling
pathways have not been well-documented. There are only limited studies that have examined the
inflammation-associated signaling pathways of L. acidophilus and B. animalis subsp. lactis, two common
strains of probiotics used in fermented dairy products, especially the comparison and interaction
between these probiotics. The aim of the present study was to investigate the anti-inflammatory effects
and associated mechanisms of L. acidophilus, B. animalis subsp. lactis and their combination in LPS- and
TNF-α-induced inflammatory IECs.
2. Materials and Methods
2.1. Cell Culture
Human colon cancer cell line HT-29 cells were purchased from the Food Industry Research
and Development Institute (Hsinchu, Taiwan) and incubated in 9-cm culture dishes as a monolayer
in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine
serum (FBS), 1% L-glutamine (v/v) and 1% penicillin/streptomycin and maintained at 37 ◦C in a
humidified atmosphere of 5% CO2. Cells were sub-cultured following enzymatic digestion using 1%
trypsin solution.
2.2. Bacterial Strains
L. acidophilus and B. animalis subsp. lactis (Chr. Hansen, Denmark) were grown in the
Man-Rogosa-Sharpe (MRS) broth overnight at 37 ◦C in anaerobic conditions. Viable bacteria were
counted by plating serial dilutions on MRS agar. Both strains of probiotics were heat-inactivated by
water-bath at 60 ◦C for 30 min, then collected by centrifugation at 500× g for 10 min at 4 ◦C and washed
in phosphate-buffered saline (PBS), as described in previous studies [18,19].
2.3. Treatments of Cells
HT-29 cells were seeded in a 24-well microtiter plate at a density of 3 × 105 cells/well in volume
of 400 μL medium for one day. Cells as an inflammatory group were treated with non-FBS medium
containing LPS (1 μg/mL) and TNF-α (20 ng/mL) from Escherichia coli O58:B5 (L6529 Sigma-Aldrich,
St. Louis, MO, USA) for 24 h [20]. Cells as intervention groups were added to probiotics at the
designated multiplicity of infection (MOI) of 0.1, 1, 10 [21], and incubated in 5% CO2 at 37 ◦C with
non-FBS medium containing LPS and TNF-α. The culture medium was harvested and analyzed for IL-8
secretion by enzyme-linked immunosorbent assay (ELISA). We chose the doses of probiotics with an
inhibitory effect on IL-8 secretion for comparing the anti-inflammatory effects of single and combined
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probiotics. Cells were incubated with or without probiotics (L. acidophilus, B. animalis subsp. lactis or
both), then medium and cells were collected and analyzed by ELISA and Western blot, respectively.
2.4. Cell Viability Assay
HT-29 cells were seeded in a 96-well microtiter plate at a density of 1 × 104 cells/well in
volume of 100 μL medium. Cells were treated with L. acidophilus, B. animalis subsp. lactis or
both and with LPS and TNF-α for 24 h. After the above treatments, cells were incubated with
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye (0.5 μg/μL) at 37 ◦C for 4 h.
Absorbance of the product was read at 570 nm by ELISA reader.
2.5. Analysis of IL-8 Secretion by ELISA
IL-8 levels in HT-29 conditioned media were measured by a commercially available ELISA kit
(BioLegend, San Diego, CA, USA).
2.6. Analysis of Protein Expression by Western Blot
The analytical procedures were modified from previous studies [22,23]. Cells were sonicated
for 20 min and then lysed cells were centrifuged at 10,000× g for 10 min at 4 ◦C. Supernatants
were collected and the protein concentration was determined using the Bio-Rad Bradford assay
(Bio-Rad, Hercules, CA, USA). Samples (each containing 30 μg of supernatant protein) were mixed
with NuPAGE LDS sample buffer and β-mercaptoethanol (Invitrogen, Carlsbad, CA, USA), heated at
95 ◦C for 10 min, cooled to room temperature and electrophoretically resolved on 10% NuPAGE
Bis-Tris gels (Invitrogen, Carlsbad, CA, USA). Proteins were then transferred to polyvinylidene
difluoride (PVDF) membrane, which was then blocked with blocking buffer (TBST containing 5%
albumin) at room temperature for 1 h. The blot was probed with TLR2 (1:1000 dilution, BioVision,
Milpitas, CA, USA), phosphorylated p65 NF-κB (p-p65 NF-κB, 1:1000 dilution, Bioworld, Dublin,
OH, USA), phosphorylated p38 MAPK (p-p38 MAPK, 1:1000 dilution, BioVision, Milpitas, CA,
USA), cyclooxygenase-2 (COX-2, 1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
intercellular adhesion molecule-1 (ICAM-1, 1:1000 dilution, BioVision, Milpitas, CA, USA) or vascular
cell adhesion molecule-1 (VCAM-1, 1:1000 dilution, Abbiotec, San Diego, CA, USA) polyclonal antibody
at 4 ◦C for 16 h. After being washed extensively to eliminate nonspecific binding, the membrane was
incubated with the secondary alkaline phosphatase-labeled antibody at room temperature for 1 h and
incubated with 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium (BCIP/NBT) substrate
solution (Sigma-Aldrich Inc., St. Louis, MO, USA) for 20 min in the dark. The reactive solution was
removed, and the reaction was stopped using 50% methanol. Blot intensities were quantified using
Bio-Rad Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). All experimental data
are triplicates.
2.7. Statistical Analysis
Data are expressed as means and standard deviations. The difference among groups was analyzed
by one-way analysis of variance (ANOVA) and Duncan’s multiple range test using SAS software
(SAS Institute, Cary, NC, USA). The significant difference was set at p < 0.05.
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3. Results
3.1. Effects of Different Doses of Single Probiotics on IL-8 Secretion in Inflammatory HT-29 Cells
HT-29 cells stimulated with LPS and TNF-α secreted significantly higher IL-8 levels than did
unstimulated cells (Figure 1A,B). L. acidophilus at MOI of 1 and 10 significantly decreased IL-8 secretion
in inflammatory HT-29 cells (Figure 1A). B. animalis subsp. lactis at MOI of 10 showed an inhibitory
effect on IL-8 secretion (Figure 1B). As a result, we chose L. acidophilus at MOI of 1 as group A, B.
animalis subsp. lactis at MOI of 10 as group B, and combination of L. acidophilus at MOI of 1 and B.
animalis subsp. lactis at MOI of 10 as group AB for further studies.
Figure 1. Effects of different doses of single probiotics on IL-8 secretion in inflammatory HT-29 cells.
All values except for control are mean ± SD (n = 3). Bars with the same letter are not significantly
different from one another determined by Duncan’s multiple range test, p< 0.05. (A) The inhibitory effect
of L. acidophilus on IL-8 secretion; (B) the inhibitory effect of B. animalis subsp. lactis on IL-8 secretion.
3.2. Effects of Pro-Inflammatory Factors and Probiotics on Cell Viability
The viabilities of HT-29 cells were not different among groups after 24 h of incubation (Figure 2),
showing that pro-inflammatory factors (LPS and TNF-α) and probiotics (alone or in combination) did
not affect the growth of HT-29 cells.
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Figure 2. Effects of pro-inflammatory factors and probiotics on viability of HT-29 cells. All values
except for control are mean ± SD (n = 3). There is no significant difference among groups determined
by Duncan’s multiple range test, p < 0.05. C, control; I, TNF-α (20 ng/mL) with LPS (1 μg/mL);
A, L. acidophilus at MOI of 1 with TNF-α (20 ng/mL) and LPS (1 μg/mL); B, B. animalis subsp. lactis at
MOI of 10 with TNF-α (20 ng/mL) and LPS (1 μg/mL); AB, L. acidophilus at MOI of 1 and B. animalis subsp.
lactis at MOI of 10 with TNF-α (20 ng/mL) and LPS (1 μg/mL). Control group is used as the reference.
3.3. Effects of Probiotics on IL-8 Secretion in Inflammatory HT-29 Cells
A shown in Figure 3, all probiotics-treated inflammatory HT-29 cells (groups A, B and AB) had
significantly lower IL-8 levels than did cells stimulated with LPS and TNF-α (group I). In addition,
the IL-8 level was significantly lower in group AB than in either group A or B.
Figure 3. Effects of probiotics on IL-8 secretion in inflammatory HT-29 cells. All values except for
control are mean ± SD (n = 3). Bars with the same letter are not significantly different from one
another determined by Duncan’s multiple range test, p < 0.05. C, control; I, TNF-α (20 ng/mL) with
lipopolysaccharide (LPS) (1 μg/mL); A, L. acidophilus at MOI of 1 with TNF-α (20 ng/mL) and LPS
(1 μg/mL); B, B. animalis subsp. lactis at MOI of 10 with TNF-α (20 ng/mL) and LPS (1 μg/mL);
AB, L. acidophilus at MOI of 1 and B. animalis subsp. lactis at MOI of 10 with TNF-α (20 ng/mL) and LPS
(1 μg/mL).
3.4. Effects of Probiotics on the Expression of Inflammation-Related Proteins in Inflammatory HT-29 Cells
Groups A, B and AB had significantly higher expression of TLR2 (Figure 4A) and lower expressions
of p-p65 NF-κB (Figure 4B), p-p38 MAPK (Figure 4C) and COX-2 (Figure 4D) than did group I. Group
AB showed the best inhibitory effect on the expressions of inflammation-related proteins, including
p-p65 NF-κB (Figure 4B), p-p38 MAPK (Figure 4C) and COX-2 (Figure 4D). B. animalis subsp. lactis
treatment (groups B and AB) significantly decreased ICAM-1 expression compared with group I, and
this inhibitory effect was more potent in group AB than in group B (Figure 4E). L. acidophilus alone
(group A) had no inhibitory effect on ICAM-1 expression but it enhanced the efficacy of B. animalis
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subsp. lactis when they were used in combination (group AB, Figure 4E). All probiotics-treated groups
(groups A, B and AB) had significantly lower VCAM-1 expressions than did group I, while L. acidophilus
treatment (groups A and AB) showed a better inhibitory effect on VCAM-1 than did B. animalis subsp.
lactis alone (group B), as shown in Figure 4F.
Figure 4. Effects of probiotics on the expression of inflammation-related proteins in inflammatory HT-29
cells. All values are mean ± SD (n = 3). Bars with the same letter are not significantly different from
one another determined by Duncan’s multiple range test, p < 0.05. C, control; I, TNF-α (20 ng/mL) with
LPS (1 μg/mL); A, L. acidophilus at MOI of 1 with TNF-α (20 ng/mL) and LPS (1 μg/mL); B, B. animalis
subsp. lactis at MOI of 10 with TNF-α (20 ng/mL) and LPS (1 μg/mL); AB, L. acidophilus at MOI of 1
and B. animalis subsp. lactis at MOI of 10 with TNF-α (20 ng/mL) and LPS (1 μg/mL). (A), expression
of toll-like receptor 2 (TLR2); (B), expression of phosphorylated p65 nuclear factor kappa B (p-p65
NFκB); (C), expression of phosphorylated p38 mitogen-activated protein kinase (p-p38 MAPK); (D),
expression of cyclooxygenase-2 (COX-2); (E), expression of intercellular adhesion molecule-1 (ICAM-1);
(F), expression of vascular cell adhesion molecule-1 (VCAM-1).
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4. Discussion
The present study demonstrated that both L. acidophilus and B. animalis subsp. lactis significantly
reduced the secretion of IL-8 and the expressions of p-p65 NF-κB, p-p38 MAPK, VCAM-1 and COX-2,
as well as increased the expression of TLR2 in LPS- and TNF-α-induced inflammatory IECs. B. animalis
subsp. lactis significantly reduced the expression of ICAM-1 and this inhibitory effect was enhanced by
L. acidophilus, which did not affect ICAM-1 expression directly. The combination of two strains showed
the best anti-inflammatory activity. These results suggest that both L. acidophilus and B. animalis subsp.
lactis possess a potent anti-inflammatory activity in inflammatory IECs and there is an interaction
between these two strains of probiotics.
Lactobacillus is an important genus of probiotics, which plays an essential role of
immunomodulation in the intestinal mucosa. For example, L. acidophilus DDS-1 demonstrated a superior
survival rate, good adhesion capacity and strong immunomodulatory effect under experimental
conditions with or without LPS stimulation [24]. Most L. acidophilus species can be well adapted and
are able to survive during harsh conditions of digestion [24]. Due to this stability, L. acidophilus has been
considered an ideal vehicle for mucosal-targeted delivery of drugs [24]. The amount of L. acidophilus
remained almost unchanged in the gut for a long time [25].
The modulatory effects of L. acidophilus on intestinal inflammation and the immune system are
dependent on the stimulation in IECs. L. acidophilus significantly increased COX-2 expression and
prostaglandin E2 (PGE2) secretion in unstimulated Colo320 cells, but not in TNF-α-induced cells [26].
L. acidophilus NCFM could rapidly but transiently induce the production of pro-inflammatory cytokines
and chemokines in unstimulated Caco-2 cells [21]. In addition, L. acidophilus NCFM activated the
pathogen-associated molecular pattern (PAMP) receptor TLR2 and enhanced the phosphorylation of
p65 NF-κB and p38 MAPK in unstimulated Caco-2 cells [21]. The activation of TLR2-mediated NF-κB
and MAPK signaling pathways played a key role in the production of cytokines and chemokines in
IECs [21].
In contrast, L. acidophilus showed an anti-inflammatory effect in IECs stimulated by bacterial
ligands or pro-inflammatory cytokines. L. acidophilus Bar13 were effective in inhibiting IL-8 production
in HT-29 cells stimulated by TNF-α, IL-1β or LPS [27]. L. acidophilus DDS-1 significantly upregulated
anti-inflammatory IL-10 and downregulated pro-inflammatory TNF-α production and IL-8 levels in
LPS-treated HT-29 cells [24]. L. acidophilus LAB20 increased the transepithelial electrical resistance
(TER) of enterocyte monolayers and thus strengthened intestinal barrier function [16]. L. acidophilus
LAB20 also showed anti-inflammatory capacity by attenuating the LPS-induced IL-8 production in
HT-29 cells [16]. The results suggest that this strain may balance the IL-8 expression of IECs in response
to stimulation by LPS from Gram-negative bacteria in the intestine. Our study used LPS and TNF-α to
induce inflammatory responses of HT-29 cells and the results were in agreement with the above studies,
showing an anti-inflammatory effect of L. acidophilus. Some animal studies also demonstrated an
anti-inflammatory activity of L. acidophilus in the intestinal tract. L. acidophilus administration reduced
colonic leukotriene B4 (LTB4) production, inducible nitrogen oxide synthase (iNOS) expression and
myeloperoxidase (MPO) activity in the TNBS model of rat colitis [17]. L. acidophilus inhibited colitis by
inducing goblet cell differentiation, interfering with endoplasmic reticulum stress and suppressing
NF-κB activation in dextran sulfate sodium (DSS)-treated mice [28]. These findings suggest that
L. acidophilus can be used as a potent immunomodulator for IBD treatment.
Probiotics modulate immune- and inflammation-associated signaling pathways by gastrointestinal
digested products of probiotics and bacterial metabolites. The active compounds of L. acidophilus for the
anti-inflammatory effect may include either cell components or secretory factors. Cell wall components
play a critical role in modulating intestinal inflammation and immune function. Some components of
L. acidophilus, such as cell wall-associated polysaccharides, proteins and LTAs, could directly inhibit
NF-κB activation in HT-29 cells [28]. The surface-layer protein (SLP) from L. acidophilus is closely related
to a human health-promoting effect via modulation of the immune system. For example, SLP extracted
from L. acidophilus NCFM was found to inhibit the production of reactive oxygen species (ROS),
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nitrogen oxide (NO), PGE2, TNF-α and IL-1β through attenuating the activation of MAPK and NF-κB
in LPS-induced RAW264.7 cells [29]. This SLP inhibited NO and PGE2 production by downregulating
the protein expression levels of iNOS and COX-2 [29]. On the other hand, the cell-free supernatant of
L. acidophilus was able to downregulate IL-8 expression in HT-29 cells stimulated by LPS [30]. Otte et al.
(2009) indicated that distinct probiotics could specifically and significantly decrease the induced COX-2
expression in IECs, most likely mediated by released factors such as protein, butyrate and propionate
and in part by bacterial DNA [26]. A preliminary study of Kainulainen et al. (2015) suggested that
exopolysaccharide (EPS) of L. acidophilus LAB20 may have a role in its immunomodulatory activity [16].
Bifidobacteria make up 3–5% of adult microflora and thus constitute one of the predominant
species of the human colonic microflora [31]. They are more abundant in human gut microbiota than
Lactobacilli [32] and showed a moderate to low adhesion capacity of IECs [24]. B. animalis subsp. lactis
has well-established probiotic characteristics and proven beneficial health effects for gastrointestinal
health and immune function [33]. This strain also has potent anti-inflammatory and anti-proliferative
effects [10]. The capacity of Bifidobacteria to inhibit LPS-induced NF-κB activation is strain-dependent
in IECs. For example, B. bifidum was reported as a promising candidate for probiotic intervention
in inflammatory diseases of the gastrointestinal tract [31]. A recent study screened new probiotic
strains for IBD management by combining in vitro and in vivo methods and found that the best
anti-inflammatory capacity in peripheral blood mononuclear cells (PBMCs) from healthy donors were
observed for Bifidobacteria, while the anti-inflammatory profile of Lactobacilli was strain-dependent [6].
B. bifidum PI22, the strain that exhibited the most protective capacity against acute colitis, was only
slightly efficacious against chronic colitis in TNBS-treated mice. This strain inhibited the expression of
genes encoding chemokine C-X-C motif ligand 2 (CXCL2), IL-1β, TNF-α, IL-6 and IL-17 [6]. In contrast,
B. lactis LA804 which was less efficacious in the acute model was the most protective against chronic
colitis by downregulating the expression of genes for CXCL2, IL-1β and TNF-α in TNBS-treated
mice [6].
Similar to L. acidophilus, the modulatory effects of B. animalis subsp. lactis on intestinal inflammation
and the immune system are also dependent on the stimulation used in IECs and animal models.
B. lactis BB12 transiently triggered the phosphorylation of p65 NF-κB and p38 MAPK in unstimulated
native epithelium after the initial monoassociation of rats and in unstimulated Mode-K IECs [34].
TLR2 played an important role in mediating the initial interaction of B. lactis BB12 with the intestinal
epithelium [34]. This study suggested that probiotics could transiently trigger innate signal transduction
and pro-inflammatory gene expression in the intestinal epithelium in the early stages of bacterial
colonization [34].
In contrast, B. animalis subsp. lactis showed an anti-inflammatory effect in IECs stimulated
by bacterial ligands or pro-inflammatory cytokines and in animals treated with pro-inflammatory
compounds. B. lactis inhibited NF-κB and its regulated genes for COX-2, matrix metalloproteinase-9
(MMP-9) and vascular endothelial growth factor (VEGF) in HT-29 cells stimulated with IL-1β, TNF-α
or LPS [10]. Another study showed that B. animalis ssp. lactis UABla-12 was able to downregulate IL-8
levels in LPS-treated HT-29 cells [24]. Our study used LPS and TNF-α to induce inflammatory responses
of HT-29 cells and showed an anti-inflammatory effect of B. animalis subsp. lactis, in agreement with
previous studies. Animal studies also confirmed the anti-inflammatory activity of this strain of
probiotics. For example, B. lactis treatment reduced colonic TNF-α production and the expressions
of iNOS and COX-2 in TNBS model of rat colitis [17]. B. lactis prevented DSS-induced acute colitis
and CAC in mice and could be a therapeutic agent for IBD as well as a potential preventive agent for
CAC [10].
Previous studies found that Bifidobacterium strains’ DNA was effective in limiting epithelial
pro-inflammatory responses in IL-10-deficient mice and in HT-29 cells challenged with TNF-α;
however, the pro-inflammatory response to LPS in HT-29 cells was not inhibited by probiotic
DNA [31]. These authors indicated that the anti-inflammatory compound is neither actively secreted
by Bifidobacteria nor released from lysed cells. The mechanisms by which whole cells of Bifidobacteria
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inhibit inflammatory responses are distinct from their DNA [31]. Recent studies have focused on
the surface-associated structural components of Bifidobacteria, such as EPS, peptidoglycan, LTA and
lipoglycans [35]. The biosynthesis of EPS has been described in several species of Bifdobacterium and it
seems that these molecules play a relevant role in their immunomodulatory and anti-inflammatory
capabilities [36].
The synergistic effect of different probiotic strains may have a higher impact on host cells
compared to single probiotic strains. Some studies on the anti-inflammatory effects of probiotics were
performed using mixtures of different probiotic strains, mainly probiotics belonging to Lactobacillus and
Bifidobacterium genera [31]. Clinical reports have found that administration of mixed probiotics exhibits
a combinatorial effect in the host [35]. The enhanced efficacy of multi-strain/combinatorial therapy
may arise due to a combination of several probiotic mechanisms, with each strain making their own
contributions [35]. Some combined probiotics have been shown to possess a good anti-inflammatory
activity in vivo and in vitro. A combination of Streptococcus thermophilus ATCC19258 and L. acidophilus
ATCC4356 had a pronounced effect on the phosphorylation of p38 MAPK and extracellular signal
regulated kinase (ERK)1/2 in HT-29 cells with or without the stimulation of interferon-γ (IFN-γ) or
TNF-α [30]. In addition, this probiotic combination reduced the phosphorylation of the nuclear factor
of kappa light polypeptide gene enhancer in B-cells inhibitor α (IκB-α) [37]. These results suggest that
the probiotic combination may activate the MAPK signaling pathway but inhibit the NF-κB signaling
pathway in IECs challenged by pro-inflammatory cytokines. VSL#3 probiotics significantly ameliorated
the disease activity index (DAI), prevented the decrease of tight junction proteins including occludin
and zonula occludens (ZO)-1 and increased the expression of p-p38 MAPK and phosphorylated ERK
(p-ERK) in DSS-treated rats [38]. Furthermore, tight junction proteins (occludin and ZO-1), p-p38
MAPK and p-ERK in the VSL#3 group were significantly higher than those in either the control or
TNF-α group in TNF-α-induced HT-29 cells [38]. This study suggests that VSL#3 probiotics may
enhance the tight junction and protect the epithelial barrier in vivo and in vitro by activating the p38
MAPK and ERK signaling pathways. Ultrabletique, a probiotic cocktail, exerted an anti-inflammatory
effect and contributed to the rapid recovery of DSS-induced acute colitis in mice [39]. The results were
associated with reduced expressions of TLR4, iNOS and NF-κB in colonic tissues [39].
There are limited studies investigating the interaction between different probiotics. L. acidophilus
Bar13 and B. longum Bar33 were effective in inhibiting IL-8 secretion in HT-29 cells stimulated by TNF-α,
IL-1β or LPS, and B. longum Bar33 presented the highest effect [27]. Both strains showed the potential
to protect enterocytes against an acute inflammatory response [27]. However, a combination of these
two strains did not show an additive effect. Another study demonstrated that each of L. acidophilus,
B. lactis or their combination had an individual modulatory impact on the immune system, including
regulatory T (Treg) cells and effector T helper (Th) cells, of UC patients [13]. However, there is no
synergistic effect between these two strains. B. lactis had a more stimulatory effect on the Treg cells of
UC patients, although it also stimulated the effector Th cells [13]. Based on the IL-10 and transforming
growth factor-β (TGF-β) levels of PBMCs stimulated by probiotics, the authors supposed that B. lactis
could be a better candidate for Treg cells stimulation compared with L. acidophilus and mixed probiotics
in UC patients. Our study found that both L. acidophilus and B. animalis subsp. lactis significantly
suppressed inflammation in LPS- and TNF-α-stimulated HT-29 cells and that the combination of these
two strains showed the best anti-inflammatory effect. Our results also indicated that TLR, NF-κB and
MAPK signaling pathways and their associated factors, such as adhesion molecules and inflammatory
mediators, played important roles in the observed anti-inflammatory activity. The two strains may
have an interaction through these pathways.
TLRs are pattern recognition receptors (PRR) expressed by various cells in the gastrointestinal
tract, including IECs [8]. TLRs represent the first point of contact between environment and organism
and are powerful molecular regulators by which the immune system may sense the environment and
protect the host from pathogens or endogenous threats [40]. TLRs are membrane bound and provide
pathogen surveillance, which upon ligand binding, activate NF-κB signaling and lead to the production
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of pro-inflammatory cytokines, chemokines and antimicrobial peptides [12]. TLR signaling in IECs
plays several crucial roles in maintaining healthy gut epithelial barrier that includes proliferation
of epithelial cells, production of antimicrobials, maintenance of tight junction and modulation of
immune system [36]. TLR signaling in the gut is involved in either maintaining intestinal homeostasis
or inducing an inflammatory response [8]. Under normal conditions, IECs show low expression of
TLRs and are therefore unresponsive to TLR stimuli; under inflammatory conditions, epithelial TLR
expression is increased, which contributes to both inflammation and immune tolerance [8]. Epithelial
TLR2 activation has been described to protect against barrier disruption in IECs [8].
TLR2 recognizes a wide range of ligands, among which the best characterized are lipoproteins
highly expressed on the outer membrane of Gram-positive bacteria [40]. The cell wall of probiotic
bacteria contains peptidoglycan, lipoproteins and lipopeptides, described as TLR2 ligands, and thus
TLR2 plays an important role in the recognition of anti-inflammatory probiotic bacteria [36].
The immunomodulatory role of LTA in probiotic Lactobacillus through TLR2 recognition is well
established. Although these biopolymers have long been identified in Bifidobacterium, their roles in
PRR-mediated interaction in host have not yet been well studied [35]. In contrast, the activation of
TLR4 by LPS from Gram-negative bacteria leads to the secretion of pro-inflammatory mediators in the
intestinal mucosa, mainly through the activation of the transcription factor NF-κB [39]. TLR2 ligation
may induce a suppressive effect on TLR4-mediated inflammatory responses via the expression or
activation of TLR negative regulators [12]. The present study showed that L. acidophilus and B. animalis
subsp. lactis, either alone or in combination, significantly enhanced TLR2 expression in HT-29 cells
stimulated with LPS and TNF-α, suggesting the potential of these probiotics in protecting IECs against
bacteria- and cytokine-mediated inflammation.
NF-κB transcriptional system in IEC plays an essential role in the regulation of inflammation
in patients with various intestinal disorders [10]. It regulates the transcription of a series of genes
involved in acute responses to injury and in chronic intestinal inflammation including the genes
for IL-1β, TNF-α, IL-6, IL-8, COX-2, ICAM-1, and so on [31]. NF-κB is activated through a wide
range of stimuli such as TNF-α, IL-1β and LPS [31] and acts as a central regulator of the IEC innate
immune response and as an essential transcription factor for integrating the pro-inflammatory response
to infection with enteroinvasive bacteria [41]. In addition, NF-κB, as an important downstream
pathway in LPS-mediated signal responses, is also closely related to tumor growth, inflammation and
apoptosis [29]. Probiotics can alter the NF-κB pathway at many different levels including degradation,
ubiquitination and inhibition of proteasome function [39]. Induction of the nuclear export of complexes
formed by nuclear factor NF-κB and peroxisome proliferator-activated receptor-γ (PPAR-γ) is another
anti-inflammatory mechanism induced by probiotics [39].
MAPK proteins, including ERK, c-Jun N-terminal kinase (JNK), and p38 protein kinases,
are activated to act on their respective substrates to regulate the inflammatory response in
LPS-stimulated cells [29]. Activation of the MAPK signaling pathway by LPS can indirectly activate
the downstream NF-κB pathway, initiate protein expression and stimulate complex physiological
responses [29]. Probiotics can affect the MAPK signaling pathway independent of NF-κB signaling.
Suppression of p38 phosphorylation has been associated with the inhibition of IL-8 secretion without
impacting on IL-8 mRNA levels or the activation of NF-κB [14]. Probiotic-induced changes in
phosphorylation levels of p38, JNK and ERK1/2 MAPKs can affect cytokine secretion and apoptosis [14].
The present study showed that LPS and TNF-α stimulation significantly increased the
phosphorylated forms of p65 NF-κB and p38 MAPK in HT-29 cells, suggesting the activation of
NF-κB and MAPK signaling pathways. Inflammatory cells treated with either L. acidophilus or
B. animalis subsp. lactis had significantly lower expression of phosphorylated p65 NF-κB and p38
MAPK proteins compared with untreated cells. Furthermore, the combination of L. acidophilus and
B. animalis subsp. lactis showed the best inhibitory effect on the activation of NF-κB and MAPK. These
results suggest that the two strains of probiotics may exert an anti-inflammatory effect by modulating
NF-κB and MAPK signaling pathways in IECs.
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IL-8 is a chemokine produced by many types of cells, including IECs [11]. IL-8 is responsible
for the initiation of inflammatory cascades and the recruitment of neutrophils into the mucosa of
lesions [16]. It also plays important roles in angiogenesis and the metastasis of tumors [11]. In response
to enteropathogens infection the IECs release IL-8 and other pro-inflammatory molecules that initiate
an acute inflammatory response [27]. A prolonged infection can result in a massive and long-lasting
IL-8 release by IECs [27]. LPS, IL-1α, IL-1β, IL-10, IFN-γ and TNF-α regulate IL-8 production in various
cell types [11]. HT-29 cells produce IL-8 after stimulation by TNF-α and IL-1β, but not by IFN-γ, IL-10
or IL-13 [11]. TNF-α plays a guiding role in the production of IL-8, and NF-κB establishes a feedback
mechanism via autocrine/paracrine factors to regulate the expression and activation of IL-8 [42].
COX-2 plays an important role in inflammation. A variety of extracellular and intracellular
stimuli, including LPS and TNF-α, rapidly induce the expression of COX-2 [43]. There are strain- and
stimulation-specific effects of probiotics on COX-2 expression in IECs. Both probiotic E. coli Nissle and
mixed probiotics VSL#3 had no effect on basal COX-2 expression but decreased stimulated COX-2
activity, protein expression and PGE2 secretion, while L. acidophilus increased COX-2 expression and
PGE2 secretion in unstimulated Colo320 and SW480 IECs and in gastrin-induced Colo320 cells but not
in TNF-α-induced Colo320 cells [26]. Although the precise mechanisms regulating COX-2 expression
in IECs have not been fully clarified, activator protein-1 (AP-1) and p38 MAPK are the only regulatory
elements identified in IECs so far [26].
The present study found that stimulation by LPS and TNF-α significantly increased the secretory
level of IL-8 and the expression of COX-2 in HT-29 cells, showing a typical inflammatory response.
In contrast, the inflammatory cells treated with either L. acidophilus or B. animalis subsp. lactis had
significantly lower IL-8 level and COX-2 expression compared to those without probiotics treatment.
Additionally, combination of L. acidophilus and B. animalis subsp. lactis showed the best inhibitory
effect on IL-8 secretion and COX-2 expression. These effects are in agreement with those on NF-κB
and MAPK and suggest that these two strains of probiotics are able to suppress inflammation by
modulating IL-8 secretion and COX-2 expression in IECs.
Cell adhesion molecules (CAMs) are categorized as cadherins, selectins, integrins and
immunoglobulin-like adhesion molecules (IgCAMs) such as mucosal addressin cell adhesion molecule
1 (MAdCAM-1), ICAM-1 and VCAM-1. They are required for the binding of leukocytes to tissue
components and the directional movement of leukocytes toward inflamed sites [44]. Human IECs
are normally lack of ICAM-1 and VCAM-1 expressions but induction of their expressions has been
reported in response to pro-inflammatory cytokines such as IL-1β, IL-6 and IFN-γ [45]. Our study also
induced the expressions of ICAM-1 and VCAM-1 by LPS and TNF-α. ICAM-1 and VCAM-1 are closely
related to NF-κB and MAPK signaling pathways. The binding sites for NF-κB have been identified in
the promoter regions of the genes for ICAM-1 and VCAM-1 [46]. Another study has indicated that
there is a possible relationship between inhibition of MAPKs and decreased expression of ICAM-1 and
VCAM-1 [45].
ICAM-1 is constitutively expressed by several types of cells, including leukocytes, endothelial
cells and IECs [47,48]. The major agonists for ICAM-1 expression are bacterial products (such as LPS)
and pro-inflammatory cytokines (such as TNF-α, IL-1 and IFN-γ) released at inflammatory sites [47].
Expression of ICAM-1 in human IECs is upregulated following infection with invasive bacteria and
stimulation with TNF-α and IFN-γ [47]. Transcription of ICAM-1 is under regulation by cytokines
such as IL-1β, TNF-α and IFN-γ as well as by growth factors and stress oxidants through various
signaling pathways, including NF-κB and AP-1 pathways [44]. ICAM-1 plays an important role in both
innate and adaptive immune responses. It is involved in the transendothelial migration of leukocytes
to inflammatory sites, as well as interactions between antigen presenting cells (APC) and T cells [48].
ICAM-1 on IECs is involved in the immune defense, including attraction of neutrophils to the surface
defect, adhesion of transmigrated neutrophils to face the luminal content and binding of microbial
surface molecules [44]. Both active UC and CD are associated with marked infiltration of inflammatory
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cells, while ICAM-1 is involved in leukocyte infiltration [49]. ICAM-1 plays a specific role in the
pathogenesis of IBD, so loss of ICAM-1 function may be effective in controlling IBD [44].
VCAM-1 is inducible and predominantly expressed in endothelial cells and also on the surface
of other cells, including macrophages and cancer cells [50]. The expression of VCAM-1 is activated
by pro-inflammatory cytokines, including TNF-α, and also by ROS, oxidized low-density lipoprotein
(oLDL), high glucose concentration, TLR agonists (such as LPS) and shear stress [50]. VCAM-1 is an
important modulator of lymphocyte and monocyte trafficking [46]. VCAM-1 was originally identified
as a cell adhesion molecule that helps regulate inflammation-associated vascular adhesion and the
transendothelial migration of leukocytes such as macrophages and T cells [50]. Recent evidence
suggests that VCAM-1 is closely associated with the progression of various immunological disorders
and cancers, so it is a potential therapeutic target in these diseases [50]. Experimental studies have
shown that blockade of VCAM-1 results in a higher inhibition of leukocyte adhesion in colonic
venules and a potent effect on preventing or reversing established inflammation in various animal
models [51–53].
In human intestinal microvascular endothelial cells, ICAM-1 is constitutively expressed and
VCAM-1 is not detectable in basal conditions but a marked increase in both adhesion molecules
is observed after challenges of these cells with IL-1β, TNF-α or LPS [46]. In the murine intestine,
the constitutive level of VCAM-1 expression is substantially lower than that of ICAM-1; however,
a significant increase in the endothelial cell surface density of VCAM-1 is noted by cytokine
stimulation [46]. Remarkable increases in VCAM-1 expression have also been documented in
rodent models of chemically induced colitis, as well as in colitis of IL-10 knockout mice [46,51,52].
In these animal models, the expression of ICAM-1 was not increased or was only slightly elevated,
whereas increased expressions of MAdCAM-1 and VCAM-1 were observed. VCAM-1, in contrast with
ICAM-1, is not involved in physiological leukocyte recirculation and selective blockade of its function
might attenuate the inflammatory response without altering physiological immune mechanisms [46].
Specific blockade of the adhesion molecules such as ICAM-1 involved in leukocyte recruitment to the
inflamed intestine is considered to be one of the most promising therapeutic targets for IBD [53,54].
Limited studies have investigated the effect of probiotics on adhesion molecules. Riedel et al.
(2006) reported that B. bifidum S17 decreased mRNA level of ICAM-1 in LPS-induced HT-29 cells [31].
Angulo et al. (2006) demonstrated that L. casei attenuated leukocyte recruitment in experimental
colitis induced by TNBS in rats [55]. This effect was possibly related to the suppression of ICAM-1
upregulation, although VCAM-1 expression was unaffected. Chu et al. (2010) indicated that L. plantarum
treatment improved the histological damage score and interfered with the upregulation of adhesion
molecules such as ICAM-1 in IL-10 knockout mice [49]. In addition to whole probiotics, the cell
wall components of probiotics also play an important role in regulation of adhesion molecules and
other inflammatory-related factors. Kim et al. (2012) showed that LTA from L. plantarum inhibited
TNF-α-induced inflammatory responses, including increased IL-8, iNOS, NO and ICAM-1, in HT-29
cells through inhibition of the NF-κB and MAPK signaling pathways [11].
Our study successfully induced strong expressions of ICAM-1 and VCAM-1 in HT-29 cells
stimulated with LPS and TNF-α. Interestingly, L. acidophilus and B. animalis subsp. lactis showed a
different impact on ICAM-1 and VCAM-1. L. acidophilus and B. animalis subsp. lactis, either alone or in
combination, significantly decreased VCAM-1 expression in inflammatory HT-29 cells compared with
those untreated with probiotics. L. acidophilus showed higher efficacy on VCAM-1 inhibition than did
B. animalis subsp. lactis. However, L. acidophilus alone did not inhibit ICAM-1 expression but enhanced
the efficacy of B. animalis subsp. lactis which significantly decreased ICAM-1 expression in inflammatory
HT-29 cells. It shows a synergistic effect between two strains of probiotics. ICAM-1, associated with the
recruitment and adhesion of neutrophils, is known to play a determining role in acute inflammatory
conditions, while VCAM-1 is more relevant as a mediator of chronic inflammatory diseases in which
the recruitment of lymphocytes is the main cellular event [44,55]. Blocking ICAM-1 and VCAM-1
may have therapeutic benefits for the acute inflammatory component of IBD in SAMP-1/Yi adoptive
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transfer model mice [56]. These findings suggest that B. animalis subsp. lactis may have the potential to
alleviate acute inflammation in the gut, while L. acidophilus may be a candidate for remission of chronic
intestinal inflammation. Combination of two strains seems to have the best anti-inflammatory activity
in the intestinal tract and may be a candidate adjuvant for IBD treatment.
5. Conclusions
In conclusion, the present study showed that L. acidophilus and B. animalis subsp. lactis exerted
a potent anti-inflammatory effect through modulating TLR2-mediated NF-κB and MAPK signaling
pathways in inflammatory IECs. Both strains, especially their combination, may have the potential to
be developed as a novel adjuvant for IBD therapy.
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Abstract: Vitamin D has been linked to human health benefits that extend far beyond its
established actions on calcium homeostasis and bone metabolism. One of the most well studied
facets of extra-skeletal vitamin D is its activity as an immuno-modulator, in particular its potent
anti-inflammatory effects. As a consequence, vitamin D deficiency has been associated with
inflammatory diseases including inflammatory bowel disease (IBD). Low serum levels of the major
circulating form of vitamin D, 25-hydroxyvitamin D (25-OH-D) are significantly more prevalent
in patients with IBD, particularly in the winter and spring months when UV-induced synthesis of
vitamin D is lower. Dietary malabsorption of vitamin D may also contribute to low serum 25(OH)D in
IBD. The benefits of supplementation with vitamin D for IBD patients are still unclear, and improved
vitamin D status may help to prevent the onset of IBD as well as ameliorating disease severity.
Beneficial effects of vitamin D in IBD are supported by pre-clinical studies, notably with mouse
models, where the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH)2D) has been shown
to regulate gastrointestinal microbiota function, and promote anti-inflammatory, tolerogenic immune
responses. The current narrative review aims to summarise the different strands of data linking
vitamin D and IBD, whilst also outlining the possible beneficial effects of vitamin D supplementation
in managing IBD in humans.
Keywords: vitamin D; IBD; Crohn’s disease; ulcerative colitis; supplementation; deficiency
1. Introduction
Inflammatory bowel diseases (IBD) are chronic, disabling diseases precipitating inflammation
and ulceration throughout the gastro-intestinal tract (GIT). IBD is characterised by diarrhea, nocturnal
defecation, abdominal pain, weight loss, and fatigue. The two principal forms of IBD are Crohn’s
disease (CD) and ulcerative colitis (UC). Where UC usually only affects the colon, CD may affect the
entire GIT from mouth to anus. IBD is common in developed, westernised countries with highest
prevalence estimates of; UC 505 per 100,000 and CD 322 per 100,000 population in Europe and UC
249 per 100,000 and CD 319 per 100,000 population in North America [1]. The incidence of IBD is
rapidly increasing in newly industrialised countries strongly implicating environmental factors [2].
The pathogenesis of IBD is not fully understood, but key influences are thought to include genetics,
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environmental factors, immune response, and gut microbiota [3]. The gut microbiota has emerged as
an important feature in innate and adaptive immunity [4], with microbial colonisation of the gut being
essential for the development of a mature immune system [5]. One explanation for the ongoing increase
in IBD is the adverse effect of modern lifestyles on the composition and function of gut microbiota,
including high saturated fat/high sugar diets and the use of antibiotics [6].
It is recognised that the availability of vitamin D is important in regulating gut mucosal
immunity [3]; with studies suggesting that vitamin D may affect gut epithelial integrity, innate
immune barrier function, and the development and function of T cells [7–9]. Although vitamin D
deficiency is common in people with IBD it is not established if this is a cause or a consequence of
the disease. However, there are suggestions that in genetically predisposed individuals, vitamin D
deficiency may be a contributing factor in the development of IBD [7]. There is growing evidence that
vitamin D status may affect disease activity. As such consideration should be given to screening and
management of vitamin D deficiency in this patient group [10–12].
This narrative review explores the prevalence of vitamin D deficiency in people with IBD and the
possible benefits to patients in treating this deficiency. Consideration is given to the management of
vitamin D deficiency via exposure to sunlight, dietary sources and supplementation.
2. Vitamin D Deficiency in IBD
2.1. Defining Vitamin D Deficiency
Vitamin D-deficiency is a common health issue across the globe, but it is especially prevalent
in Northern European countries. Despite this, defining vitamin D deficiency in human populations
remains a contentious issue. In 2010 the Institute of Medicine (IOM) defined vitamin deficiency as serum
concentrations of 25-OH-D less than 20 ng/mL (50 nmol/L) [13]. Subsequently the Endocrine Society
issued slightly different guidelines, defining vitamin D insufficiency as being serum 25-OH-D levels
below 30 ng/mL (75 nmol/L) [14]. In the UK, the Scientific Advisory Committee on Nutrition (SACN)
have taken a different approach [15], recommending that a serum 25-hydroxyvitamin D (25-OH-D)
level of <25 nmol/L is the threshold at which vitamin D deficiency, and associated complications such
as poor musculoskeletal health, is likely to develop. However, other guidelines and studies suggest
that levels of 25-OH-D below 25–50 nmol/L constitute deficiency with levels >75 nmol/L indicating
sufficiency [14,16–19]. The threshold between 51–74 nmol/L 25-OH-D may then be termed insufficiency.
Crucially, these varying recommendations for vitamin D sufficiency and insufficiency continue to be
based on the classical skeletal actions of vitamin D, and there are no current recommendations for
more recently reported extra-skeletal actions of vitamin D and additional effects are associated with
pharmacologic doses of vitamin D.
Both the Endocrine Society [14] and the National Osteoporosis Society [20] recommend that
screening for vitamin D deficiency should be carried out in those at risk of vitamin D deficiency;
they include people with IBD/malabsorptive disorders in the at risk group. Treatment for deficiency
is recommended at a cut off of <50 nmol/L [14,20]. Nonetheless, current UK National Institute for
Health and Care Excellence (NICE) and American College of Gastroenterology (ACG) guidance on the
management of patients with CD and UC [21–24] do not address vitamin D deficiency in these patients.
2.2. Prevalence of Deficiency in IBD
Vitamin D deficiency is a public health concern with the NICE recommending oral supplementation
in specific population groups including infants and children under 4 years, pregnant or breastfeeding
women, people over 65 years of age and those who have low or no exposure to the sun. For example,
those who cover their skin for cultural reasons, are housebound or confined indoors [25]. The population
prevalence of vitamin D deficiency (serum 25-OH-D <40 nmol/L) in some westernised countries is
reported to be between 30% [26,27] and 47% [28] with the highest levels reported for those people with
darkly pigmented skin. However, people with IBD are likely to be at increased risk of developing
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vitamin D deficiency for a number of reasons including: impaired absorption of nutrients and bile salt
malabsorption, restricted dietary intake, and medical advice to avoid/protect against sunlight exposure
while taking immuno-suppressive treatments such as thiopurines [29].
A number of studies have evaluated the prevalence of vitamin D deficiency and insufficiency
in people with IBD [30] (Table 1). Prevalence of vitamin D deficiency is highest during winter and
spring and lowest during summer and autumn [31]. Where available reported prevalence in Table 1
corresponds with winter/spring levels. These studies suggest that vitamin D deficiency is generally
higher in patients with CD than UC and usually higher than that of the general population. However,
previous work by the authors suggest it is not standard clinical practice to measure vitamin D in these
groups [30]. It is also important to recognise that whilst serum 25-OH-D deficiency has been widely
reported for CD and UC, this may not necessarily reflect the status of other vitamin D metabolites.
Notably analysis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH)2D) has shown
higher serum levels of this metabolite in patients with CD relative to UC patients [32]. The suggestion
from this and other studies is that the increased inflammation in CD is associated with enhanced
extra-renal conversion of 25-OH-D to 1,25-(OH)2D to support gastrointestinal anti-inflammatory
immune responses. Measurement of serum levels of 1,25-(OH)2D is generally rare, but it is interesting
to note that serum levels of this metabolite correlated inversely with bone mineral density in CD
patients [32]. The functional impact of vitamin D on skeletal homeostasis in IBD is still unclear, and it
is possible that link between elevated serum 1,25-(OH)2D and bone loss simply reflects the greater
severity of inflammatory disease. Inflammation itself can drive osteopenia through pro-inflammatory
cytokines [33]. Impaired vitamin D status has been reported to be a risk factor for low bone mineral
density (BMD) in IBD patients in some studies [34], but not in others [35], and single nucleotide
polymorphism variants of the gene for the vitamin D receptor (VDR) have been shown to protect
against low BMD in patients with IBD [36]. Supplementation with vitamin D and calcium has been
shown to improve BMD in pediatric [37] and adult [38] IBD patients.
Table 1. Prevalence of vitamin D deficiency and insufficiency in inflammatory bowel disease (IBD) [30].












Bours et al [39] 185 50 (15) UC 34
131 47 (15) CD 44
Caviezel et al [40]
57 41 (13) UC 44
99 41 (14) CD 58
25 48 (15) IBS 28
Frigstad et al [41] 178 39 UC 44 7
230 40 CD 53 8
Gilman et al [42] 50 38 (10) CD 44 6
Kabbani et al [43] 368 44 (10) UC
29.9
597 CD 30
Kuwabara et al [44] 41 39 (15) UC 60
29 32 (7) CD 100
McCarthy et al [45] 32 37 (11) CD 50 41
32 37 (11) HC 25 1
Pappa et al [46] 36 15 (3) UC 25
94 15 (4) CD 38
Sentongo et al [47] 112 16 (4) CD 16
Siffledeen et al [48] 242 40 (10) CD 22 8
Suibhne et al [49] 81 36 (11) CD 90 63
70 36 (9) HC 51
Ulitsky et al [50] 101 42 UC 67 46
403 43 CD 76 51
Veit et al [51]
18 16 (2) UC 83 50 28
40 17 (2) CD 73 40 15
116 15 (2) HC 75 27 10
UC = Ulcerative colitis; CD = Crohn’s disease; IBS = irritable bowel syndrome; HC = healthy control.
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2.3. Vitamin D Deficiency in IBD—Cause or Consequence
Though vitamin D deficiency in IBD is well documented it is unclear if this is a cause or
a consequence of the disease. It is notable that the highest prevalence of the disease appears in more
temperate climates with lower levels of sunlight [8]. Some studies have suggested a correlation between
vitamin D deficiency and increased disease activity [41,43,52–54]. Low vitamin D levels associated with
IBD may be due to dietary restriction or low UV light exposure, but it is also important to recognise
that genetic factors also contribute to variations in circulating vitamin D [55]. Single nucleotide
polymorphisms (SNP) for components of the vitamin D system have been shown to contribute to the
variation of serum 25-OH-D levels in IBD patients [56]. However, the contribution of SNPs to serum
levels of 25-OH-D in IBD patients is very small (3%) [56], and subsequent Mendelian randomisation
analyses have not shown any link between genetic determinants of vitamin D status and risk of IBD [57].
It is still unclear whether these observations support a causative relationship between vitamin D status
and the development of IBD. A prospective cohort study of 72,719 women (age, 40–73 years) enrolled in
the Nurses’ Health Study found that a higher predicted vitamin D status was associated with a reduced
risk of developing CD [58]. However, it would seem that grounds for a causative relationship are most
likely to be found in laboratory evidence of the functional effects of vitamin D, suggesting an effect of
the active form of vitamin D on immune responses related to IBD [59].
3. Functional Effects of Vitamin D in IBD—Analysis of In Vitro and In Vivo Models
The mechanistic basis for a role for vitamin D in IBD stems firstly from studies
of immuno-modulatory properties of 1,25-(OH)2D. These include antibacterial [60–62] and
anti-inflammatory [63,64] actions on cell from the innate and adaptive immune system that modulate
the pathology of gastrointestinal dysregulation and inflammation. Vitamin D also appears to play
a pivotal role in the maintenance of gastrointestinal barrier integrity by regulating proteins associated
with epithelial cell gap junctions [65–67]. The barrier function of vitamin D is also linked to its impact
on the gastrointestinal microbiota, with serum 25-OH-D status in humans being correlated with
changes in gastrointestinal bacterial genera associated with inflammatory immune responses [68,69].
In this way vitamin D has the potential to both prevent the onset of IBD via effects on barrier function
and microbiota homeostasis, and also ameliorate disease progression through anti-inflammatory
immune responses.
The beneficial effects of vitamin D on gastrointestinal barrier function and immune surveillance are
strongly supported by studies of mouse models that have incorporated dietary vitamin D restriction and
genetic manipulation of the vitamin D metabolic and signaling system. Mice lacking the gene for the
vitamin D receptor (VDR) that binds 1,25-(OH)2D show increased severity of experimentally-induced
colitis that mimics IBD [70]. Similar observations have also been made for mice lacking the gene for
1α-hydroxylase, the enzyme that converts 25-OH-D to 1,25-(OH)2D [71]. Thus, in mice, inability to
synthesise or recognise 1,25-(OH)2D was associated with increased IBD severity. This is due, in part,
to impaired anti-inflammatory adaptive immune function [70], but has also been linked to disruption
of the normal gastrointestinal epithelial barrier [66]. Interestingly, in mice with dietary vitamin D
restriction increased colitis severity was associated with elevated levels of normal commensal bacteria
within the gastrointestinal sub-mucosal epithelium, further underlining the importance of vitamin
D in maintaining barrier integrity and surveillance of the gut microbiota [72]. The bioavailability
of vitamin D for barrier and immunomodulatory activity within the gastrointestinal tract may also
be influenced by the serum vitamin D binding protein (DBP) that transports vitamin D metabolites
in the circulation. Although 25-OH-D binds with high affinity to DBP, it has been reported that the
unbound or ‘free’ fraction of serum 25-OH-D is the most biologically active for immune responses to
vitamin D [73]. Thus, the interaction between DBP and 25-OH-D may play a key role in gastrointestinal
responses to vitamin D. For example, mice raised on diets containing exclusively vitamin D2 showed
much lower serum levels of 25-OH-D compared to mice raised on vitamin D3 only. However, because
25-OH-D2 binds with lower affinity to DBP than 25-OH-D3, the levels of free 25-OH-D were similar
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in the two groups of mice and both showed similar patterns of experimentally induced colitis [74].
These observations suggest that free 25-OH-D may be a more sensitive marker of the protective
effects of vitamin D on IBD. In addition to observations from mouse models, evidence from studies of
humans also supports a link between vitamin D and IBD. This includes reports that 1,25-(OH)2D is
a potent stimulator of nucleotide-binding oligomerisation domain containing 2 (NOD2), an intracellular
pathogen-recognition receptor [75]. Mutations in the gene for NOD2 (CARD15) are associated with the
development of CD [76,77], and vitamin D status may therefore act as a key environmental trigger for
those individuals who are genetically predisposed to CD. Figure 1 is a schematic representation of
the expression of VDR and the CYP27B1 gene (responsible for the production of 1α-hydroxylase) in
human colonic epithelial cells and antigen presenting cells.
Figure 1. Vitamin D and barrier function in the gastrointestinal tract. Schematic representation of the
expression of the vitamin D receptor (VDR) and vitamin D-activating enzyme (CYP27B1) in human
colonic epithelial cells, antigen presenting cells such as dendritic cells (DC), and T cells. Immune
responses to vitamin D occur either via systemic 1,25-dihydroxyvitamin D (1,25-(OH)2D) or local
conversion of 25-hydroxyvitamin D (25-OH-D) to 1,25-(OH)2D. Possible target mechanisms include: 1)
interface with microbiota (induction of antibacterials such as angiogenin, cathelcidin (LL37), defensins
or intracellular pathogen recognition proteins such as nucleotide-binding oligomerisation domain
containing 2 (NOD2)); 2) T cell homing to sites of inflammation; 3) suppression of inflammatory Th17
and Th1 cells and induction of tolerogenic Treg and Th2 cells; 4) enhanced expression of epithelial
membrane junction proteins
4. Managing Vitamin D Deficiency in IBD—Sources of Vitamin D
4.1. Sunlight Exposure
The main source of vitamin D in humans is via synthesis in the body stimulated by sunlight
exposure [78]. The vitamin D precursor 7-dehydrocholesterol is produced by the liver and is stored in
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the skin. On exposure of the skin to ultraviolet B-light, this is converted to pre-vitamin D3 and enters the
circulation. In the liver pre-vitamin D3 is converted to the inactive form 25(OH)D3. Renal conversion
of 25(OH)D3 produces active form 1,25-(OH)2D3 [78].
Lack of adequate exposure to sunlight is likely to lead to vitamin D deficiency with levels
<25 nmol/L [15]. However, it is difficult to determine what adequate exposure is. The British
Dermatology Association in their 2010 consensus statement on the use of sun-exposure to prevent
vitamin D deficiency noted the results of Rhodes et al [79]; the time to produce vitamin D is generally
short and certainly before skin begins to burn or redden. The study found that sunlight exposure for
an equivalent of 13 minutes of UK summer midday sun (approximate latitude 53.4808◦ N, 2.2426◦ W),
three times per week over a six-week period was sufficient to increase serum vitamin D levels above
50 nmol/L. The study was carried out in Caucasian participants with one third of their skin exposed
to simulated sunlight and wearing no sunscreen [79]. Darker skin required a longer exposure to
sunlight to produce vitamin D, so, it would not be possible to have a single recommendation for all
skin types. In addition, Rhodes et al note that excessive cutaneous exposure to sunlight may in fact
lead to degradation of vitamin D but they do not quantify what excessive exposure is [79]. A more
recent global consensus statement on the treatment and prevention of rickets suggests that the use
of sunlight exposure to prevent or treat vitamin D deficiency is not feasible [80]. The authors note
that there is no safe threshold of ultra violet exposure that allows for sufficient vitamin D synthesis
without increasing the risk of skin cancer [80]. This is of particular relevance to patients with IBD,
where there is an increased risk of non-melanoma skin cancer in those who have received thiopurines
to treat IBD [81].
4.2. Dietary Sources
The majority of naturally occurring vitamin D in food is found in animal products [82] and, as in
humans, the quantity of vitamin D found in animal products will vary according to the vitamin D status
of the animal. This will be influenced by the animal’s diet, if they receive vitamin D supplementation
in their feed and their exposure to sunlight [83]. In the USA the addition of vitamin D to livestock feed
has been shown to improve the quality of the meat [84]. Despite the emphasis on animal sources of
vitamin D, Black et al [85], stress the importance of further research in to edible plant-based foods in
providing vitamin D in the diet.
SACN [15] confirmed that the recommended daily intake for vitamin D from all sources (food
and oral supplementation) is 400 IU per day for those aged 4 years and above. SACN estimate that
this is a sufficient amount to maintain vitamin D levels >25 nmol/L. However, this remains below the
levels recommended by the Endocrine Society and National Osteoporosis Society [14,20]. Nonetheless,
maintaining this moderate intake from food sources alone is difficult where there are few foods
containing significant quantities of vitamin D.
NHS Choices [86] recommend the following sources of vitamin D:




• fortified foods—such as fat spreads and breakfast cereals
There are notable differences in the amount of vitamin D in each of these foods. Oily fish is a good
source of vitamin D even though there are inter-source variations, such as differences between wild
salmon and farmed salmon. However, oily fish may not be commonly consumed in some national
diets. An analysis of UK Biobank dietary intake data showed that, of 164,573 sets of participant data,
only 20% reported consuming two portions of oily fish per week [87]. The main dietary sources of
vitamin D intake in UK adults aged 19–64 were; oily fish (11% of vitamin D intake), cereals (13%),
eggs and egg dishes (13%), fortified fats (19%), and meat (providing 30% of total vitamin D intake) [15].
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The UK National Diet and Nutrition Survey [88] reports that in adults aged 19–64 years, mean daily
intake of vitamin D from dietary sources alone was 112 IU. When oral supplementation was included
intakes increased to 356 IU in men and 136 IU in women, still below the modest recommended
400 IU/day.
Dietary Intake of Vitamin D in People with IBD
Studies have suggested that people with IBD may restrict their diet to help manage the symptoms
of their disease. This has been shown particularly in people with CD and CD-related strictures [89] and
even in remission diet may be sub-optimal. A cross sectional study was carried out with 67 CD patients
in remission in Canada. Results showed that intake of vitamins C, D, niacin, thiamin, magnesium,
phosphorus, potassium, and zinc were all significantly lower in CD patients compared to a control
sample (p < 0.05) [90]. A recent UK cross sectional study of 67 patients with IBD (40 CD, 23 UC)
found that 97% of patients reported food avoidance [91]. Commonly avoided foods were vegetables
and wheat products. Mean vitamin D intake was 283 IU/day in the reported cohort. A further
small cross-sectional [92] study of dietary intake in 31 patients with IBD in Iceland reported that
patients avoided dairy (60%) and processed meat products (55%) to manage symptoms of their IBD.
Some patients reported that fish had a positive effect on their symptoms (22%). A cross-sectional
study carried out in the Netherlands [93] of 165 patients with IBD compared to healthy controls,
demonstrated that patients with IBD consumed more meat and poultry with an average difference of
15.0g/day (95% CI 8.50–21.4); less dairy products at −36.3 g/day (95% CI −65.8–−6.84); and slightly less
fish at −1.42 g/day (95% CI −0.94—−3.79). The findings of these studies would suggest that patients
with IBD are unlikely to consume adequate amounts of vitamin D rich foods to achieve the moderate
recommended intake.
4.3. Vitamin D Supplementation
Oral supplements containing vitamin D are widely available both over the counter and in the
form of prescription only medicines. Some may be single or multi-nutrient preparations. Supplements
usually contain either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3); both forms of vitamin
D are metabolised by the liver to 25(OH)D. However, studies suggest that vitamin D2 appears to yield
less 25-OH-D than an equal amount of vitamin D3, with vitamin D3 being more effective at raising
blood levels of 25-OH-D in humans [94,95]. For this reason, vitamin D3 supplementation is often
recommended [14,20].
The dose of vitamin D supplementation required to prevent deficiency is an issue for debate.
The European Food Safety Authority [96] has set an upper tolerable limit for vitamin D supplementation
of 4,000 IU daily in adults. In line with the SACN report [15], current NICE [25] recommendations are
400 IU vitamin D daily. The IOM [13] suggest an intake of 600 IU daily to maintain a 25-OH-D level of
>50 nmol/L, with the Endocrine Society [14] recommending a daily intake for adults of 1500 IU–2000IU.
However, these guidelines do not address the risks for people with inflammatory, malabsorptive
diseases such as IBD. A recent review has suggested that in IBD doses of 1800 IU–10,000 IU daily may
be required [97]. With such a wide dosing range it is difficult to determine the amount that is likely to
be most effective.
5. Benefits of Treating Vitamin D Deficiency in IBD
It is widely accepted that vitamin D supplementation should be provided during corticosteroid
treatment in IBD for prevention of deterioration of bone health, forming standard guidance. There is
increasing interest in research investigating prescribing vitamin D supplementation for modulating
inflammatory biochemical processed in IBD [97]. Oral supplementation of vitamin D has been
shown to be safe with only minor side-effects which on the whole are generally tolerated among
children, with no difference with dosage regimes such as 2000 IU/day versus 50,000 IU/week [98,99].
Adult studies show similar safety profiles [97], with meta-analysis confirming this with the most
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common side-effects including thirst, nausea, dry mouth, headaches, minor gastrointestinal upset,
drowsiness, and fatigue [100,101].
Supplementation of 40,000IU of cholecalciferol weekly successfully significantly increased vitamin
D levels in patients with active UC and among subjects with inactive UC and non-UC sufferers.
Moreover, there was an associated significant reduction in inflammatory markers of colitis: both
C-reactive protein (CRP) and fecal calprotectin [69]. This is not a finding in every study, however.
A study from Korea whilst establishing a negative correlation between vitamin D levels and CRP in
those with CD, supplementation had no impact upon CRP and disease indices; no association seen
with vitamin D levels, CRP and disease indices in those with UC [102]. Whilst not meeting statistical
significance (p = 0.06) relapse of CD was less common among subjects supplemented with 1200IU of
vitamin D3, a group also showing an increase in serum vitamin D3 with supplementation [101].
With immuno-modulatory and biologic therapy increasing the incidence of infections, it is of
interest that upper respiratory tract infections were less commonly observed in those supplemented,
and indeed the greatest protective effect was observed among those with vitamin D deficiency provided
with a modest 500 IU per day (versus placebo) [103].
Vitamin D also impacts upon hospitalisation and need for surgery. In an observational study of
patients with both UC and CD, those with an insufficient serum vitamin D (25-OH-D) had an increased
risk of requiring both hospitalisation and surgical intervention than those who were never deficient.
This was independent of treatment strategies with immuno-modulators and anti-TNF alpha medication.
This study measured vitamin D levels and different time points and identified those in whom the levels
rose to normal, the majority of whom were taking supplements. This group significantly reduced their
risk of requiring surgery with a drop in CRP also noted [12]. Whilst the study by Govani et al [104]
did not examine vitamin D levels, they used the US National inpatient sample database, identifying
patients with CD requiring surgery and established a UV exposure index based at 3-digit zip-code level.
It was identified that those exposed to greater UV had a reduced risk of surgical intervention [104].
Vitamin D deficiency has been shown to be a risk for the development of colo-rectal cancer in
people with IBD [105]. Whilst the study by Ananthakrishnan et al does not examine supplementation
of vitamin D, their study of 2809 patients with vitamin D assay results (at least one) and development of
cancer revealed that deficiency of vitamin D was associated with an increased risk of cancer: odds ratio
1.82 (95%CI 1.25–2.65), with an 8% reduction in risk for every 1 ng/mL increase in vitamin D level [105].
A recent randomised controlled trial on recurrence of adenoma in people without an inflammatory
bowel disease showed less-promising results [106]. In the trial participants were randomised to receive
either vitamin D, calcium, both agents, or placebo. No significant difference was found in any of
the treatment regimens on the recurrence of adenoma. However, it is important to note that only
participants with 25-OH-D levels >30 nmol/L <225 nmol/L were included [106]. Therefore, it can be
argued that these results do not relate to a population who are vitamin D deficient such as those with
IBD. Further research is warranted into the effects of treatment of vitamin D deficiency in IBD and the
impact on the development of colo-rectal cancers in this group.
IBD and anemia are linked, with the action of hepcidin implicated. Observational data has
confirmed vitamin D deficiency is associated with increased hepcidin concentration and anemia [107].
This observational data has been strengthened with an interventional study revealing that even a short
period of two-weeks of vitamin D supplementation was sufficient to not only increase serum vitamin
D, but reduce serum CRP and hepcidin levels [108].
Vitamin D effects have been postulated to have an immuno-modulatory effect; a vitamin D
analogue was shown to act as a TNF-alpha inhibitor of peripheral blood mononuclear cells, especially
when used in conjunction with Infliximab, a TNF-alpha inhibitor [109]. Observation among 173 subjects
receiving anti-TNF alpha medication showed those with a normal vitamin D level had an increased
odds ratio 2.64 (95% CI 1.31–5.32, p = 0.0067) of having achieved remission at 3-months compared
with those with low levels [110]. This finding is echoed in another retrospective observational study
revealing that patients with IBD with an insufficient vitamin D level at initiation of anti-TNF alpha
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treatment were more likely to stop treatment due to loss of response (HR 3.49; 95%CI 1.34–9.09),
again suggesting a beneficial effect of vitamin D repletion [111].
Meta-analysis of randomised control trials have been clear in identifying that supplementation,
whilst on the whole was well tolerated and did increase serum vitamin D levels, were too heterogeneous
in nature with regards to dosing and follow up-periods to draw any significant findings with
improvements in serum inflammatory markers of CRP and ESR. There was however recognition
that there were significantly fewer relapses in those supplemented with vitamin D (OR 0.34; 95%CI
0.20–0.58) but analysis by dosing did not yield further significant findings [100].
6. Conclusions
Vitamin D plays a significant role in the maintenance of gastrointestinal barrier integrity,
surveillance of the gut microbiota and inflammatory immune responses. These mechanisms are
important in both preventing the development of IBD and ameliorating symptoms of the disease.
Nonetheless, vitamin D deficiency is common in people with IBD with prevalence being higher than the
general population and somewhat higher in CD than UC [30]. The reasons for this are multi-factorial
but include lack of sun exposure due to immuno-suppressive treatments, dietary restrictions [90],
and impaired absorption of nutrients.
Whilst vitamin D deficiency is more common among those with IBD, data has been unable to
establish if the relationship is causative or as a result of inflammation. Many serum markers of nutrition
are affected by inflammation, making it challenging to understand cause or effect. However, through
understanding of the mechanisms of action there is emerging evidence that vitamin D deficiency may
be implicated in disease severity, if not in part the etiology of IBD.
There is a wealth of evidence revealing that intervention with oral vitamin D supplementation is
safe and well tolerated. It has been more challenging to identify the advantages of restoring vitamin D
levels in clinical disease progression, but more studies are beginning to reveal benefits. Aside from
the well recognised skeletal effects, there is growing evidence for IBD disease outcome benefits from
the normalisation of 25-OH-D serum levels in people with IBD. Benefits include: reduced risk of
surgery in those with CD [12], reduction in inflammatory markers [69], reduction in the development
of anemia [112], improved response to anti-TNF alpha treatment [111], and a reduction in the risk
of colo-rectal cancer [105]. One study revealed a reduction in upper respiratory tract infections [91].
These benefits warrant attention to the vitamin D status of people with IBD. Several key questions
remain to be answered. Firstly, it is still unclear what is the optimal circulating level(s) of 25-OH-D for
prevention and/or management of IBD. Current guidelines such as the Institute of Medicine in North
America [13], and Science Advisory Council on Nutrition in the UK [15] have been developed based
on the regulation of calcium homeostasis and bone metabolism. As yet there are no similar guidelines
for extra-skeletal effects of vitamin D. This is further complicated by the recent report of a human
subject with homozygous deletion of the vitamin D binding protein (DBP) gene [113]. The woman in
question had almost undetectable circulating levels of 25-OH-D but was nevertheless normocalcemic
and had only had mild changes in bone metabolism, but had severe ankylosing spondylitis. This case
report suggests that total serum measurement of 25-OH-D may not be the most accurate determinant
of vitamin D ‘status’, but rather unbound or free 25-OH-D (which was relatively normal in the woman
with the DBP gene deletion) is the driving force behind many actions of vitamin D [114]. This is likely
to be an important consideration in future studies of vitamin D supplementation and clinical impact.
Maintaining or improving vitamin D intake by diet or increased sun exposure is problematic for
people with IBD. Improvement in vitamin D status can be achieved by oral supplementation. There is
however a lack of consistent outcome data for significant improvement in IBD outcomes, with variation
in duration and dosing of supplementation, and many studies being retrospective in nature. The data
surrounding enhanced response to biologic therapies with normalised vitamin D levels suggest that,
with more interventional, double-blind, placebo controlled randomised trials, that individualisation of
160
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IBD management with supplementation of vitamin D in those who are deficient offers an important
strategy in improving clinical outcomes.
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Abstract: Inflammatory bowel diseases (IBD) are currently considered multifactorial pathologies in
which various combined environmental factors act on a genetic background, giving rise to a chronic
inflammation of the gastrointestinal tract. Among the various environmental factors, it now seems
clear that the diet plays the major role in IBD onset and progression. Several clinical studies have
attempted to understand the impact of diet in the development and progression of these diseases
in order to establish useful guidelines for their management. However, the modest and sometimes
contradictory results did not lead to the definition of shared dietary suggestions. On the other hand,
food fads and recommendations based on anecdotal episodes are often followed by IBD patients to
improve their diet. This review provides a critical overview of existing data on the role of diet as a risk
factor for IBD. The methodology used was that of analyzing the results of clinical studies conducted
on diet and IBD over the last 12 years through PubMed, as well as analyzing the most relevant studies
on nutrients and their possible roles in IBD through the knowledge of the mechanisms by which they
can modulate the microbiota or the intestinal physiology.
Keywords: Inflammatory Bowel Disease (IBD); Mediterranean Diet; Western-style Diet (WSD);
Nutritional Approach
1. IBD and Environmental Risk Factors
The etiology of inflammatory bowel disease (IBD) remains unclear. The most accredited theory
is the interplay between genetic susceptibility and exposure to environmental risk factors, such as
pollution, stress, diet, pathogen infections, antibiotic treatment and cigarette smoking, also known as
the exposome paradigm [1]. Many studies evidence a rise in both the incidence and prevalence of IBD
in traditionally low-incidence areas, such as southern Europe, Asia and most developing countries
where Western lifestyle and nutritional habits are progressively being adopted [2]. The prevalence of
IBD has also increased significantly in the pediatric population [3].
Many studies have concluded that people emigrating from low-prevalence regions, such as
Asia, to high-prevalence countries like northern Europe are at greater risk of developing IBD. This is
especially true for first-generation immigrant children who show similar IBD incidence and prevalence
patterns to the indigenous population [4].
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These findings would seem to reduce the importance of a genetic predisposition to IBD and
incriminate major lifestyle changes for the rising IBD rates observed in developing countries,
in immigrant populations moving to high-prevalence countries, and children in developed countries.
These considerations suggest that environmental factors significantly modify the expression of Crohn’s
Disease (CD) and Ulcerative Colitis (UC). IBD would therefore appear to be a worldwide disease
linked to environmental factors such as the diet, lifestyle and pollutants prevalent in industrialized
urban societies [4,5].
Diet is a key environmental factor. It plays a major role in the homeostasis of the gut
microenvironment, influencing the gut’s microbial composition and functioning, the gut barrier,
host immunity and the gut physiology by regulating gut hormone release [6,7]. The diet in the
developed “Western” world is very different from the traditional diet of previous generations when
the prevalence of IBD was considerably lower. The most radical change has been the switch from a
plant-based to an animal-sourced diet. This radically modified the gut microbiota and microbiome
decreasing the amount of bacteria involved in fiber degradation, such as Prevotella and Treponema. [8,9].
Another important change is the increased presence of xenobiotics in food and especially in meat.
Xenobiotics are chemical substance that are not naturally produced or expected to be present within
the organism and that mainly derive from environmental pollution or from pesticide, widely used in
conventional agriculture. Xenobiotics can undergo the bio-magnification process in intensively farmed
animal meat. In fact, changes in the gut microbiome and xenobiotic metabolism have been found in
children with Crohn’s disease [10].
Recent data suggest that another important change brought about by the Western diet is an overall
higher calorie intake, especially from sugar, refined carbohydrates, animal proteins and ultra-processed
foods. The role of these latter in gut homeostasis is still under investigation [11], and there are not
in-depth studies linking ultra-processed foods and IBD, however, it is becoming increasingly evident
that some food additives have negative effects on the gut microbiota.
In conclusion, diet may well play a key role in both the pathogenesis and clinical course of IBD.
As a result, diet should become an effective tool to optimize the efficacy of the conventional treatment
of these diseases.
2. The Microbiota and IBD
The human gut is colonized by a specific and dynamic subset of trillions of microorganisms.
Fundamental for our body functions, these microorganisms weigh about 1 kg—significantly more
than all the cells of the human body—and contain more than 100 times as many genes as the human
genome. They constitute the so-called ‘gut microbiota’ of the host’s gastrointestinal tract [12].
The human microbiota comprises different types of microorganisms, including bacteria
(prokaryotes), archaea, fungi, protists, and viruses. Its composition differs significantly in the
different regions of the gut. Indeed, the displacement of microbial communities within the intestinal
tract can sometimes give rise to pathologies such as the small intestinal bacterial overgrowth (SIBO)
syndrome [13].
The gut microbiota and its host exist in a symbiotic relationship. Together they form a
sort of “super-organism” with a wide range of functions. These include digesting substrates,
producing nutrients, developing and regulating the immune system, preventing the growth of
harmful microorganisms by forming a barrier against colonization or invasion, and detoxifying certain
xenobiotics [14]. An adequate biodiversity of the microbiota plays an important role not only for the
correct functions of the intestine but also in other organs and systems, such as the enteric and central
nervous system [15]. Brain and microbiota interactions have led to the recognition of a new term
called "microbiota-gut-brain axis". This term refers to a two-way communication system that allows
intestinal microbes to change the physiology of the brain and the brain to modulate the intestinal
functions. The evidence of this two-way communication comes from multiple studies that have
shown that stressful events in an individual’s life can alter the composition of the intestinal microbiota,
169
Nutrients 2019, 11, 1033
as well as reciprocally, the infection of intestinal pathogenic bacteria can induce anxiogenic behavior in
mice [16,17]. Moreover, impaired responses of the central nervous system to stressors have also been
clearly demonstrated in patients with microbiota alterations due to active Crohn’s disease [18].
Another characteristic of the gut microbiota is its inter-individual variability due to genetic
predisposition and factors such as environmental microbes, geography, climate, sanitation, pollution,
diet and lifestyle (Figure 1). It follows that the composition of an individual’s microbiota changes
continuously in a mutualistic response to extrinsic and intrinsic variables. Excessive alterations of
the gut microbiota lead to an intestinal imbalance between protective and harmful bacteria, called
dysbiosis. This condition seems to be responsible for the inadequate response of the immune system to
both external and intestinal epitopes, and may contribute to the loss of oral tolerance. This imbalance
can have serious effects during infancy and early childhood when the microbiota is still maturing [19].
Dysbiosis may also be a leading contributory cause of several gut microbiota-related diseases, including
IBD [20,21].
Figure 1. Factors implicated in the modulation of the microbiota ecology (A) and complex microbiota
interactions with the gastrointestinal physiology (B). PYY, Peptide YY; GLP-1, Glucagon-like peptide-1;
CCK, Cholecystokinin; GIP, Gastric inhibitory polypeptide; 5-HT, 5-hydroxytryptamine or Serotonin.
While many studies have clearly demonstrated the presence of severe intestinal permeability
alterations during the active phases of IBD, permeability seems to recover during the remission phase.
It should be noted, however, that modest alterations in intestinal permeability are difficult to be
measured in vivo [22].
IBD are associated with alterations in the composition of the intestinal microbiota, namely a
significant reduction of bacterial diversity, an increase in several pro-inflammatory components called
“pathobionts”, such as Proteobacteria and Actinobacteria, and the depletion of “health-promoting”
anti-inflammatory bacterial genus, such as Faecalibacterium and Roseburia [23].
During the acute phases of IBD, altered intestinal permeability causes commensal bacteria
and microbial antigens to translocate from the lumen to the submucosa, giving rise to local and
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systemic inflammation. These translocations activate the immune cells, which in turn release
numerous pro-inflammatory cytokines, activating an inflammatory loop and inducing chronic intestinal
inflammation [24].
The microbiota’s plasticity allows the gut microbiome to respond rapidly to changes in dietary
patterns. The fermentable carbohydrates, protein, fat, and sugars ingested modulate the levels of
beneficial and harmful microbes, toxic microbial metabolites and protective metabolites, such as
short-chain fatty acids (SCFAs) [25].
Dietary fibers, polysaccharides, sugars (i.e. lactose) and peptides that are not digested by host
enzymes in the upper gut are partly degraded by the gut microbiota in the cecum and colon through
a process called fermentation. The major products of fiber fermentation are SCFAs, in particular,
acetate, propionate, and butyrate [26]. SCFAs play important multifactorial roles in energy homeostasis,
host immune function [25,27] and general gut physiology [25,28] (Table 1). As a result, the amount of
SCFAs synthesized, especially in the colon, has been adopted as an indirect measure of microbiota
health [28]. High salt consumption also affects the gut microbiome of both mice and humans by
lowering the intestinal survival of Lactobacillaceae [29].
Table 1. The multifactorial role of the SCFAs in energy homeostasis in host immune function and host
physiology [25,27,28]. GABA, gamma-Aminobutyric acid; CNS, Central Nervous System; ENS, Enteric
Nervous system; PYY, Peptide YY; GLP-1, Glucagon-like peptide-1.
CNS Activity Metabolic Regulations Immune Homeostasis
GABA production in CNS






Release of major appetite and glucose
regulatory peptides (PYY, GPL1) (L-cell)
Enhancement of IL-10 (DC)
IL-18 biosynthesis (IEC)
Treg polarization
Reduction of TNF, IL-6, IFN (DC)
IEC barrier fortification
IgA promotion
The modulation of intestinal microbiota can be also implemented through probiotics. Probiotics
have been defined by the World Health Organization (WHO) as "live microorganisms which,
when administered in adequate quantities, confer health benefits to the host". They can play
beneficial effects on the digestive system, through multiple mechanisms including interference with
potential pathogenic microorganisms, improvement of the barrier function, immunomodulation and
the modulation of neurotransmitter synthesis [30,31]. The impact of probiotics on IBD has been the
subject of numerous studies. Data derived from studies on animal IBD models showed a high potential
of different bacterial strains in modulating the clinical course of experimental IBD. Instead, on humans
the experimental results showed little evidence of efficacy on Crohn’s disease (CD), modest data on
Ulcerative Colitis (UC) but a good support for patients affected by pouchitis, the inflammation of the
ileal pouch which is created in the management of IBD patients [32].
It has recently been demonstrated that several dietary components can alter the intestinal
microbiota. These include xenobiotics belonging to the group of environmental contaminants, but also
additives normally used for the preparation of ultra-processed foods. The xenobiotics capable to
have negative effects on the microbiota include organochlorine pesticides [33], glyphosate [34] and
perfluorooctanesulfonic acid [35]. All these components have been found in human breast milk,
and may therefore negatively modulate the microbial ecology of babies whose unstable microbiota
could rapidly develop into a permanently altered gut environment [35]. The effect of food additives
added to ultra-processed foods will be discussed in detail below.
Studies of IBD-associated microbiome have evidenced the important role played by the gut
environment in the manifestation of IBD. It has also been observed that among the environmental
factors associated with microbiota development and alterations, diet plays a key role in modulating the
composition and functions of the microbiome and epithelial barrier, and may even influence epigenetic
changes. It follows that the food may deeply modulate the microbiome-gut axis and therefore it may
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represent an important therapeutic tool to counteract dysbiosis and modify the natural history of IBD,
bearing out the motto “We are what we eat” [7].
3. Evolution of the Human Diet
The first dramatic change in human nutrition occurred about 10,000 years ago during the Neolithic
age with the transition of the hunter/gatherer society to one based on agriculture and livestock farming.
This change profoundly modified man’s diet. Instead of a wide range of different foods that changed
with the seasons and with the migratory patterns of animals, our diet became restricted to a few
domesticated plants and farmed animal species. For the human metabolism this meant a dramatic
change in glycemic load, fatty acid composition, macro- and micro-nutrient concentration and total
fiber content. Indeed, in evolutionary terms, this dietary change is so recent that the human species
has not had enough time to adapt its gastro-intestinal physiology [36]. Many foods common in the
new diet were completely absent in the hunter/gatherer society. Milk, for example, was consumed only
during breastfeeding, and dairy products were completely absent [37]. The first evidence of dairy milk
consumption has been dated to about 6,000 years ago [2,38]. Cereals are another interesting example.
At the beginning of the Holocene age (12,000–10,000 years ago), cereals—always unrefined—were still
rarely eaten. The first evidence of white flour production has been traced back to around 3500 Before
Christ (BC) in ancient Egypt [39], but the widespread consumption of highly refined flours began only
150–200 years ago [40].
The second truly revolutionary change in the human diet was the introduction of industrialized
food following the Second World War. Driven by the so-called “green revolution”, which made
widespread use of agricultural chemicals, industrialized food production led to a huge rise in the
availability of refined cereals, sugar, cheese, butter and coffee (Figure 2). Before this, sugar had been
a rare component of the human diet. The first evidence of crystallized sugar can be traced back to
500 BC in India [41]. Before that, the only source of sugar had been honey, available in very limited
amounts and only at certain times of the year. Even subsequently, sugar remained a rare commodity.
Before the industrial revolution, the annual average sugar consumption in the United States was 6.8 kg
per person while in 1970 it exceeded 55 kg, and in 2000 stood at 69 kg [42].
Figure 2. Variation in average food consumption of the population in Italy, one of the countries where
the Mediterranean diet was initially discovered, from the end of the 1800s to the early 2000s. The basis
of comparison (100%) is the period 1861–1871. Data source: Italian National Research Institute for Food
and Nutrition (INRAN), 2013.
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Industrialization and the advent of intensive farming also involved a change in farmed animal
feed. As a result, the quality of farmed meat, and especially its fat content, is today completely different
from the wild animal meat consumed by hunter/gatherers. This is because mammal fat stores are
localized in subcutaneous and abdominal adipose tissue in the form of saturated fatty acids (SFAs),
while polyunsaturated and monounsaturated fatty acids (PUFAs and MUFAs) prevail in the muscles.
It has been estimated that prior to domestication, wild animals consumed most of their subcutaneous
and abdominal fat reserves, with the result that our hunter ancestors ate meat with high levels of
muscle-stored PUFAs and MUFAs and little or no SFAs [43–46]. Industrial farming, on the other hand,
has led to hyper-fed animals with high percentages of accumulated SFAs [45,46].
First extracted around 5000 years ago, vegetable oils were not initially used as a food. It was
only with industrialization and the introduction of new extraction techniques that seed oils became
products for human consumption (Figure 2). With the advent of hydrogenation in 1980, hydrogenated
vegetable fats suddenly became part of our daily diet. Overall, the increase in dietary fat has certainly
had an impact on the microbiota and GI diseases [47].
Salt consumption seems to have started at the beginning of the Neolithic age, although its massive
consumption only began with the industrial revolution. This has led to an inversion of our ingested
sodium/potassium ratio compared to the Neolithic diet. Today, 90% of the salt in the Western-style
diet (WSD) comes from processed foods [36]. Food industrialization has also caused a sharp drop
in the consumption of fruits and vegetables, and therefore fibers, vitamins and potassium [44,48].
In conclusion, industrialization and the resultant change in diet caused a sudden rise in man’s net acid
load after digestion, also known as the Potential Renal Acid Load, PRAL. This is because staple WSD
foods like cheese, refined cereals and meat are net acid producers while the vegetable-rich diet of our
pre-agricultural ancestors was a net base producer [49].
The dramatic change in man’s diet is still ongoing. Ultra-processed foods, recently classified as
the NOVA-4 group [50], are now readily available and today account for over 50% of the total energy
intake of the United States population [11,51].
4. The Western-Style Diet and Its Pro-Inflammatory Foods
Compared to traditional regional diets, such as Mediterranean, Indian, Japanese and South East
Asian, the WSD contains significantly higher amounts of simple refined carbohydrates, saturated fats,
red meat, dairy products and industrialized foods, and a concomitantly lower quantity of vegetables,
fruits, legumes, whole cereals, raw foods and fibers in general (Figure 3). In fact, the WSD consists
mainly of calorie-dense foods high in saturated fats, glycemic carbohydrates and animal proteins.
Many studies have looked at the association between WSD and obesity, hypertension [52], chronic
kidney disease [53] and other non-communicable diseases [54]. Their findings clearly show that the
WSD may promote intestinal inflammation through various mechanisms, including alterations of
the microbiota [55–58]. Although the relationship between the WSD and IBD has been only partially
investigated [59,60], it is nonetheless true that the WSD contains nutrients able to elicit a direct or
indirect pro-inflammatory effect on the intestine through one of the three components involved in
gut physiology: the immune system, the microbiota, and the intestinal barrier. Moreover, the WSD
is low in nutrients and micronutrients with anti-inflammatory and anti-oxidant proprieties. It is
therefore not unreasonable to consider the transition to the WSD, also defined as diet westernization,
as one of the major environmental factors responsible for the rising incidence and prevalence of IBD.
A very interesting in-depth study on the effects of this dietary switch on the intestinal microbiota of
children has been recently published [61]. The authors clearly demonstrate that the gradual increase
of animal proteins (meat and dairy products), saturated fats, and processed and refined foods to the
rural vegetarian diet of urban African children drastically changed their microbial profiles and gut
functioning. The sharp drop in fiber intake as a result of the dietary change was found to lead to
a concomitant fall in microbial populations able to ferment dietary fibers and a sharp rise in other
bacterial groups able to metabolize animal proteins, animal fats and sugars. The westernization of
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the diet has involved and overwhelmed even the traditional oriental diets, such as the Japanese or
that of South East Asia, which are diets geographically associated with a low prevalence of IBD [62].
The potential implications of WSD components on the gut immune system, the microbiota and the
intestinal permeability will be analyzed in detail in the following sections of this review.
Figure 3. Comparison between the Mediterranean diet (upper) and the Western-style diet (lower)
pyramids. The Mediterranean diet pyramid is inspired by the eating habits of Greece, Southern Italy,
and Spain before 1950s. The principal aspects of this diet include high consumption of fruits, vegetables,
unrefined cereals, legumes and olive oil, moderate to high consumption of fish, moderate consumption
of dairy products and low consumption of non-fish meat.
5. Carbohydrates
Carbohydrates are classified on the basis of their chemical structure into mono- and
di-saccharides (simple sugars, such as glucose, fructose, sucrose), oligosaccharides (fructo- and galacto-
oligosaccharides), and polysaccharides (starch, cellulose, inulin). A fraction of the carbohydrates
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ingested remains undigested in the small intestine and passes to the large intestine to be fermented
and/or excreted. For this reason, carbohydrates are also classified according to their absorbability
in the small intestine. For example, simple sugars and starches are hydrolyzed and absorbed in the
small intestine and are therefore known as available carbohydrates. Inulin, fructo-oligosaccharides and
galacto-oligosaccharides, known as resistant starches, are not hydrolyzed in the small intestine but
fermented by the large bowel microbiota, and are therefore called unavailable carbohydrates. Finally,
insoluble fibers including plant cell-wall polysaccharides, such as cellulose and pectin, and some
storage polysaccharides, such as inulin and oligosaccharides, are also called non-digestible components
because they pass through the digestive tract largely intact, exerting a laxative effect by changing the
osmotic properties of the luminal content and by increasing the intestinal fecal mass. The quality
of the carbohydrate ingested, for example, whether mono-, di- or oligo-saccharides, also seems to
impact the clinical course of IBD. In fact, a correlation has been observed between fructose and lactose
malabsorption and IBD severity [59,63]. In light of this evidence, a fructose- and lactose-free diet has
been proposed for IBD patients [59].
Lactose malabsorption is frequently detected in IBD, especially in CD patients. However,
prevalence is ethnicity dependent, being higher among Asian populations. Moreover, although
lactose avoidance may improve symptoms in patients with lactose intolerance, evidence of objective
disease improvement is currently lacking. Studies of a lactose-free diet in IBD patients are currently
underway [59].
High consumption of fermentable carbohydrates such as glucose, fructose, sucrose, lactose or
polyols (sorbitol, mannitol, xylitol and maltitol) has been shown to exceed the intestine’s absorptive
ability, increasing dysbiosis and gut permeability, thus promoting inflammation. These fermentable
carbohydrates, which include oligo-, di-, and monosaccharides and polyol, are known as FODMAPs
(Table 2). Being poorly absorbed, they are rapidly fermented by bacteria in the gut, giving rise to a high
osmotic load. This is the rationale behind the FODMAP-exclusion diet. Firstly proposed for Irritable
Bowel Syndrome (IBS) patients, the FODMAP-exclusion diet was applied for a limited period to a
few IBD patients [64] in an attempt to alleviate their IBS-like symptoms, such as bloating, flatulence,
crampy pain, and diarrhea, but proved very limited benefit. Moreover, since undernutrition is a
common feature of IBD, the use of this very restrictive diet should be carefully considered [64].
Table 2. Carbohydrates included or excluded in the low-FODMAPs diet.
Food Group Include Exclude
Fruit
Bananas, strawberry, raspberry, blueberry, orange,
mandarin, clementine, cantaloupe, grapes, melons, lemon,
lime, kiwi, passion fruit
Apple, applesauce, apricots, blackberries, cherries,
nectarines, pears, peach, plum, prune, watermelon,
grapefruit, dried fruit
Vegetables
Carrots, celery, corn, alfalfa, bean sprouts, bell pepper,
broccoli (<1/2 cup), bok choy, cucumber, eggplant, green
bean, kale, lettuce, potato, spinach, spring onion (green
top), squash, tomato, turnip, zucchini
Brussels sprouts, asparagus, avocado, beetroot,
cauliflower, cabbage, garlic, leek, mushroom, onion,
pea shallot, snow pea, sweet corn, sweet potato
Grains Rice, oats Wheat, rye
Legumes Certain legumes (soya) Many legumes (chickpeas, lentils, beans)
Dairy Lactose-free yoghurt and milk; almond, coconut, rice orsoy “milk”, hard cheese, low-lactose cheese
Cow, goat, sheep milk, buttermilk, soymilk, soft
cheese cream and ice cream
Beverage Fruit juice and vegetable juices from permitted foods, wine Soft drinks, sports drinks, fruit juice and vegetablejuices from unpermitted foods, alcohol
Other Maple syrup Honey and sweeteners
Turning to complex carbohydrates, several epidemiological studies have observed associations
between the consumption of refined carbohydrates and the risk of developing IBD. However, these data
are not sufficiently statistically significant to allow confirmation of this hypothesis [7]. Nonetheless,
the WSD contains many different refined carbohydrates, such as sucrose and starch found especially in
soft drinks, white bread, cakes, and desserts, all high-density energy-rich but nutrient-poor products.
In the long term, they may cause alterations of the gut microbiota and immune system, increasing the
risk for many diseases including IBD [65]. Other dietary approaches have been proposed in an attempt
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to improve IBD symptoms. These include the “specific carbohydrate diet” (SCD), first described by
Haas and co-workers in 1924 to treat celiac disease, and subsequently applied to IBD patients [66,67].
The SCD excludes gluten and complex carbohydrates since they are poorly absorbed and lead to
bacterial fermentation, which in turn induces dysbiosis in the gut lumen due to pathobiont expansion
(Table 3). Only monosaccharides such as glucose, fructose and galactose are permitted. Clinical trials,
albeit involving very few patients, reported improvements in bowel symptoms, with some patients
able to discontinue at least one of their IBD medications at the end of the SCD trial period [67].
Table 3. Carbohydrates included or excluded in the Specific Carbohydrate Diet (SCD).
Food Group Include Exclude
Fruit All fresh fruit Canned fruit (because of possible added sugars and starches)
Vegetables Fresh vegetables Canned or frozen vegetables (because of possible addedsugars and starches), potatoes and yams
Grains None All cereal grain
Legumes Certain legumes (lentils, split pea) Certain legumes (chickpeas, soybeans) and soybean “milk”
Dairy Lactose-free dairy (milk, cheese andyogurt) Milk and all dairy products
Beverage Wine Instant tea, coffee and beer
Other Honey, Corn syrup, chocolate
In conclusion, if poorly absorbed, all carbohydrates may be fermented, promoting dysbiosis and
inflammation. An excess of any kind of carbohydrate in IBD patients with intestinal malabsorption may
easily exacerbate existing intestinal dyshomeostasis, which in turn may contribute to dysmetabolism
of other nutrients, such as fats.
It is therefore reasonable to conclude that IBD diets should carefully monitor the intake of simple
and complex carbohydrates and strictly limit lactose, especially in patients intolerant to this sugar.
In fact, exclusion of specific carbohydrates (known as carbohydrate monotony) is a common feature of
the different diet-based IBD therapies, in light of the suggestion that carbohydrate variation could be
linked to IBD pathogenesis [68]. It does, however, seem unlikely that a single sub-group of foods could
be the cause of IBD.
6. Proteins
Several mechanisms of action have been postulated to explain the possible negative impact
of high protein (HP) consumption in IBD patients. One hypothesis is that the intestine’s limited
capacity to assimilate proteins, especially in IBD patients, leads to non-absorbed proteins to reach
the colonic lumen where they alter microbiota composition by reducing the abundance of bacteria
like Roseburia/E.Rectale, considered health-promoting microorganisms for their ability to produce
butyrate [69]. In fact, HP diets appear to induce IBD-like dysbiosis [70]. Rats fed a HP diet showed
increased prokaryotic protease activity, a phenomenon apparently linked to the pathogenesis of
IBD [71]. HP diets may also lead to an imbalance of metabolites of protein catabolism by colonic
bacteria (ammonium, hydrogen sulfide, p-cresol and phenol), which could damage colonocytes and the
intestinal barrier [72,73]. Several animal studies on colitis have also demonstrated that proteins derived
from red meat, milk and dairy products can exacerbate colitis. However, human epidemiological
data only partially support these findings. This is probably due to the complexity of the human diet
and diverging nutritional data collection methods [70]. In fact, two epidemiological studies have
shown a correlation between IBD and high animal protein intake derived from meat and fish but
not from eggs or dairy products, while no correlation was found with the consumption of vegetable
proteins [74,75]. Two meta-analyzes conducted in 2011 and 2015 also indicate that the consumption
of red, white and processed meat may be considered risk factors for the development of IBD [6,76].
Conversely, two more recent studies have produced conflicting results as to a correlation between meat
consumption and IBD activity. The first, by Opstelten et al. [77] involving 165 patients with IBD in
remission and 1469 healthy controls, indicated that although IBD patients eat more meat than controls,
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there was no correlation with disease exacerbation. The second study on 53 patients with active disease
and 50 in remission concluded that meat is a risk factor for active disease [77,78]. In addition to the
protein metabolism mechanism already discussed, it has also been hypothesized that the effect of meat
consumption on the onset and course of these diseases could be linked to the cooking process, which
notoriously leads to the formation of carcinogenic or mutagenic molecules such as heterocyclic amines,
acrylamide and polycyclic aromatic hydrocarbon, associated with endothelial damage and altered
immune responses [79]. However, the most convincing studies on meat and IBD have focused on the
risk of high saturated and high n-6 polyunsaturated fatty acid (PUFA) intake as a consequence of high
meat (especially red meat) consumption.
Gastro-resistant proteins are another point of attention when structuring an IBD diet since the
abundance of gastro-resistant proteins in some foods can alter intestinal permeability. Gluten is a
gastro-resistant protein complex. Its digestion gives rise to toxic and antigenic peptides (especially
alpha-gliadin peptides), which may not only interfere with the tight junction between enterocytes
but also with enterocyte survival, affecting the intestinal barrier. This, together with strong evidence
of gluten sensitivity in IBD patients [80], has led to the gluten-free diet being recommended for
IBD sufferers. Indeed, a gluten-free diet is often self-imposed by patients in an attempt to alleviate
symptoms. Ancient wheat varieties, although seemingly giving rise to similar amounts of toxic and
antigenic gluten peptides [81], have been shown to ameliorate gut and systemic inflammation in a
range of patients, including IBS sufferers [82]. For this reason, ancient varieties of low immunogenic
impact grains, such as Senatore Cappelli (Triticum turgidum durum) and Enkir (Triticum monococcum),
or a novel grain variety with low gluten immunogenicity like Tritordeum [83] should be considered for
inclusion in the IBD diet. Being gluten-free, rice has also been suggested as a complex carbohydrate
suitable for the IBD diet. This includes whole grain rice, provided it is cooked at length [84].
Milk and dairy products contain large quantities of caseins, gastro-resistant proteins known to
increase dysbiosis, inflammation and intestinal permeability in the mouse gut [85]. For this reason,
milk and dairy foods are excluded in most IBD diets and indeed, commonly restricted by IBD patients
themselves [86]. On the other hand, fermented milk products have shown positive effects on IBD
patients. Kefir was administered in a randomized controlled trial to 25 IBD patients with positive
effects on clinical parameters, such as erythrocyte sedimentation rate, C-reactive protein, bloating,
general-feeling scores, and the Lactobacillus bacterial load evaluated in patient feces [87]. Yogurt was
administered to IBD patients in a double-blind placebo-controlled clinical trial with beneficial effects on
the mean numbers of Lactobacillus, Bifidobacterium, and Bacteroides in the feces of the treated group [88].
In conclusion, although performed with only a few patients, the studies conducted so far would
seem to suggest that the IBD diet should reduce the overall amount of meat, eliminate red and processed
meat, and eliminate or greatly reduce gluten and dairy products (caseins), with the sole exception of
yogurt and kefir.
7. Fats
Recent epidemiological data attribute a protective effect to n-3 PUFAs in UC prevention and
therapy [89,90]. Conversely, consumption of higher ratios of n-6/n-3 PUFAs has been associated with
increased UC incidence. The role of n-3 PUFAs in CD prevention and therapy, however, appears
complex and controversial [89]. The physiological basis for PUFAs’ role in IBD is that the eicosanoids
produced by n-3 and n-6 PUFA are key immune response regulators, being precursors of several
pro-inflammatory (n-6 PUFA) and anti-inflammatory (n-3 PUFA) molecules. It has been demonstrated
that n-6 PUFAs are more available than n-3 PUFA for eicosanoid metabolism in the UC colon mucosa.
For this reason, dietary supplementation with n-3 PUFA, and especially eicosapentaenoic acid (EPA),
can reduce the production of prostaglandin E2, thromboxane B2 and hydroxyeicosatetraenoic acid
inflammatory mediators [91–93]. The anti-inflammatory effects of n-3 PUFA have also been linked
to the synthesis of molecules like resolvins, protectins and maresins, which counteract IBD-related
dysbiosis [94], and the down-regulation of pro-inflammatory genes [95]. However, two IBD studies
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have indicated that PUFA intake may have a different impact in CD compared to UC patients. In their
study on 137 UC patients and 38 healthy controls, Wiese and collaborators [96] showed that the
concentration of inflammatory tissue cytokines in UC patients was directly related to the amount of
serum SFAs and inversely related to total PUFAs, EPA and docosahexaenoic acid (DHA), confirming
the protective role of n-3 PUFAs in UC. But a recent study by Scoville and collaborators [97] on
116 CD patients and 27 healthy controls showed that n-3 PUFA serum concentrations were directly
related to disease severity. In particular, the authors found EPA concentration to be strongly related
to pro-inflammatory serum cytokine concentrations. This datum not only suggests that fatty acid
dysmetabolism occurs in patients with CD but also that n-3 PUFA and EPA serum levels may also
have a negative effect in CD patients. Conversely, no correlation with SFA concentration was observed
in UC patients [97]. Interestingly, both studies, which administered the same amounts of meat, total
fat, and SFA to IBD patients and healthy controls, found that n-6 PUFA/n-3 PUFA ratios were similar in
CD patients and healthy subjects, despite higher respect the WHO recommendations.
In summary, we may conclude that high fat intake should be avoided in IBD sufferers since high fat
diets may lead to an accumulation of secondary bile acids, such as deoxycholic acid, which can inhibit
Bacteroidetes and Firmicutes phyla growth, leading to IBD-like dysbiosis [7]. However, a prospective
study carried on 170,805 women showed no correlation between fat consumption and IBD risk,
but rather a positive correlation between high trans-unsaturated fat intake and UC risk [89]. In addition,
the intake of n-3 PUFA and EPA in particular, within foods or supplements, may have positive effects
on health, but only for UC patients.
8. Dietary Fibers
Dietary fibers are non-digestible complex carbohydrates present in plants. They are grouped
according to their solubility or insolubility in water. Since humans lack fiber-specific enzymes, fibers
remain mainly undigested and are therefore not absorbed by the gastrointestinal tract. However,
small amounts of the ingested fibers are fermented by the bacteria in the gut, especially in the colon.
Present in fruits, vegetables, cereals and legumes, dietary fibers can exert a protective role against IBD
through four independent mechanisms [90]:
Reducing intestinal transit time;
Increasing the synthesis of SCFAs such as acetate, butyrate and propionate, which may positively
modulate intestinal inflammation;
Improving gut microbiota composition, thus counteracting IBD-related dysbiosis;
Contributing to the maintenance of intestinal barrier functions.
No conclusive studies exist evidencing the efficacy of dietary fibers in slowing IBD progression [98].
A study conducted by Andersen and collaborators [90] showed no association between average fiber
intake (total fiber, fiber from fruit, vegetables and cereals) and the subsequent development of CD
or UC. Moreover, it has been shown that fibers may exacerbate gastrointestinal (GI) symptoms,
such as abdominal distension, flatulence, constipation, and diarrhea in IBD patients during remission
periods [99]. It is therefore reasonable to postulate that a high fiber diet is not beneficial for individuals
with insufficient “fiber-degrading bacteria” in their gut microbiota [100]. However, while this type of
diet may be contraindicated for patients during disease flares, it is nonetheless highly recommended,
with appropriate adjustments, after remission in an attempt to approximate the 30g/die WHO
recommended intake.
As suggested by Eswaran and collaborators [99], patients in remission should receive a diet with
low levels of insoluble fibers, such as those in skinned vegetables like zucchini, carrots, eggplants,
green beans and chards. The vegetables should be very well cooked and consumed as a cream, at least
initially. Peeled fresh fruit is another option, providing small quantities of insoluble fiber. Putting
ingredients through a juice extractor will further reduce the amount of insoluble fiber present in fruit,
vegetables and legumes while maintaining most of the soluble fiber fraction, vitamin and mineral
content. There is also some unsubstantiated evidence that fruit and vegetable consumption may have
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a protective immune-modulating effect on IBD patients since they contain protective compounds that
may help to prevent disease flares [101]. Another source of insoluble fibers is whole grain cereals.
Here too, it seems appropriate to include cereals in the diet only after remission, doing it gradually
to avoid worsening of the disease-related GI symptoms [84,99]. Although many IBD patients avoid
foods containing fibers, this may lead to micronutrient deficiency and aggravate the malnutrition often
presented by sufferers of this disease.
9. Micronutrients
IBD patients tend to suffer from nutrient malabsorption and/or have erroneous nutritional
patterns [102], with the result that many are likely to present micronutrient, vitamin and mineral
deficiencies. Since micronutrient deficiency may affect immune system physiology and thus facilitate
disease relapse, diet or supplementation adjustment strategies could be a key to improove patients’
quality of life [103]. The main vitamin deficiencies found in IBD-patients are of fat-soluble vitamins
A (retinol and retinoids) and D, and water-soluble vitamins B12 and B9 (folic acid). Experimental
models have provided some evidence that vitamin A (provided as retinol) supplementation attenuates
intestinal inflammation and improves the gut environment, with significant benefits to health [65].
As antioxidants, vitamins A have a probable protective role against free radicals and oxidative damage,
both of which are increased in these patients [104].
As well as regulating bone, calcium, and phosphorus metabolism, Vitamin D has a key role in
intestinal defense mechanisms, regulating the adaptive and innate immune systems and suppressing
microbial invasion of the epithelium [105,106]. Vitamin D deficiency has been detected in 16% to 95%
of IBD sufferers, mainly in CD patients [107]. This may be due to several factors, such as intestinal
malabsorption, low exposure to sunlight, lack of physical activity, or insufficient dietary intake. Therapy
targeting the vitamin D3 signaling pathway has been suggested in IBD since it may regulate both
innate and adaptive immune functions. However, the overall effect of vitamins on IBD is still not
well understood, and the clinical studies performed have shown contrasting results. A Danish study
conducted between 2005 and 2008 randomized 94 IBD patients to receive oral vitamin D3 or placebo.
Although patients receiving vitamin D3 showed a reduced risk of clinical relapse (from 29% to 13%),
this was not statistically significant [108]. Similarly, a more recent Iranian study on 108 IBD patients
found that oral vitamin D3 supplementation gave rise to lower serum TNF levels, which, however,
were also not statistically significant [109].
Folic acid, or folate, is available in several vegetables and is absorbed in the duodenum and
proximal jejunum. Both micronutrients are essential for cell metabolism, and folate deficiency is
often correlated with vitamin B12 deficiency, this latter mainly available in animal products. Despite
their ample availability in food, folate and vitamin B12 absorption occurs in areas often damaged by
phlogosis, which may be the cause of impaired uptake in IBD-patients [110].
Trace elements are another important avenue of ongoing research into the prevention and control
of IBD. Iron deficiency is very frequent in IBD and the leading cause of anemia among IBD patients.
In a recent study, 27% of all CD and 21% of all UC patients were found to have anemia [111]. An iron-,
heme- and nonheme-rich diet or oral/parenteral supplementation is therefore mandatory. However,
iron—and especially ferrous sulfate—is a known pro-oxidative agent, raising concern that oral iron
may increase oxidative stress in patients with colitis [112].
Zinc is an essential micronutrient, an enzyme co-factor involved in cellular immunity, cell growth
and wound healing. Zinc deficiency has been associated with excessive loss of GI secretions due to
chronic diarrhea or fistula drainage in IBD patients. Prevalent in 15% to 40% of IBD patients, it has also
been associated with hospitalization, surgery and other disease complications [113].
Selenium is a non-metal trace element existing in both the inorganic and organic form. It is
translationally incorporated as selenocysteine into selenoproteins, which can modulate various cellular
pathways involved in inflammation. Adequate selenium intake is thus essential for normal immune
functions [114]. In fact, selenium deficiency has been correlated with gastrointestinal inflammation and
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altered gut microbiota composition [115]. Epidemiological studies suggest that selenium serum levels
are inversely correlated with IBD incidence. Moreover, selenium blood concentrations were found to
be significantly lower in Caucasians and Asiatic IBD patients, especially in CD [116,117]. Although
further studies are necessary to assess the mechanism underlying the effect of selenium deficiency in
IBD, it would seem important to ensure adequate selenium intake in all IBD patients.
10. Food Additives and Ultra-Processed Food
Ultra-processed foods (NOVA 4 classification) are the result of a series of industrial processes,
many requiring sophisticated equipment and technology. Ultra-processed food manufacture entails
fractioning whole foods into different substances, their chemical modification and subsequent assembly
with other modified and unmodified food products. The industrial techniques used include extrusion,
molding, pre-frying, and the addition of “cosmetic” palatability additives [50]. The presence of high
levels of ultra-processed food in the diet has already been linked to a number of non-communicable
diseases including cancer, obesity and type 1 and 2 diabetes [118–120]. Despite this, however, the role
of these foods on the intestinal microbiota, and on IBD in particular, has never been investigated.
However, there is well-documented scientific evidence of the negative effects on the microbiota of food
additives typically present in a considerable number of ultra-processed foods. Various studies have
clearly shown the negative effect of non-caloric artificial sweeteners often present in carbonated soft
drinks on microbiome composition and functioning [121]. The sweetener sucralose has been shown to
reduce the relative amount of Clostridium cluster XIVa in mice feces [122]. Dietary emulsifiers have
also been shown to directly alter human microbiota composition and gene expression in an ex vivo
model [123], while maltodextrins, commonly used for the production of soft drinks, candy and sport
energy products, have been found to cause microbiota alterations [124] and affect gut epithelial cells,
reducing mucus production and exacerbating gut inflammation [125].
The commonly used food additive carrageenan has been shown to induce intestinal inflammation
in animal models. Although there is little evidence of the role carrageenan may play in the development
of IBD since direct carrageenan assessment trials in man are unethical, animal studies have clearly
demonstrated that this additive induces IBD-like histopathological features, alters the microbiome,
and disrupts the intestinal epithelial barrier [126]. Red meat, eggs naturally contain high levels of
sulfites due to their high cysteine content, which can become a substrate for the production of hydrogen
sulfide (H2S) by sulfate-reducing bacteria. However, sulfites are also abundantly used as food additives
to limit bacterial contamination. Generally considered safe for human consumption, they are present
in food and alcoholic beverages in quantities up to 5000 parts per million (ppm). However, even at
lower concentrations, sulfites have been shown to damage beneficial bacteria, such as Lactobacillus
and S. thermophilus in the human gut [127]. Sulfites can be produced by intestinal microbiota even
starting from taurine (from the bacterium B. wadsworthia) which is a typical ingredient of energy drinks
or from chondroitin sulfate, a widely used food supplement in the treatment of osteoarthritis [128].
Some studies have found that patients with UC show a higher production of H2S in the gut, but it is not
clear whether this increased synthesis is simply linked to the increased intestinal inflammation [128].
11. Alcohol
Small quantities of alcohol are first metabolized in the stomach. Larger amounts are absorbed
in the small intestine and may reach the large bowel from the bloodstream where it is metabolized
by luminal bacterial alcohol dehydrogenase, producing the toxic compound acetaldehyde [129,130].
Severe dysbiosis has been associated with chronic alcohol abuse. In addition, the high sugar content of
some alcoholic drinks may be associated with osmotic diarrhea [131]. A study of 52 Crohn’s and 38 UC
patients with an alcohol consumption pattern similar to the general population found that although
75% of the IBD patients reported worsening of their symptoms, this could not be related to alcohol
intake [132]. In 2018, a prospective cohort study of 262,451 subjects enrolled in six countries showed
no association between alcohol use and the onset of IBD [133]. Interestingly, two studies have found
180
Nutrients 2019, 11, 1033
a correlation between UC disease activity and sulfite, an additive commonly used also in processed
alcoholic drinks [134,135]. In conclusion, although there are insufficient data to define alcohol as a risk
factor for IBD, its toxic effect on colon mucosa strongly suggests limiting alcohol intake in IBD sufferers.
12. Nutritional approach in IBD
Recently, numerous new dietary philosophies have become popular. These include the paleo
and the vegan diets, often recommended in the management of gastrointestinal diseases such as IBD.
However, there is no clinical evidence to support their use in IBD [113]. The only nutritional approach
with strong evidence of efficacy is Exclusive Enteral Nutrition (EEN), a diet based on foods classified
according to their nitrogen content as: elemental (amino acid based), semi-elemental (oligopeptide
based) and polymeric (whole protein based). EEN has proved as efficacious as steroid treatment in
inducing remission of CD in children and adults but not of UC [136]. Although the above-mentioned
low FODMAPs diet has been mainly used to alleviate symptoms in IBS patients, there are currently
no consistent data supporting its use in IBD. A pilot study conducted on 52 CD and 20 UC patients
showed that 50% of patients had an improvement in abdominal pain, bloating, and diarrhea [137].
A double-blind controlled placebo cross-over trial was conducted with 32 patients with quiescent
disease and IBS-like symptoms that had proved responsive to a Low-FODMAP diet. Patients were
randomly assigned to receive fructans, galacto-oligosaccharides, sorbitol, glucose or placebo. The study
found that only fructans exacerbated symptoms in patients, which casts into question the real usefulness
of the low FODMAPs diet in IBD [138]. Another uncontrolled clinical trial included a semi-vegetarian
diet as an “add-on therapy” to the biological drugs used to induce remission. 26 adults and 11 children
with recently diagnosed CD and 9 adults with relapsing CD received a lacto-ovo semi-vegetarian
diet that included fish once a week and meat once every 2 weeks. Results showed an increase of the
expected remission rate in all patients [139]. Yet another study of CD patients on a semi-vegetarian
diet for two years reported the absence of CD relapse in 15 of the 16 patients treated [140]. The IgG
exclusion diet, on the other hand, is a personalized regime based on preliminary blood titration of food
IgG. Two studies conducted by the same research group have demonstrated the efficacy of this diet.
The first, an open-label pilot study, was conducted on 40 symptomatic CD patients [141] while the
second was a randomized study enrolling 76 subjects with active CD. In this second study, the foods
most frequently excluded were milk, beef, pork and eggs. The personalized diet significantly improved
patients’ quality of life and disease activity, measured using the Crohn’s Disease Activity Index (CDAI)
and Harvey-Bradshaw Index (HBI) [142].
Although SCD diet is one of the most popular among IBD patients, it has many restrictions making
compliance difficult. Obih and collaborators [143] conducted a retrospective study on 26 IBD children
who had followed the SCD for 3–48 months, 18 of whom were receiving concomitant medication
therapy. 12 of the 26 patients showed improvements in their clinical and inflammatory markers.
It should, however, be noted that in the medium and long term the SCD diet may cause adverse
effects, such as weight loss and nutritional deficiencies. Patients following this diet must therefore be
carefully monitored.
Another study on the SCD, involving 50 adult IBD (mainly colonic CD) patients, obtained a better
symptom score and a higher quality of life. Some patients were even able to maintain clinical remission
without medication [144]. The fecal microbiota of patients on the SCD was observed to have a higher
biodiversity index compared to matched patients eating a WSD [144]. These data suggest that the SCD
may be a good starting point from which to plan a dietary regime for IBD patients, especially in the
maintenance phase.
13. Conclusions
Although the study data are still often unsubstantiated, it is important not to underestimate the
role diet can play in supporting conventional IBD therapies, not only helping to induce and maintain
clinical remission, but above all, improving patient quality of life.
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While controversy still surrounds the exact role played by diet in the development of IBD,
there are indications that diet may significantly modulate disease onset and activity. No formal dietary
guidelines exist, however, for patients with IBD. The wide variability of study results is due in part
to the design limitations of what are largely underpowered, retrospective studies, and in part to the
heterogeneous disease subtypes (UC, CD) recruited to the studies.
The complexity of the human diet makes it very difficult to identify individual foods as risk
factors. It is in fact more likely that complex nutritional patterns very different from either the
traditional Mediterranean diet or other traditional diets matching our evolutionary status may impact
pathogenesis and the clinical course of IBD. In evolutionary terms, in fact, people in industrialized
countries can be described as nutritionally mismatched and more susceptible - to degrees depending
on their genetic background - the many non-communicable diet-related diseases, including IBD.
We now know the mechanisms of action whereby certain food groups may have a negative impact
on the microbiota, triggering intestinal inflammation or intestinal permeability. We also know that the
Western population tends to eat excessive amounts of “dangerous” foodstuffs. As mentioned above,
the reason why studies have failed to provide strong evidence of dietary efficacy could be due to
individual variability as well the small patient series studied. However, as one of the factors involved
in the onset and progression of IBD, diet requires further in-depth study, especially since IBD patients
tend to have disordered and unbalanced eating patterns. Although guidelines on IBD prevention
and treatment are starting to appear (Figure 4) [60], it must be remembered, however, that they are
based more on logical assumptions and animal models than on evidence provided by broad controlled
human clinical studies.
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Carbohydrates: White rice, 
basmati rice, rice noodles, oats, 
ancients grains bread and pasta, 
fresh potatoes (frozen potatoes 
or chips are not allowed) 
 
Fresh chicken, fresh fish, eggs. 
Once a week fresh unprocessed 
beef steak (lean meat) 
 
Peeled fruit and vegetables: 
tomatoes, cucumbers, carrot 
fresh spinach (side portion), 
zucchini, apple (if no tight 
stricture), bananas, few 
strawberry, kiwi, slice melon 
Fresh onion or garlic or ginger 
 
Condiments: Olive oil, canola oil, 
pepper, paprika, cinnamon stick  
 
Fresh herbs: mint leaves, 
oregano, coriander, rosemary, 
sage, basil, thyme 
 
Beverages: water, herbal tea, 
freshly squeezed orange or 
lemon juice daily (not from 
cartons or bottles), and 
vegetables drinks and 
Lactose-free or fermented dairy 
products (kefir, yoghurt and low 
amount of milk), vegetal milks 
(almond, coconut, rice, or oat), 
low amounts of hard (goat or 
sheep) cheese 
 




Wheat, breakfast cereals,  
bread for toast of any kind,   
pizza , gluten-free industrial 
products  
 
Processed or smoked meats 
and fish: sausages, lunched 
meats, salami, fish sticks 
Dairy products: Cow, goat, 
sheep milk, cow cheese, 
buttermilk, soft cheese, cream 
and ice cream. 
 
Legumes: Beans, chickpeas, 
soybeans and soymilk 
 
Condiments: salt, margarine 
sauces, salad dressing, syrup, 
jam of any kind 
 
Canned products, canned 
fruits and canned or frozen 
vegetables 
 
Packaged snacks: potato 
snacks, popcorn, nuts snacks. 
 
Candies, cake and dessert, 
milk-chocolate 
 
Beverages: all soft drinks, all 
sport energy drinks, beer, 
alcoholic drinks, fruit juices, 
instant tea and coffee 
preparations 
 
Sugars: sorbitol, mannitol, 
xylitol and maltitol , corn syrup 
 









Carbohydrates: Whole rice, whole red and black 
rice 
 
Legumes: lentils, split peas, soybean sprouts 
 
Beverages: Espresso or American coffee, wine 
 
Sugars: table sugar (max 2-3 teaspoons a day for 
permitted beverages) 
 
Dark chocolate (Cocoa minimum 80%) 
 
Figure 4. A possible diet for IBD: dietary foods and factors potentially affecting positively or negatively
host intestinal barrier, immunity and microbioma in IBD patients.
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Abstract: Vitamin D has recently been discovered to be a potential immune modulator. Low serum
vitamin D levels have been associated with risk of relapse and exacerbation of clinical outcomes in
Crohn’s disease (CD) and ulcerative colitis (UC). A retrospective, longitudinal study was conducted
to determine the association between vitamin D levels and inflammatory markers and clinical disease
activity in inflammatory bowel disease (IBD). In addition, circulating 25(OH)D3 progression was
evaluated according to vitamin D supplementation. Participants were separated into three groups
according to their vitamin D level: severe deficiency (SD), moderate deficiency (MD) and sufficiency
(S). Serum 25(OH)D3 was inversely correlated with faecal calprotectin (FC) for CD and UC but
was only correlated with C-reactive protein (CRP) for UC patients. In the multivariate analysis of
FC, CRP and fibrinogen (FBG), we predicted the presence of a patient in the SD group with 80%
accuracy. A deficiency of 25(OH)D3 was associated with increased hospitalisations, flare-ups, the use
of steroids and escalating treatment. Supplemental doses of vitamin D were likely to be insufficient
to reach adequate serum levels of 25(OH)D3. Vitamin D intervention studies are warranted to
determine whether giving higher doses of vitamin D in IBD might reduce intestinal inflammation or
disease activity.
Keywords: vitamin D; Crohn’s disease; ulcerative colitis; faecal calprotectin; C-reactive protein
1. Introduction
Vitamin D is a lipophilic hormone synthesised in the skin under the influence of ultraviolet (UV)
sunlight. Although most foods contain little vitamin D, it can be obtained from the diet to a lesser
extent. The most important sources of this vitamin are fatty fish and egg yolk [1,2].
UV type B light exposure causes 7-dehydrocholesterol transformation into cholecalciferol or
vitamin D3. However, this UV-mediated conversion varies with time of the year, latitude and
altitude. During approximately six months of the year, UVB radiation intensity is insufficient for
vitamin D synthesis at 45◦ latitude near sea level (e.g., France or Italy). This period of time increases
with the distance from the equator and is also known as vitamin D winter [3]. Along these lines,
in countries where there is limited skin exposure to sunlight a dietary supply of vitamin D is important.
Cholecalciferol is hydroxylated in the liver into 25-hydroxyvitamin D3 (25(OH)D3) and subsequently
in the kidney into 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), or calcitriol, the active metabolite [4]
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(Figure 1). These two steps are catalysed by the enzymes 25-hydroxylase (CYP2R1) and 1α-hydroxylase
(CYP27B1) that belong to the family of cytochrome P450 mixed function oxidases (CYPs). CYP2R1
has only been identified in the microsomal fraction of liver. However, although the kidney is the
main source of 1,25(OH)2 D3, several other tissues also express CYP27B1. The regulation of the
renal CYP27B1 differs from that of the extrarenal version [5]. In this way, renal CYP27B1 is activated
by the parathyroid hormone (PTH) and inhibited by fibroblast growth factor 23 (FGF23) as well as
by 1,25(OH)2D3 itself. Elevated calcium suppresses CYP27B1 by means of the suppression of PTH,
and elevated phosphate suppresses CYP27B1 by means of FGF23 stimulation, although these ions can
have direct effects on renal CYP27B1 on their own [5]. Thus, it is known that CYP27B1 is expressed in
numerous tissues where vitamin D3 can act as an intracrine or paracrine signal. In this way, several
immune system cell types express both CYP27B1 and the vitamin D receptor, with CYP27B1 production
controlled by a number of immune-specific inputs [3].
Figure 1. Vitamin D metabolism and functions. Under ultraviolet B light (UVB) exposure,
7-dehydroxycholesterol is converted to vitamin D3 in the skin. First, hydroxylation occurs in the
liver where it is converted to 25-hydroxyvitamin D3. 25-hydroxyvitamin D3 is further converted in
the kidney to its active metabolite, 1α,25-dihydroxyvitamin D3. In the kidney, 1α-hydroxylase is
stimulated by the parathyroid hormone (PTH) and feedback inhibited by 1α,25-dihydroxyvitamin D3.
1α,25-dihydroxyvitamin D3 targets the intestine, kidney and bone to regulate calcium and phosphate
homeostasis. Adapted from Lim et al [6].
The half-life of 1,25(OH)2D3 is very short, ranging from 20 to 40 hours [7]; therefore, its serum
determination is not clinically relevant. However, the 25(OH)D3 half-life ranges from 12 to 19 days [8],
so it appears to be the most reliable source of systemic vitamin D. 1,25(OH)2D3 has its effect on the
classic target organs such as bone, intestine and kidney and stimulates calcium transport from these
organs to the peripheral blood stream [4].
Calcitriol can influence the expression of targets genes by binding to the vitamin D receptor (VDR),
which is present in many cell populations and tissues, such as immune cells. Vitamin D promotes the
intestinal absorption of calcium and phosphate and is critical for bone growth and remodelling. Now,
however, it is well established that the physiological importance of vitamin D levels extends beyond
its classical role in calcium and bone metabolism. Serum vitamin D levels have been associated with
inflammatory diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis, systemic lupus
erythematosus, multiple sclerosis, atherosclerosis, and asthma. Regarding inflammation, it has become
clear that vitamin D inhibits production of proinflammatory cytokines like IL-6 or TNFα in monocytes
via the inhibition of p38 MAP kinase [9], and it can promote anti-inflammatory T-cell pathways to
stimulate the antimicrobial effects of macrophages [10].
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In terms of gut homeostasis, vitamin D plays a role in protecting the intestinal epithelial barrier,
immunity and microbiota, all of which are directly involved in IBD [11].
In-vitro 1,25(OH)2D3 treatment can protect the intestinal epithelial barrier in ulcerative colitis
(UC) patients by regulating various pathways involved in tight junction proteins [12]
Similar studies have proposed that lack of VDR leads to hyperfunction of Claudin-2. Claudin-2 is
an epithelial protein that forms a water channel to permit the paracellular passage of water through its
pores in the epithelium, and its expression is restricted to colonic proliferative cells. An overexpression
of Claudin-2 permits intestinal leakage, and is associated with active disease in IBD and reduction of
intestinal VDR [13].
Other genetic changes in the VDR gene can contribute to a greater risk for CD. Patients with
Crohn’s disease (CD) who are homozygous for a certain single nucleotide polymorphism (SNP) in the
VDR gene have lower levels of VDR protein expressed in serum monocytes. These individuals have
an overactivation of lymphocytic adhesion molecules and a higher risk of developing a penetrating
phenotype of CD [14].
Vitamin D has effects on both innate and adaptive immune pathways. 1,25(OH)2D3 modulates the
expression of cationic antimicrobial peptides like defensins and cathelicidins. VDR signals through distal
enhancers in the NOD2 gene, leading to the expression of defensin beta 2 in macrophages. However,
this response was absent in macrophages from patients with CD homozygous for nonfunctional NOD2
variants [15]. It should be noted that NOD2 is also known as IBD1. This gene is located on chromosome
16, in the susceptibility locus for CD, which is responsible for familial aggregation of this disease [16].
It has also been reported that DNA copy number of the beta-defensin gene cluster is highly polymorphic
within the healthy population, whereas CD patients appear to present a lower copy number. This
results in a diminished beta-defensin expression, predisposing patients to major susceptibility to
colonic CD [17]. An induction of human cathelicidin antimicrobial peptide gene was observed under
the influence of 1,25(OH)2D3 in colon cancer cells and other tissues [18,19]. Vitamin D is also involved
in immune regulation by modulating the role of dendritic cells and macrophages through two methods:
firstly, 1,25(OH)2D3 inhibits IL-12, a pivotal interleukin in Th1 development [20]; secondly, it promotes
IL-10 to stop maturation from dendritic cells to serum monocytes and leads to apoptosis in mature
dendritic cells [21]. Regarding adaptive immunity, 1,25(OH)2D3 affects T-cell polarisation by inhibiting
T helper 1(Th) (IFN-gamma production) and promoting Th2 cell development (IL-4, IL-5, and IL-10
production) from naïve T-cells [22]. It has been demonstrated in controlled studies that higher vitamin
D levels in UC patients were associated with protective anti-inflammatory serum cytokine profiles [23].
Gut microbiota have become the main research topic in intestinal homeostasis. One recent study
demonstrated that individuals with significant intake of vitamin D had different microbiota strains from
those without a significant vitamin D intake. These patients had plenty of Bacteroidetes, Prevotella
and Megasphera strains, traditionally associated with a noninflammatory status [24]. In another study,
administration of vitamin D to CD patients resulted in significant change in the gut microbiota with
a high abundance of some strains such as Alistipes and Roseburia that were not observed in healthy
controls [25]. In murine induced colitis, Alistipes finegoldii played a protective role [26]. Roseburia genii
are part of commensal bacteria that produce short-chain fatty acids, especially butyrate, affecting colonic
motility, immunity maintenance and anti-inflammatory properties [27]. Therefore, administration of
vitamin D might have a positive effect on CD by modulating the intestinal bacterial composition and
also by increasing the abundance of potential beneficial bacterial strains [25].
Regarding the epidemiology of vitamin D deficiency in IBD, there is a systematic review and
meta-analysis that defined this deficiency as serum 25(OH)D3 below 25 ng/mL. In this study, the
prevalence was 38.1% in CD and 31.6% in UC [28].
The latest evidence suggests that low vitamin D levels are involved in changing disease activity
and inflammatory markers in IBD. However, these studies sometimes fail to confirm which comes
first: are vitamin D levels an independent predictor of clinical activity or it is just a mere bystander of
increased inflammation?
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Due to chronic malabsorption, IBD patients and particularly those with CD are at greater risk
of certain nutritional deficiencies. Micronutrients, including hydro and lipophilic vitamins, iron,
calcium and zinc, are the most common problems [29]. Malabsorption, maldigestion and upper protein
requirements are directly related to clinical disease activity.
It is unknown why quiescent IBD has a greater prevalence of vitamin D deficiency than other
risk groups [30]. Even in patients with IBD in clinical remission, vitamin D malabsorption has
been confirmed. This fact led to controversy among researchers about oral intake as standard
supplementation. According to several prospective studies, IBD patients with vitamin D deficiency
are at greater risk of relapse, hospitalisations and flare-ups [2,31–35]. Schäffler et al. described a
correlation between the use of a TNF-alpha inhibitor and higher vitamin D levels in CD patients.
This correlation could be explained by a better disease control of these patients [34]. However, they
detected a correlation between a higher disease activity and lower vitamin D levels in UC but not in
CD. Moreover, the same authors found that in CD located in the small intestine, CD patients after
small intestine resections showed significant lower vitamin D levels. Other resections did not lead to
changes in the vitamin D levels; therefore, the small intestine plays an important role in vitamin D
absorption, particularly in IBD [34]. Despite the immune-modulation role of vitamin D confirmed in
translational studies, knowledge about its molecular action in IBD is still scarce. Exhaustive study of
vitamin D immune pathways is imperative to identifying new supplementation strategies that correct
this deficiency. It is also necessary to establish true sufficiency levels of vitamin D to have a goal for
supplementation therapy.
As a result of these findings, our group posed a study to assess outcomes in IBD activity depending
on vitamin D status. Thus, the association between vitamin D deficiency and inflammatory markers
and clinical disease activity could be evaluated. We also hypothesised that oral supplementation
according to practice guidelines was not enough to acquire vitamin D sufficiency.
2. Materials and Methods
2.1. Study Design and Patient Enrolment
We conducted a retrospective, longitudinal and observational study of patients with UC and CD,
defined by European Crohn’s and Colitis Organization (ECCO) guidelines criteria, which had serial
determinations of vitamin D serum samples from the IBD Unit of Hospital Universitari i Politècnic la
Fe, a tertiary centre, between 2015 and 2018. Formal consent was collected from all the patients and an
ethical committee, according to the declaration of Helsinki, approved the study.
A total of 84 patients divided into three groups according to the 25(OH)D3 (ng/mL) level
were enrolled in our study. The first vitamin D serum sample collected was used as a baseline to
separate patients into groups and according to core event. A cut-off of <15 ng/mL was considered
severe deficiency (SD), >15 and <30 ng/mL moderate deficiency (MD) and >30 ng/mL sufficiency (S).
Progression of vitamin D and supplementation from baseline was evaluated. Clinical disease activity
(flare-ups, hospitalisations, times to visit IBD clinic, escalating treatment, use of steroids) in the six
months before and the six months after the core event was monitored. In addition, inflammatory
markers (CRP, FC and fibrinogen (FBG)) were collected to explore the inflammatory status around
the vitamin D core event. Two determinations before and two determinations after to the core event
were needed for patient inclusion (Figure 2). Two or more consecutive 25(OH)D3 determinations
were also required. Other relevant descriptive variables: age, sex, IBD (EC or UC), extraintestinal
manifestations, and current therapy (anti-TNF, immunomodulators, etc.) were considered. We sought
active supplementation, establishing at least 25,000 IU (international units) of oral, subcutaneous or
intramuscular cholecalciferol monthly as adequate supplementation.
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Figure 2. Study timeline.
Patients under 18 years, pregnant patients, those with a previous colectomy in UC, those who
had CD surgery in the last three months, those with colorectal cancer or another tumour, those with
a severe infection during the time of study and those with malabsorption disease were excluded
from enrolment.
Disease activity and laboratory markers were collected from our software OrionClinic (Version 11).
Suitable patients to enroll in this study were found by crossing vitamin D measurements from iGestlab
software (Cointec iGestlab© 2013. v1.9.9.815, Orihuela, Alicante, Spain) and IBD Unit clinical histories.
Patients with several vitamin D samples, inflammatory markers and IBD diagnosis were filtered to
assess enrolment.
Serum 25(OH)D3 levels (ng/mL) were measured by automated chemiluminescence analyser
LIAISON® XL (DiaSorin, Sialuggia, Italy).
A total of 252 patients from IBD Unit and vitamin D measurements were evaluated to enroll.
Ultimately, 41 patients with SD, 28 with MD and 16 with sufficient vitamin D levels met the
inclusion criteria.
2.2. Statistical Analysis
An ANOVA test on ranks (Kruskal–Wallis test) was performed to compare inflammatory markers
with the three different Vitamin D groups (severe deficiency, moderate deficiency and sufficiency).
Moreover, a multiple comparison procedure was conducted to quantify the extent of the differences
between the groups. The Pearson correlation test was applied to study calprotectin-CRP-fibrinogen
correlations with vitamin D. The evolution of vitamin D, FC, CRP and FBG was evaluated by mixed
linear regression models. A random effect factor was included to amend the nonindependence of the
data (longitudinal study).
Given some patients were supplemented with vitamin D, a comparative study was done with
this group and the nonsupplemented ones to analyse the evolution of this parameter. Additionally,
the association between vitamin D levels and markers of clinical activity (hospitalisations, flare-ups,
escalating treatment, number of times they visited the clinic and the use of steroids) was studied
through logistic regression models.
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All models included the covariates sex, age and type of disease (CD or UC) as possible confounding
factors. R statistic software (3.5.1 version, https://www.r-project.org/), Sigmaplot (SYSTAT, San José,
CA, USA) and Minitab (State College, PA, USA) were used in this work. A significance level of 5% was
selected. Multivariate discriminant analysis was performed with SIMCA-P (Umetrics, Umeå, Sweden).
3. Results
This study evaluated three concerns: Firstly, the correlation between vitamin D levels, expressed
as 25(OH)D3, with both systemic and intestinal inflammation in IBD patients. Secondly, the association
between vitamin D deficiency and clinical disease activity markers, collected in a period of time between
six months before and after the randomly selected vitamin D core event. During this period, data on
admissions, flare-ups, times the patient needed to visit the clinic, the use of steroids and the need for
escalating treatment were collected. Thirdly, which patients benefitted from active supplementation
was explored.
3.1. Descriptive Statistics
First, a normality study for the continuous quantitative variables (vitamin D, FC, CRP and FBG)
was carried out. None of the inflammatory markers (FC, CRP, FBG) followed a normal distribution but
their logarithmic transformation leads to data that were normally distributed (Figure 3). However,
the vitamin D central values did follow a normal distribution.
Figure 3. Normality study of FC (A,B) and vitamin D (C,D). Note the nonparametric distribution of FC.
Tables 1 and 2 show some of the statistical parameters obtained from the descriptive parametric
and nonparametric study. The data have been grouped according to their vitamin D content. The central
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and dispersion values derived from the parametric and nonparametric treatment of the data are shown.
Table 1 shows the parametric descriptive statistics where the deviation of the data with respect to normal
behavior is clearly shown. The high values of MSSD (mean of the squared successive differences)
clearly indicate a non-random distribution of the results. To obtain a more accurate description of
central values and dispersion of inflammatory markers according to their vitamin D content, a robust
descriptive statistical study is shown in Table 2. The median of the of inflammatory markers tends
to increase when lower vitamin D levels were found. The significant differences found between the
groups are noteworthy. The median of all determinations of FC in the group SD was 345.7 μg/g, while
in the MD and S groups it was 63.5 and 29.7 μg/g, respectively. The medians of the CRP determinations
in the SD, MD and S groups were 5.6, 1.5 and 1.4 mg/dL, respectively.
Table 1. Statistical parameters obtained from vitamin D and inflammatory markers grouped according
to vitamin D content.
CI a (95%)
Variable Group Mean StDev CI− CI+ Skewness Kurtosis MSSD
Vitamin D S 40.43 12.7 37.0 43.9 1.34 1.42 78
MD 24.36 4.7 23.3 25.5 0.32 −0.16 17
SD 17.83 8.1 16.3 19.3 0.85 0.39 65
CRP S 2.28 2.37 1.8 2.8 1.82 3.5 1.5
MD 2.80 3.07 2.3 3.3 1.71 3.01 4.3
SD 23.6 51.0 16 31 4.48 24.2 1102
FC S 54 64 39 69 4.09 19.72 2567
MD 141 164 111 172 1.81 3.00 15,020
SD 868 1278 665 1070 2.31 5.24 508,909
FBG S 423 93 401 445 0.35 −0.51 4140
MD 412 107 392 432 0.57 −0.13 6703
SD 497 133 475 517 0.08 −0.77 5576
a confidence interval; MSSD: mean of the squared successive differences.
Table 2. Robust statistical parameters obtained from vitamin D and inflammatory markers grouped
according to vitamin D content.
CI a (95%)
Variable Group Min Q1 Median Q3 Max CI− CI+
Vitamin D S 20.5 32.2 36.2 43.0 74.30 34.1 43.9
MD 15.3 20.6 24.7 27.4 37.5 22.4 25.5
SD 4.5 12.2 15.1 22.7 45.7 14.3 19.3
CRP S 0.20 0.60 1.45 2.97 11.8 0.9 2.0
MD 0.20 0.60 1.50 3.82 16.5 1.1 2.2
SD 0.30 1.90 5.60 15.6 364 4.5 7
FC S 19.6 26.7 29.7 50.7 434 28 37
MD 17 27.6 63 229 738 43 98
SD 19 97 346 1065 6450 216 444
FBG S 262 356 411 491 664 387 446
MD 201 325 406 475 700 365 432
SD 151 390 478 602 813 456 502
a confidence interval.
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3.2. Qualitative Variables Study
Other qualitative variables were also considered and appear in Table 3. The mean age of the
patients was 43.7 years, and 39 of the patients were women (46%). Some 60 patients had CD (71%)
and 25 presented as UC (29%). Forty-four patients (52%) were supplemented with vitamin D, almost
all of them in the SD group. Extraintestinal manifestations were clustered into articular (eight
patients) and dermatological manifestations (two patients). Four cases of CD with perianal disease
were observed. We collected data on the treatments given during the period of study: biologics
(anti-TNFα, vedolizumab, ustekinumab), immunosuppressive agents (azathioprine, methotrexate,
6-mercaptopurine and tacrolimus) and the need for steroids therapy.
Six patients from the SD group required a combination of vedolizumab and steroids during the
time of study. None of the individuals in the MD or S groups were on vedolizumab. Some 30 patients
from the SD group were on anti-TNFα therapy, 12 of them in combination with azathioprine and eight
of them with steroids requirement. However, only 17 patients were on anti-TNFα therapy in MD and
S groups altogether. Only three of them required steroids and seven patients were on combination
therapy with azathioprine.
Table 3. Baseline clinical characteristics of patients meeting inclusion criteria.
Clinical Characteristic
Number of Participants (Percentage) or
Mean ± Standard Deviation
Age, years 43.7 ± 15.9
Female sex 39 (46)
Crohn’s disease 60 (71)
Ulcerative colitis 25 (29)
Perianal disease 4 (5)
Extraintestinal manifestations 10 (12)








Clinical disease activity markers collected included flare-ups, hospitalisations, number of times
patients visited the clinic, changing or escalating treatment and need for steroid therapy. We found
remarkable results between the groups according to vitamin D levels. Among the patients with SD,
16 patients (41%) were hospitalised at least once and 23 patients (58.9%) had at least one flare-up during
the time of the study (Figure 4). In the MD group along with the S group, only four flare-ups and one
hospitalisation were reported. In the SD group, patients visited the clinic an average of 5.33 times,
while in the MD and S groups they visited 3.61 times.
Changes or escalations in current therapy were made for 69.23% of the patients with SD, while
only 8.7% in the MD and S groups required such changes. Eighteen patients in the SD group (46.15%)
required steroids during the time of study, while only three patients in the SD and S groups did (6.53%).
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Figure 4. Results of the study of certain qualitative variables depending on vitamin D levels (SD or
MD+S).
3.3. Linear Correlation Study of Quantitative Variables
Table 4 shows the median and interquartile range values of inflammatory markers.
In nonsupplemented patients, the median and interquartile range of FC increased in cases of severe
deficiency. This also occurred when vitamin D was supplemented, but to a lesser extent. A similar
behaviour was observed for CRP in terms of the median but not for the interquartile range.
Table 4. Median and interquartile range of FC and CRP grouped by vitamin D levels for patients with
and without vitamin D supplementation.
FC, μg/g CRP, mg/dL
Group Median Q3–Q1 Median Q3–Q1
Not supplemented
S 33 25 1.3 1.8
MD 85 211 1.9 4.2
SD 524 2230 8.9 3.1
Supplemented
S 29 38 2.3 4.6
MD 55 328 2.1 4.9
SD 362 943 6.7 3.1
A nonparametric linear correlation study of vitamin D with FC, CRP and FBG was performed.
A Pearson correlation coefficient (R) of −0.533 (p < 0.001) was obtained for vitamin D and FC in all
patients. When two groups of patients were considered, both CD and UC showed a good correlation
(Figure 5). As can be seen, this correlation was almost independent of the disease, given there was no
significant differences between both slopes for UC and CD (p = 0.686).
For CRP, in patients with UC and CD, a Pearson correlation coefficient of −0.512 and −0.16 (p = 0.01
and 0.256), respectively, was obtained (Figure 5). These results demonstrate a strong correlation
between CRP and vitamin D exclusively in patients with UC, not in CD. Therefore, there are significant
differences between the correlation slopes (p = 0.02). No linear correlation was found between FBG
values and vitamin D levels (R near 0).
The statistical normality study of FC, CRP and FBG showed a non-normal distribution and,
as a consequence, a Kruskal–Wallis test for groups comparison was performed. Significant differences
for FC were found between the medians of the SD (345 μg/g), MD (46 μg/g) and S (30 μg/g) groups
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with a p-value < 0.001 (Figure 6). A similar study for CRP also showed significant differences (p = 0.01)
while no differences were obtained for FBG. Figure 7 shows box and whisker plots of inflammatory
markers depending on vitamin D levels. Data were normalised for representation purposes. As can be
seen, there were significant differences at 99% (**) in the contents of CRP and FC depending on the
vitamin D levels.
Figure 5. Linear correlation graphs of FC and CRP (log transform) with vitamin D for UC (A) and CD
(B) patients. Red, blue and green points correspond to SD, MD and S vitamin D level, respectively.
Figure 6. Box and whisker plot to represent the nonparametric variable FC, the values inside the box
conform the 25th and 75th percentile, while the horizontal line that crosses the box marks the median.
The values outside the whiskers are considered atypical.
201
Nutrients 2019, 11, 1059
Figure 7. Box and whisker plot using normalised values of inflammatory markers depending on
vitamin D levels. (**) correspond to significant differences at 99% (Dun’s test for multiple comparisons
on the Kruskal–Wallis test).
A multivariate discriminant analysis of FC, CRP and FBG shows a discriminant level of 80%.
In this way, 74% of SD patients and 85% of S patients were correctly classified by the model.
3.4. Vitamin D Progression
The progression of vitamin D levels over time was evaluated. Patients were divided according to
active supplementation. The mean vitamin D determination in the third event did not reach more than
25 ng/mL of vitamin D despite supposedly adequate supplementation. The Bonferroni test indicated
significant differences between situations 0 with 1 and 0 with 2, while showing no differences between
situations 1 and 2. This behaviour was the same in the group of patients who were supplemented and
not supplemented (Figure 8).
Figure 8. Evolution of vitamin D content in nonsupplemented individuals (A). The graph presents
the lines of regression of the contents and their slopes. Active supplementation (B) did not guarantee
levels of sufficiency in these patients.
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3.5. Categorical Variables Study
For the categorical variables, a logistic regression analysis was used. Negative binomial
regression showed an association between the SD group and a higher probability of having flare-ups,
hospitalisations and clinic visit (p-value = 0.002). Graphically, it can be seen that for vitamin D levels
below 20 ng/mL, the flare-up and hospitalisation rates increased exponentially regardless of the group
(Figure 9).
There was a correlation between those patients in the SD group and the probability of receiving
treatment with steroids. Another correlation was also observed with the probability of introducing
changes or the need for escalating treatment. All these results were statistically significant (p < 0.001).
Figure 9. Logistic regression of clinical disease activity markers with vitamin D content. From A to E:
Flare-ups, hospitalisations, clinic visits, use of steroids and escalating treatment, respectively.
4. Discussion
In this retrospective longitudinal study, we succeeded in describing an inverse correlation between
serum vitamin D levels and both systemic inflammatory markers (CRP) and intestinal inflammatory
markers (FC). Our findings confirm that vitamin D levels are also correlated with clinical disease
activity, as represented in hospitalisations, flare-ups, number of clinic visits, use of steroids and changes
in therapy. Additionally, we evaluated the vitamin D progression under oral supplementation, finding
an insufficient absorptive capacity.
Other studies support the association between vitamin D and inflammation. In a cross-sectional
study, Meckel et al. [32] demonstrated that serum 25(OH)D3 concentrations are inversely correlated
with endoscopic and histologic inflammation and disease activity. In addition, they found that
25(OH)D3 concentrations correlated with the mucosal expression of VDR as well as epithelial junction
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proteins. Moreover, in a retrospective cohort of 60 patients, it was reported that vitamin D was inversely
correlated with erythrocyte sedimentation rate (ESR), FC and clinical disease activity measured by
Harvey–Bradshaw Index > 5 [36].
Supporting the results of our study, Kabbani et al. [37], in one of the largest prospective cohort
studies, demonstrated that patients with low vitamin D levels required more hospitalisations, biologic
therapy, steroids, surgeries and healthcare utilisation. We have demonstrated a strong correlation
between vitamin D and FC as other authors [38] have done in similar studies. We describe an inverse
correlation between vitamin D status and systemic inflammation (CRP levels) in UC. In another
prospective study, Gubatan et al. [39] demonstrated that those patients with vitamin levels below
35 ng/mL were at greater risk of future clinical relapse.
However, there are some uncertainties not resolved yet concerning vitamin D influence on IBD.
Several translational studies are emerging to attempt to understand its hormonal pathophysiology,
and there are some interventional studies trying to evaluate its active supplementation. Despite the
importance of sunlight exposure in vitamin D levels, only a few studies have considered the season
where the sample was collected. Baseline vitamin D levels are not yet established to evaluate deficiency
and sufficiency. Thus, it is difficult to assess which patients are at real risk of developing clinical
consequences. In our study, we set that limit at <15 ng/mL, but other authors set it at <20 or <35 ng/mL.
The extent of the supplementation that should be given to our patients and what leads to sufficiency
during IBD clinical activity is also unclear.
In our study, several limitations must be considered. Despite describing a strong association
between vitamin D deficiency and higher inflammatory markers and disease activity, we cannot
confirm a causal relationship due to the retrospective collection of data. A notable cohort study of
patients was included in our study, but the inclusion enrolment was in only one single centre by the
main researcher. Thus, methodological flaws are possible, including selection bias. Finally, our study is
observational and limited by the inability to account for potential unmeasured confounders. Although
we evaluated active vitamin D supplementation, we did not consider baseline dietary vitamin D
intake, summer or winter season measurement, body mass index, physical activity and adherence
to medical therapy and supplementation. There is a relationship between vitamin D receptor genes
(VDR), autophagy and gut microbial assemblage that is essential for maintaining intestinal homeostasis
and contributes to the pathophysiology of IBD. However, genetic data regarding VDR polymorphisms
has not been considered in this study.
Garg et al. [40] designed an interventional study on vitamin D supplementation where the enrolled
IBD patients were given up to 10,000 IU (international units) of oral cholecalciferol. Despite achieving
improved symptom-based activity scores and a mean of 41.6 ng/mL of 25(OH)D3, no significant
reduction in FC levels was observed. It is remarkable that there was no control group in this study.
Sharifi et al. [41], on the other hand, in a randomised trial, demonstrated a significant decrease in CRP
and ESR levels with a single dose of 30,000 IU intramuscular vitamin D supplement. These results
support the findings in our study in terms of insufficient supplementation. Doses recommended
by guidelines, although suitable for bone health, appear to be clearly insufficient for IBD patients.
Considering chronic oral malabsorption, future studies are warranted to explore significant differences
in clinical scores or intestinal inflammation depending on the route of vitamin D administration.
A higher target 25(OH)D3 concentrations during active supplementation should also be evaluated to
clarify beneficial outcomes in IBD patients.
5. Conclusions
Vitamin D deficiency is now recognised as another predictor of clinical disease activity according
to recent research. This study demonstrates that low serum circulating 25(OH)D3 is associated with
intestinal inflammation (FC) in IBD and systemic inflammation (CRP) in UC. Deficiency of 25(OH)D3
is associated with more hospitalisations, flare-ups, use of steroids and escalating treatment. Standard
vitamin D oral dose of supplementation is probably insufficient to reach normal serum 25(OH)D3.
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Vitamin D intervention studies are warranted to determine whether raising serum 25(OH)D3 level
with higher doses of oral vitamin D in IBD may reduce intestinal inflammation or disease activity.
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Abstract: Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of
the gastrointestinal tract; it is a heterogeneous and multifactorial disorder resulting from a complex
interplay between genetic variation, intestinal microbiota, the host immune system and environmental
factors such as diet, drugs, breastfeeding and smoking. The interactions between dietary nutrients and
intestinal immunity are complex. There is a compelling argument for environmental factors such as diet
playing a role in the cause and course of IBD, given that three important factors in the pathogenesis of
IBD can be modulated and controlled by diet: intestinal microbiota, the immune system and epithelial
barrier function. The aim of this review is to summarize the epidemiological findings regarding diet
and to focus on the effects that nutrients exert on the intestinal mucosa–microbiota–permeability
interaction. The nature of these interactions in IBD is influenced by alterations in the nutritional
metabolism of the gut microbiota and host cells that can influence the outcome of nutritional
intervention. A better understanding of diet–host–microbiota interactions is essential for unravelling
the complex molecular basis of epigenetic, genetic and environmental interactions underlying IBD
pathogenesis as well as for offering new therapeutic approaches for the treatment of IBD.
Keywords: diet; inflammatory bowel disease; microbiota; intestinal barrier; nutrients; immunity
1. Introduction
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the
gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two principal types
of IBD. Its prevalence has been increasing worldwide, with the highest incidence found in Western
countries [1]. The precise etiology of IBD remains unclear; however, interactions between genetic,
microbiotic and environmental factors are associated with its pathogenesis [2]. There is a compelling
argument for environmental factors such as diet playing a role in the cause and course of IBD [3],
given that three important factors in the pathogenesis of IBD can be modulated and controlled by diet:
intestinal microbiota, the immune system and epithelial barrier function.
Patients with IBD tend to present with malnutrition, especially when they are having a flare
or have chronic, only partially controlled, intestinal inflammation. Currently, to deal appropriately
with malnutrition is considered a clinical quality criterion, especially for preventing the complications
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that can arise under a malnutrition situation (e.g., infections, postsurgical complications, immunity
alterations). Thus, there is a tendency to at least consider the patient’s nutritional status before
surgery [4], and a guide has recently been published with dietary recommendations [5]. However, the
gastroenterologist typically gives little advice to patients with IBD regarding daily diet or nutrient
considerations. Patients are often told, “eat what you can tolerate,” and discussion on diet is typically
very limited. Despite the scarce attention gastroenterologists give to nutrients, approximately 40%
of patients with CD believe that diet can control symptoms, and approximately 80% believe diet is
important in the overall management of the disease [6]. Some 40% of patients with IBD have attempted
various diet therapies, often without the assistance of a physician or dietician [7].
Perturbations related to dietary intake are thought to relate to the consumption of a dietary pattern
that negatively alters gut microbiota composition and intestinal permeability [8]. Recent experimental
evidence has suggested a crucial factor of barrier dysfunction in the onset of IBD [9]. The aim of this
review is to summarize the epidemiological findings regarding diet and to focus on the effects that
nutrients exert on intestinal mucosa–microbiota–permeability interaction.
2. Diet Influences Inflammatory Bowel Disease: Epidemiological Clues
Epidemiological studies have shown associations between the intake of specific dietary components
and the risk of developing IBD [10–17]; however, association does not necessarily imply causality.
These studies must be considered with caution, given that methodological inconsistencies and a recall
bias could be affecting the results observed. Furthermore, in a complex disease with dietary triggers,
it can be difficult to unravel the role of individual dietary risk factors because dietary patterns often
involve exposure to clusters of nutrients. These clusters are favored by the industrial processing
of food.
Classically, no environmental factor has been claimed to impact directly on the pathogenesis of
IBD, apart from tobacco [18]. However, a recent systematic review and meta-analysis have shown that
breastfeeding provides a protective factor against the development of CD and UC, both in pediatric
and adult-onset disease. This inverse association is consistent in studies worldwide and supports
the recommendation of breastfeeding in infancy to reduce the risk of IBD development [19]. Further
research on the effects of breast milk on the microbiome and modulation of the innate immune system
are needed.
A systematic review of the literature, initially including 2085 publications, was published in
2011 [20]. Nineteen studies fulfilled the inclusion criteria, containing a total of 2609 patients with
IBD (1340 UC and 1269 CD). The authors concluded that a high intake of total fats, polyunsaturated
fatty acids (PUFAs), omega-6 fatty acids and meat were consistently associated with increased risk of
developing UC as well as CD. High vegetable intake was consistently associated with decreased risk
of UC, whereas fiber and fruit intake were consistently associated with reduced risk of CD.
Dietary fats are associated with an increased or decreased risk for IBD, depending on the type
of fat. Among 170,805 women followed over 26 years, a high intake of dietary long-chain omega-3
PUFAs was associated with a reduced risk of UC. In contrast, high intake of trans-unsaturated fats was
associated with an increased risk of UC [15]. Various data have been extracted from an analysis of
366,351 individuals with IBD from the European Prospective Investigation into Cancer and Nutrition
study cohort. Globally, a dietary imbalance with a high consumption of sugar and soft drinks and a
low consumption of vegetables has been associated with UC risk [12]. Regarding fats, a sub-study
analyzing 126 incident cases of UC showed that the patients ranking in the superior quartile of linoleic
acid intake had a higher risk of developing UC [21]. Similarly, another analysis considering 70 incident
cases of CD has shown that higher intake of the omega-3 PUFA docosahexaenoic acid prevents CD
development [22]. A recent population-based study of environmental risk factors shows an increased
risk of CD with frequent fast-food consumption (Western diet) before the diagnosis [23]. A Western
diet typically contains high levels of omega-6 PUFAs and low levels of omega-3 PUFAs. The ratio
between the intake of omega-6 and omega-3 PUFAs is considered a risk factor for IBD.
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Data from the Nurses’ Health Study including 170,776 participants showed that higher long-term
fruit intake was associated with a lower risk of CD but not UC [15]. Multiple studies have reported a
negative association between dietary fiber intake from fruits or fruits and vegetables and subsequent
risk of CD. Fiber is the dietary component with the greatest agreement in epidemiological studies. In a
recent prospective study [24], fiber from fruit has also been implicated in preventing the establishment
of pouchitis in patients with UC. It is important to remember that the fiber implicated in these effects is
soluble fiber, which is fermentable by bacteria. Soluble fiber is usually less present in food; however,
the proportion of insoluble to soluble fiber could be the factor limiting tolerance to various foods.
Animal proteins have also been claimed to increase the risk of IBD [10]. A prospective study
(E3N) that included 67,581 French women showed that high animal protein intake was associated with
a significantly increased the risk of IBD, particularly with UC. However, other smaller studies have not
confirmed this risk [20]. In a separate study evaluating dietary intake and relapse of UC, red meat
was found to have the strongest association (odds ratio 5.19; 95% confidence interval 2.09–12.9) with
relapse [14].
Food additives have been progressively increasing in processed food. Both sweeteners and
emulsifiers, used to enhance the texture and stability of foods, have been shown to disrupt
host–microbiota interaction and to facilitate intestinal inflammation [25]. However, it is difficult
to ascertain whether the additives are risk factors because most of the questionnaires used to assess
dietary intake do not evaluate food additives.
Currently, it seems clear that dietary patterns are more important than individual foods for
considering the risk of IBD. The consumption of vegetables, fruits, olive oil, fish, grains and nuts
(prudent diet) was associated with a decreased risk of developing CD in both boys and girls in a
Canadian pediatric study. A Mediterranean dietary pattern is high in extra-virgin olive oil, vegetables,
fruit, legumes, nuts and seeds, with a moderate consumption of fish, poultry and milk products,
and is low in processed foods, baked goods and red and processed meat. This dietary pattern is high
in monounsaturated fats, omega-3 PUFAs, fermentable fiber and polyphenols, and adherence to a
Mediterranean dietary pattern is associated with lower levels of inflammation biomarkers [26].
3. Impact of Nutrients on Intestinal Permeability, Microbiome and Immunity
Dietary fiber is not digested or absorbed by host cells, given that mammalian cells largely lack
the necessary enzymes to degrade them. Instead, dietary fiber is subjected to bacterial fermentation
in the gastrointestinal tract. Although a wide range of bacteria ferment dietary fiber, each bacterium
has a substrate preference based on its enzymatic activity. Thus, dietary intervention can remodel
the gut microbial composition by customizing the content of dietary fiber [27]. Short-chain fatty
acids (SCFAs), such as acetate, propionate and butyrate, are the major end products of microbial
fermentation of dietary fiber. They are key energy substrates used by colonocytes [28]. Butyrate
enhances intestinal epithelial barrier function via hypoxia-inducible factor-1, which regulates the
integrity of epithelial tight junctions [28–30]. It also increases the synthesis of the MUC2 protein,
the main component of intestinal mucus [31,32]. Thus, a lack of dietary fiber might compromise
epithelial integrity and mucus production due to insufficient SCFA generation, resulting in impaired
intestinal barrier function [33]. Recently, it has been observed that consumption of a low-fiber diet
leads to the disruption of intestinal barrier function through a mechanism that is independent of
SCFAs. In the absence of dietary fiber, some commensal bacteria use host mucus glycans to meet their
energy needs [34]. As a result, these mucolytic bacteria become the predominant species within the gut
microbiota. Importantly, a bloom of mucolytic bacteria results in the degradation of the colonic mucus
layer that renders the host susceptible to enteric pathogens [34] (Figure 1). These changes facilitate
bacterial adherence and translocation into the epithelium, which introduce immunomodulatory effects.
In summary, a diet poor in soluble fiber can condition both dysbiosis and a subsequent decrease in the
mucus layer, which increases the permeability already affected by the fiber-poor diet.
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Figure 1. Interaction of dietary fiber with the gut microbiota.
The gut microbiota is thought to play a crucial role in human health and prevention of disease
through a variety of mechanisms, including the production of short-chain fatty acids (SCFAs), which are
important for maintaining gut homeostasis and optimal immune function. Ingested fiber can influence
fecal microbiota profiles, cause changes in the complex gastrointestinal environment and promote the
growth of bacteria in general and potentially beneficial bacteria in particular.
Fat- and refined sugar-rich diets can condition a low production of butyrate, which has been
described in patients with CD, together with a diminution in the butyrate receptor [35] Butyrate
plays an important role in downregulating inflammation by suppressing transcription of cytokines
and increasing differentiation and the population of lamina propria Tregs [33,35,36]. Butyrate can
also enhance innate immunity by upregulating defensins and cathelicidins in animal models [36].
Defensins have been reported to be permanently decreased in patients with IBD, and whether a dietary
intervention could reverse this condition deserves further investigation. High-fat diets (without high
sugars) have been shown to increase tumor necrosis factor (TNF)-α and interferon-γ expression, and to
decrease levels of colonic Tregs [37].
Dietary amino acids play important roles in gut homeostasis. Amino acid metabolic profiles in
the blood, urine, feces and intestinal tissues are also altered in patients with IBD and correlate with the
severity of the disease. Additionally, metagenomic studies have revealed that amino acid biosynthesis
genes are downregulated and amino acid transporter genes are upregulated in the gut microbiome
of patients with IBD, indicating that the gut microbiota lessens the production of amino acids and
increases the rate of their use [38,39]. Certain amino acids are critical for immune T-cell function as
well as for the proliferation of macrophages [40,41]. Thus, the demand for certain amino acids by host
cells and the gut microbiota can increase as a consequence of inflammation.
Tryptophan is an essential amino acid that can be found in fish, meat and cheese. Its metabolites,
such as kynurenine, indole-3-aldehyde and indole-3-acetic acid, can act as ligands for the aryl
hydrocarbon receptor, a critical regulator of immunity and inflammation involved in adaptive immunity
and intestinal barrier function [42–44]. Indoleamine 2,3 dioxygenase-1 (IDO1) is ubiquitously expressed
in epithelial cells, dendritic cells and macrophages. IDO1 is the first step in the kynurenine pathway,
a major route for tryptophan catabolism. IDO1 regulates the differentiation and maturation of adaptive
immune cells [45]. Kynurenine is an initial metabolite of IDO1-mediated tryptophan catabolism and
the kynurenine/tryptophan ratio is a surrogate marker of IDO1 activity. A recent clinical study has
shown that serum tryptophan levels are lower and the kynurenine/tryptophan ratio is elevated in
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patients with IBD compared with healthy controls [15]. Additionally, indoleamine 2,3-dioxygenase 1
(IDO1) mRNA expression in colonic tissues is significantly higher in IBD and correlates with disease
severity, suggesting the kynurenine pathway is upregulated in IBD.
Arginine and glutamine are two semi-essential amino acids that can impact gut homeostasis
and innate immunity. Both are diminished in prospective cohorts of patients with IBD, and both
are implicated in wound repair mechanisms [46]. Furthermore, arginine regulates macrophage
differentiation into the M1 or M2 phenotype following environmental cytokine guidance, whereas
glutamine reduces oxidative stress and cytokine production via downregulation of the NF-kB and
signal transducer and activator of transcription proteins (STAT) signaling pathways.
The upregulation of amino acid metabolic pathways is one of the major inflammation-related
metabolic shifts in the host and the microbiota. In other words, host cells and resident microbes have
an increased demand for certain amino acids in the context of IBD. Thus, dietary supplementation of
these amino acids is a key strategy for the treatment of IBD. However, it is noteworthy to mention that
other amino acids can fuel pro-inflammatory responses in IBD, and restriction of certain amino acids
can attenuate intestinal inflammation. A more thorough understanding of the specific roles various
amino acids play in IBD and supplying the optimal amount of anti-inflammatory amino acids while
limiting the consumption of proinflammatory amino acids can lead to the development of effective
amino acid-based dietary interventions.
4. Mesenteric Fat and Epigenetic Considerations
Today, patients with IBD sometimes have malnutrition with obesity, associated with metabolic
syndrome. Obesity has also been associated with the development of more active IBD, with a higher
demand for therapeutic resources. Patients with IBD, especially CD, present fat-wrapping or “creeping
fat,” which corresponds to ectopic adipose tissue extending from the mesenteric attachment and
covering the majority of the small and large intestinal surface. Mesenteric adipose tissue in patients with
IBD presents several morphological and functional alterations; e.g., it is more infiltrated with immune
cells such as macrophages and T-cells. This fat tissue is not an “innocent bystander,” but actively
contributes to intestinal and systemic inflammatory responses [47]. It overexpresses peroxisome
proliferator-activated receptor gamma (PPAR-γ), which is a “master” regulator of the adipogenesis
program and the major orchestrator of visceral adipose tissue Treg accumulation, phenotypes and
function. Mesenteric adipose tissue is colonized by luminal bacteria, and PPAR-γ expression is
modulated by several bacterial stimuli. Thus, the presence of metabolically active adipose tissue
should be taken into consideration when attempting to change the alterations facilitating bacterial
adherence and/or clearance and permeability regulation of innate/adaptive immunity.
Similarly, epigenetic modulation of gene expression should be contemplated when considering how
other environmental factors can affect the mucosa–microbiome–immunity interplay. A Westernized
high-fat diet, full of refined carbohydrates, is strongly associated with the development of IBD, contrary
to a diet high in fruit, vegetables and omega-3 PUFAs, which is protective against it [26]. Epigenetic
mechanisms could explain the connection between genes and environmental factors in triggering the
development of IBD. The definition of epigenetics refers to heritable alterations of gene expression
events that are caused independently of genetic information carried by the primary DNA sequence.
The main epigenetic mechanisms controlling gene expression include DNA methylation, histone
modifications and small and long noncoding RNAs [48]. The main objective of epigenetics is to
modulate gene expression without modifying the basic DNA sequence. All the mechanisms involved
in epigenetics are involved in correct cell development, differentiation, function and homeostasis.
Moreover, these mechanisms are influenced by exposure to environmental factors, persist through
mitosis and meiosis and, more importantly, can be reversed. Recent advances have indicated that
epigenetic variation has an important influence on interactions between nutrients and the genome,
which modifies disease risk [49,50]. Diet is known to influence epigenetic changes associated with
disease and to modify gene expression patterns in a state of disturbed immunity. A number of nutrients
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have been shown to modulate immune responses and can potentially counteract inflammatory
processes [51]. Some studies have suggested that secondary plant metabolites, such as polyphenols,
might modulate gene expression, chromatin remodeling and DNA methylation [52]. Epigenetic
effects have also been shown for other dietary components, such as curcumin [53]. Moreover, specific
components of the Mediterranean diet, particularly nuts and extra-virgin olive oil, have recently been
found to be able to induce methylation changes in several peripheral white blood cells, showing a
role for specific fatty acids in epigenetic modulation [54]. Thus, considering the status of epigenetic
mechanisms in particular patients, it is important to understand whether a dietary intervention could
help or not.
5. Diet as Possible Therapy
Despite the fact that a growing body of knowledge related to diet is emerging in terms of IBD
pathogenesis, there is no strong evidence for dietary interventions helping to induce remission or to
maintain response. Dietary therapies, such as enteral exclusive nutrition (EEN), have traditionally and
primarily been used to induce remission in early or new-onset CD. EEN has been shown to be effective
for inducing clinical remission, improving nutritional status, improving body composition, inducing
mucosal healing and decreasing proinflammatory cytokines in pediatric and adult patients with CD.
EEN has been extensively used for induction of remission in pediatric CD, in which avoidance of
steroids is critical for childhood growth. However, EEN has been less often used for adult patients.
Although some studies have assessed EEN in adults, most were less conclusive and had multiple
confounding factors; thus, this practice is uncommon in adults with CD [55]. EEN involves the
exclusive use of liquid nutrition in the form of medical formulas, without exposure to other foods,
usually for 6–8 weeks. This effect does not depend on the protein source (a type of formula), but it does
depend on the exclusion of ordinary table food [56]. Several recent pediatric studies have demonstrated
and confirmed that EEN can induce remission in 60%–86% of children, accompanied by a significant
decrease in inflammatory markers, such as the erythrocyte sedimentation rate, C-reactive protein
and fecal calprotectin [57–59]. This recent body of literature has evaluated the long-term benefits
associated with the use of EEN in mild-to-moderate pediatric CD. In comparison with the use of
steroids, and corrected for disease severity, EEN has been associated with higher remission rates, better
growth and longer steroid-free periods, but it did not differ in regard to other outcomes such as relapse.
The benefit of EEN was lost when partial enteral nutrition (PEN) was used instead, with access to a
free diet granted to patients [60]; thus, reaffirming the principle of exclusivity, suggesting that the
mechanism depends on the exclusion of a free diet. However, a recent study has shown that PEN can
be effective in combination with a “prudent pattern diet” [61]. In this study, PEN, with an exclusion diet
based on components hypothesized to affect the microbiome or intestinal permeability, was effective for
induction of remission in children and young adults with CD. Several randomized controlled trials are
being developed in order to confirm this observation (NCT01728870, NCT 02843100, NCT02231814).
The idea of maintaining remission with diet is compelling and challenging at the same time.
On the one hand, once remission is established, it is certainly possible that diet will be sufficient to
maintain homeostasis and to prevent the cascade of proinflammatory events leading to flare-ups;
however, long-term studies are challenging to perform, and adherence becomes a serious concern.
Long-term studies on the maintenance of remission have largely focused on the use of semi-elemental
EEN [62,63]. These data show promise for the use of semi-elemental EEN in the maintenance of CD.
On the other hand, an interesting idea has been revealed by a recent study showing that, in patients
with moderate to severe CD undergoing infliximab treatment (anti-TNFα therapy), combined EEN
therapy of ≥600 kcal/day led to an increase in the remission maintenance rate, preventing loss of
response to infliximab therapy [64]. These studies illustrate the potential benefit of elemental nutrition
in the maintenance of remission in patients with CD; however, there are as yet no data to support
this hypothesis.
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Regarding fatty acids, PUFAs comprise two main groups of fats: omega-3 and omega-6 fatty
acids. Omega-6 is considered an inflammatory fat, whereas omega-3 is anti-inflammatory. In human
IBD, a systematic review has not supported the notion that supplementation of omega-3 fatty acids
can induce and maintain remission of IBD [65]. The latest Cochrane review has reached a similar
conclusion [66]. Interestingly, several studies have demonstrated that different genotypes can be
associated with the variable response to nutritional intervention with omega-3 PUFAs. For example,
genetic polymorphisms of TNFα and PPARγ have been associated with an altered response to
nutritional intervention with omega-3 PUFAs [67]. In IBD, genetic polymorphisms, such as CYP4F3
and caspase 9+93C/T, modify the association between dietary fatty acid intake and risk of IBD [68].
Thus, specific mutations should also be considered before considering dietary therapeutic interventions.
6. Conclusions
Apart from EEN in specific situations, no strong evidence has been found to provide solid
dietary intervention recommendations for patients with IBD. However, evidence and knowledge are
accumulating and have suggested that pertinent studies should be prospectively developed in order to
characterize potential dietary therapeutic possibilities. This body of knowledge leads us to recommend
that a “prudent” diet or a “Mediterranean diet” should be advised to patients. Given that diet has been
shown to be important for intestinal homeostasis and to avoid disruption of intestinal permeability,
the consumption of vegetables, fruits, olive oil, fish, grains and nuts should be recommended, together
with avoidance of the use of excessive additives and industrialized food processing.
Dietary recommendations for patients with IBD should emerge in a personalized manner, taking
into consideration nutrient knowledge, the individual mucosa–microbiome–immunity interplay, the
status of epigenetic changes and creeping fat metabolism. Dietary recommendations cannot be
generalized for all patients, however. Given that the above elements differ per patient, no single dietary
intervention can offer the same improvement for all patients. Thus, future studies should take this
factor into account and be designed accordingly.
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5. Forbes, A.; Escher, J.; Hébuterne, X.; Kłęk, S.; Krznaric, Z.; Schneider, S.; Shamir, R.; Stardelova, K.;
Wierdsma, N.; Wiskin, A.E.; et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease.
Clin. Nutr. 2017, 36, 321–347. [CrossRef] [PubMed]
6. McDonald, P.J.; Fazio, V.W. What can Crohn’s patients eat? Eur. J. Clin. Nutr. 1988, 42, 703–708. [PubMed]
7. Moser, G.; Tillinger, W.; Sachs, G.; Maier-Dobersberger, T.; Wyatt, J.; Vogelsang, H.; Lochs, H.; Gangl, A.
Relationship between the use of unconventional therapies and disease-related concerns: A study of patients
with inflammatory bowel disease. J. Psychosom. Res. 1996, 40, 503–509. [CrossRef]
8. Maynard, C.L.; Elson, C.O.; Hatton, R.D.; Weaver, C.T. Reciprocal interactions of the intestinal microbiota
and immune system. Nature 2012, 489, 231–241. [CrossRef] [PubMed]
214
Nutrients 2019, 11, 1062
9. Martini, E.; Krug, S.M.; Siegmund, B.; Neurath, M.F.; Becker, C. Mend Your Fences: The epithelial Barrier and
its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Cell Mol. Gastroenterol. Hepatol.
2017, 23, 33–46. [CrossRef]
10. Jantchou, P.; Morois, S.; Clavel-Chapelon, F.; Boutron-Ruault, M.C.; Carbonnel, F. Animal protein intake and
risk of inflammatory bowel disease: The E3N prospective study. Am. J. Gastroenterol. 2010, 105, 2195–2201.
[CrossRef]
11. D’Souza, S.; Levy, E.; Mack, D.; Israel, D.; Lambrette, P.; Ghadirian, P.; Deslandres, C.; Morgan, K.;
Seidman, E.G.; Amre, D.K. Dietary patterns and risk for Crohn’s disease in children. Inflamm. Bowel Dis.
2008, 14, 367–373. [CrossRef]
12. Racine, A.; Carbonnel, F.; Chan, S.S.; Hart, A.R.; Bueno-de-Mesquita, H.B.; Oldenburg, B.; van Schalk, F.D.;
Tjønneland, A.; Dahm, C.C.; Key, T.; et al. Dietary patterns and risk of inflammatory bowel disease in Europe:
Results from the EPIC study. Inflamm. Bowel Dis. 2016, 22, 345–354. [CrossRef]
13. Shoda, R.; Matsueda, K.; Yamato, S.; Umeda, N. Epidemiologic analysis of Crohn disease in Japan: Increased
dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of
Crohn disease in Japan. Am. J. Clin. Nutr. 1996, 63, 741–745. [CrossRef] [PubMed]
14. Jowett, S.L.; Seal, C.J.; Pearce, M.S.; Phillips, E.; Gregory, W.; Barton, J.R.; Welfare, M.R. Influence of dietary
factors on the clinical course of ulcerative colitis: A prospective cohort study. Gut 2004, 53, 1479–1484.
[CrossRef]
15. Ananthakrishnan, A.N.; Khalili, H.; Konijeti, G.G.; Higuchi, L.M.; de Silva, P.; Korzenik, J.R.; Fuchs, C.S.;
Willett, W.C.; Richter, J.M.; Chan, A.T. A prospective study of long-term intake of dietary fiber and risk of
crohn’s disease and ulcerative colitis. Gastroenterology 2013, 145, 970–977. [CrossRef]
16. Costea, I.; Mack, D.R.; Lemaitre, R.N.; Israel, D.; Marcil, V.; Ahmad, A.; Amre, D.K. Interactions between the
dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn’s
disease. Gastroenterology 2014, 146, 929–931. [CrossRef]
17. Chan, S.S.; Luben, R.; van Schaik, F.; Oldenburg, B.; Bueno-de-Mesquita, H.B.; Hallmans, G.; Karling, P.;
Lindgren, S.; Grip, O.; Key, T.; et al. Carbohydrate intake in the etiology of Crohn’s disease and ulcerative
colitis. Inflamm. Bowel Dis. 2014, 20, 2013–2021. [CrossRef] [PubMed]
18. Torres, J.; Caprioli, F.; Katsanos, K.H.; Lobatón, T.; Micic, D.; Zerôncio, M.; Van Assche, G.; Lee, J.C.;
Lindsay, J.O.; Rubin, D.T.; et al. Predicting outcomes to optimize disease management in inflammatory
bowel diseases. J. Crohns. Colitis. 2016, 10, 1385–1394. [CrossRef] [PubMed]
19. Xu, L.; Lochhead, P.; Ko, Y.; Claggett, B.; Leong, R.W.; Ananthakrishnan, A.N. Systematic review with
meta-analysis: Breastfeeding and the risk of Crohn’s disease and ulcerative colitis. Aliment. Pharmacol. Ther.
2017, 46, 780–789. [CrossRef] [PubMed]
20. Hou, J.K.; Abraham, B.; El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: A
systematic review of the literature. Am. J. Gastroenterol. 2011, 106, 563–573. [CrossRef] [PubMed]
21. Tjonneland, A.; Overvad, K.; Bergmann, M.M.; Nagel, G.; Linseisen, J.; Hallmans, G.; Palmqvist, R.; Sjodin, H.;
Hagglund, G.; Berglund, G.; et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology
of ulcerative colitis: A nested case-control study within a European prospective cohort study. Gut 2009, 58,
1606–1611, Epub 23 Jul 2009. [CrossRef]
22. Chan, S.S.; Luben, R.; Olsen, A.; Tjonneland, A.; Kaaks, R.; Lindgren, S.; Grip, O.; Bergmann, M.M.;
Boeing, H.; Hallmans, G.; et al. Association between high dietary intake of the n-3 polyunsaturated fatty
acid docosahexaenoic acid and reduced risk of Crohn’s disease. Aliment. Pharmacol. Ther. 2014, 39, 834–842.
[CrossRef]
23. Niewiadomski, O.; Studd, C.; Wilson, J.; Williams, J.; Hair, C.; Knight, R.; Prewett, E.; Dabkowski, P.;
Alexander, S.; Allen, B.; et al. Influence of food and lifestyle on the risk of developing inflammatory bowel
disease. Intern. Med. J. 2016, 46, 669–676. [CrossRef] [PubMed]
24. Godny, L.; Maharshak, N.; Reshef, L.; Goren, I.; Yahav, L.; Fliss-Isakov, N.; Gophna, U.; Tulchinsky, H.;
Dotan, I. Fruit consumption is associated with alterations in microbial composition and lower rates of
pouchitis. J. Crohns. Colitis. 2019, 4. [CrossRef] [PubMed]
25. Chassaing, B.; Koren, O.; Goodrich, J.K.; Poole, A.C.; Srinivasan, S.; Ley, R.E.; Gewirtz, A.T. Dietary
emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519,
92–96. [CrossRef] [PubMed]
215
Nutrients 2019, 11, 1062
26. Taylor, L.; Almutairdi, A.; Shommu, N.; Fedorak, R.; Ghosh, S.; Reimer, R.A.; Panaccione, R.; Raman, M.
Cross-sectional analysis of overall dietary intake and mediterranean dietary pattern in patients with crohn’s
disease. Nutrients 2018, 10, 1761. [CrossRef] [PubMed]
27. Salyers, A.A.; West, S.E.; Vercellotti, J.R.; Wilkins, T.D. Fermentation of mucins and plant polysaccharides by
anaerobic bacteria from the human colon. Appl. Environ. Microbiol. 1977, 34, 529–533. [PubMed]
28. Marsman, K.E.; McBurney, M.I. Dietary fiber increases oxidative metabolism in colonocytes but not in distal
small intestinal enterocytes isolated from rats. J. Nutr. 1995, 125, 273–282. [CrossRef]
29. Kelly, C.J.; Zheng, L.; Campbell, E.L.; Saeedi, B.; Scholz, C.C.; Bayless, A.J.; Wilson, K.E.; Glover, L.E.;
Kominsky, D.J.; Magnuson, A.; et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and
Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host. Microbe. 2015, 17, 662–671. [CrossRef]
[PubMed]
30. Saeedi, B.J.; Kao, D.J.; Kitzenberg, D.A.; Dobrinskikh, E.; Schwisow, K.D.; Masterson, J.C.; Kendrick, A.A.;
Kelly, C.J.; Bayless, A.J.; Kominsky, D.J.; et al. HIF-dependent regulation of claudin-1 is central to intestinal
epithelial tight junction integrity. Mol. Biol. Cell. 2015, 26, 2252–2262. [CrossRef] [PubMed]
31. Peng, L.; Li, Z.R.; Green, R.S.; Holzman, I.R.; Lin, J. Butyrate enhances the intestinal barrier by facilitating
tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J. Nutr.
2009, 139, 1619–1625. [CrossRef] [PubMed]
32. Burger-van Paassen, N.; Vincent, A.; Puiman, P.J.; van der Sluis, M.; Bouma, J.; Boehm, G.; van Goudoever, J.B.;
van Seuningen, I.; Renes, I.B. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids:
Implications for epithelial protection. Biochem. J. 2009, 420, 211219. [CrossRef] [PubMed]
33. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.;
Kato, T.; et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.
Nature 2013, 504, 446–450. [CrossRef] [PubMed]
34. Desai, M.S.; Seekatz, A.M.; Koropatkin, N.M.; Kamada, N.; Hickey, C.A.; Wolter, M.; Pudlo, N.A.; Kitamoto, S.;
Terrapon, N.; Muller, A.; et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier
and enhances pathogen susceptibility. Cell 2016, 167, 1339–1353.e21. [CrossRef]
35. Bach Knudsen, K.E.; Lærke, H.N.; Hedemann, M.S.; Nielsen, T.S.; Ingerslev, A.K.; Gundelund Nielsen, D.S.;
Theil, P.K.; Purup, S.; Hald, S.; Schioldan, A.G.; et al. Impact of Diet-Modulated Butyrate Production on
Intestinal Barrier Function and Inflammation. Nutrients 2018, 10, 1499. [CrossRef]
36. Wang, H.; Shi, P.; Zuo, L.; Dong, J.; Zhao, J.; Liu, Q.; Zhu, W. Dietary Non-digestible polysaccharides
ameliorate intestinal epithelial barrier dysfunction in il-10 knockout mice. J. Crohns. Colitis. 2016, 10,
1076–1086. [CrossRef] [PubMed]
37. Ma, X.; Torbenson, M.; Hamad, A.R.; Soloski, M.J.; Li, Z. High-fat diet modulates non-CD1d-restricted
natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis. Clin. Exp.
Immunol. 2008, 151, 130–138. [CrossRef] [PubMed]
38. Morgan, X.; Tickle, T.; Sokol, H.; Gevers, D.; Devaney, K.; Ward, D.; Reyes, J.A.; Shah, S.A.; LeLeiko, N.;
Snapper, S.B.; et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
Genome. Biol. 2012, 13, R79. [CrossRef]
39. Davenport, M.; Poles, J.; Leung, J.M.; Wolff, M.J.; Abidi, W.M.; Ullman, T.; Mayer, L.; Cho, I.; Loke, P.
Metabolic alterations to the mucosal microbiota inflammatory bowel disease. Inflamm. Bowel. Dis. 2014, 20,
723–731. [CrossRef]
40. Ren, W.; Liu, G.; Yin, J.; Tan, B.; Wu, G.; Bazer, F.W.; Peng, Y.; Yin, Y. Amino-acid transporters in T-cell
activation and differentiation. Cell Death Dis. 2017, 8, 1–9. [CrossRef]
41. Langston, P.K.; Shibata, M.; Horng, T. Metabolism Supports Macrophage Activation. Front. Immunol. 2017, 8,
61. [CrossRef] [PubMed]
42. Palego, L.; Betti, L.; Rossi, A.; Giannaccini, G. Tryptophan biochemistry: Structural, nutritional, metabolic,
and medical aspects in humans. J. Amino Acids 2016, 2016, 1–13. [CrossRef]
216
Nutrients 2019, 11, 1062
43. Lee, J.S.; Cella, M.; McDonald, K.G.; Garlanda, C.; Kennedy, G.D.; Nukaya, M.; Mantovani, A.; Kopan, R.;
Bradfield, C.A.; Newberry, R.D.; et al. AHR drives the development of gut ILC22 cells and postnatal
lymphoid tissues via pathways dependent on and independent of Notch. Nat. Immunol. 2012, 13, 144–152.
[CrossRef] [PubMed]
44. Mezrich, J.D.; Fechner, J.H.; Zhang, X.; Johnson, B.P.; Burlingham, W.J.; Bradfield, C.A. An interaction
between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010,
185, 3190–3198. [CrossRef] [PubMed]
45. El-Zaatari, M.; Bass, A.J.; Bowlby, R.; Zhang, M.; Syu, L.J.; Yang, Y.; Grasberger, H.; Shreiner, A.; Tan, B.;
Bishu, S.; et al. Indoleamine 2,3-Dioxygenase 1, increased in human gastric pre-neoplasia, promotes
inflammation and metaplasia in mice and is associated with type II hypersensitivity/autoimmunity.
Gastroenterology 2018, 154, 140–153.e17. [CrossRef] [PubMed]
46. Wagner, S.J.; Schmidt, A.; Effenberger, M.J.P.; Gruber, L.; Danier, J.; Haller, D. Semisynthetic diet ameliorates
Crohn’s disease–like ileitis in TNFΔARE/WT mice through antigen-independent mechanisms of gluten.
Inflamm. Bowel Dis. 2013, 19, 1285–1294. [CrossRef]
47. Gonçalves, P.; Magro, F.; Martel, F. Metabolic inflammation in inflammatory bowel disease: Crosstalk
between adipose tissue and bowel. Inflamm. Bowel Dis. 2015, 21, 453–467. [CrossRef]
48. Ventham, N.T.; Kennedy, N.A.; Nimmo, E.R.; Satsangi, J. Beyond gene discovery in inflammatory bowel
disease: The emerging role of epigenetics. Gastroenterology 2013, 145, 293–308. [CrossRef]
49. Legaki, E.; Gazouli, M. Influence of environmental factors in the development of inflammatory bowel
diseases. World J. Gastrointest. Pharmacol. Ther. 2016, 7, 112–125. [CrossRef]
50. Aleksandrova, K.; Romero-Mosquera, B.; Hernandez, V. Diet, gut microbiome and epigenetics: Emerging
links with inflammatory bowel diseases and prospects for management and prevention. Nutrients 2017, 30,
962. [CrossRef]
51. Burdge, G.C.; Hoile, S.P.; Lillycrop, K.A. Epigenetics: Are there implications for personalised nutrition?
Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 442–447. [CrossRef]
52. Remely, M.; Lovrecic, L.; de la Garza, A.L.; Migliore, L.; Peterlin, B.; Milagro, F.I.; Martinez, A.J.;
Haslberger, A.G. Therapeutic perspectives of epigenetically active nutrients. Br. J. Pharm. 2015, 172,
2756–2768. [CrossRef]
53. Reuter, S.; Gupta, S.C.; Park, B.; Goel, A.; Aggarwal, B.B. Epigenetic changes induced by curcumin and other
natural compounds. Genes Nutr. 2011, 6, 93–108. [CrossRef] [PubMed]
54. Arpón, A.; Milagro, F.I.; Razquin, C.; Corella, D.; Estruch, R.; Fitó, M.; Marti, A.; Martínez-González, M.A.;
Ros, E.; Salas-Salvadó, J.; et al. Impact of consuming extra-virgin olive oil or nuts within a mediterranean
diet on dna methylation in peripheral white blood cells within the predimed-navarra randomized controlled
trial: A role for dietary lipids. Nutrients 2017, 10, 15. [CrossRef]
55. Ruemmele, F.M.; Veres, G.; Kolho, K.L.; Griffiths, A.; Levine, A.; Escher, J.C.; Amil-Dias, J.; Barabino, A.;
Braegger, C.P.; Bronsky, J.; et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of
pediatric Crohn’s disease. J. Crohns Colitis. 2014, 8, 1179–1207. [CrossRef] [PubMed]
56. Lee, D.; Baldassano, R.N.; Otley, A.R.; Albenberg, L.; Griffiths, A.M.; Compher, C.; Chen, E.Z.; Li, H.;
Gilroy, E.; Nessel, L.; et al. Comparative effectiveness of nutritional and biological therapy in north american
children with active crohn’s disease. Inflamm. Bowel Dis. 2015, 21, 1786–1793. [CrossRef] [PubMed]
57. Levine, A.; Turner, D.; Pfeffer-Gik, T.; Amil-Dias, J.; Veres, G.; Shaoul, R.; Staiano, A.; Escher, J.; Kolho, K.L.;
Paerregaard, A.; et al. Comparison of outcomes parameters for induction of remission in new onset pediatric
Crohn’s disease: Evaluation of the porto IBD group “growth relapse and outcomes with therapy” (GROWTH
CD) study. Inflamm. Bowel Dis. 2014, 20, 278–285. [CrossRef] [PubMed]
58. Connors, J.; Basseri, S.; Grant, A.; Giffin, N.; Mahdi, G.; Noble, A.; Rashid, M.; Otley, A.; Van-Limbergen, J.
Exclusive enteral nutrition therapy in paediatric crohn’s disease results in long-term avoidance of
corticosteroids: Results of a propensity-score matched cohort analysis. J. Crohns Colitis. 2017, 11, 1063–1070.
[CrossRef]
59. Cohen-Dolev, N.; Sladek, M.; Hussey, S.; Turner, D.; Veres, G.; Koletzko, S.; Martin de Carpi, J.; Staiano, A.;
Shaoul, R.; Lionetti, P.; et al. Differences in outcomes over time with exclusive enteral nutrition compared
with steroids in children with mild to moderate crohn’s disease: Results from the growth cd study. J. Crohns
Colitis. 2018, 12, 306–312. [CrossRef]
217
Nutrients 2019, 11, 1062
60. Levine, A.; Wine, E. Effects of enteral nutrition on Crohn’s disease: Clues to the impact of diet on disease
pathogenesis. Inflamm. Bowel Dis. 2013, 19, 1322–1329. [CrossRef]
61. Sigall-Boneth, R.; Pfeffer-Gik, T.; Segal, I.; Zangen, T.; Boaz, M.; Levine, A. Partial enteral nutrion with a
Crohn’s disease exclusion diet is effective for induction of remission in children and young adults with
Crohn’s disease. Inflamm. Bowel Dis. 2014, 20, 1353–1360. [CrossRef] [PubMed]
62. Takagi, S.; Utsunomiya, K.; Kuriyama, S.; Yokoyama, H.; Takahashi, S.; Iwabuchi, M.; Takahashi, S.;
Kinouchi, Y.; Hiwatashi, N.; Funayama, Y.; et al. Effectiveness of an “half elemental diet” as maintenance
therapy for Crohn’s disease: A randomized controlled trial. Aliment. Pharmacol. Ther. 2006, 24, 1333–1340.
[CrossRef]
63. Yamamoto, T.; Nakahigashi, M.; Umegae, S.; Kitagawa, T.; Matsumoto, K. Impact of long-term enteral nutrition
on clinical and endoscopic recurrence after resection for Crohn’s disease: A prospective, non-randomized,
parallel, controlled study. Aliment. Pharmacol. Ther. 2007, 25, 67–72. [CrossRef]
64. Hisamatsu, T.; Kunisaki, R.; Nakamura, S.; Tsujikawa, T.; Hirai, F.; Nakase, H.; Watanabe, K.; Yokoyama, K.;
Nagahori, M.; Kanai, T.; et al. Effect of elemental diet combined with infliximab dose escalation in patients
with Crohn’s disease with loss of response to infliximab: CERISIER trial. Intest. Res. 2018, 16, 494–498.
[CrossRef]
65. Turner, D.; Shah, P.S.; Steinhart, A.H.; Zlotkin, S.; Griffiths, A.M. Maintenance of remission in inflammatory
bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses. Inflamm. Bowel.
Dis. 2011, 17, 336–345. [CrossRef] [PubMed]
66. Turner, D.; Zlotkin, S.H.; Shah, P.S.; Griffiths, A.M. Omega 3 fatty acids (fish oil) for maintenance of remission
in Crohn’s disease. Cochrane Database Syst. Rev. 2009, 21, CD006320. [CrossRef]
67. Paradis, A.M.; Fontaine-Bisson, B.; Bossé, Y.; Robitaille, J.; Lemieux, S.; Jacques, H.; Lamarche, B.; Tchernof, A.;
Couture, P.; Vohl, M.C. The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism
influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men.
Am. J. Clin. Nutr. 2005, 81, 523–530. [CrossRef]
68. Ananthakrishnan, A.N.; Khalili, H.; Song, M.; Higuchi, L.M.; Lochhead, P.; Richter, J.M.; Chan, A.T. Genetic
polymorphisms in fatty acid metabolism modify the association between dietary n3: n6 intake and risk of
ulcerative colitis: A prospective cohort study. Inflamm. Bowel Dis. 2017, 23, 1898–1904. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Inflammatory Bowel Diseases and Food Additives:
To Add Fuel on the Flames!
Rachel Marion-Letellier 1,2,*, Asma Amamou 1,2, Guillaume Savoye 1,2,3 and Subrata Ghosh 4
1 INSERM unit 1073, Normandie University, UNIROUEN, 22 boulevard Gambetta, F-76183 Rouen, France;
asma.amamou@etu.univ-rouen.fr (A.A.); guillaume.savoye@chu-rouen.fr (G.S.)
2 Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN,
F-76183 Rouen, France
3 Department of Gastroenterology, Rouen University Hospital, 1 rue de Germont, F-76031 Rouen, France
4 Institute of Translational Medicine, University of Birmingham, Birmingham B15 2TT, UK;
sughosh@ymail.com
* Correspondence: rachel.letellier@univ-rouen.fr
Received: 28 April 2019; Accepted: 16 May 2019; Published: 18 May 2019
Abstract: Inflammatory bowel diseases (IBDs) develop in genetically predisposed individuals in
response to environmental factors. IBDs are concomitant conditions of industrialized societies, and diet
is a potential culprit. Consumption of ultra-processed food has increased over the last decade in
industrialized countries, and epidemiological studies have found associations between ultra-processed
food consumption and chronic diseases. Further studies are now required to identify the potential
culprit in ultra-processed food, such as a poor nutritional composition or the presence of food additives.
In our review, we will focus on food additives, i.e., substances from packaging in contact with food,
and compounds formed during production, processing, and storage. A literature search using PubMed
from inception to January 2019 was performed to identify relevant studies on diet and/or food additive
and their role in IBDs. Manuscripts published in English from basic science, epidemiological studies,
or clinical trials were selected and reviewed. We found numerous experimental studies highlighting
the key role of food additives in IBD exacerbation but epidemiological studies on food additives on
IBD risk are still limited. As diet is a modifiable environmental risk factor, this may offer a scientific
rationale for providing dietary advice for IBD patients.
Keywords: colitis; food additive; diet; emulsifiers; high salt diet; inflammatory bowel diseases
1. Introduction
The most common types of inflammatory bowel diseases (IBDs) are Crohn’s disease (CD)
and ulcerative colitis (UC). IBD etiology is unknown, but IBDs develop in genetically predisposed
individuals in response to environmental factors and the result of an exacerbated mucosal immune
response to intestinal microbiota. IBDs are concomitant conditions of industrialized societies [1].
Indeed, IBD prevalence has continued to increase in Western countries, and newly industrialized
countries in Asia, the Middle East, Africa, and South America have exhibited a rapid increase of IBD
prevalence [1].
Environmental factors are supposed to play a decisive role in the pathogenesis of IBDs. Diet is
considered to be a potential culprit and we previously reviewed the potential effect of specific nutrients
in IBDs [2]. With this study, we aimed to focus on another potential dietary culprit: food additives.
Consumption of ultra-processed food (UPF) has increased over the last decade, in particular in
industrialized societies [3–5], and studies from the French web-based NutriNet-Santé cohort have
found an association between UPF consumption and chronic diseases, such as a higher cancer risk [6].
UPF now represent an important part of the diet of French individuals: UPF accounted for 16% of
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food consumed by weight, corresponding to 33% of total energy intake [7]. In addition, the authors
also reported an association between these dietary patterns and a higher irritable bowel syndrome
risk (OR Q4 vs. Q1 [95% CI]: 1.25 [1.12–1.39], p-trend < 0.0001) [7]. Similar associations between UPF
consumption and chronic diseases are globally observed, such as metabolic syndrome in the US [4]
or depression in Spain [5]. Further studies are now required to identify the potential culprit in UPF,
such as a poor nutritional composition or the presence of food additives. In our review, we will focus
on food additives, i.e., substances from packaging in contact with food, and compounds formed during
production, processing, and storage.
2. IBD Patients and Dietary Beliefs
Diet is a crucial point for IBD patients [8–10] and exclusion diets are commonly reported.
In a French study, the dietary beliefs of 244 IBD patients were studied using a questionnaire of
14 items [8]. The majority of IBD patients (58%) believed that food can play a role in causing a relapse
and this strongly affects quality of life because IBD patients may refuse outdoor dining for fear of causing
IBD symptoms [8]. In a study conducted in the UK, 400 IBD patients received a dietary questionnaire
and data from this study were in accordance with the French study. In this study, deteriorating
symptoms were associated with certain foods from 60% of IBD patients [10]. Similar results were found
in a Dutch study conducted in 294 IBD patients through an online questionnaire [9]. Interestingly,
81% of IBD patients from the Dutch study reported that their main nutritional knowledge came from
their own experience, while 71% reported that they received professional dietary advice mainly from
dieticians [9]. In a Spanish study, the majority of IBD patients (86%) refrained from eating some foods
to avoid a worsening of flare-ups [11]. In pediatric IBD populations, food avoidance is also commonly
reported for 53% of patients [12].
3. A Pinch of Salt
Processed food is a high provider of dietary sodium chloride (NaCl). Few recent studies have
evaluated the potential impact of dietary salt in colitis models [13–15] (Figure 1). Tubbs et al. calculated
the NaCl content of a series of available foods in grocery and fast food restaurants using the SELF
Nutrition database, and they reported that these foods contained approximately 4% w/w NaCl [13].
Increased concentration of NaCl from 10 to 80 mM induced inflammatory cytokine production, such
as the IL (interleukin)-23/IL-17 pathway in normal intestinal lamina propria mononuclear cells [14].
High-salt diet (HSD) exacerbated chemically induced colitis, while pharmacological inhibition of
p38/MAPK abrogated its effect in both models [14]. Tubbs et al. demonstrated the deleterious effect
of HSD in numerous colitis models, such IL-10-/- or infectious colitis [13]. Interestingly, Aguiar et al.
reported that dietary salt exacerbated colitis but by itself can trigger gut inflammation by increasing
intestinal permeability and inflammatory histological score [15]. More recently, HSD also has been
shown to have a deleterious impact on intestinal microbiota by decreasing Lactobaccilus levels and
short-chain fatty acid production [16].
These studies raised the potential role of dietary salt as an environmental trigger for IBD
development by creating a deleterious environment that is more vulnerable to inflammatory insults.
Dietary phosphate has been less studied than dietary salt. Nevertheless, dietary inorganic
phosphate is abundant in processed food as a food additive, in particular in fast foods and processed
meats. Phosphate intake is two or three times higher [17]: 1655 mg/day for men and 1190 mg/day for women
in the US compared to dietary reference intake at 700 mg/day in industrialized countries. Its deleterious
effect on intestinal inflammation has also been demonstrated. Sugihara et al. fed Sprague–Dawley rats
with a diet containing 0.5% to 1.5% phosphate for 7 days before colitis induction [18]. As standard
animal diet contains approximatively 5000 mg/kg of phosphate, i.e., 0.5%, the range of phosphate from
0.5% to 1.5% used in the study mimics the human exposure range from 1- to 3-fold of the recommended
dietary intake. Dietary phosphate exacerbates colitis by accentuating body weight loss by increasing
disease activity index and by activating NF (Nuclear factor)-κB [18]. The authors of the study also
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found an in vitro increased inflammatory response by 2 mM phosphate in liposaccharide (LPS)-treated
RAW264 cells [18].
To our knowledge, only one study has reported clinical data concerning salt consumption and
IBDs [19]. In a US cohort from 194,711 women, the authors of this study reported that dietary intake of
potassium (Ptrend = 0.005) but not sodium (Ptrend = 0.440) was inversely associated with risk of CD [19].
The authors did not observe any significant association between both dietary potassium and sodium




















Figure 1. High-salt diet promotes intestinal inflammation. High-salt diet exposure led to higher
intestinal permeability and dysbiosis. High-salt diet induced p38 MAPK phosphorylation and NFAT5
in lamina propria mononuclear cells activation with a subsequent expression of inflammatory cytokines
expression such as IL17, IL22, and TNFα.
4. Take the Bitter with the Sweet
Carbohydrates are obviously part of a normal diet but their excessive consumption is a feature
of the Westernized diet. In addition, industrialized food contains hidden sugars, such as lactose as
a texturing agent in sausages. There is currently no evidence of an association between carbohydrate
intake and IBD risk in epidemiological studies [20]. Results from the prospective EPIC (European
Prospective Investigation into Cancer and Nutrition) study, when excluding cases occurring within
the first 2 years after dietary assessment, found a positive association between a “high sugar and soft
drinks” pattern and UC risk (1.68 [1.00–2.82]; Ptrend < 0.05). When the authors considered the foods
most associated with the pattern, high consumers of sugar and soft drinks were at higher UC risk only
if they had low intakes of vegetables [21], but the amount of consumed sugar was not mentioned.
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Those with pediatric IBDs had a lower intake of carbohydrates compared to the general population,
in particular a decreased intake of food types high in sugar [12].
Polysaccharides are commonly added in UPF as emulsifiers, coating agents, stabilizers, or bulking
agents. These ingredients enable a better palatability and a longer shelf like of these products. Some of
these ingredients have been studied in experimental models of IBDs [22–25].
Nickerson et al. focused their studies on the effect of the dietary polysaccharide maltodextrin to
bacterial-induced intestinal inflammation [22–24]. Maltodextrin is commonly found in processed food
and medications. Nickerson et al. demonstrated that maltodextrin can promote Salmonella survival in
multiple cell types [24]. They also studied the effect of maltodextrin on CD-associated adherent-invasive
Escherichia coli (AIEC) and found that the presence of maltodextrin enhanced AIEC adhesion by a better
biofilm formation [22]. Maltodextrin consumption may promote intestinal dysbiosis and contribute
to disease susceptibility. In a recent study, maltodextrin in drinking water exacerbated intestinal
inflammation in an indomethacin-induced enteropathy model or in DSS (Dextran sodium sulfate)-colitis.
The mechanisms behind maltodextrin’s deleterious effects involved endoplasmic reticulum stress and
led to mucin-2 depletion [25].
The consumption of sweeteners is becoming more and more frequent in the US general population.
A recent study on 16,942 participants reported that 25% of children and 41% of adults in the US consumed
foods and beverages containing low-calorie sweeteners [26]. Two large Swedish prospective cohort
studies consisting of 83,042 participants did not find any association between sweetened beverages
consumption and risk of later-onset CD or UC [27]. In South Korea, food additive consumption (such as
sucralose) cannot explain the increased incidence of IBDs [28]. Increased IBD incidence started before
the 1980s in South Korea, while sucralose was only approved in 2000 [28]. A recent study demonstrated
the deleterious impact of an artificial sweetener called Splenda in experimental IBDs [29]. Splenda
contains 1% sucralose and 99% maltodextrin. The authors of this study investigated the impact of
6 weeks of supplementation with Splenda in SAMP1/YitFc mice that spontaneously developed ileitis.
Splenda supplementation induced ileal myeloperoxidase activity and promoted dysbiosis, in particular
an expansion of proteobacteria [29].
Carrageenan is a polysaccharide commonly used as a food additive. In experimental models,
it is also commonly used to induce an inflammatory response in vitro or in vivo [30,31]. The daily
consumption of carrageenan in the US diet is approximatively 250 mg per adult. Recently, a small
clinical trial was conducted to evaluate the potential benefit of a carrageenan-free diet in UC patients [32].
Patients were instructed to follow a carrageenan-free diet by avoiding carrageenan-containing-food and
received either 100 to 200 mg of carrageenan capsules or placebo capsules. Carrageenan-supplemented
patients had some higher inflammatory parameters, such as a higher clinical disease index and higher
IL-6 and fecal calprotectin [32]. Carrageenan also has an impact on intestinal microbiota [33]. Colitis
induction by carrageenan at 20 mg/L in drinking water decreased the level of an anti-inflammatory
bacteria Akkermansia muciniphila [30].
Chassaing et al. did a remarkable study on two emulsifiers, carboxymethylcellulose (CMC) and
polysorbate-80 (P80), on gut barrier [34–36]. They added emulsifiers in the mouse drinking water
at a relative low level for 12 weeks in wild-type or IL-10-deficient mice [35]. Dietary emulsifiers
altered gut microbiota composition and induced hyperpermeability [35]. Emulsifiers promote colitis
in IL-10-/- mice by increasing inflammatory markers such as fecal lipocalin-2 or myeloperoxidase
activity [35]. They demonstrated microbiota involvement in mediating the emulsifier effect by
transferring intestinal microbiota from emulsifier-treated mice into unexposed germ-free mice; upon
doing so, they observed that colonized germ-free mice had the same response [35]. They confirmed
in a second study the direct impact of the emulsifiers on the microbiota using a mucosal simulator
of the human intestinal microbial ecosystem; they observed that emulsifiers-promoted flagellin
levels [36]. In another study, Chassaing et al. investigated whether emulsifiers can impact colon
carcinogenesis [34]. They exposed mice with colitis-associated cancer to the same emulsifiers for
13 weeks and they observed that emulsifiers promote carcinogenesis through intestinal microbiota
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alteration, the establishment of a pro-inflammatory environment, and increased proliferation marker
Ki67 [34]. Interestingly, they demonstrated in a recent study that emulsifiers also had a significant
impact on anxiety [37], and psychological co-morbidities are commonly observed in IBD patients and
IBD experimental models [38].
One-third of IBD patient underwent irritable bowel syndrome-like symptoms [39] and a recent
meta-analysis confirmed that dietary restriction of fermentable oligosaccharide, disaccharide,
monosaccharide, and polyol (FODMAP) reduced functional gastrointestinal symptoms such as
bloating [40]. In heathy volunteers, mechanisms behind low-FODMAP diet involved decreased
Bifidobacterium and reduced breath hydrogen [41].
5. Put the Pedal to the Metal
Aluminum is an abundant element commonly used in our environment. It is used in processed
foods and cooking materials such as food packaging or foils. Cosmetic products and drugs are also
a source of aluminum. The European Food Safety Authority set the tolerable weekly intake of 1 mg
aluminum/kg body weight. Pineton de Chambrun et al. investigated the dietary effect of aluminum
in colitis models. The strength of this study from Lille University is that the aluminum dose of
1.5 mg/kg/day that they used was relevant to human exposure [42]. Four weeks of oral administration
of aluminum has been shown to worsen chemically-induced colitis models. Indeed, macroscopic
and histologic scores and myeloperoxidase activity were higher in colitis mice exposed to aluminum.
They also found a similar effect in IL-10-/- mice. Exposure of epithelial cells lines with aluminum
phosphate increased constitutive or LPS-induced cytokines mRNA level. Interestingly, aluminum
exposure also delays mucosal repair capacity by inhibiting proliferating processes [43]. IBD patients
often suffer from visceral pain even in remission periods [39], and a recent study from the same team
has shown that dietary exposure of aluminum also induced visceral hypersensitivity in rodents [44].
This effect persisted over time after treatment cessation and involved mast cell activation [44].
6. To Add or Not to Add
Titanium dioxide (TiO2) is a food pigment which increases opacity and confers a white color [45].
Dietary sources of TiO2 are numerous, from sweets to toothpaste, and it is often used to provide
a natural whiteness and opacity to foods, such as icing on cakes. TiO2 has an optimal particle diameter
of 200–300 nm, but a nano-sized fraction can be found because of manufacturing processes. These TiO2
nanoparticles, in Europe listed as E171, are commonly used as a food additive. We previously
investigated the effects of microparticles on macrophages from CD patients, and we observed that
microparticles alone did not induce an immune response [46]. By contrast, microparticles act as
adjuvants to induce potent cytokine responses in the presence of bacterial antigens such as LPS [46].
In addition, macrophage function has been shown to be impaired in the presence of high concentrations
of microparticles [46]. Houdeau et al. investigated the specific effect of E171 on gut barrier [47]
at a relevant range for human exposure, because modeling of human exposure to TiO2 estimates
an exposure of 2–3 mg/kg/day for children under the age of ten [48]. After one week of dietary exposure
to TiO2 at 10 mg/kg, titanium can be detected in Peyer’s patches in rats [47] and it is associated
with an unfavorable immune cell balance: an increased CD11b/c+ CD103+ MHC-II+ dendritic cell
proportion and a decreased proportion of regulatory T cells [47]. This TiO2 effect is not transient
because it lasts after 100 days of TiO2 treatment [47]. In addition, long-term exposition for 100 days is
associated with low-grade colon inflammation and induced aberrant crypt foci in a chemically induced
carcinogenesis model [47]. The effect of dietary exposure to titanium dioxide at 50 to 500 mg/kg
on colitis development has been investigated [49]. Dietary titanium dioxide exacerbates acute DSS
colitis by inducing a shortening of the colon and increasing infiltration and histological inflammatory
scores [49]. The same experiment was performed in inflammasome Nlrp3-/- mice, and the results
showed that dietary TiO2 at 500 mg.kg−1 did not reproduce colitis exacerbation in Nlrp3/- compared
to the response of the wild type mice. The mechanisms behind the dietary effect of TiO2 on colitis
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involved NLRP3. In vitro works demonstrated the accumulation of TiO2 in human intestinal epithelial
and macrophage cell lines in a dose-dependent manner [49]. In addition, TiO2 at 20 to 100 μg/mL
stimulates oxidative stress and increased intestinal permeability in human intestinal epithelial cell
lines. Rogler et al. found that patients with active UC exhibited increased blood levels of titanium [49].
In extra-intestinal organs, dietary exposure at 2.5 to 10 mg/kg to TiO2 for 6 months upregulated
renal TGFβ and SMAD, signaling pathways involved in fibrosis [50]. We speculate that dietary
TiO2 may also promote IBD-induced intestinal fibrosis, but this effect has not been yet documented.
Two recent studies have proposed a dietary intervention to counteract TiO2-induced inflammation in
mice. The administration of both flavonoids naringenin or quercetin inhibits TiO2-induced arthritis by
decreasing cytokine production and oxidative stress [51,52].
Oral bisphenol A is a chemical used in food packages. Oral bisphenol A at a dose lower to the
tolerable daily intake was able to induce intestinal hyperpermeability in rats, and this effect occurs
in a dose-dependent manner [53]. In trinitrobenzene sulfonic acid (TNBS)-induced colitis, perinatal
exposure of dietary bisphenol A increased myeloperoxidase activity in female rats but not in male
rats [53].
Dietary bisphenol A induced visceral hypersensitivity in response to colorectal distension [53].
A recent study highlighted the effect of bisphenol A in chemically induced colitis in ovariectomized
female mice, and the authors demonstrated that bisphenol A exposure led to a worsened colitis through
intestinal microbiota metabolites, such as a decreased level of tryptophan [54].
Food heat treatment leads to neoformed compounds such as Maillard reaction products. Exposure
to these Maillard reaction products alleviated inflammatory response [55] and dysbiosis in colitis
models [56].
7. Exclusion Diets
Exclusion diets are commonly followed by IBD patients [57]. These exclusion diets have poor or
no scientific rationale but expose IBD patients to nutritional deficiencies. The last European Society for
Clinical Nutrition and Metabolism (ESPEN) guidelines about clinical nutrition in IBD patients declared
that there is no IBD diet in active disease (strong consensus—96% agreement) [58]. We will limit our
section to a few exclusion diets that may explain some benefits to limit food additive exposure.
Exclusive enteral nutrition (EEN) is recommended as first intention treatment to induce remission
in children or teenagers with CD [58], although EEN is not recommended in adult patients.
The mechanisms behind EEN are not fully understood, but it may involve dysbiosis correction
or gut barrier maintenance [59]. EEN mechanisms may also involve the absence of specific deleterious
food components, such as food additive exposure.
There is also concern about the presence of pesticides in the food chain, although there is still no
evidence connecting pesticides to IBDs [60]. A recent study from the NutriNet French cohort found
that more frequent organic food consumption decreased cancer risk [61].
We previously mentioned the effect of nanoparticles in gut barrier dysfunction in preclinical
models, and two clinical trials have investigated the impact of low or microparticle-free diet in IBD
patients. The first one was a very small trial in 20 CD patients that showed a beneficial effect of low or
microparticle-free diet in ileal CD patients, such as decreased corticosteroids intake [62].
The second study included 84 active CD patients for 16 weeks [63] and the authors did not find
any benefit of the microparticle exclusion on inflammatory disease activity index, fecal calprotectin,
or intestinal permeability [63]. We previously reported the effects of carrageenan on gut barrier in
preclinical models. A small pilot study investigated the effect of carrageenan-free diet in 12 UC
patients [32]. Three out of ten UC patients who followed the carrageenan-free diet for 12 months
relapsed compared to three out of five patients in the control group (RR (Relative risk) 0.50, 95% CI
0.15 to 1.64), but it may be difficult to conclude that there are potentially beneficial effects because of
the very small size of the study.
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Lactose-free diets are common in IBD patients. In a small recent study on 78 IBD patients from
Iceland, 60% (47 patients) reported limiting their dairy consumption or even excluding it, but only
eight of them used calcium supplements [64]. Acquired lactase deficiency is commonly reported in CD
patients, in particular in proximal CD. In a clinical trial in 77 UC patients published in 1965, milk-free
diets had only a benefit for one out of five patients [65] and did not justify dairy-restricted diets in all
IBD patients. In 29 pediatric UC patients, exclusion of cow milk proteins had no influence on induction
and/or maintenance of remission [66].
Paleolithic diet is another exclusion diet without scientific rationale. Its principles are that our
gastrointestinal system did not evolve alongside our modernized diet and may explain numerous
inflammatory diseases. This diet excludes a lot of foodstuffs, such as ultra-processed foods or cereals,
and is limited to wild meats and a non-cereal, plant-based diet. To our knowledge, the only published
data about paleo diet and IBDs is a Hungarian case report about a teen CD patient’s refractory to
treatments. This CD patient had a clinical remission after 2 weeks on a paleo diet and was still in
remission 15 months later [67]. Extrapolation from a unique case control study is not permitted,
and exclusion of so many foodstuffs may be associated with numerous nutritional deficiencies.
One-third of IBD patients underwent IBS-like symptoms, and partial exclusion of some fermentable
components may be associated with benefits to functional symptoms. For example, in a small study
with 16 CD patients in remission, a strict exclusion diet of wheat and dairy products for 2 weeks
significantly decreased function symptoms such as abdominal pain [68]. In a prospective study with
89 IBD patients in remission, a low-FODMAP diet for 6 weeks reduced IBS-like symptoms while it
increased quality of life in patients [69].
Exclusion diets are not recommended and may expose patients to numerous nutritional deficiencies.
In addition, cofounding factors are often observed, leading to unjustified dietary exclusion. Recently,
a double-blind clinical trial identified that fructan composition, instead of gluten, induced functional
symptoms in patients with self-reported non-celiac gluten sensitivity [69]. Similar results were
previously reported concerning lactose intolerance [70]. Avoiding some foods has been identified as
a risk factor for malnutrition in IBD patients in a Spanish cohort [71]. Of note, malnutrition increased
further complications, such as higher surgery and hospitalization rates, and malnutrition is associated
with altered quality of life in IBD patients [11,72]. In addition, exclusion diets may limit socializing and
dining because many IBD patients reportedly refused dining out because doing so would not conform
with their exclusion diet [11]. Exclusion of dairy products such as in a lactose-free diet or paleo diet
may increase osteoporosis risk in IBD patients, while gluten-free diets are associated with decreased
microbiota diversity.
8. Conclusions
Diet is a modifiable environmental risk factor and food additives may act as potentiators of
disease. Diet is a crucial point for IBD patients and exclusion diets appear to offer an alternative
allowing for relative control of disease development. Nevertheless, the last ESPEN guidelines did
not recommend any exclusion diet for induction or maintenance of remission in IBD patients but
advised IBD patients to undergo counselling by a dietitian to avoid malnutrition. In addition, it has
been recently reported that IBD patients in remission have an unbalanced dietary profile for essential
nutrients [73]. Rather than exclusion diets, home-made food may be prioritized to decrease food
additive amounts and enable patients to control their exposure to many hidden ingredients, such as
added salt or sugars. Home-made food is already recommended in the last nutritional guidelines in
France and, contrary to exclusion diets, cooking can represent a form of a convivial time, allowing
a better quality of life with increased socialization. In addition, obesity is more and more frequent
in IBD patients [74] and food preparation from scratch may be associated with a decreased risk of
obesity [75] or decreased amount of dietary energy from ultra-processed food [76].
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Abbreviations
AIEC Adherent-invasive Escherichia coli
CD Crohn’s disease
CMC carboxymethylcellulose
EEN exclusive enteral nutrition
ESPEN European Society for Clinical Nutrition and Metabolism
FODMAP fermentable oligosaccharide, disaccharide monosaccharide, and polyol
HSD High-salt diet
IBD inflammatory bowel diseases
LPS liposaccharide
NFAT5 nuclear factor of activated T cells 5
NLRP NOD-like receptor pyrin
P80 polysorbate-80
SCFA short-chain fatty acid
SMAD small mothers against decapentaplegic
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Abstract: Patients frequently wonder whether their dietary pattern influences the course of
inflammatory bowel disease (IBD). Many patients even avoid certain foods that aggravate their
symptoms. Although interest in nutritional interventions is rising among physicians, the current
application of nutritional interventions in the IBD population is limited due to the lack of scientific
evidence from clinical trials. Several studies, however, have identified associations between diet, gut
microbiota, intestinal epithelial integrity, and mucosal immune responses. In patients consuming
predominantly a Western diet high in n-6 poly-unsaturated fatty acids (PUFAs), sugars, and meat,
and low in fruits and vegetables, an impaired gut epithelial barrier and disturbances in the intestinal
microbiota have been observed, resulting in a chronic mucosal inflammation. An anti-inflammatory
diet may restore this disbalance. In this review, we discuss the effects of diet on the composition of
the microbiota, the gut epithelial barrier function, and the mucosal immune system.
Keywords: inflammatory bowel disease; dietary modification; exclusive enteral nutrition; lifestyle
modification; Mediterranean diet
1. Introduction
Inflammatory bowel diseases (IBDs), consisting of Crohn’s disease (CD) and ulcerative colitis
(UC), are chronic immune-mediated disorders that can have a large impact on the wellbeing and
quality of life of patients worldwide [1,2]. More than 1.5 million Americans are affected by IBDs, as are
over 2.2 million Europeans [3], and the incidence of IBDs is increasing in newly industrialized countries
in Africa, Asia, and South America [4]. Both diseases are characterized by a relapsing-remitting disease
course, necessitating aggressive medical therapies in some cases [1,2].
Diet is important for patients with IBD. Patients often ask their physician whether the food they
eat can influence the course of their inflammatory bowel disease. Very little data is available to answer
this question. Data from studies in oncology show that eating or avoiding certain foods can increase or
decrease the risk for developing colorectal cancer and other digestive cancers, and that this is probably
related to the pro-inflammatory aspects of certain foods. This would suggest that nutrition may also
affect both the pathogenesis and the disease course of IBD.
Additionally, it appears that dietary patterns in the decades before the onset of CD have been
associated with the development of this disease. Patients who followed a healthy diet characterized
by high fruit, vegetable, and fish intake during high school were 50% less likely to develop CD [5].
High intake of sugar and soft drinks combined with a low intake of vegetables was associated with UC
risk [6].
These observations appear to be corroborated by observations in developing countries and among
immigrants from developing countries: adaptation to a Western lifestyle with a Western diet increases
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both the incidence and prevalence of IBD in these populations [7,8]. The Western diet is high in fat
(animal and milk fats, n-6 polyunsaturated fatty acids (PUFAs)) and refined sugars, and contains little
fiber and healthy fats (n-3 PUFA). Apart from increasing the risk of developing IBD, the disease course
may also be influenced by dietary patterns. Intake of a diet with a high fat content or a low ratio
of pro-inflammatory n-6 to anti-inflammatory n-3 fats was associated with a higher level of disease
activity [9–11].
This suggests that a Western diet is an environmental risk factor for developing IBD.
2. Diet, Symptoms, and Food Avoidance
A number of studies have assessed CD patients’ perception of the role of food and nutrients in
gastrointestinal symptoms. Kinsey and Burden [12] found that 42% of IBD patients reported that
food affected their symptoms “a lot” or “severely”, and 51% of the respondents indicated that diet
was important or extremely important as a means of controlling symptoms. Another study found
that an even higher percentage, around 70% of patients, thought that diet could trigger a disease
flare [13]. Spicy foods are often considered a potential culprit: in a study by Limdi et al., 80% of the
patients thought that eating food that was too spicy could result in a disease [14]. Specific items in
the diet may aggravate symptoms such as abdominal pain, bloating, and diarrhea, whereas other
dietary products alleviate these complaints. For instance, eating products with a high fat content,
raw vegetables, and fruits and drinking carbonated beverages were perceived to increase the risk of a
relapse by 40–50% of the patients [14]. The perceived relationship between specific foods and IBD
complaints and disease activity leads to a high level of food avoidance. Casanova et al. [13] found
that during remission, 77% of patients avoid certain foods, and this increased to 86% in patients with
active disease. The avoidance of certain products increases the risk of vitamin and other biochemical
deficiencies, and also increases the risk of malnutrition, which was estimated to occur in around 14%
of the IBD population [13]. Currently, only a diet low in fermentable oligosaccharides, disaccharides,
monosaccharides, and polyols (FODMAPS) has been shown to reduce complaints in a substantial part
of the IBD population [15].
3. Exclusive Enteral Nutrition
Although certain dietary patterns may be related to a higher risk of developing IBD or a higher
risk of disease activity, this does not show that dietary adjustments can influence the disease course
or induce remission in patients with active disease. High quality studies in this area are lacking,
and this is reflected in the results of a recent meta-analysis on the efficacy of the most studied
dietary intervention, exclusive enteral nutrition (EEN), in which all conclusions were based on
“very low quality evidence” [16]. EEN is a completely liquid formula containing all macro- and
micronutrients a patient needs. EEN formulas can be classified as elemental (monomeric—free
amino acids, glucose, oligosaccharides, and small amounts of essential fatty acids), semi-elemental
(oligomeric—dipeptides, tripeptides, disaccharides, and medium chain triglycerides) or polymeric
(whole protein, oligosaccharides, and long-chain triglycerides). Interventional studies have shown that
clinical remission and mucosal healing can be achieved when a patient’s diet is replaced by exclusive
enteral nutrition. However, the most successful studies have been performed in pediatric patients
(Table 1). In a prospective trial, 34 children with newly diagnosed CD received EEN. Twenty-six
patients completed at least 6 weeks of EEN. Early clinical remission at week 8 was achieved in 84% of
the patients and 76% of the patients had early biochemical remission [17]. Early complete or nearly
complete endoscopic mucosal healing was associated with a reduction in endoscopic relapse, anti-TNF
(tumor necrosis factor) use, and hospitalization 1 year after EEN. In a 10-week prospective open label
study on 37 children who had recently been diagnosed with active CD, 19 children received polymeric
EEN to induce remission while 18 children received corticosteroids to induce remission. [18]. At
week 10, clinical remission was comparable between both groups, but the number of patients with
mucosal healing was significantly higher in the polymeric EEN group than the corticosteroid group
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(p < 0.05). A recent meta-analysis of studies in pediatric patients (consisting of the Borrelli [18] and
Terrin [19] papers—see Table 1) found that 83% of pediatric patients achieved remission with EEN,
compared to 61% on steroids, but this reached statistical significance only in the per-protocol analysis
(Relative risk (RR) 1.43, 95% CI 1.03 to 1.97) [16]. EEN is currently the first-line treatment to induce
remission in children with active CD [20,21]. No placebo-controlled trials have been performed in
adults with active CD. However, in the controlled studies performed in adults comparing EEN with
steroids, steroids appeared to be more effective in inducing remission than EEN [22–24], and a recent
meta-analysis confirmed this: steroids were more effective in inducing remission than placebo (Table 1;
RR 0.65, 95% CI 0.52 to 0.82; p < 0.05) [16]. There was no difference in efficacy between elemental,
semi-elemental, and polymeric diets; however, a non-significant trend favoring very low fat and low
long-chain triglycerides was observed. The lack of efficacy in adults may be due to non-compliance.
Adults more often stop the EEN due to intolerance, and this may be related to the taste or to the method
of delivery (a nasogastric tube) or unpalatability when the EEN is ingested orally [16]. Based on these
studies, European Crohn and Colitis Organisation (ECCO) guidelines state that enteral therapy is only
appropriate as an add-on treatment to support nutrition and not as a primary therapy in adults with
active CD [25].
Table 1. Details of papers on EEN referenced in the manuscript.










Clinical remission EN: 45%
vs. CS: 73%, p < 0.05
Grover [17] 34 children Nutrison No control 8 weeks Clinical remission 84%;mucosal healing 42%
Borrelli [18] 37 children Polymeric diet(PD)
Corticosteroids
(CS) 10 weeks
Clinical remission PD: 79%
vs. CS: 67%, p = ns.
Mucosal healing PD: 74%
vs. CS: 33%, p < 0.05




90% vs. CS: 50%, p < 0.01
Maintenance of remission
Takagi [26] 51 adults Half-elemental diet(HED)
Regular Diet
(RD) 1 year
Relapse rate 1 year 35% in
HED vs. 64% in RD





Relapse rate: ED 53%,
6-MP 40%, control 73%













Induction: 69.4 in combo




CD: Crohn’s disease; EEN: exclusive enteral nutrition. For a full review of the efficacy of EEN in inducing remission
in active Crohn’s disease, please see Narula et al. [16].
EEN has also been successful in preventing relapse in children with quiescent disease [29]. In
adults, a prospective study randomly assigning 26 patients to a “half elemental” diet and 25 patients
to a free diet resulted in a significantly lower relapse rate in the “half elemental” diet group after a
mean follow-up of nearly 1 year compared to the patients who continued their own diet [26]. The
compliance to the assigned intervention was similar in the two groups. In a study on 95 patients
with CD in remission, 6-mercaptopurine (6-MP) was compared to an elemental diet and to a control
group [27]. After 24 months, both the elemental diet and the 6-MP were significantly more effective in
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maintaining quiescent disease compared to patients in the control group (p < 0.05). No significant
difference in the number of patients in remission was observed between the 6-MP and elemental diet
group, suggesting that both interventions were equally able to maintain remission, although this may
also be related to the relatively small sample size. A meta-analysis on EEN as an add-on treatment to
anti-tumor necrosis factor (TNF) therapy found that the combination improved outcomes compared to
anti-TNF without a dietary prescription [28]. Both the number of patients that reached remission as
well as the number of patients that were in remission after a year increased significantly when the
anti-TNF treatment was combined with the enteral nutrition (p < 0.01).
Together, this shows that enteral nutrition can induce remission, maintain remission, and improve
the efficacy of other treatments. However, limited palatability and tolerability limit the applicability of
this intervention.
4. Anti-Inflammatory Diet
Although EEN seems to reduce patients’ abdominal symptoms and inflammation [16–18], it is not
completely clear how treatment with EEN results in these beneficial effects. However, in general, three
mechanisms have been identified through which a diet could affect an inflamed bowel, although these
mechanisms will undoubtedly interact. The current understanding of CD pathogenesis points to a
continuum of interactions between the intestinal microbiota, the immune system, and the epithelial
barrier function, and all three are amenable to specific environmental factors, such as diet [30,31]. We
will discuss these three factors below.
5. Intestinal Barrier Function
Patients with active Crohn’s disease (CD) have an increased intestinal permeability. Even when
little inflammation is present, intestinal integrity may still be reduced. This is associated with an
elevated risk of a disease flare [32] and gastrointestinal complaints [33]. Intestinal permeability
is controlled via tight junctions (TJs). TJs seal the paracellular space between the epithelial cells,
thereby separating luminal content such as bacterial products and food antigens from the interstitium.
TJs are selectively permeable for water, ions, and small molecules, however, a small proportion of
luminal pathogens can cross the TJs. Patients that are susceptible to this translocated content develop
an exaggerated mucosal immune response, resulting in an increased gut permeability—a “leaky
gut” [34,35]. An increased intestinal permeability is also linked to the development of several diseases,
including cardiovascular disease, diabetes, and non-alcoholic fatty liver disease (NAFLD) [35–38].
Improving intestinal barrier function may reduce gastrointestinal complaints and decrease the risk
of a flare and the rise of metabolic diseases. The gut is continuously exposed to antigens in the food
we consume. These dietary antigens may interact with the gut microbiota, changing its composition.
This can result in an increased intestinal permeability, leading to an exaggerated immune response.
Pathogens such as Escherichia coli O127:H6 (EPEC) and O157:H7 (EHEC), and bacterial toxins from,
for instance, Clostridium difficile interfere with TJs between the epithelial cells, leading to an increased
permeability. Also, the non-pathogenic E. coli strain C25 induces defects in the TJ complexes [39].
On the other hand, in a mouse model of necrotizing enterocolitis, Bifidobacteria preserved TJs and
thereby intestinal barrier function [40]. The non-pathogenic yeast Saccharomyces boulardii supports
barrier integrity and stimulates regeneration of damaged intestinal tissue in different diseases [41].
Dietary interventions such as EEN may be able to influence intestinal permeability [42,43]. In vitro,
TNF-alpha decreased the TJ integrity of a monolayer culture. A polymeric formula completely restored
the intestinal integrity of these monolayers [44]. Interleukin-10 knockout mice with colitis treated with
EEN had an increased expression of TJs at a correct location and reduced epithelial apoptosis [45].
However, as discussed above, the lack of efficacy of EEN in adults may be due to the fact that EEN is
unpalatable and/or that EEN is administered via a nasogastric tube. More palatable oral diets may be
a solution for this problem. The Mediterranean diet (MD), rich in fresh vegetables, fruits, legumes,
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minimally processed whole-grains, nuts, fish, and olive oil, reduces systemic inflammation and is
associated with increased diversity in gut microbiota and intestinal integrity [37,46,47].
6. Gut Microbiota
Our intestines are colonized with large numbers of bacteria, archaea, viruses, and eukaryotic
microbes that form the gut microbiota [48]. The microbiota protects us against pathogens, regulates
local immune responses, and has an important impact on host metabolic functions. In the first three
years of life, the microbiota is shaped [49]. Next to antibiotic therapy and severe illness in these years,
diet influences the composition of the microbiota. The composition of the microbiota depends on
our dietary patterns, which can have both short-term and long-term effects on the variety of the gut
microbiota [50]. There is a wide variation in the gut microbiota composition in the elderly [51]. These
variations are associated with specific food patterns of these people and separate healthy elderly from
those in long-term residential care [50]. The microbiota of the latter has been shown to be significantly
less diverse than that of healthy elderly, resulting in increased frailty [50]. Changes in the diversity
of the microbiota have been correlated with an increased incidence of chronic inflammatory diseases
such as obesity [52], type 2 diabetes [53], cardiovascular disease [54,55], asthma [56], rheumatoid
arthritis [57], colorectal cancer [58], and IBD [59,60].
There is growing evidence that a predominantly Western diet, high in fat and refined sugars,
influences the composition of the microbiota. Consumption of high-fat milk and sugar-sweetened soda
is linked to a lower diversity, whereas buttermilk and high polyphenol content beverages are associated
with high microbiota diversity [61]. De Filippo et al., compared the gut microbiota of children aged 1–6
years living in Florence (Italy), where they consume a typical diet of the developed world, with children
in Boulpon, a village in Burkina Faso, where they eat a traditional rural African diet high in fibers [62].
The microbiota of the children from Boulpon comprised less Firmicutes and Enterobacteriaceae (Shigella
and Escherichia) compared to the children from Florence. Prevotella, Xylanibacter (Bacteroidetes), and
Treponema (Spirochaetes) were exclusively present in the microbiota of the children from Boulpon,
possibly as a result of high fiber intake. These bacteria can ferment xylan and cellulose, resulting in
the production of short-chain fatty acids (SCFAs). SCFAs are an important source of energy for the
mucosa, regulate homeostasis in the colon, and maintain an anti-inflammatory state [63]. Marchesi et
al. [64] demonstrated that CD patients have decreased levels of butyrate, an abundant bioactive SCFA,
and reduced levels of SCFAs in general in comparison to healthy subjects. A plant-based diet rich in
polysaccharides and low in fat and sugars may select for SCFAs-producing bacteria and may be used in
the maintenance of remission in patients with inflammatory diseases such as IBD. Microbial structures
can rapidly be altered by a change in diet. In a two-week food exchange trial, African Americans
consumed a high-fiber/low-fat African diet and rural Africans consumed a high-fat/low-fiber Western
diet [65]. “Africanization” of the diet led to a 2.5-fold increase of butyrate in the colon as a result of
fermentation of fibers by changes in microbiota, whereas in Africans consuming a Western diet, the
amounts of butyrate were reduced by 50%. In concordance, a study among 14 obese men showed that
diet-driven changes occurred within 3–4 days but were also reversed within the same time frame [66].
7. Immune Responses
The consumption of processed foods in developed countries has led to an excess of salt intake.
Increased dietary salt intake is a risk factor for the development of cardiovascular diseases and
autoimmune diseases through the induction of pathogenic T helper 17 (Th17) cells [67], a cell type
which plays a pivotal role in the pathogenesis of CD [30]. Mutations in the nucleotide-binding
oligomerization domain-containing protein 2 (NOD2) gene is associated with CD. NOD-like receptors
(NLRs) sense muramyl dipeptide (MDP), present in all Gram-negative and -positive bacteria, leading to
bacterial clearance. Mutations in the NOD2 gene, as seen in patients with IBD, are linked to less clearance
of bacteria and suppression of the anti-inflammatory cytokine interleukin (IL)-10 [68]. Another family
of innate immune receptors associated with IBD are the Toll-like receptors (TLRs). TLRs are expressed
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by dendritic cells, and TLR2 and TLR4 are upregulated under inflammatory conditions [2]. TLR2 and
TLR4 are increased in the mucosa of patients with IBD compared to healthy controls, resulting in the
loss of mucosal homeostasis [68]. Specific dietary patterns can influence the expression of both families
of innate immune receptors. For instance, a diet high in fat and carbohydrates increased the expression
of TLR2 and TLR4 [69]. Plasma concentrations of lipopolysaccharide (LPS) were also increased [69].
The consumption of orange juice during this meal, however, prevented the enhanced expression of
both TLRs and LPS. This was probably due to the reactive oxygen species (ROS)-suppressive effect
of flavonoids (naringenin and hesperidin) in the orange juice. A meal high in fibers did not result in
an increased concentration of LPS and the induction of TLR2 and TLR4. The authors concluded that,
although the content of LPS in a high-fiber meal is comparable to a meal high in fat and carbohydrates,
the inflammatory nature of the latter possibly reduced the integrity of the mucosal barrier that normally
prevents the translocation of bacterial products from the gut. In a mouse model of CD, a Western diet
induced gene transcription of NOD2 and increased gut permeability, allowing the adherent-invasive
E. coli to colonize, which resulted in an inflammatory state [70]. Together, these data suggest that
a Western diet, high in salt, fat, and carbohydrates, may contribute to the development of IBD in
predisposed patients, and to the loss of remission in patients with quiescent disease.
8. A Mediterranean Diet as an Anti-Inflammatory Diet
A Mediterranean diet (MD) is able to promote a healthy microbiota, reduce systemic inflammation,
and reduce intestinal permeability. Two clinical trials evaluating the effect of a MD have been performed
in patients with rheumatoid arthritis (RA) and were systematically reviewed by Forsyth et al. [71].
McKellar et al. [72] assigned patients with RA aged 30–70 years to either a 6-week hands-on cooking
workshop (2 h per week delivered by nutritionists and teaching staff from local colleges), whereas
the control group received a hand out with the general principles of a healthy diet. In this study, the
MD reduced symptoms and improved physical functioning. The second study was a randomized
controlled trial by Sköldstam et al. [73]. In this study, patients were randomized between a Cretan diet
versus an ordinary Western diet. Symptoms, physical functioning, and biomarkers of inflammation
(i.e., C-reactive protein (CRP)) improved in the intervention arm. The authors of the systematic review
concluded that joint pain could be reduced and joint function could be improved using a MD. In
addition, the risk of cardiovascular disease, which is substantially elevated in RA patients, could also
be reduced by a MD. Our group recently performed a trial in 38 IBD patients using a group-based
Mediterranean diet intervention (Molendijk et al., ECCO 2019) [74]. Patients with quiescent IBD that
were willing to change their lifestyle, including dietary habits, were enrolled. Support was provided
during three instruction and feedback days, and patients were able to use an online peer support
platform. In this study, we found that 70% of patients were able to alter their dietary habits toward a
more Mediterranean pattern. Second, we found that quality of life, as assessed with the short-IBD
questionnaire, was increased and CRP was decreased in the active group. The magnitude of the
changes in CRP and quality of life was correlated to the magnitude of the dietary change.
Together, these data suggest that a MD can increase the wellbeing of patients with inflammatory
disorders. Whether a MD can alter the disease course or reduce inflammation is uncertain. However,
the fact that the CRP was reduced in the Mediterranean arm is in this respect encouraging.
9. Conclusions
Recent studies have shown promising results of dietary alterations, such as the introduction of a MD,
on the three most important players in the pathogenesis of IBD: intestinal permeability, gut microbiota
composition, and inflammatory responses. Although patients are interested in lifestyle advice and a
subset of physicians is eager to employ lifestyle-related interventions, the current application of lifestyle
interventions in clinical practice is limited. This has a number of causes, such as lack of evidence-based
interventions (which intervention works) and evidence-based practices (how to apply the intervention
in clinical practice). What is clear is that networks have to be established, with physicians of
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different backgrounds, dieticians, physical therapists, and (physician-)scientists as participants. These
collaborations will facilitate the development and implementation of these interventions.
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Abstract: Colorectal cancer (CRC) remains the third most common cause of cancer-related death in
the United States and the fourth globally with a rising incidence. Inflammatory bowel disease (IBD)
is a chronic immunologically mediated disease that imposes a significant associated health burden,
including the increased risk for colonic dysplasia and CRC. Carcinogenesis has been attributed to
chronic inflammation and associated with oxidative stress, genomic instability, and immune effectors
as well as the cytokine dysregulation and activation of the nuclear factor kappa B (NFκB) signaling
pathway. Current anti-inflammation therapies used for IBD treatment have shown limited effects on
CRC chemoprevention, and their long-term toxicity has limited their clinical application. However,
natural food-based prevention approaches may offer significant cancer prevention effects with very
low toxicity profiles. In particular, in preclinical and clinical pilot studies, strawberry and black
raspberry have been widely selected as food-based interventions because of their potent preventive
activities. In this review, we summarize the roles of strawberry, black raspberry, and their polyphenol
components on CRC chemoprevention in IBD.
Keywords: colorectal cancer; inflammatory bowel disease; colorectal cancer; dysplasia;
berries; chemoprevention
1. Introduction
Inflammatory bowel disease (IBD) (e.g., Crohn’s disease and ulcerative colitis) is a chronic
immunologically mediated disease that develops in interactions between genetics, immunology,
the environment, and the microbiome [1,2]. IBD is highly prevalent in North America and Europe,
affecting about 1.3 million people in the United States and 2.2 million people in Europe [1]. Moreover,
the rising prevalence of IBD has been reported across other countries worldwide. Notably, patients
with IBD are at the increased risk of developing colorectal cancer (CRC), which further increases the
urgency of understanding and treating this disease [3].
In IBD, chronic inflammation induces oncogenic mutations, genomic instability, immune
microenvironment changes, early tumor promotion, and angiogenesis. These factors are likely
related to the increased risk of CRC in IBD [4]. Importantly, supporting the association between chronic
inflammation in IBD and CRC risk, the results of studies employing 5-aminosalicylate (5-ASAs) to target
and reduce inflammation identified some chemopreventive effects in IBD [5]. In population-based
Nutrients 2019, 11, 1261; doi:10.3390/nu11061261 www.mdpi.com/journal/nutrients242
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cohorts, the incidence of CRC in patients with ulcerative colitis was 2.4-fold higher than in the
controls [6]. Furthermore, some results suggested that at 10 years after the initial onset of ulcerative
colitis around 2% of patients with ulcerative colitis developed CRC: 8% after 20 years and 18% after
30 years of disease duration [7]. Previous data also showed that 2.9% of Crohn’s disease patients
developed CRC within 10 years after the initial onset of the disease, and that percentage increased to
5.6% after 20 years and 8.3% after 30 years. Due to multifocal tumors and cell histopathology, CRC that
develops in IBD patients tends to have a worse prognosis and survival rate compared to sporadic CRC
in the advanced stage [8]. Additionally, the mean age for developing CRC in IBD patients (40–50 years)
tends to be lower than the mean age for sporadic CRC (60 years) [4].
Due to the increased risk and poorer prognosis associated with CRC in individuals with IBD,
its early detection and prevention are essential. In adults aged 50–75 years with an average risk of
CRC, the US Preventive Services Task Force recommends yearly CRC screening by a fecal occult blood
test (FOBT), sigmoidoscopy every five years, and colonoscopy every 10 years. In patients with IBD,
a colonoscopy is recommended every one to two years beginning at 8–10 years from the diagnosis of
the disease as well as multiple colonic biopsy specimens for dysplasia detection to screen for dysplasia
or CRC [9]. Although chemoprevention is another important goal for IBD-related CRC management,
the current therapies used in IBD have shown little to no effect, and the long-term toxicity associated
with these treatments limits their clinical application for this purpose.
Diets that are high in animal fat and low in fruit and vegetables can be important triggers of
both IBD and cancers [10,11]. Based on the associations between diet and cancers, natural food-based
prevention approaches may represent a promising strategy. Notably, food-based approaches involving
components of fruits and vegetables, vitamins, minerals, probiotics, and herbal medicines have shown
potential cancer prevention effects with low toxicity profiles. Flavonoids, which are a major class of
polyphenols that occur naturally in fruit and vegetables, have shown promising in vitro anti-colon
cancer effects. Additionally, several case-control and cohort studies have verified the inverse association
between flavonoid intake and CRC [12–14]. In particular, berries are a good source of polyphenols,
especially anthocyanins, micronutrients, and fiber, which suggests that these foods may be associated
with benefits for cardiovascular and immune health as well as chemoprevention [15]. Moreover,
strawberry and black raspberry have been widely selected for food-based interventions in preclinical
and pilot clinical studies because of their potent activity in the prevention of oral, esophageal, colon,
skin, and prostate cancer [16–20]. Strawberry is the most commonly consumed berry type on the current
market. Our previous study showed the significant chemoprevention effects of strawberry in CRC
mouse model and its role in inflammation inhibition [18]. We also demonstrate that black raspberry
inhibits oxidative stress, the inflammation mediators, cyclooxygenase-2 (COX-2) and inducible nitric
oxide synthase (iNOS) and exhibits superior anti-cancer effects than inhibitors of COX-2 and iNOS
in an animal model [21,22]. In this review, we summarize the roles of strawberry, black raspberry,
and their polyphenol components on CRC chemoprevention in IBD.
2. Animal Models of Inflammatory Bowel Disease and IBD-Related Colorectal Cancer
Genetic engineering models can produce IBD in animals, such as muc-2 deficiency, muc-2/C3GnT
dual deletion, muc-2/Core 1-derived O-glycans deficiency, P-gp deficiency, T-bet knockout, IKK-γ or
IKK-β deletion, STAT3 deficiency, STAT3/IL-22 dual deficiency, XBP1 deletion, IL-10 deficiency, and IL-7
overexpression [2,11]. These targeted genes are responsible for epithelial barrier function, intestinal
permeability, oxidative stress, cytokine, inflammation and immune effector regulation signaling
pathway, and gut microflora etc. Additionally, colonic epithelium injures, ectogenic immunogenic
response, adoptive transfer of naïve CD4+ T cells to immune deficiency animals are strategies to induce
IBD in animals. In Dextran sulfate sodium (DSS) model, DSS in drinking water is toxic in the epithelial
lining of the colon and produce severe colitis. DSS treatment combined with gene deficiency in immune
effectors regulation, cytokine response and immune response signaling pathways can enhance the
inflammation in animals. Intrarectal injection of the haptenating agent 2,4,6-trinitrobenzene sulfonic
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acid (TNBS) or 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone) can cause ulcerative colitis
with different features. The inflammation in the TNBS model is regulated by TH1-mediated immune
response with CD4+ T cells, neutrophils and macrophages infiltration showing symptoms including
severe diarrhea, weight loss, and rectal prolapse similar to Crohn’s disease. TNBS model is used
for the immune-related studies for Crohn’s disease. The oxazolone model driven by NKT cells and
IL-13 is considered as a valuable model for ulcerative colitis. The regulatory T cell deficiency in
naïve CD4+ T cells is a critical factor for inflammation in the transfer model. This model is ideal for
immunoregulation and regulatory T cell research.
In studies on colon carcinogenesis and chemopreventive screening interventions for CRC in IBD,
gene engineering mouse model such as apc mutation, apc deletion, smad mutation, smad 3 knockout,
rag2-deficiency, k-ras mutation have been used [23]. In chemically induced preclinical models, murine
treated with azoxymethane (AOM)/DSS has been a commonly used model for IBD-related CRC
research for over a decade. AOM is a metabolite of 1,2-dimethylhydrazine (DMH) and the carcinogen
to induce CRC in murine. It is important to note that AOM-induced tumors showed histopathological
characteristics similar to human CRC, such as frequent K-Ras, β-catenin mutation, and microsatellite
instability [24]. When combined with AOM, DSS works as a promoter of colorectal carcinogenesis
through an initial acute inflammation phase. To induce colon carcinogenesis in murine, a single
intraperitoneal injection of AOM at 10 mg/kg body weight or less can be given, followed by one to three
cycles of 2% or 3% DSS in drinking water. In this method, tumors typically form 14 weeks after the
AOM injection. Multistep tumor histogenesis can be efficiently reproduced in the AOM/DSS murine
model. As found in our former studies, intraepithelial neoplasia, including changes ranging from
dysplasia to adenoma and adenocarcinoma, were observed (Figure 1) [18]. T lymphocytes and other
immune cells typically found in CRC patients are also frequently observed in tumors developed in
AOM/DSS murine models. Therefore, AOM/DSS murine models are important for the investigation of
inflammation-induced colon carcinogenesis and chemoprevention strategy screening.
Figure 1. Histopathology of azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal
cancer (CRC) in mice. (A) The representative macroscopic appearance of a mouse colon
treated with AOM/DSS; (B) The representative hematoxylin and eosin stained sections showing
different histopathology of mouse colon, including normal (a), dysplasia (b), adenoma (c),
and adenocarcinoma (d).
3. Molecular Mechanisms Associated with Chronic Inflammation and Colorectal Cancer
3.1. Inflammation-Dependent Oxidative Stress
Previous studies identified that carcinogenesis in IBD was related to reactive nitrogen intermediates
(RNI) and reactive oxygen species (ROS) [3,25,26]. RNI and ROS are produced by neutrophils and
macrophages, and they may cause oxidative damage to DNA, proteins, and lipids in the surrounding
mucosal cells [3,23,24]. RNI, an indicator of nitrosative stress, is associated with nitrotyrosine,
which is formed when peroxynitrite interacts with protein tyrosine. Hence, nitrotyrosine can serve
as an important biomarker. In murine treated with AOM/DSS, more numerous and concentrated
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nitrotyrosine positive cells were observed as well as the greater expression of iNOS [18]. ROS are small
oxygen-derived molecules produced by various biochemical and physiological oxidative processes,
including superoxide (O2−), hydroxyl (OH), peroxyl (RO2), and alkoxyl (RO), hypochlorous acid
(HOCl), ozone (O3), singlet oxygen (O2), and hydrogen peroxide (H2O2) [21]. The imbalance in
the generation and elimination of ROS and RNI was found to lead to oxidative stress. Hepatic
malondialdehyde (MDA) levels, which are indicators of oxidative stress, were increased in murine
treated with AOM/DSS [27]. Enzymatic and nonenzymatic antioxidants, such as superoxide dismutase,
catalase, glutathione peroxidase and glutathione reductase, were decreased in an AOM/DSS mouse
model [27]. Deficiencies in antioxidant genes, such as transcription factor NF-E2-related factor 2 (Nrf-2)
and glutathione peroxidase 3 (Gpx3), were associated with increased numbers of aberrant crypt foci
and tumors with higher dysplasia [28,29].
In patients with IBD-associated CRC, increased RNI and ROS concentrations were related to
oxidative damage and active DNA damage response at cancer sites [30,31]. In AOM/DSS mouse
models, knocking down genes that code for DNA damage repair-related enzymes, e.g., Alkyladenine
DNA glycosylase (Aag), mutY DNA glycosylase (Mutyh), 8-oxoguanine DNA glycosylase 1 (Ogg1),
may increase CRC incidence [9,30,32]. Overall, there is sufficient evidence from animal studies to
support the carcinogenic role of inflammation-dependent oxidative stress in CRC developed from IBD.
3.2. Genomic Instability
Genomic instability includes base pair mutation, microsatellite instability, chromosome
abnormality, gene fusion, gene copy number change, and other small or large structural variations.
Inflammation-dependent oxidative stress is also related to high genomic instability in IBD. Genomic
instability profiles were found significantly different between IBD-related CRC and sporadic CRC [33].
For example, mutations in IDH1 R132, BRAF V600E; the amplification of FGFR1, FGFR2, ERBB2; and the
fusion protein EML4-ALK are more commonly found in IBD related CRC compared to sporadic CRC.
Microsatellite instability formed by the malfunction of genes coding for DNA repair mismatch enzymes
was found to be a clinical feature of Lynch syndrome and sporadic CRC, but not IBD-related CRC [34].
Little overlap between microsatellite instability in IBD-related CRC and sporadic CRC has been
found [35,36]. Aneuploidy is higher in IBD-related CRC than in sporadic CRC, and it could function
as an independent factor for the prediction of dysplasia and CRC developed in IBD patients [25,37].
Due to the higher inflammation-dependent oxidative stress and genomic instability in IBD, the critical
molecular events in CRC development in sporadic CRC differ from those in IBD-related CRC. For
example, the loss of heterozygosity in chromosome 17p, the locus of TP53 (a well-known tumor
suppressor) and mutations of TP53 occurred earlier in IBD-related CRC than in sporadic CRC [3,38].
Other study found that the frequency of TP53 mutation in inflamed, non-dysplastic colonic epithelia
was correlated with increased oxidative stress [39]. TP53 mutation may be caused by oxidative stress
and inflammation in IBD, which promote carcinogenesis of IBD-related CRC. Inflammation-dependent
oxidative stress and genomic instability play critical roles in IBD-related carcinogenesis.
3.3. Cytokines
A pro-inflammatory microenvironment also contributes to carcinogenesis in IBD. Studies on
IBD-associated CRC patients and AOM/DSS mouse models showed that activated neutrophils,
fibroblasts, dendritic cells, macrophages, and T cells were present in IBD related CRC tissue [40–43].
The cytokines released by these effectors in a pro-inflammatory microenvironment also showed distinct
roles in carcinogenesis in IBD. For instance, the tumor necrosis factor (TNF), which is released by
monocyte/macrophage lineages and plays an important role in cell proliferation, differentiation and
death, was shown to be increased in an AOM/DSS mouse model [44]. Hence, TNF-α antagonists could
significantly reduce the number and size of tumors in this model [18,45]. Interleukin 1 (IL-1)/interleukin
6 (IL-6) axis activation was found to be involved in IBD related CRC carcinogenesis. In IBD, IL-6
is mainly released by monocytes, macrophages, and by T and B lymphocytes. IL-1 produced by
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neutrophils has also been shown to promote the development of CRC in IBD by inducing IL-6
production in intestine-resident mononuclear phagocytes [43]. High expressions of IL-1β and IL-6
were found in an AOM/DSS mouse model [18]. Knocking down IL-6 in AOM/DSS mouse models
reduced the number of tumors developed [46,47]. The IL-23/IL-17 axis, including IL-17A, IL-17F, IL-22,
and IL-23, are also important cytokines in IBD. The elevated IL-17A and IL-17F in IBD patients are
released by Th17 cells. The successful development of Th17 cells to induce chronic inflammation was
found to be dependent on the high levels of IL-21, IL-23, IL-6, and TGF [48,49]. IL-23 was found to
be essential for the expression of TNFα, IL-6, and TNFγ in the pro-inflammatory microenvironment.
These cytokines have the potential to bind to receptors or transcriptional factors in order to activate
related signaling pathways to promote carcinogenesis.
3.4. NFκB
A key molecular component in the pro-inflammation molecular network is nuclear factor kappa
B (NFκB). Under normal circumstances, NFκB dimers remain in the cytoplasm by binding to the
specific inhibitors of NFκB (IκBs). Cell stimulation activates IκB kinase (IKK) subunits (α, β and
γ) to induce the degradation of IκB proteins. The unbound NFκB then translocates to the nucleus
and initiates transcription of several hundred target genes to promote the carcinogenesis of CRC.
Lipopolysaccharide (LPS), and pro-inflammatory cytokines TNFα, IL-1, and CD40 ligand can activate
the NFκB pathway. In inflammatory cells, NFκB is generally activated by reacting to bacteria, virus,
and necrotic cell production as well as some inflammatory cytokines. The activation of NFκB could
induce its downstream pathways including growth and survival signals as well as angiogenic factors.
In malignant cells, NFκB reacts to inflammatory cytokine, growth, and survival signals and angiogenic
factors released from inflammatory cells and regulate cell cycle related genes, thus, induce apoptosis
inhibition effects and promote invasion and metastasis. Specifically, in AOM/DSS mouse models,
studies found that in myeloid cells, IKK-β-driven NFκB promoted the production of cytokines that
acted as growth factors in pre-malignant enterocytes. In enterocytes, IKK-β-driven NFκB was found to
activate anti-apoptotic genes, thereby suppressing the apoptotic elimination of pre-neoplastic cells.
3.5. Microbiome
The alteration in composition and function of bacterial microbiota and fungal microbiota are
considered as significant factors for IBD development [50,51]. The gut microbiome is linked to chronic
inflammation in IBD [52]. The cytokines and increased ROS production induced by inflammation
favors the outgrowth of some bacteria or kill others, and shape the gut microbiome. The gut microbiome
plays an important role in the host immune system. Gut microbiome regulates the function of T help
cell profile, CD4+ Treg cell, the production of several interleukins, such as (IL)-17A, IL-17F, IL-21,
and IL-22. Compared to healthy people, IBD patients have more bacteria with inflammatory function
and fewer bacteria with anti-inflammatory function [50,51,53,54]. Bacteria with anti-inflammatory
effects such as Faecalibacterium prausnitzii, Blautia faecis, Roseburia inulinivorans, Ruminococcus torques,
and Clostridium lavalense decreased and adhesion-invasive Escherichia coli with pro-inflammatory effects
increased in IBD patients.
4. Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease with
Anti-Inflammation Pharmaceuticals
One of the first therapies used to treat IBD is 5-ASA, which inhibits the production of
cyclo-oxygenase and prostaglandin, thromboxane synthetase, platelet activating factor synthetase,
and IL-1 to reduce the acute inflammatory response [5,52]. However, a systematic review and
meta-analysis conducted by Velayos and colleagues that assessed 5-ASA for CRC chemoprevention
showed only a slight preventative role of 5-ASA in CRC development [52]. The chemopreventive effects
of corticosteroid are not clear, as toxicities from long-term use have limited its implementation as a
chemopreventive agent [5]. A major trial that was conducted to assess the roles of immunomodulators,
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such as azathioprine, 6-mercaptopurine, and methotrexate, showed no significant protective effects on
CRC [5]. Both azathioprine and 6-mercaptopurine can inhibit purine nucleotide synthesis, metabolism
and the DNA/RNA production in immune effectors, and methotrexate can inhibit DNA/RNA production
by competitively inhibiting dihydrofolate reductase during tetrahydrofolate synthesis. Thus, these
drugs may inhibit DNA/RNA productions in other somatic cells and increase the risk of gene structure
change and genomic instability. The side effects of immunomodulators have been associated with
increased risks of lymphoma and non-melanomatous skin cancers, thus, limit the use of these
medications in IBD patients in the clinical setting. NSAIDs, which inhibit the conversion of arachidonic
acid to prostaglandins in the cyclo-oxygenase-2 pathway, have some chemoprevention effects on CRC.
The U.S. Preventive Services Task Force (USPSTF) recommends aspirin for adults aged 50–59 to prevent
CRC. However, most of the IBD patients are diagnosed in their 20 s and 30 s [55], and USPSTF didn’t
recommend aspirin for adults younger than 50 to take aspirin for colon cancer prevention. The role
of aspirin in chemoprevention of IBD related CRC is limited. Moreover, several pieces of evidence
showed that NSAIDs promote IBD development [2]. Overall, agents that target inflammation have
shown modest results in preventing CRC development in IBD patients.
The complexity of the inflammatory pathways and multiple processes involved in CRC
carcinogenesis indicates that a multitude of targets exist; hence, new chemoprevention agents are
needed to address this issue. The additive and synergistic activities of multiple bioactive phytochemicals
in natural food products may have greater overall efficacy and safety in cancer prevention. Hence,
in the following section, we discuss the chemoprevention effects of black raspberry and strawberry
on CRC.
5. Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease with Berries
5.1. Efficiency of Strawberry and Black Raspberry in Cell Lines and Animal Models
The major investigational models and findings on the chemoprevention effects associated with
strawberry and black raspberry are summarized in Table 1. The black raspberry extract showed
anti-cancer activity in HT-29 colon cancer cells by regulating the cell cycle and apoptosis signaling
pathways [56,57]. In the DSS-treated ulcerative colitis mouse model, the short-term black raspberry
intervention reduced the degree of mucosal ulceration, suppressed the levels of pro-inflammation
cytokines TNF-α and IL-1β, and inhibited the COX-2 and NFκB signaling pathways [58]. When
the berry intervention was extended for a longer period of time, the number of macrophages and
neutrophils infiltrating the colon tissue decreased and the hypermethylation of tumor suppressor
genes increased [59]. In another model of ulcerative colitis using IL-10 knockout mice, a diet of 5%
black raspberry was shown to significantly reduce ulceration in colonic mucosa and submucosa, which
are associated with aberrant epigenetic dysregulation in the Wingless/Integrated (Wnt) signaling
pathway [60].
Table 1. Preventive effects of black raspberry and strawberry on Inflammatory Bowel Disease (IBD)
and CRC.
Systems Major Findings Ref.
Black Raspberry
1. CRC Cell Lines
HT-29 /HT-116 cell lines Regulating cell cycle and apoptosis [56,57]
2. Animal Models of IBD
DSS treated mouse Colonic epithelium acute injury↓, ulceration↓,TNF-α and IL-1β↓, COX2 and NFκB↓ [58]
DSS treated mouse
Ulceration↓, macrophages and neutrophils
infiltrated the colon tissue↓, NFκB↓, Dkk3↑,
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Table 1. Cont.
Systems Major Findings Ref.
IL-10 knockout mice Ulceration↓, Wnt pathway↓, wif1, sox17, andqki↑,dnmt3b, hdac1, hdac2, and mbd2↓ [60]
3. Animal Models of IBD-Related CRC
Mouse epidermal JB6Cl41 cells AP-1, NFκB, and COX-2↓ [61,62]
AOM induced rat model ACF multiplicity↓, total tumor multiplicity↓,urinary 8-OHdG↓ [63]
Muc2−/−mice COX-2, TNF-α, IL-1, IL-6, and IL-10 ↓ [64]
4. Clinical Studies of CRC
CRC patients GM-CSF and IL-8↓, Ki-67↓, apoptosis↓ [65]
CRC patients Wnt pathway↓ (SFRP2, WIF1, β-catenin,E-cadherin), DNMT1↓ [66]
Strawberry
1. CRC Cell Lines
HT-29 cell lines Proliferation↓, cell apoptosis and p21WAF1↑ [57,67]
CaCo-2 Proliferation↓ [68]
HCT-116 Proliferation↓ [69]
2. Animal Models of IBD
Gum acacia induced IBD rats
Disease activity index↓, lesion scores↓,
antioxidant enzymes myeloperoxidase↑, tissue
catalase↑, superoxide dismutase↑
[70]
3. Animal Models of IBD-Related CRC
AOM/DSS mouse
Tumor incidence↓, nitrosative stress↓, TNF-α,
IL-1β, IL-6, COX-2 and iNOS ↓, PI3K, Akt, ERK
and NFκB↓
[18]
Note: ↓, decrease; ↑, increase.
In mouse epidermal JB6Cl41 cells, carcinogen BaP diol-epoxide (BPDE) treatment activated the
activator protein 1 (AP-1), NFκB, and COX-2, which were then inhibited by the methanol extract
of black raspberry [61,62]. In an AOM-induced aberrant crypt foci rat model, black raspberry
diets significantly reduced the aberrant crypt foci multiplicity, total tumor multiplicity, and urinary
8-hydroxy-2′-deoxyguanosine (8-OHdG) levels [63]. A black raspberry diet was also significantly
associated with reduced expression of COX-2 and pro-inflammatory cytokines TNF-α, IL-1, IL-6,
and IL-10. Interestingly, when it was compared to the mechanism associated with tumor development
in Apc1638+/−mice, the inhibition of β-catenin was found only in Apc1638+/−mice [64].
Strawberry extracts were shown to inhibit HT-29 proliferation by stimulating cell apoptosis
and p21WAF1 [57,67]. Strawberries also showed significant anti-tumor effects on CRC cells CaCo-2
and HCT-116 [68,69]. In a gum acacia-induced IBD rat model, ethanolic extract of Fragaria vesca,
a wild strawberry, decreased the disease activity index and lesion scores and increased antioxidant
enzymes including myeloperoxidase, tissue catalase and superoxide dismutase [70]. In the AOM/DSS
mouse model, 2.5%, 5%, or 10% (wt%) lyophilized strawberry significantly decreased tumor incidence,
suppressed nitrosative stress, decreased the inflammation mediators TNF-α, IL-1β, IL-6, COX-2 and
iNOS, and inhibited the phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt (Protein Kinase
B), extracellular signal-regulated kinase (ERK), and NFκB [18].
In comparison to other berries, black raspberry and strawberry showed the potential for superior
effects in CRC cell lines. In a study that compared the pro-apoptosis effects of six popularly consumed
berries (blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry), black
raspberry and strawberry showed the most significant pro-apoptotic effects in CRC cell lines [57].
In another study that compared different berry extracts, strawberries showed the best anti-proliferation
effects with an EC50 value of 20 ug/mL [68].
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5.2. Efficiency of Black Raspberry in Clinical Studies
It is reported that a phase I study with black raspberry has been conducted in patients with
CRC. The overall objective of this study is to identify measurable genetic and epigenetic biomarkers
modulated by black raspberry in patients with CRC. This study demonstrates that 60 g of black raspberry
powder per day for nine weeks significantly modulate the Wnt pathway through demethylating tumor
suppressor genes SFRP2 and WIF1, and decrease the expression of β-catenin and E-cadherin. Black
raspberry also decreases the expression of DNMT1, GM-CSF and IL-8 as well as the proliferation of
biomarker Ki-67 and apoptosis [65,66]. The reports on the effects of strawberry on CRC or IBD are
not available.
5.3. Major Bioactive Components in Berries
Anthocyanins are flavonoid compounds that are responsible for the colors of most fruits and
vegetables, and they contribute to the protective effects of fruits and vegetables against chronic diseases
and cancer (Figure 2). According to our previous studies, anthocyanins are the main components
in strawberry and black raspberry (Table 2) [18,22]. Among the anthocyanins, cyanidin rutinoside
is the most abundant in black raspberry, whereas pelargonidin glucoside is the most abundant in
strawberry. Pelargonidin rutinoside is the only anthocyanin that has been identified in both black
raspberry and strawberry. Following anthocyanins, ellagic acid and derivatives are the second most
abundant components of strawberry although they are rare in black raspberry. Among ellagic acid
and its derivatives, agrimoniin is the main component of strawberry. Additionally, ellagitannins
account for about 10% of the phytochemical components in black raspberry and strawberry. Flavonols
have also been identified in both black raspberry and strawberry, but in much lower concentrations
than anthocyanins.
Figure 2. Structure of anthocyanins. (A) The structural classification of the six most common
anthocyanins; (B) The structural classification of the four most common anthocyanins identified in
strawberry and black raspberry.
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pelargonidin glucoside 367.7 41.1 cyanidin rutinoside 2924.7 58.2
pelargonidin malonyl glucoside 83.9 9.4 cyanidin xylorutinoside 916.3 18.2
pelargonidin rutinoside 55.3 6.2 cyanidin glucoside 245.1 4.9
cyanidin glucoside 14.9 1.7 cyanidin sambubioside 103.5 2.1
pelargonidin rutinoside 38.3 0.8
130.4 58.4% 4227.9 84.2%
Ellagitannins Ellagitannins
ellagitannin 64.1 7.2 sanguiin H6 173.2 3.4
ellagitannin 11.4 1.3 ellagitannin 783-1 101.1 2.0
ellagitannin 23.1 2.6 ellagitannin 933-2 75.8 1.5
Lambertianin 20.3 2.3 elagitannin 783-2 75.8 1.5
ellagitannin 935-1 62.8 1.3
ellagitannin 933-1 50.5 1.0
Lambertiannin 31.3 0.6
ellagitannin 935-2 7.9 0.2
118.9 13.3% 578.5 11.5%
Ellagic acid and derivatives Ellagic acid and derivatives
Agrimoniin 144.5 16.2 methyl ellagic acid pentoside 16.0 0.3
ellagic acid rhamnoside 23.1 2.6 ellagic acid 9.3 0.2
ellagic acid 7.3 0.8 ellagic acid rhamnoside 5.8 0.1
myricetin hexoside, EA
derivative (coelution) 3.8 0.1
174.9 19.5% 34.8 0.7%
Flavonols Flavonols
quercetin hexuronide 58.8 6.6 quercetin hexuronide 82.2 1.6
kaempferol glucoside/hexuronide 14.5 1.6 rutin (quercetin rutinoside) 75.4 1.5
kaempferol malonyl hexoside 5.1 0.6 quercetin xylorutinoside 24.2 0.5
78.4 8.8% 181.8 3.6%
Berry extracts and anthocyanin compounds have been studied both in vivo and in vitro.
Table 4 provides a summary of the role of anthocyanins in CRC cell lines or animal models.
Anthocyanin-enriched fractions from black raspberry inhibited cell growth in HT-29 and HCT-119
cells [57,67,69,71–93]. In CRC, an anthocyanin-enriched extract of black raspberry showed effects
similar to black raspberry powder on CRC cell lines in suppressing cell proliferation, inducing apoptosis,
decreasing the activity of DNMT1 and DNMT3B and of demethylate CDKN2A, SFRP2, SFRP5 and
WIF1 in the Wnt pathway [60,71]. Cyanidin-3-glycoside, which is the anthocyanin found in black
raspberry, decreased DNA strand breakage in human colon epithelial cells (HCEC), and it reduced
cytotoxicity induced by peroxyl radicals by suppressing apoptosis and decreasing the sub-G1 phase of
the cell population in Caco-2 CRC cells [72,73]. Cyanidin-3-O-beta glucopyranoside and its aglycon
form, cyanidin chloride, was shown to have the potential to function in inhibiting cell growth and
proliferation and in decreasing the ROS level in Caco-2 cells [74]. Strawberry extracts also showed cell
growth and proliferation inhibition effects, antioxidative effects, and p21WAF1 suppression effects
in HT-29, HCT-116 cells [57,66,70]. The anthocyanins identified in other fruit and vegetables that
showed anti-cancer effects in CRC cells lines included the anthocyanins found in black raspberry
and strawberry.
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Table 3. Effects of anthocyanins in IBD and IBD-related CRC.
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cyanidin-3-glycoside Cell lineHCEC Decreased DNA strand breakage cyanidin-3-glycoside [72]
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Table 4. Effects of anthocyanins in IBD and IBD-related CRC.
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The distribution of anthocyanins has been found in almost all tissues. The black raspberry
phytochemicals, cyanidin-3-rutinoside and cyanidin-3-xylosylrutinoside, have been detected in oral
cancer tissues in patients after the administration of oral troches containing freeze-dried black raspberry
powder as well as in prostate tissue in mice models after a diet of black raspberry powder [94,95].
Importantly, bioavailability and pharmacokinetic studies of strawberry anthocyanins showed that
only modest amounts of ingested anthocyanins were absorbed from the upper small intestine. Most
phytochemicals enter the colon where the substantial microbial metabolism and interaction with
the colonic epithelium take place [18]. Protocatechuic acid (PCA) is one of the main metabolites
of anthocyanins that can be absorbed by animals and humans. PCA significantly inhibited cell
proliferation and colony formation in colon cancer SW 480 cells [75]. PCA also prevented diarrhea and
bleeding in DSS-treated rats, and it decreased pro-inflammatory cytokines, nitric oxide concentration,
and oxidative damage as well as the expression of COX-2 and iNOS [90]. Additionally, PCA diets may
decrease the number of aberrant crypt foci, ornithine decarboxylase activity and the expression of
AgNOR in AOM-induced CRC rat models [88,89]. In strawberries, 4-hydroxybenzoic acid (4HBA) was
considered a metabolite of pelargonidin-3-glucoside, but it did not show anti-cancer activity in colon
cancer in a limited number of studies [96,97].
The growth and spread of cancer depended not only on the biological characteristics of the
tumor cells but also on the host immunology response. Black raspberry extracts and the single
anthocyanins component cyanidin-3-rutinoside and quercitin-3-rutinoside were shown to inhibit T
cell proliferation, limit myeloid-derived suppressor cells (MDSC) expansion, and suppress MDSC
capacity [98]. Cyanidin-3-glucoside and cyanidin-3-rutinoside also reduced the inflammation cytokines
TNF-α, IL-6, IL-1 β in lipopolysaccharide (LPS)-treated murine macrophage RAW264.7 cells [99].
In contrast to the consistent effects of anthocyanins in black raspberry and strawberry on
chemoprevention, the results of studies that assessed the ellagitannin components of berries in
chemoprevention have varied. Some studies found that ellagitannins were the most responsible for
the anti-cancer activity of berry extracts [56,67]. However, the findings of other studies suggested
that berry ellagitannins may not be sufficient for the prevention of many cancers, such as esophageal
squamous cell carcinoma, because various concentrations of ellagitannins showed no differences in
chemoprevention [100].
A recent study that used a high-resolution 1H NMR-based multivariate statistical model showed
that anthocyanins, cyanidin 3-rutinoside, and cyanidin 3-xylosylrutinoside were the predominant
contributors to the anti-cancer effects of black raspberry. However, in the same study, salicylic acid
derivatives (salicylic acid glucosyl ester), quercetin 3-glucoside, quercetin 3-rutinoside, p-coumaric acid,
epicatechin, methyl ellagic acid derivatives (methyl ellagic acetyl pentose), and citric acid derivatives
were also shown to contribute significantly to anti-cancer effects [101].
Anthocyanins have brought the research community’s attention in the field of IBD [102,103].
In our opinion, anthocyanins are the major components responsible for the chemoprevention effects of
black raspberry and strawberry. This opinion is based on five main lines of evidence: (1) anthoycanins
are the most abundant components in black raspberry and strawberry; (2) the anti-cancer effects of
anthocyanins and the role of anthocyanins in immune modification are well-documented; (3) PCA,
the metabolites of anthocyanins in black raspberry, show chemoprevention effects similar to those
of black raspberry; (4) anthocyanins are found in cancer tissues; (5) the colon is the major site of the
metabolism of anthocyanins. However, because other components also significantly contribute to
anti-cancer effects, it is clear that further studies are needed to assess the chemopreventive compounds
in black raspberry and strawberry.
5.4. Mechanisms Associated with Preventative Effects of Berries on Colon Cancer
The benefits of berries in reducing antioxidative stress are well known. In a study that compared
the antioxidant role of 10 phenolic compounds in strawberry extracts, the most potent antioxidants
identified by a trolox equivalent antioxidant capacity (TEAC) assay were cyanidin-3-glucoside,
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cyanidin-3-pelargonidin, and kaempferol [66]. Moreover, urinary 8-OHdG levels and tissue nitrosative
stress are important biomarkers of oxidative stress, which were reduced by the intake of black raspberry
and strawberry [18,63]. Overall, several studies using cell lines, animal models, and human clinical
trials of strawberry and black raspberry reported significantly decreased oxidative and inflammatory
signals, such as COX-2 and NFκB. However, not all related signals were shown to be regulated by
either black raspberry or strawberry, including the following: DNA repair-related enzymes, such as
Aag, Mutyh, Ogg1; enzymatic and nonenzymatic antioxidants, such as SOD; and the antioxidant genes
Nrf-2, Gpx3. Therefore, these molecular processes should be examined in future studies.
One form of genomic instability is the loss of heterozygosity, which in previous studies was
reduced by the topical application of the black raspberry gel on oral intraepithelial neoplasia lesions
(17p13 location containing TP53 genes are included in the loss of heterozygosity). Hypermethylation,
or the increased number of methyl groups added to the promoter region, were shown to function to
inhibit the transcription of target genes. Similar to the loss of heterozygosity, hypermethylation was
shown to be an important approach in deactivating tumor suppressor genes during carcinogenesis.
As previously mentioned in this review, black raspberry powder and anthocyanin-enriched extract
of black raspberry worked to demethylate CDKN2A, SFRP2, SFRP5, and WIF1 in the Wnt pathway
through suppressing DNMT1 and DNMT3B [60,71]. In a phase Ib study on the effects of black
raspberries on rectal polyps in patients with familial adenomatous polyposis, a greater number of the
demethylated transcription start sites and the increased expression of DNMT1 was found in patients
who received a black raspberry intervention compared to those that did not [104]. Combined with the
demonstrated antioxidant effects of black raspberry and strawberry, the above evidence suggests the
potential of black raspberry and strawberry to prevent inflammation-dependent oxidative stress and
genomic instability in colon epithelial cells.
In a DSS-treated ulcerative colitis mouse model, an intervention employing a long-term black
raspberry diet resulted in the decreased infiltration by macrophages and neutrophils in colon tissue [61].
Black raspberry and strawberry were both associated with the reduced expression of COX-2 and
the pro-inflammatory mediators, COX-2, iNOS, TNF-α, IL-1, IL-6, and IL-10 in cell studies, animal
models, and clinical trials [17–22]. Cytokine GM-CSF and IL-8 were also found to be decreased by
black raspberry powder in untreated colon cancer patients [67]. Black raspberry also altered innate
immune cell trafficking in NMBA-induced esophageal squamous cell carcinoma in a rat model [105].
Single anthocyanins cyanidin-3-rutinoside and quercitin-3-rutinoside inhibited MDSC expansion and
modulated T lymphocyte proliferation [98]. Hence, another interesting area for further research is the
regulation of immune effectors by black raspberry and strawberry.
NFκB is present in almost all cell types, and it is involved in inflammation, cell differentiation,
and carcinogenesis. The cyclin-dependent kinase inhibitor, p21WAF1/Cip1, was induced by black
raspberry in a Muc2−/−mice CRC model [64]. In addition, the cell proliferation markers Ki-67, c-Jun,
p27, Erk1/2, MAPK, and AKT were regulated by treatment with black raspberry or strawberry [18,103,
104,106]. Oxidative stress activates MAPK family members, including p38 MAPK and JNK, which
subsequently activated genes involved in cellular proliferation. MAPK is activated by a range of
stimuli, and it mediates several physiological processes, which are observed during carcinogenesis.
AKT signaling plays an important role in multiple cellular processes, including cell proliferation,
survival, motility, and angiogenesis. The induction of cell survival by AKT is mediated through NFκB
signaling. The activation of the AKT and ERK pathways acts synergistically to promote the mechanistic
target of rapamycin signaling, which controls NFκB activity [18,20]. NFκB was also found to regulate
cell apoptosis during carcinogenesis. Black raspberry and strawberry increased apoptosis markers,
TUNNEL staining, and the Bcl-2/Bax ratio in both animal models and human patients [16,105–108].
NFκB is required for the stabilization of snail, which is the transcription factor involved in regulating
the expression of E-cadherin to induce cell migration and invasion induced by inflammatory cytokines.
The inhibition of NFκB was found to potentially induce the degradation of Snail, which increased
the expression of E-cadherin and hence inhibited cell migration and invasion. NFκB signaling was
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an important molecular event associated with the chemoprevention effects of black raspberry and
strawberry on IBD-induced CRC. The mechanisms associated with the chemoprevention effects of
black raspberry and strawberry are summarized in Figure 3.
Figure 3. Possible mechanisms of the inhibition of IBD-related CRC by strawberry and black
raspberry. MDSC: myeloid-derived suppressor cells; RNI: reactive nitrogen intermediates; LOH:
Loss of heterozygosity; MSI: microsatellite instability.
6. Conclusions
Strawberry and black raspberry have been shown to have potential cancer prevention effects with
low toxicity profiles in IBD-related CRC. Inflammation-induced carcinogenesis has been associated
with oxidative stress, genomic instability, immune effectors, cytokine dysregulation, and the NFκB
signaling pathway. In contrast to anti-inflammation pharmaceuticals, strawberry and black raspberry
interventions have shown to have a synergistic role in multiple molecular events, including suppressing
cytokines release, decreasing oxidative stress, reducing genomic instability, and inhibiting NFκB and
related signaling pathways. The chemopreventive activity of strawberry and black raspberry is likely
due to multiple nutrients and bioactives, especially anthocyanins. The clinical translational application
of berries in IBD patients for CRC prevention is limited, which may suggest that this “low-hanging
fruit” should be assessed in future clinical trials on colon cancer prevention in IBD. The evidence to
date is a step toward the development of specific phytochemicals and metabolites as chemopreventive
agents based on the principles of pharmacognosy.
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Abstract: Inflammatory Bowel Disease (IBD) is a chronic disorder associated with immune
dysregulation and chronic inflammation of the digestive tract. While it is poorly understood,
the role of nutrition and nutrient status in the etiology of IBD and its associated outcomes has
led to increased research relating to micronutrient deficiency. This review offers an overview of
recent literature related to micronutrient absorption and outcomes in adults with IBD. Although the
absorption and IBD-related outcomes of some micronutrients (e.g., vitamin D and iron) are well
understood, other micronutrients (e.g., vitamin A) require further research. Increased research and
clinician knowledge of the relationship between micronutrients and IBD may manifest in improved
nutrient screening, monitoring, treatment, and outcomes for people living with IBD.
Keywords: Inflammatory Bowel Disease; micronutrients; vitamin; mineral; deficiency
1. Introduction
Inflammatory Bowel Diseases (IBD) (including Crohn’s Disease (CD) and Ulcerative Colitis (UC))
are complex disorders involving immune dysregulation, leading to infiltration and destruction of
the gastrointestinal tract. At its core, IBD results from an imbalance between pro-inflammatory and
anti-inflammatory signaling, however the etiology of this imbalance, and of IBD itself, remains poorly
understood [1]. An expanding body of literature implicates a shared role of genetics and the environment
in the development of disease. The contributing role of environmental factors in the pathogenesis of
IBD is further substantiated by observed rising IBD incidence rates in populations that have immigrated
from geographic regions of low disease prevalence to regions where the disease is more prevalent [2].
Population-based studies highlight an association between increased intake of total fat, processed meat,
and protein (common components of ‘Western’ diets), and the incidence of IBD [3,4].
In turn, IBD itself affects nutrition intrinsically by disrupting the absorption of nutrients in the gut,
and extrinsically through reduced total food intake due to pain and fatigue, as well as the avoidance of
food groups that exacerbate their symptoms [5–11]. Given differences in disease location between CD
(commonly involving the ileocecal junction but can affect any part of the gastrointestinal tract) and
UC (localized to the rectum and colon), and the distribution of nutrient absorption sites within the
gut, the spectrum of the association between IBD and nutrient status varies in both magnitude and
selectivity [12,13]. Micronutrient status is further impacted by increased gastrointestinal losses and
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the surgical treatment of IBD itself, which decreases the amount of mucosal surface area available for
absorption [14]. The effect of selected micronutrient deficiencies on patient outcomes has been difficult
to characterize. The severity of deficiency often moves lockstep with disease severity, making it difficult
to draw conclusions about the specific impact of micronutrient levels on patient outcomes without
experimental interventional studies to eliminate known or residual confounding effect. This review
seeks to highlight many of the common micronutrient deficiencies associated with IBD and examine
the reciprocal relationship between micronutrients and IBD with respect to absorption and outcomes.
Furthermore, this review aims to examine current recommendations for micronutrient supplementation
and screening for patients with IBD.
2. Literature Review
2.1. Materials & Methods
An initial literature search was performed in order to develop a set of well-studied and clinically
relevant micronutrients. Medline, Pubmed, Embase and CINAHL databases were searched for English
language peer-reviewed articles published during 2009–2019 using the keywords ‘inflammatory
bowel disease’ and, ‘micronutrients’ alongside, ‘deficiency’, ‘outcomes’, ‘screening’, and/or ‘treatment’.
This search strategy resulted in 1334 articles. Articles were excluded if they did not focus on the adult
IBD patients or patient outcomes. From this, a subset of 160 papers were used to determine which
micronutrient deficiencies warranted further investigation.
Individual literature searches for each micronutrient were performed, with no exclusion criteria.
Each search followed the same formula of keywords, with ‘inflammatory bowel disease’ and the
vitamin in question, as well as the modifiers, ‘outcomes’, ‘deficiency’, ‘supplementation’, or ‘therapy’.
From these subsearches, all relevant results were included. Finally, snowballing was used to find
additional sources that were not returned by the search.
2.2. Micronutrients
Micronutrients are categorized as having four main roles in supporting major body function:
cofactors in metabolism, coenzymes in metabolism, genetic controls, and antioxidants [15].
Therefore, deficiency of essential micronutrients leads to deleterious downstream effects involving
metabolism, gene expression and oxidative stress [15]. In the context of IBD, the role of micronutrients
in genetic control and antioxidation are of particular importance [16]. Vitamin A, B, and E have been
implicated in regulating immune responses and homeostasis within the gut, inhibiting the release
of inflammatory cytokines and favoring the differentiation of regulatory (TREG) lymphocytes over
proinflammatory TH17 lymphocytes [16]. In healthy patients, production of reactive oxygen species
(ROS) is balanced by the activity of antioxidative micronutrients such as vitamins A and E, as well as
enzymes requiring trace metals (zinc and selenium as examples) as cofactors [16]. In IBD, immune
dysregulation and inflammation result in the increased production of ROS, further underlying the
importance of antioxidative micronutrients in mitigating IBD pathogenesis [17]. This relationship
creates a chicken and the egg situation: Is increasing disease severity responsible for micronutrient
deficiencies by impairing absorption? Or are dwindling levels of micronutrients, which act as
antioxidants and immune regulators, responsible for progression of disease?
2.3. Vitamins
2.3.1. Vitamin A
Vitamin A, and its active metabolite retinoic acid, have widespread effects through the body. In the
context of the immune response, retinoic acid signaling results in expression of Foxp3, a transcription
factor that leads to the differentiation of naïve T cells to TREG cells [18–21]. These TREG cells attenuate
the immune response through the release of anti-inflammatory cytokines [22,23]. Conversely, retinoic
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acid inhibits the expression of IL-6 receptors, preventing the differentiation of naïve cells into
proinflammatory TH17 cells [20]. Furthermore, retinoic acid induces the expression of α4β7 and CCR9
on T cells [24]. The expression of these molecules causes T cells to preferentially migrate into the gut
wall following exposure to antigen [25].
Vitamin A absorption chiefly occurs in the proximal intestine and can be directly converted into
retinoic acid in the gut by enterocytes [26]. Given that vitamin A stores in the liver buffer decreasing
levels in the blood, measuring serum vitamin A does not accurately assess the total amount present
in the body [27]. Soares-Mota et al., 2015 used relative dose response testing to indirectly assess
liver stores of vitamin A in 38 Brazilian patients with CD and 34 healthy subjects. They found
that deficiencies in vitamin A stores were significantly more common in those suffering from CD
(37% vs. 12%, p < 0.005). Interestingly, they did not find any association between vitamin A deficiency,
disease location, or disease activity [27].
Provitamins of vitamin A have also been examined in the context of IBD. One such provitamin,
β-carotene, has been well studied [28]. Compared to controls, β-carotene levels in IBD patients have
been shown to be significantly decreased, with further decrease in those with active disease [29].
As well, supplementation with β-carotene lead to disease amelioration in a dextran sodium sulfate
(DSS) murine model of colitis [30]. Conclusions are much harder to draw from results of human trials.
Firstly, in the articles reviewed by Rezaie et al., 2007, each study uses β-carotene alongside other
antioxidative micronutrients, making it difficult to judge its effect [31]. Furthermore, the review notes
that the studies used small doses of β-carotene and did not see normalization of β-carotene serum levels.
The one study reviewed that used high dose antioxidants, including β-carotene, saw decreases in the
required corticosteroid dose, while all other studies were negative [31,32]. Again, without elucidating
the effect of β-carotene supplementation in isolation, it is impossible to determine its clinical utility.
It is also difficult to distinguish whether any effects are due to its conversion to vitamin A or its own
antioxidative ability.
The role of non-provitamin A carotenoids in IBD will only be described briefly, as their role in the
context of IBD requires further elucidation. Presently, deficiencies of these carotenoids, namely lycopene
and lutein, have been described in IBD patients [30,33]. However, the clinical significance of these
deficiencies in IBD is unclear. While the effect of dietary supplementation has not been determined,
a single retrospective study using the self-reported dietary records of 56 UC patients in remission
associated higher lycopene and lutein intake with decreased fecal blood and mucus, with no change
in abdominal pain [34]. Lutein was also able to attenuate ulceration of the GI tract in DSS murine
models [35]. Given the exceeding rarity of clinical serum testing for these compounds, and the
lack of data surrounding their supplementation, significant further research is required before any
recommendation can be made.
Given the ability of vitamin A to attenuate intestinal inflammation in murine models and the
prevalence of deficiency in the Brazilian CD population, further research into the role of vitamin A in
IBD is warranted [27,36]. At this point, research regarding vitamin A supplementation in IBD is limited
to two small studies published in 1985, (Wright et al., 1985: n = 86; Norrby et al., 1985, n = 8) [37,38].
Neither of these papers found a significant benefit of supplementation. However, drastic changes in
the management and treatment of IBD over the past 30 years, combined with small sample sizes in
both studies make this an attractive topic to revisit using well-designed clinical trials [39].
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2.3.2. Folate
While folate (also known as vitamin B9) deficiency has classically been associated with anemia
in IBD patients, it’s role in IBD is likely more complex than previously thought. Not only is folate
essential in the synthesis of nucleotides, but it is implicated in the regulation of TREG cells [40]. In vitro,
folate acts as a pro-survival signal for TREG cells [41,42]. Similarly, in murine models, deficiency in
folate leads to the reduction of TREG cells in the intestine [40]. Murine models have also demonstrated
a predisposition towards intestinal inflammation in mice being fed diets deficient in folate [42,43].
Furthermore, folate deficiency (as well as B12 deficiency) inhibits the conversion of homocysteine to
methionine, which results in increased levels of homocysteine in the blood and intestinal mucosa of a
significant portion of IBD patients [44]. Homocysteine acts as a pro-oxidant amino acid, increasing
oxidative stress in the body [45]. Homocysteine also promotes the secretion of pro-inflammatory
chemokines, and the differentiation of naïve CD4+ T cells into pro-inflammatory TH17 cells [46].
Homocysteine levels are correlated with thrombotic events, and interestingly, IBD patients have an
increased prevalence of thrombosis compared to those without IBD (5-year prevalence, 7.5% vs. 4.5%,
p < 0.001) [47]. Furthermore, the patients are at increased risk of mesenteric ischemia (HR 11.2),
and female IBD patients have significantly higher risk of MI (HR 1.6) and stroke (HR 2.1) [48].
Folate is absorbed in the jejunum following its conversion from folate polyglutamate to
monoglutamate in the gut [49]. Further conversion in the liver results in the production of the
metabolically active tetrahydrofolate (THF) [49]. Folate levels are significantly lower in patients with
both CD and UC, with one prospective study of 180 IBD patients suggesting that 22.2% of CD patients
and 4.3% of UC patients are deficient [50]. While the mechanism behind folate deficiency has not
been well categorized, jejunal dysfunction and reduced intake of folate-containing foods are likely
contributors. Furthermore, the use of methotrexate or sulfasalazine in IBD treatment leads to errors of
folate metabolism and absorption [51,52].
While anemia is common in IBD patients, the authors were unable to find a study that assessed
the proportion of patients with megaloblastic anemias in the setting of folate deficiency. Furthermore,
folate supplementation remains a relatively unexplored topic. At this point, only the effect of
supplementation on colorectal cancer has been described. A meta-analysis of 10 such articles
determined that folate supplementation significantly lowers the risk of colorectal cancer in IBD
patients (HR 0.58; 95% CI: 0.36–0.66) [53]. However, the studies analyzed used varying doses of folate,
making recommendations difficult. The effect of folate supplementation on homocysteine levels in the
intestinal mucosa, and the risk of thrombotic event, are logical targets of future research.
2.3.3. Vitamin B12
Unlike the micronutrients discussed above, no direct connection between vitamin B12 (cobalamin)
and immune regulation has been described. Vitamin B12 has been included in this review due to the
clinical consequences of its deficiency, as well as the impact of CD on the site of its intestinal absorption.
Vitamin B12 is essential in the metabolism of macronutrients, synthesis of DNA, and nerve function [54].
Deficiency is associated with macrocytic anemia via impaired folate metabolism, neurologic damage,
and hyperhomocysteinemia [54]. While serious, these complications are uncommonly reported in
IBD patients. In order to be absorbed, vitamin B12 requires activation by intrinsic factor produced
in the stomach. Following activation, vitamin B12 is only absorbed via specific receptors present in
the terminal ileum [55]. This location makes its deficiency a particular concern in CD, as a significant
proportion of CD patients develop ileal disease [56].
Numerous studies exist that assess B12 status in IBD patients and the results vary [50,57–60].
In recent years, both a systemic review and meta-analysis of the literature have concluded that IBD is
not associated with significantly lower serum B12 levels [61]. However, surgical resection of the ileum
is associated with B12 deficiency [61]. Meta-analysis by Pan et al., 2017 suggests that patients with ileal
resections were disproportionately underrepresented in the literature surrounding B12 deficiency [61].
Considering that ileal disease is common in CD, and upwards of 50% of CD patients require surgery
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within 10 years of diagnosis, patients with ileal resection, and therefore B12 deficiency, likely represent
a larger group than described [62].
2.3.4. Vitamin D
The relationship of IBD and vitamin D is likely the most complicated of the IBD-micronutrient
relationships. While normally associated with calcium metabolism and bone health, the role of vitamin
D in the regulation of the immune response has been the topic of much research in recent years [16].
In the gut, vitamin D’s active form 1α,25-dihydroxyvitamin D3 (calcitriol) alters the T cell response,
favoring TREG cells and inhibiting production of proinflammatory cytokines [63]. Calcitriol also impairs
the function of interstitial dendritic cells, limiting their ability to activate T cells within the gut [63].
Furthermore, direct signaling via vitamin D receptors on T cells leads to upregulation of programmed
death receptors and the downregulation of the activating receptor CD69 [64]. These properties provide
a rational physiological means by which vitamin D deficiency affects IBD pathogenesis. This is further
substantiated by murine models of IBD in which vitamin D supplementation improves symptoms,
and deficiency increases symptoms [65,66].
Vitamin D is acquired through the diet, however the majority of vitamin D is synthesized
endogenously in the skin [67]. Once acquired, vitamin D must then be metabolized step-wise in the
liver and kidney into its active form 1α,25-dihydroxyvitamin D3 [67]. Vitamin D deficiency is common
in IBD patients, with a meta-analysis identifying deficient vitamin D levels in 57.7% of CD patients [68].
The exact reason for vitamin D deficiency in IBD is not well understood. Considering that few foods
naturally contain vitamin D, deficiency is likely a combination of reduced intake to diet restrictions
and aversions, as well as impairment of the absorption of fat-soluble vitamins [69].
Literature correlating vitamin D deficiency with IBD disease activity is abundant and relatively
homogenous [70–75]. However, there exists a limited amount of data in patients whose vitamin D levels
have been restored through supplementation. Broadly, vitamin D levels are inversely associated with
inflammatory markers, while positively associated with bone mineral density (BMD), anti-inflammatory
cytokine production, and response to anti-tumor necrosis factor (TNF) therapy [70,76–80]. In both CD
and UC, vitamin D deficiency is also associated with more frequent relapses of disease, disease severity,
risk of colorectal cancer [81–83]. Similarly, a landmark longitudinal study of 965 American IBD
patients saw a significant association between low vitamin D concentration and increased utilization of
healthcare, increased pain, and decreased quality of life [84]. This study also found that vitamin D
normalization significantly reduced healthcare utilization in the same population [84]. Ananthakrishnan
et al., 2013 have corroborated this finding, showing that normalization of vitamin D levels reduces
risk of surgery in CD patients [85]. In terms of BMD, concurrent supplementation with calcium and
vitamin D led to significantly increased BMD in the hip and lumbar spine [86,87].
Dosing of vitamin D for effect in IBD is not well-established [88]. Doses of vitamin D3 at
4000 IU/day are adequate in correcting deficiency but given the conflicting evidence around the effect
of supplementation on disease course in the first place, the most appropriate therapeutic dose has not
been determined [88,89].
2.3.5. Calcium
Calcium homeostasis is a complex, multifaceted phenomenon. Bone, which is 60% comprised
of calcium hydroxyapatite (Ca10(PO4)6(OH)2, undergoes constant remodeling throughout life.
Therefore, the pathways responsible for the control of calcium homeostasis are critically important.
The supply of calcium involves paracellular and transcellular intestinal and renal absorption and
reabsorption [90]. Chronic intestinal inflammation of IBD, as well as dietary and lifestyle alterations and
medications used to treat IBD, impact these physiologic homeostatic pathways [7,9,87,90,91]. Intestinal
malabsorption, as a result of decreased dairy product intake, leads to low luminal ionic calcium
(Ca2+) concentrations resulting in increased transcellular active transport (versus more non-active
paracellular transport when luminal Ca2+ concentrations are high via decreased duodenal transit time
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and down regulation of protein responsible for transcellular Ca2+ transport proteins). Ca2+ is absorbed
through facilitated diffusion mediated by transient receptor potential villanoid channels (TRPV6 and
5), which are regulated by vitamin D3, parathyroid hormone, estrogens, pH- and Ca2+ dependent
regulatory mechanisms, and bidirectional Na+/Ca2+ exchange [90].
Beyond the known negative influence of vitamin D insufficiency and malnutrition, there is a relative
paucity of knowledge relating to the impact of acute and chronic intestinal inflammation itself on
Ca2+ homeostasis in the kidneys and intestine. A study by Huybers et al. demonstrated in a TNF-α
overexpressing mouse model of Crohn’s ileitis that multiple epithelial proteins involved in Ca2+ absorption
and transport, including TRPV6, were down regulated [92]. As a result of changes in the expression of Ca2+
transport genes, bone resorption increased. When these same mice were treated with methylprednisone,
similar inhibitory effects were seen in TRPV6 and calbindin D9K mRNA and protein. Although limited
data exists in IBD, a very small (n = 4) study of CD patients in remission revealed intestinal absorption of
Ca2+, as well as response to 1,25(OH)2D3, to be similar to that of controls [92].
In addition to calcium, phosphate (Pi) homeostasis is important in the maintenance of BMD.
Prolonged phosphate deficiency may lead to bone demineralization (osteomalacia and rickets).
Although little is known about the impact of intestinal inflammation on Pi absorption, as with serum
Ca2+ it is known that serum levels of Pi do not reflect minor alterations in active mineral transport.
Therefore, it is very uncommon to observe changes in serum Ca2+ or Pi in IBD patients. The Klotho
gene, a multifunctional protein, has been implicated in the regulation of both Ca2+ and Pi metabolism
through its influence on transepithelial Ca2+ transport via promotion of transport channel recruitment
and retention. Thurston et al., have demonstrated renal Klotho to be significantly down-regulated in
various murine models of colitis via TNF and IFN-gamma [93].
Through complex absorptive, transport, and hydroxylation mechanisms, vitamin D3 is converted
to the hormonally active form of vitamin D, 1,25(OH)2D3, which is responsible for most, if not all,
of the biological effects of vitamin D. 1,25(OH)2D3 has a pleiotropic role and is a key regulator of
bone turn-over, with the potential to facilitate both osteoclastic and osteoblastic pathways. Numerous
studies have demonstrated the association between vitamin D deficiency or insufficiency and IBD when
compared with control or healthy individuals [94,95]. The mechanisms for this observed associations in
IBD may include intestinal malabsorption, decreased dietary intake, disrupted enterohepatic circulation,
renal insufficiency and inadequate sunshine exposure. Given the association between IBD and decreased
vitamin D status, numerous interventional studies have been conducted in an attempt to determine
the impact of vitamin D supplementation on IBD-related clinical outcomes. The data related to BMD
loss or accrual have been mixed [90,96,97]. In fact, there have been several studies that suggest, in the
setting of active inflammation, that high concentrations of 1,25(OH)2D3 may promote the development
of osteoporosis in CD [98]. Likewise, the outcomes of studies relating to bone formation and resorption
in IBD patients have been conflicting, likely due to flaws in study design, power, confounding factors,
IBD complexity, and challenges related to understanding and measuring bone turn-over rates in both
adults and children with IBD. More well designed and adequately powered clinical studies are required
to definitely answer these questions relating to bone formation and resorption in IBD [90].
The presumption that the BMD effects observed in IBD are simply as a result of vitamin D3 and
calcium deficiency has more recently been recognized to be overly simplistic. The complex interplay
between the inflammatory disease process itself and the mediators of mineral homeostasis and bone
(re)absorption complicates efforts to clearly elucidate the role that these nutrients and hormones play
in the pathogenesis of metabolic bone disease in patients with IBD, as well as the role that acute and
chronic inflammation may play in alterations of mineral and hormonal homeostasis.
2.3.6. Vitamin K
The mechanism of vitamin K absorption is two-fold. Vitamin K is both directly absorbed from
the diet and produced in the gut by commensal GI flora. As a cofactor, vitamin K is crucial to
the production of coagulation factors and in the maintenance of bone [99]. As well, much like
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many of the other micronutrients discussed, vitamin K is implicated in immune signaling and
inflammation [16]. Poor vitamin K levels are associated with increasing levels of IL-6 in the blood,
a pro-inflammatory cytokine that is implicated in IBD pathology [100,101]. Similarly, in murine
models, vitamin K supplementation reduced intestinal inflammation in the presence of the bacterial
antigen lipopolysaccharide (LPS), while deficiency aggravated disease in DSS models of colitis
in mice [102,103]. This provides a dual rationale for vitamin K supplementation in IBD: avoid
complications such as bleeding and bone loss, while hopefully pushing the body away from
pro-inflammatory immune pathways.
Vitamin K deficiency is found in 31% of IBD patients, with dysregulation of the gut biota and bile
salt malabsorption proposed as mechanisms [69]. In these patients, low levels of vitamin K are associated
with low BMD, as well as clinical activity and duration of disease [104–106]. In long-standing IBD,
the prevalence of osteoporosis can be as high as 41% [107]. Considering this, and the adverse outcomes
associated with fractures, BMD is of critical importance in IBD management. Daily supplementation of
vitamin K over 12 months was unable to alter the indices of bone health in IBD patients with vitamin K
deficiencies [108]. Furthermore, in rheumatoid arthritis, which shares some common inflammatory
pathophysiology with IBD, vitamin K supplementation did not significantly alter the level of IL-6 or
the clinical activity of disease in patients [109]. Given the link of vitamin K deficiency to low BMD and
high IL-6, these results are disappointing.
2.4. Metals
2.4.1. Iron
Aside from vitamin D, iron is likely the micronutrient that has been most heavily studied in
the context of IBD. Iron has attracted attention due to the high portion of IBD patients who suffer
from anemia [110]. The mean prevalence of anemia calculated by meta-analysis is 16% in outpatients,
increasing to 68% in inpatients [99]. As well, the overall portion of IBD patients with iron deficiency
is 45% [111]. The physiological means by which IBD causes iron-deficiency is straight forward.
Mucosal bleeding leads to iron loss in the stool, meanwhile inflammatory changes altering hepcidin
and iron metabolism impact iron absorption [112].
Anemia, and the associated fatigue, can be one of the most crippling symptoms of IBD, with quality
of life scores mirroring hemoglobin (Hb) levels [113]. On this basis alone, the treatment of iron-deficiency
anemia in IBD is paramount. Current recommendations suggest the end goal of iron supplementation
is the normalization of iron store levels, as well as Hb [114]. Oral and intravenous iron products
are available for use in IBD. Clinically, and in meta-analysis, intravenous iron supplementation is
associated with significantly fewer GI side effects, as well as slightly greater increases in Hb [115].
However, the patient’s quality of life did not significantly differ between intravenous and oral iron [116].
Importantly, anemia reoccurs rapidly in IBD, further necessitating the use of iron maintenance
therapies [117]. In line with this, European Crohn’s and Colitis Organization (ECCO) guidelines
suggest that patients who have been treated for iron-deficiency anemia be monitored every 3 months
for the first year, and every 6–12 months for the recurrence of anemia [114].
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2.4.2. Zinc
As a cofactor, zinc is intimately involved in the regulation of both the innate and adaptive
arms of the immune system [118]. Importantly, zinc downregulates NF-κB signaling through the
zinc-finger protein A20, leading to decreased expression of its downstream products (namely IL-6 and
TNF-α) [119–121]. It is worth noting that certain mutations in the gene that encodes A20 (TNFAIP3)
are positively associated with the risk of developing numerous inflammatory conditions, including
IBD [121]. As well, deletion of TNFAIP3 in mice intestinal cells leads to sensitivity to DSS-induced
colitis. Conversely, zinc deficiency results in increased production of pro-inflammatory molecules in
murine models [122]. Finally, zinc also exerts an anti-oxidative effect through its inhibition of NADPH
oxidase, and its role as a cofactor for superoxide dismutase [123,124]. The relationship between zinc
and IBD on both a theoretical and genetic level, make it a micronutrient of interest to explore further.
Zinc deficiency is present in a significant portion of IBD patients (15.2–65%) [8,125]. Zinc levels are
balanced through absorption in the proximal small intestine, and excretion in intestinal and pancreatic
secretions [126]. Losses are increased in association with chronic diarrhea, high output ostomies, and high
output fistulas, which often pose a problem for IBD patients. These increased losses combined with the
malabsorptive state of intestinal inflammation are likely responsible for zinc deficiency in IBD patients.
Clinically, an association has also been observed between zinc deficiency and IBD. A prospective
study of 170,756 women over 26 years found that increasing zinc intake was inversely corelated with
CD risk [127]. Furthermore, an American cohort study of 773 CD and 233 UC patients highlighted the
relationship between zinc deficiency and adverse patient outcomes. They found that zinc deficiency
was associated with a significant increase in hospitalizations (CD: OR 1.44. 95% CI [1.02–2.04]; UC: OR
2.14, 95% CI [1.07–4.29]), surgery (CD: OR 2.05, 95% CI [1.38–3.05]; UC: OR 1.64, 95% CI [0.59–4.52]),
and complications (CD: OR 1.50, 95% CI [1.04–2.15]; UC: OR 1.97, 95% CI [0.94–4.11]) [128]. In patients
who were able to achieve normal zinc levels within 12 months, the risk of adverse outcomes returned to
baseline [128]. Although zinc deficiency is associated with disease activity and worse outcomes, a single
small cross-over trial (n = 14) that explored the effect of daily zinc supplementation did not show changes
in the level of pro-inflammatory cytokines, or disease activity [129]. Given the positive results seen by
Siva et al., 2017, larger trials following zinc supplementation may be a reasonable step forward [128].
2.4.3. Selenium
Much like zinc, selenium is integral to the immune function. Selenoproteins, through which
selenium exerts its effect, encompass a group of proteins with diverse pro- and anti-inflammatory
effects that are beyond the scope of this review. Relevant to IBD, glutathione peroxidases (GPx) utilize
selenium to mitigate the effect of ROS [130]. Whereas loss of the genes encoding GPx proteins results
in increased severity of disease in DSS murine models [131–133].
Selenium deficiency is common in IBD patients with a recent study reporting 30.9% of patients
as deficient, and numerous others observing levels that were significantly decreased compared to
control [134–139]. In DSS-treated mice, selenium deficiency leads to increased severity of disease and
upregulation of pro-inflammatory TH1 cytokines [140,141]. In humans, selenium deficiency has been
investigated for its possible role in cardiovascular disease, however a recent review by Benstoem et al.,
2015 describes the literature as “inconclusive” [142].
Selenium supplementation in the context of IBD has not been documented in the literature outside of
murine models. In these models, supplementation ameliorated cox-dependent inflammation by altering
the PGE2 pathway [143,144]. Given the abundance of animal data, and the strong physiological link
between selenium and immune function, the study of selenium therapy should be a future focus. Table 1
presents the immune implications of micronutrient deficiencies, including selenium, in adult IBD patients.
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Table 1. Immune implications of micronutrient deficiencies in IBD.
Micronutrient Level in IBD Purported Pathogenic Role of Deficiency
Vitamin A ↓ [27]
↓ TREG cell differentiation [18–21]
↑ TH17 cell differentiation [20]
↓ T cell migration into the gut [25]
Folate ↓ [43]
↓ TREG cell survival [31,32]
↑ Proinflammatory signaling [37,39]
↑ Oxidative stress [37,38]
Vitamin B12 =↓ in patients with ileal resection [54] –
Vitamin D ↓ [61]
↑ T cell activation [56]
↑ Proinflammatory signaling [56]
↓ Decreased T cell turnover [57]
Calcium ↓ [87,90,91] –
Vitamin K ↓ [62] ↑ Proinflammatory signaling [84,85]
Iron ↓ [104] –
Zinc ↓ [8,118] ↑ Proinflammatory signaling [114]↑ Oxidative stress [116,117]
Selenium ↓ [134–139] ↑ Proinflammatory signaling [141]↑ Oxidative stress [130]
This table presents the immune implications of micronutrient deficiencies in adult IBD patients. The arrows describe the effect
of IBD on the level of micronutrient present in the individual, as well as the effect on the purported pathogenic role related to
that micronutrient. For example, ↑ indicates an increase, ↓ indicates a decrease, and=↓indicates about the same or less.
3. Recommendations and Conclusions
The understanding of the role of micronutrients in immune system function has changed greatly
in recent years, as has our understanding of the pathophysiologic mechanism(s) of Inflammatory
Bowel Disease (IBD). However, the etiology of IBD and the role that micronutrients play in the
development of IBD is still unclear. There are clear physiologic links between immune-regulating
micronutrients and the balance of pro- and anti-inflammatory processes in the gut (see Table 1) [16].
However, experimental models often oversimplify what is experienced clinically (see Table 2). The same
is true of micronutrients with anti-oxidative effects [16,17]. In addition, the bidirectional relationship
of deficiency and disease makes the exact role of each micronutrient difficult to characterize, as IBD
impacts nutritional status through both decreased intake (impaired absorption, avoidance of trigger
foods, decreased appetite, decreased surface area secondary to resection, etc.), and increased gastric
losses (chronic diarrhea, intestinal blood loss, mucus losses, etc.). The effect of micronutrients on
outcomes is most easily understood in the context of iron, in which IBD leads to iron deficiency,
and deficiency leads to anemia. However, for the other micronutrients, the relationship between IBD,
deficiency, and clinical outcomes is much less clear. Table 2 presents the clinical outcomes associated
with level of micronutrients discussed in this paper, in adult IBD patients.
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Table 2. Clinical outcomes associated with micronutrient levels in IBD.
Micronutrient Effect of Deficiency Effect of Supplementation
Vitamin A – –







↑ Inflammatory markers [70,77]
↑ Healthcare utilization [84]
↑ Disease activity [70–75]
↑ Risk of colorectal cancer [83]
↓Quality of life [72,85]
↑ Bone mineral density
↓ Risk of surgery
Vitamin K ↓ Bone mineral density [104–106]↑ Bleeding risk [99]
↔ Disease activity
↔ Bone mineral density
Iron Iron-deficiency anemia Resolution of anemia↑ Quality of life [113]
Zinc





Selenium ? Cardiovascular disease [142] –
This table presents the clinical outcomes associated with micronutrient levels in IBD. The arrows describe the effect
of IBD on the level of micronutrient present in the individual, as well as the effect on the purported pathogenic role
related to that micronutrient. For example, ↑ indicates an increase, ↓ indicates a decrease,↔ indicates a potential
increase or decrease, and ? indicates that the outcome is unknown.
hile association studies suggest the benefit of treating deficiency of iron, zinc and vitamin D, similar
studies have not been performed for other micronutrients. Similarly, literature regarding the use of
supplementation as therapy is limited to a few, small scale studies that only targeted specific subgroups
of patients [37,38,129]. These factors make specific recommendations on dosage for supplementation
difficult. At this point, current European Society for Clinical Nutrition and Metabolism (ESPEN)
recommendations suggest that micronutrient levels be assessed annually in IBD patients, with the
correction of any deficit with supplementation [145]. Guidelines for iron supplementation are more
specific, suggesting iron repletion therapy in all IBD patients with iron-deficiency anemia, with the end
goal of therapy being the normalization of both hemoglobin and iron stores [114]. Intravenous iron
should be considered in patients with clinically active disease and those who are intolerant of oral iron,
while oral iron should be considered in those with inactive disease or milder anemia [114]. The dose of
iron is dependent on the route and formulation chosen, however a response of 2 g/dL within 4 weeks
is appropriate [114]. As for zinc, a 3-month course of daily supplementation with 200 mg of ZnSO4
normalizes zinc serum concentrations in deficient IBD patients [146]. Given that zinc citrate has similar
bioavailability and is more palatable to patients its use may be preferred [147]. In addition, one author
suggests increasing zinc supplementation in patients with diarrhea in order to offset increased GI loses,
at a rate of 30–40 mg elemental zinc for every liter of stool output [148].
For the other nutrients discussed in this paper, evidence-based recommendations for
supplementation in the context of IBD do not exist. Rather, clinicians should focus on the correction of
any micronutrient deficiencies that are found using appropriate oral therapy. Previous authors have
posited varying suggestions on dosage with regards to reversing deficit, with high dose oral therapy as
the common theme among them. A 2003 review by Eiden highlights such suggestions in IBD patients
and is a valuable reference for clinicians with deficient IBD patients [149].
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The development of specific recommendations for supplementation and micronutrient levels
to targets is a priority. In order to do so, large, well-designed, controlled studies focused on
supplementation are required. Given the consistency of the observed association between zinc and
vitamin D and IBD clinical disease activity and inflammation, further study of supplementation of
vitamin D and zinc as an adjunct to therapy is appropriate [16,36]. Given their link to immunity
and oxidation, further characterization of the role of vitamin A, B9, and K in IBD pathogenesis is
also warranted.
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Abstract: Dramatic changes in the environment and human lifestyle have been associated with the
rise of various chronic complex diseases, such as inflammatory bowel disease (IBD). A dysbiotic gut
microbiota has been proposed as a crucial pathogenic element, contributing to immune imbalances
and fostering a proinflammatory milieu, which may be associated with disease relapses or even the
initiation of IBD. In addition to representing important regulators of the mucosal immunity and the
composition of the gut microbiota, food components have been shown to be potential environmental
triggers of epigenetic modifications. In the context of chronic intestinal inflammation, dietary
habits and specific food components have been implicated as important modulators of epigenetic
mechanisms, including DNA methylation, which may predispose a person to the increased risk of
the initiation and evolution of IBD. This review provides novel insights about how dietary factors
may interact with the intestinal mucosa and modulate immune homeostasis by shaping the intestinal
ecosystem, as well as the potential influence of diet in the etiopathogenesis and management of IBD.
Keywords: inflammatory bowel disease; dietary habits; food components; gut microbiota; immune
homeostasis; epigenetic changes
1. Introduction
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC),
is regarded as a heterogeneous disease of unknown etiology, with an unpredictable clinical course and
usually labeled as a chronic disabling disorder [1,2]. Although the mechanisms leading to the development
of IBD are rather complex and have not yet been completely elucidated, the current information points to
a multifactorial origin. The chronic inflammatory process underlying the pathogenesis of IBD reflects a
dysregulated immune response, stemming from a conflicting interaction involving several environmental
factors, an altered innate immunity, and a predisposing genetic background [3–6].
Information derived from epidemiological studies has revealed consistent associations between the
increase in the occurrence in IBD and other autoimmune and chronic inflammatory disorders, and the decline
in infectious diseases, accompanied by the use of antibiotics, immunizations, and overall improvements in
sanitary conditions and the quality of water [7]. IBD has progressively become a global disease, affecting
newly industrialized nations in Asia, South America, and the Middle East [8–10]. Although the prevalence
of IBD in newly industrialized countries is still lower than in developed countries, the incidence rate is
increasing rapidly [11]. Among all the environmental changes usually associated with IBD, dietary habits
are one element, both from the patients’ perspective, including personal observations and common practical
concerns, and due to scientific evidence implicating diet as a triggering factor in disease relapses [12].
In this article, we discuss the effects of diet on IBD, especially considering the basic physiological processes
that underlie these associations.
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2. Diet and Microbiota
Although the influence of dietary habits on the intestinal microbiota has long been speculated, only
after the introduction of new technology, including next-generation DNA sequencing and metabolic
profiling, was reliable information able to be obtained [13]. For example, the microbiota composition is
currently thought of as a dynamic process that changes with age and fluctuates in consonance with
environmental exposures, including diet, among other factors [14].
The results of studies analyzing the microbial communities of the gut obtained from mammalian
species have endorsed the assumption that diet can influence microbial diversity. Such diversity has
been shown to increase from carnivores to omnivores and then to herbivores [15]. Regarding humans,
the intestinal microbiota reflects predominant omnivorous habits, but substantial inconsistencies have
been reported. For example, opposing patterns of the intestinal microbiota composition were reported
when comparing samples from African children living in rural communities with children from a
European urban center, a phenomenon that has been attributed to dietary differences [16]. In this case,
in terms of health issues, individuals from the European urban center are expected to be at increased
risk for the development of several immune-mediated disorders. Such diseases, likely including IBD,
are probably associated with the microbiome structure, often resulting from dietary incompatibilities
between the current environments and those in which humans evolved.
The Western style of diet, defined by high caloric content due to large amounts of fat and
carbohydrates, has been associated with a markedly reduced microbiome diversity [17]. In addition
to the plethora of fat, Western diets usually have high concentrations of dietary omega-6 fatty acids,
from vegetable oils, resulting in a high omega-6 to omega-3 ratio. Whereas omega-3 fatty acids, such
as a-linolenic acid from vegetables and eicosapentaenoic acid and docosahexaenoic acid from fish,
have anti-inflammatory properties, omega-6 fatty acids, particularly arachidonic acid, are considered
pro-inflammatory. This may explain why the Western diet has been regarded as a key factor for
producing intestinal inflammation [18]. Other relevant studies focusing on diet potentially affecting
the intestinal microbiota are summarized in Table 1.
Previous studies have analyzed the gut microbiota of infants and children within one population,
but few have attempted to compare the microbial composition considering distinct socio-economic,
geographic, and cultural aspects [16]. To analyze the potential effect of environmental factors on
defining how and from where a gut microbiota may be acquired, investigators characterized bacterial
species and gene contents of fecal samples from a cohort of healthy Amerindians from Venezuela, rural
Malawian communities, and metropolitan USA inhabitants. The investigators found that bacterial
diversity increases with age, and the degree of similarity among members of a family is consistent
in all three populations. The fecal microbiota of USA adults was the least diverse compared to the
others [19]. Therefore, it appears that differences in social structures and cultural traditions known to
impact food and many other environmental factors may also condition the magnitude of the circulation
of microbes among members of a family or community.
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Table 1. Relationship between gut microbiota alterations and dietary patterns.
Genus Characteristics Dietary Component Gastrointestinal (GI) Effect
Prevotella
Bacteroides Gram-negative anaerobic Diets rich in fat and carbohydrates Involved in colitis [17,20–23]
Clostridium Gram-positive anaerobic Decrease in high-fat but not high-sugar diets Affects the clinical course of inflammatorybowel disease (IBD) [21–24]
Ruminococcus Gram-positive anaerobic Fermentation of dietary fiber and decrease inhigh-fat but not high-sugar diets [21,25,26]
Streptococcus
Lactobacillus Gram-positive Constituents of the normal animal microbiota
Induces remission in ulcerative colitis (UC)
patients [21]
Escherichia Gram-negative anaerobic High-fat and high-sugar diets Overgrowth of Escherichia coli and involved incolitis [16,22,27]
Bifidobacterium Gram-positive anaerobic High-fiber diet Induces remission in UC patients [28,29]
Fusobacterium Gram-negative anaerobic - Involved in colitis and colon cancer [30]
- - Alcohol Decreased butyrate/total short chain fatty acids(SCFA) ratio in stool [31]
Source: adapted from Levine et al. [5] and Rapozo et al. [21].
3. Diet and Immune Response
Western lifestyle factors have been associated with the progressive increase in various
metabolic, autoimmune, and chronic inflammatory disorders, including IBD [32–34]. In addition to
industrialization, urbanization, the improvement of sanitary conditions, antibiotic usage, and other
factors, abundant evidence supports the involvement of dietary habits in shaping the gut microbiota
and influencing the interaction with the immune system [35–37].
Dietary fiber has been shown to interfere in host immunity via multiple pathways. Fibers and
starches present in fruits and vegetables represent a substrate for the production of butyrate and other
short chain fatty acids (SCFAs) by intestinal microbiota. Butyrate, for example, is well-recognized
as a critical element in epithelial homeostasis, but also plays an important role in downregulating
the immune response by inhibiting the transcription of inflammatory cytokines and promoting the
differentiation of lamina propria Tregs [5,38,39]. Low dietary fiber may precipitate the catabolism of
the mucous layer, leading to increased permeability and compromising the epithelial barrier against
potential pathogenic luminal bacteria [40].
Investigations based on experimental models have provided results regarding the effects of
specific diets on the immune response. For instance, a high-fat (HF) and high-sugar diet generated a
proinflammatory intestinal environment, associated with an overgrowth of Proteobacteria, reduction
in butyrate production, and expression of the butyrate GPR43 receptor, also underexpressed in CD
patients [41]. Results from another experimental model showed that HF diets led to the upregulation
of tumor necrosis factor-α (TNF-α) and interferon-γ expression, and to the decrease in the densities
of colonic Tregs [42]. A high intake of fat has been shown to have several effects on the mucosal
immune system, revealing the complex interaction between the lamina propria immune cells and
the intestinal microbiota. For example, the ingestion of high-fat meals increases the expression of
interlukein-1β (IL-1β), TNF-α, IL-6, and necrosis factor-κB (NF-κB) in the colon [43,44]. Likewise, mice
fed with cholesterol-enriched meals displayed acute inflammasome-dependent intestinal inflammation,
increasing the production of IL-1β, and driving the accumulation of CD11b+ and CD11c+ cells in the
lamina propria [45].
The increasing knowledge about the influence of the gut microbiome on the mucosal and systemic
immune response has contributed to the understanding of the mechanisms underlying the pathogenesis
of IBD and other chronic inflammatory conditions. Dysbiosis has been confirmed in samples from
patients with CD, displaying an increase in Enterobacteriales such as Escherichia coli, and a decrease
in Clostridiales such as Faecalibacterium prausnitzii [46–48]. In a study involving UC, the results
supported a role for reduced microbial diversity, although not as prominent as the dysbiosis seen
in CD [49]. A large cohort study analyzing fecal samples from four different European countries
revealed that CD and UC are distinct in terms of the microbiome [50]. Notably, some specific intestinal
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microbes can shape the immune response. For example, Listeria monocytogenes, Clostridium difficile,
and Toxoplasma gondii have been shown to elicit innate lymphoid cells-1 (ILC1) and Th1 cells, which
orchestrate the secretion of cytokines, such as interferon-gamma and TNF-α, critically important in the
immunity against those intestinal pathogens [51]. Clostridia strains have been shown to promote the
accumulation of Foxp3 Treg cells in the gut [52], which in turn down-regulate inflammatory responses,
including those in experimental colitis [53]. Some microorganisms induce the activation of subsets of
immune cells responsible for promoting intestinal inflammation, such as Th17 cells [54]. For instance,
segmented filamentous bacteria can activate Th17 cells, whereas a decrease in Th17 cell-inducing
bacteria can attenuate the severity of colitis in mice [55]. In previous studies, adherent invasive E. coli
(AIEC) and Bifidobacteria adolescentis [56,57], in addition to E. coli O157 and Citrobacter rodentium [54],
have been shown to induce populations of Th17 cells.
Dietary habits can affect human health either directly or via changes in the gut microbiota.
The gut microbiota is a highly complex and dynamic system that can be shaped by environmental
factors, including the diet [58]. Regarding the dietary factors directly or indirectly associated with the
immune response and intestinal homeostasis, diets with high concentrations of fat and sugar have been
associated with intestinal colonization with potential IBD-related pathobionts. For instance, adherent
invasive E. coli (AIEC) strains, induced by high-fat high-sugar diets, may become pathogenic when the
ligand CEACAM 6 is presented by the intestinal epithelium. Under such circumstances, AIEC may
form biofilms, adhere to, and translocate via M cells and the associated epithelium [59]. These findings
reinforce the idea that changes in the local environment exert a selective pressure on several species,
which in turn shape the microbiota according to the most adaptable microorganisms to the intestinal
milieu [60]. A selection of dietary factors that may affect the host immunity is listed in Table 2.
Table 2. Dietary patterns potentially affecting microbiota and immunity.
Dietary Component GI and Immunological Effect
High-fat, high-sugar diet
• Intestinal mucosa dysbiosis [41]
• Higher degree of crypt abscesses
• Decreased butyrate production
• Overgrowth of E. coli [41]
Milk fat (saturated fat)
• Induced pro-inflammatory Th1 immune response [61]
• Increased incidence of colitis [61]
• Dysbiosis
High-fiber diet
• Protected from acute colitis [62]
• Did not increase SCFAs production in patients with UC [62]
Animal versus plant diet
• Animal-based food increased the abundance of bile-tolerant microorganisms
and decreased the proportions of Firmicutes [27]
Alcohol • Decreased butyrate/total SCFA ratio in stool [31]
Maltodextrin
• Biofilm formation of adherent invasive E. coli [63,64]
• Enhanced E. coli adhesion independent of cellular receptor CEACAM 6 [63,64]
Source: adapted from Levine et al. [5].
4. Diet and IBD
Advances resulting from clinical and experimental investigations have demonstrated that the
microbiome might play a critical role in the pathogenesis of IBD [65,66]. In parallel, results from other
studies have supported a link between dietary patterns and the structure of the intestinal microbiome in
healthy individuals and in patients with gastrointestinal disorders, including IBD [17,27,67]. Given the
potential effects that diet can have on the composition and function of the intestinal microbiome,
diet may also be involved in the pathogenesis of IBD, either directly or indirectly. As a consequence,
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due to the associations with the microbiome and IBD, specific dietary interventions are promising
novel therapies.
Data have confirmed that food plays a crucial role in the gut microenvironment, and modifications
of dietary habits may have an important impact on the microbial composition and function, but also
on the gut barrier and immunity [5]. Previous studies demonstrated that modifications in a single
food group might produce various outcomes. For instance, changing the dietary composition from a
predominant plant- to animal-based diet results in a change in the intestinal microbial environment and
functionality, determining alterations in bile acids and sulfide metabolism, which have been implicated
in IBD pathogenesis [27,68]. In an experimental study, investigators demonstrated that a low-fiber
diet induces the expansion and activity of colonic mucous-degrading microorganisms, potentially
favoring the development of severe colitis by enteric pathogens [40]. In another experimental study,
mice fed a Western-style diet (rich in saturated fats and simple carbohydrates, but depleted in dietary
fiber), developed an alteration in the colonic microbiota, resulting in increased permeability and
a reduced inner mucus layer. Both defects could be prevented by transplanting microbiota from
chow-fed mice, whereas the administration of Bifidobacterium longum was sufficient to restore the
mucus layer [69]. These findings suggest that specific bacteria are crucial for normal mucus and
barrier function and, in humans, this information could help us to understand important mechanisms
underlying IBD pathogenesis.
Unveiling the association between diet and the development of IBD would ideally require
knowledge on dietary details before the onset of the disease. In this regard, large longitudinal studies
have been performed that have started to provide information to support specific dietary patterns as
risk factors for IBD [17]. For instance, the metabolic activity of the microbiota may present important
abnormalities in IBD. A reduced production of SCFAs, which are promoted by the presence of dietary
fiber, has been shown in UC and CD. Particularly in patients with UC, a deficient production of SCFAs
has been shown, and could not be corrected by increasing the intake of wheat bran-associated fiber
and high amylose-associated-resistant starch [5,70].
Among the dietary factors potentially implicated in the development of IBD, dietary fiber has
received special attention due to evidence showing associated protective mechanisms, including the
conversion to SCFAs [71,72], interference in the structure of the gut microbiota [16], and maintenance of
the barrier function [73]. However, a large prospective cohort study evaluating the impact of the intake
of dietary fiber from several sources failed to identify any protective effect against the development of
IBD [74].
Regarding the presumably harmful Western diet, in addition to its general composition
characterized by high animal or dairy fat and animal protein, it is important to draw attention
to the ubiquitous presence of emulsifiers, thickeners, and artificial sweeteners, many of which are
associated with abnormal intestinal permeability, dysbiosis, and intestinal inflammation in animal
models [75,76]. As an integral part of this type of diet, the common use of processed foods, usually rich
in phosphate [77], but poor in micronutrients such zinc and other nutrients including omega-3 fatty
acids, and vitamins D and E [78–80], may also be involved in the development or the predisposition to
chronic intestinal inflammation.
5. Environmental Factors and IBD
The rise of IBD in the developing world has usually been attributed to the industrialization and
urbanization of societies [11,81]. The observation of the coincident increase in immune-mediated and
inflammatory diseases in the more developed and industrialized nations has long been associated
with the hygiene hypothesis [82]. This hypothesis appears to be relatively reductionist, as it
does not explain the dynamics of IBD evolution in long-modernized Asian countries, for example.
Whereas improvements in sanitation and hygiene practices are usually related to the urban compared
to the rural environment, several other concomitant factors affecting the rise of immune-mediated
disorders need to be pondered. For example, areas with a higher prevalence of IBD also have fewer
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infections and are characterized by the widespread use of vaccines and antibiotics, in addition to the
availability of clean food and water [83–85]. Other considerations associated with modern urban life in
developed and developing nations include, for instance, population density, lifestyle modifications,
level of education, and exposure to pollutants [86]. A positive association between ambient air pollution
and IBD has been previously suggested [81], and the residential exposures to nitrogen dioxide and
sulfur dioxide were shown to increase the risk of early-onset IBD [87].
The increased risk for developing IBD has also been associated with the exposure to different
medications. Among them, the use of antibiotics has been shown to increase the risk of IBD, especially
CD [88,89]. In a nested case-control analysis of the population-based database of prescription drugs,
investigators found that patients diagnosed with IBD in childhood were more likely to have used
antibiotics during the first year of life [90]. This positive association was further corroborated,
for example, in a prospective study in which the use of antibiotics was strongly associated with
the development of CD in childhood [91]. Although causality cannot be firmly established to date,
exposure to antibiotics in childhood has been proposed to affect the normal development of tolerance
to enteric bacteria, increasing the risk of IBD [92].
Other medications have been linked to IBD. For example, oral contraceptives have been shown to
have a positive association with the development of IBD, in particular with CD [93]. In a case-control
study, investigators found a positive association between nonsteroidal anti-inflammatory drugs
(NSAIDs) and IBD [94]. In a cohort study, investigators found that the regular use of NSAIDs may
increase CD activity [95]. However, a systematic review did not find a reliable association between
the use of NSAIDs and risk of CD and UC exacerbation [96]. NSAIDs are capable of disrupting
the intestinal epithelial barrier, and this may predispose the individual to the invasion of pathogens
and may affect the intestinal homeostasis. The conflicting results regarding the association between
NSAIDs and IBD may reflect different methodologies but also the participation of other uncontrolled
environmental factors generating unanticipated and confounding effects.
Smoking is a well-established modifying factor in IBD, with opposing effects in CD and UC [97],
but the mechanism by which it regulates intestinal inflammation is still unclear. The composition of
cigarettes is heterogeneous and complex with several chemical elements that may affect different targets
in the intestinal cells and modulate the microbiota [98,99]. Other evidence suggests that chemicals
released from cigarette smoking can interfere with functions related to the immune response, such as
the production of cytokines [100], and significantly impact the microbiota [101].
The functionality of vitamin D, an important regulator of mucosal immunity, is critically related to
the exposure to sun with natural UV light [102]. Therefore, low sunlight exposure has been proposed
to be a risk factor for the development of IBD, especially CD [103,104]. This is in line with the incidence
and prevalence rates of IBD being greater in the Northern Hemisphere, where UV light is markedly
lower [105]. However, the proposed association between IBD, particularly CD, and the northern
latitudes should be interpreted not only in terms of geography, but in a wider context, where several
other variables interact in a complex and dynamic concert, with largely unpredictable outcomes.
6. Epidemiological Associations between Diet and IBD
Although a consistent correlation between environmental factors and the pathogenesis of several
disorders is usually difficult to prove due to the intervening effect of potentially confounding variables
and the uncertain dynamics of exposures, associations between IBD and diet have been reported.
The realization that the increase in the worldwide incidence of IBD and other immune-mediated diseases
began in more developed and industrialized countries, particularly in North America and Northern
Europe, has led investigators to hypothesize the global spread of a “Westernized” lifestyle [106–108].
The observation that the risk of developing IBD increases when people move from a low-risk to
high-risk area appears to further support the role of environmental factors in the detriment of genetic
predisposition, and reinforces the utility of studies examining immigration. For example, distinct
investigations showed that immigrants to Israel had a higher prevalence of IBD than populations born
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in Israel [107,109]. Another population-based study demonstrated that in Sweden, a high incidence
region, second-generation but not first-generation immigrants developed IBD at rates comparable
to the native Swedish population. These results appear to underscore the importance of early-life
exposures in determining disease initiation [110].
Epidemiological studies investigating the South Asian population indicate that the incidence
and prevalence of adult IBD are significantly lower than in North America or the U.K. [111–114].
However, higher incidences of IBD in patients from South Asia have been reported in adult individuals
who subsequently migrated to the U.K. [115], and in children migrating to British Columbia, Canada,
at rates higher than in other ethnicities, including children of Western European descent [116].
In another similar study analyzing a migrant group to investigate the role of environmental factors in
the development of IBD, Middle Eastern migrants to Australia had a significantly higher risk compared
with the Caucasian population. The results, including the analysis of additional exposures such as
smoking, antibiotic usage, and hygiene markers, suggested that migrants might be more sensitive to
environmental challenges influencing the gut microbiome [117]. This thought is further supported by
the results of a population-based study in the Asia-Pacific area in which the investigators suggested
that early childhood factors and markers of altered intestinal microbiota may modulate the risk of IBD
later in life [118].
Another study analyzing an Asian population combined a series of Chinese patients with IBD
with the sequences from RISK and PRISM cohorts of IBD patients from the United States for a
meta-analysis comparing gut microbiome profiles across ethnic groups. The investigators found
that the gut dysbiosis observed in IBD is similar among Chinese and Western populations [119].
This may lead to the question of whether the gut microbiota provides universal biomarkers in IBD
regardless of ethnicity. Results from another study suggest the existence of diverse gut microbial taxa
with differential patterns of abundance common to various immune-mediated inflammatory diseases
(IMIDs), including IBD [120]. These findings appear to corroborate the possible use of microbial taxa
patterns as biomarkers for the detection and diagnosis of IBD, but also support the idea that the gut
microbiota may constitute a common component of the etiology of IMIDs.
Several observational studies have attempted to characterize dietary patterns that could contribute
to a higher risk of IBD development. These studies pointed to an increased risk of IBD among people
consuming larger proportions of meat and fats, and a lower risk among people with diets rich in
fiber, fruits, and vegetables [121,122]. However, as in other complex diseases, it may be difficult
to interpret the role of individual risk factors, and an analysis of dietary patterns should consider
exposures to groups of foods [5], distinct food components, and cultural habits, including specificities
in food preparation.
7. Diet and Epigenetic Modifications in IBD
The epigenome, an intersection between the environment and the genome, has been implicated in
the regulation of gene expression and cellular functions, and plays an essential role in the delineation
of phenotypes and their preservation [21]. Novel information has contributed to an improved
understanding of the role of epigenetic modifications in defining the molecular basis of IBD [123,124].
Regarding IBD, the first epigenetic modifications associated with disease pathogenesis were based on
DNA methylation studies [125].
Currently, among the environmental factors, dietary factors were found to be powerful stimuli,
being associated with peculiar patterns of gene expression and epigenetic signatures [126]. For instance,
the diet supplies substrates for DNA methylation and can regulate the enzymatic activity required in
the one-carbon cycle. Consequently, elements such as folate, choline, and water-soluble B vitamins
have been implicated in methylation patterns [123,127], which are essential elements for the synthesis
and repair of DNA that modulate gene expression [128]. Experimental evidence obtained also supports
the idea that dietary nutraceuticals possess potential as epigenetic modulators. For example, data from
studies involving DNA methylation and chromatin repair indicate that polyphenols can regulate gene
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expression [129]. Polyphenols are secondary plant metabolites, common components of vegetables,
fruits, green tea, and red wine, and have been recognized for their antioxidant properties. In addition,
studies have shown beneficial effects of polyphenols through the modulation of NF-κB expression,
and chromatin remodeling via the modulation of histone deacetylases and DNA methyltransferase
activities, reversing altered gene expression [130]. In experimental IBD, resveratrol, a natural phenolic
compound, was shown to decrease inflammatory cytokines and profibrotic factors, supporting a
potential therapeutic benefit [131].
Curcumin, another natural product commonly used in cooking, has been investigated in
experimental models of IBD, demonstrating beneficial effects mediated by the suppression of
proinflammatory mediators [132]. In a randomized, multicenter, double-blind, placebo-controlled trial,
curcumin has shown beneficial results in maintenance therapy for patients with UC [133]. Although the
exact mechanisms by which curcumin may exert a wide range of biological actions have not been
established, effects have been attributed to the regulation of histone acetylation/deacetylation and the
expression of various microRNAs [134].
Several nutrients have been shown to modulate immune responses, potentially counteracting
inflammatory processes [135], in actions also mediated through epigenetic regulation [123,136].
Processed foods, deficient in micronutrients including selenium and folate, have been implicated in the
progression of diseases, such as colorectal cancer and possibly IBD [21,137–139]. In an experimental
model, a selenium-deficient diet was shown to result in markedly hypomethylated colon DNA [140].
Selenium supplementation was able to prevent tissue damage by modulating the expression of key
genes responsible for inflammation in experimental IBD [141]. Although low levels of selenium have
been detected in the serum of patients with IBD [142], studies in human IBD involving potential effects
of selenium supplementation are still limited [21].
To investigate the mechanisms underlying the potential beneficial effects of the Mediterranean
diet, an intervention with two different diets, one rich in nuts and the other one in extra-virgin
olive oil, was conducted. The evaluation of the methylation status of peripheral white blood cells
genes showed that both diets influenced methylation, characteristically of genes such as CPT1B
and GNAS involved in intermediate metabolism, inflammation, and the signal transduction process.
Therefore, the investigators concluded that the expected beneficial effects of the Mediterranean diet,
supplemented with nuts or extra-virgin olive oil, could be mediated, at least in part, through epigenetic
modifications [16,143,144].
In addition to the direct effects of dietary constituents on epigenetic modifications in human
intestinal tissues, the resident microbiota has been shown to alter host histone acetylation and
methylation. In this regard, particularly short-chain fatty acids such as acetate, butyrate, and propionate,
mostly produced by the microbial fermentation of fiber, appear to play a critical role in the epigenetic
control of the inflammatory response. In a diet poor in fiber, the inhibition of SCFA production was
correlated with disturbed chromatin effects, which were restored following supplementation with
SCFA [145]. In human IBD, SCFA-producing bacteria (Roseburia) and butyrate-producing bacteria
(Faecalibacterium) are reduced [146]. However, the application of butyrate-producing bacteria as
nutraceuticals in humans has been questioned and needs further investigation [123,147]. Figure 1
summarizes the potential interactions between diet and the microbiota and other environmental factors,
resulting in epigenetic modifications, exemplifying the effects of different diets with their respective
major characteristics.
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Figure 1. Schematic model of diet–host interactions in the intestine. The interaction between dietary
elements and the intestinal mucosa is highly complex and, in normal conditions, results in a tolerogenic
response. However, in genetically predisposed individuals, the interplay of specific dietary constituents
with the resident microbiota and other environmental factors induces epigenetic modifications that
affect the immune response, further compromising the epithelial barrier and defense mechanisms,
leading to chronic inflammation, as observed in inflammatory bowel disease (IBD).
8. Clinical Effects of Dietary Factors
Clinical experience shows that patients usually associate their symptoms or disease relapses with
the ingestion of certain foods and, as a result, they often change their diet empirically, with variable
and, at most, temporary effects. In practice, decisions on dietary modifications usually do not follow
professional nutritional advice and may have detrimental consequences [17,148–150]. In a prospective
study investigating the dietary influence in the course of UC, researchers observed that a large ingestion
of meat, more so of red and processed meat, in addition to ethanol, protein, sulfur, and sulfate, enhanced
the chances of triggering a flare [151,152]. In the case of patients with CD, a diet rich in total fat, saturated
fat, monounsaturated fatty acids, and a higher ratio of omega-6:omega-3 polyunsaturated fatty acids
(PUFAs) was related to disease relapses [153,154]. Of note, the oral administration of iron sulfate or
heme in dietary iron, which is present in meat, was shown to increase the severity of chemically-induced
colitis in rodents [155,156]. However, although a substantial number of iron-deficient patients tolerate
oral iron poorly, only a small percentage of patients with IBD have disease relapses attributed to
oral iron [157]. Anemia is a common complication of IBD, mostly multifactorial, but frequently
related to iron deficiency due to loss from bleeding and decreased iron absorption or ingestion [158].
Although many physicians have concerns regarding the management of iron deficiency in IBD, current
data suggest that oral iron therapy should be preferred in mild cases or during clinical remission,
unless patients are intolerant or have an inadequate response [159]. The aggravation of experimental
colitis following dietary iron has been associated with a marked reduction in the fecal abundance of
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Firmicutes and Bacteroidetes, and an increase in Proteobacteria [160]. Hence, poor outcomes following
oral iron replacement in patients with IBD could be related to exacerbation of the intestinal dysbiosis.
9. Dietary Interventions in IBD
Simple dietary interventions usually improve gastrointestinal symptoms in patients with IBD,
including a reduction in the ingestion of dairy products and also fermentable oligosaccharides,
disaccharides, monosaccharides, and polyols (FODMAPS) [161]. More recent data have demonstrated
the possible roles of specific dietary therapy in IBD. For example, dietary therapies, such as exclusive
enteral nutrition (EEN), have been successfully used to induce remission in early or new-onset CD [162].
Theoretically, EEN involves the isolated use of medical formulas in a liquid form without exposure
to other foods, usually for six to eight weeks [5]. This strategy is apparently more feasible in the
pediatric population, in contrast to adults. Investigations have demonstrated that EEN may induce
remission in more than 60% of children with CD followed by a significant reduction in inflammatory
markers, including the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal
calprotectin [5,163–165]. Grover et al. conducted a prospective open label study to assess mucosal
healing before and after eight weeks of EEN, and concluded that the therapy is effective for inducing
early clinical, biochemical, mucosal, and transmural remission, and was associated with improved
outcomes at one year [166].
Given practical concerns and clinical limitations, other research groups have employed a different
strategy based on the combination of partial enteral nutrition (PEN) with a specific exclusion diet granting
access to whole foods. The diet was evaluated in a retrospective cohort of children and young adults
with mild-to-moderate CD, and remission was achieved in 70% of patients. Clinical improvement was
followed by the reduction in ESR and CRP and was associated with mucosal healing [167]. Afterward, this
diet—low in animal fat, rich in complex carbohydrates, and with a moderate exposure to soluble fiber—was
evaluated for the induction of remission in children and adults failing biologics. More than 60% of the
patients achieved clinical remission, with a marked decrease in inflammatory markers [168].
Other important theoretical dietary elements, fiber, and prebiotics supplements have been
evaluated as interventions in CD. However, a systematic review of randomized controlled trials found
no evidence for the use of fiber or prebiotics to induce or maintain remission in CD [169]. No evidence
for the restriction of fiber in the absence of obstructive symptoms or stricturing disease has been
established for CD. In another study, a semi-vegetarian diet with considerable amounts of dietary fiber
was shown to induce a high remission rate with no negative effects [170]. The same group investigated
the effect of infliximab combined with a plant-based diet as first-line therapy for patients with CD
naïve to biologics and found that the combined therapy can induce remission in most cases [171].
Although the most consistent studies regarding dietary interventions in IBD usually refer to
CD, previous systematic evaluations performed by independent groups have supported the potential
beneficial effects of diet in both CD and UC according to patients’ perceptions [149,172]. In an
observational prospective cohort study, patients with UC in clinical remission were followed for one
year to investigate the effect of diet on disease relapse. The investigators identified an increased
risk of UC relapses associated with the consumption of meat (particularly red and processed meat),
eggs, and alcoholic beverages, which have been attributed to the high dietary content of sulfur [151].
In addition to red meat and eggs, milk and dairy products contain high concentrations of cysteine,
which can be used by sulfate-reducing bacteria (SRB) to produce hydrogen sulfide (H2S) [173,174].
H2S, in turn, has been shown to induce proinflammatory effects in the colon and intestinal epithelial
cells [175–177]. Some studies have demonstrated the increased presence of SRB and H2S production
in the colon of patients with UC [178–180]. However, despite all evidence suggesting a link between
sulfur or sulfate-containing foods and UC, current data do not allow a causal association. While more
controlled studies regarding SRB and H2S in UC are awaited, patients should be aware of the potential
detrimental effects of high-sulfur-containing dietary products.
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The nutritional theories of IBD pathogenesis involving carbohydrates, for example, have been based
on the increasing evidence of the beneficial effects of the Specific Carbohydrate Diet in the treatment of
both CD and UC, resulting in improvement in clinical parameters and inflammatory biomarkers [181–183].
The hypothesis that carbohydrate variation increases the predisposition to IBD has been supported by the
evidence of resultant immune dysfunction, mucosal barrier defects, and dysbiosis, which are represented
by the Westernized dietary features [1,184,185]. Carbohydrate monotony could be beneficial in IBD [186].
This has been corroborated by a successful report using the Paleo diet for a small cohort of patients with
IBD [187]. Paleo is also an exclusion diet, supposedly representing habits of the Paleolithic era, consisting of
a non-cereal, plant-based diet, including non-domesticated meats, and a low intake of carbohydrates, which
are taken from a monotonous source. The rational for the use of carbohydrate monotony derives from
the usually lower prevalence of IBD in rural or less developed communities consuming locally-produced
seasonal products [16], in contrast to the modern Westernized diet, for which the digestive tract would
theoretically not have had time to adapt [188].
In terms of dietary supplements, vitamin D appears to have a role in IBD. Vitamin D3 (animal
sources and skin exposure to ultraviolet light) and vitamin D2 (plant sources) are first hydroxylated
in the liver, and then in the kidney and extrarenal tissues, including intestinal macrophages, into the
active form 1,25-dihydroxyvitamin D. The active vitamin D binds to its specific receptor in different
tissues, including immune cells, modulating gene expression. Vitamin D deficiency has been frequently
seen in patients with IBD; therefore, it has been regarded as a protective factor against disease
development [189,190]. Particularly in patients with CD, vitamin D deficiency has been consistently
associated with disease activity [79,191,192]. Vitamin D3 supplementation for patients with CD has
been suggested to alleviate clinical manifestations [193]. In another clinical investigation, a randomized
double-blind placebo-controlled study, dietary supplementation with 1200 IU vitamin D3 daily for
12 months significantly increased the vitamin D levels, but only modestly reduced the risk of disease
relapse [194].
Currently, the exact mechanisms by which vitamin D may reduce the severity of CD are still unclear.
In a study using peripheral blood mononuclear cells, investigators found that vitamin D was able to
reduce the expression of pro-inflammatory M1 cytokines but did not induce the anti-inflammatory
M2 phenotype [195]. In other experimental studies, vitamin D deficiency, or even its impaired signaling,
were shown to worsen different models of experimental colitis through multiple effects, including
epithelial barrier disruption [196,197], reduced mucosal immunity [198], and an association with gut
dysbiosis [199,200].
10. Future Directions
Among the environmental changes associated with the progressive and global expansion of
IBD, diet has emerged as an essential regulatory element of the gut microbiome, which in turn
has been strongly associated with the pathogenesis of several complex chronic inflammatory and
autoimmune disorders. In addition to the involvement in dysbiosis, dietary components have been
shown to interfere in intestinal homeostasis, modulating the barrier function and innate immunity
mechanisms. Therefore, the accumulated scientific evidence appears to position diet as a central
element both in disease pathogenesis as a critical risk factor and also as a potential opportunity for
therapeutic interventions. Currently, several clinical trials are being conducted in different institutions
and, hopefully, novel approaches to dietary therapy will be available in the near future.
Considering the progressive burden due to IBD anticipated in the next decades, dietary
interventions appear particularly interesting, presumably due to the expected irrelevant side effects,
lower costs, and potential application in the prevention of disease initiation or relapses. For the
moment, however, the simplest approach includes the avoidance of foods that patients self-identify
as worsening their symptoms, in addition to high-fat, high-carbohydrate meals and processed foods.
Notably, dietary measures should be considered within the wider context of the patient’s routine,
not only in terms of food quality, but also changes in lifestyle, including dietary habits. For this
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purpose, while the results of large prospective controlled studies are awaited to provide more specific
dietary guidance to patients, it is important to reinforce the role of multidisciplinary teams, including
nutritionists, for offering better attention to and individualized support for patients with IBD.
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Abstract: Ageing of the human population has become a big challenge for health care systems
worldwide. On the other hand, the number of elderly patients with inflammatory bowel disease (IBD)
is also increasing. Considering the unique clinical characteristics of this subpopulation, including many
comorbidities and polypharmacy, the current therapeutic guidelines for the management of IBD
should be individualized and applied with caution. This is why the role of non-pharmacological
treatments is of special significance. Since both IBD and older age are independent risk factors of
nutritional deficiencies, appropriate dietary support should be an important part of the therapeutic
approach. In this review paper we discuss the interrelations between IBD, older age, and malnutrition.
We also present the current knowledge on the utility of different diets in the management of IBD.
Considering the limited data on how to support IBD therapy by nutritional intervention, we focus
on the Mediterranean and Dietary Approaches to Stop Hypertension diets, which seem to be the
most beneficial in this patient group. We also discuss some new findings on their hypothetical
anti-inflammatory influence on the course of IBD.
Keywords: inflammatory bowel disease; malnutrition; Mediterranean diet; older age
1. Introduction
The frequency of Crohn’s disease (CD) and ulcerative colitis (UC), two forms of inflammatory
bowel disease (IBD), is increasing worldwide [1–3]. Simultaneously with the demographic ageing of the
human population observed in recent decades, especially in developed countries, the number of elderly
IBD patients is also increasing [4–8]. Considering the definition of elderly as aged 60 years and above,
it is estimated that 25–35% of CD and UC patients meet this criterion. These data encompass both those
who were diagnosed before reaching 60 and those who were diagnosed when over 60 (elderly onset).
The latter group, representing 10–15% of all IBD patients, reflects the second peak of CD and UC
morbidity [9]. UC is the more frequent IBD subtype in this age range, since one in eight UC patients is
older than 60, compared to one in 20 CD cases [9]. A population-based cohort study by Charpentier
et al. revealed that, among elderly people suffering from IBD, 65% are between 60 and 70 years old,
25% between 70 and 80 years old, and 10% are older than 80 [10].
There is an increasing body of evidence showing several differences in the clinical course and
management of elderly IBD patients, compared with those suffering from UC or CD at a younger age.
One of the most important characteristics is a tendency for less aggressive therapeutic regimens [11–13].
On the other hand, the significance of non-pharmacological and non-surgical interventions is higher.
Since both IBD and older age are independent risk factors of nutritional deficiencies, appropriate dietary
support is needed, especially in the cases of patients older than 60 with UC or CD [12,14,15]. In this
Nutrients 2019, 11, 1421; doi:10.3390/nu11061421 www.mdpi.com/journal/nutrients302
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review, we discuss the influence of older age on the physiology of the gastrointestinal tract and the
mechanisms leading to malnutrition, especially in the context of IBD in the elderly. We summarize the
main differences in the clinical course and management of IBD in the elderly with special emphasis on the
role of diet. We also present some recommendations for nutritional support for this unique population.
In order to analyze the current literature on dietary support among elderly IBD patients, we searched
the PubMed and Web of Science databases using the key words “diet and IBD”, “elderly IBD”, “diet in
elderly people”, and “nutrition in elderly IBD patients”. We identified mainly review papers, meta-analyses,
and guidelines published after 2010. Moreover, we analyzed conference abstracts from the Congresses of
the European Crohn’s and Colitis Organisation (ECCO) in 2018 and 2019.
1.1. Elderly IBD Patient—Differences in Clinical Course and Management
There are several characteristic features of elderly IBD. The delay in the diagnosis of CD or UC
is longer than that in younger patients. This is related to less specific symptoms and to a frequent
co-existence of other comorbidities and polypharmacy. Differential diagnosis encompasses many
entities like ischemic colitis, infectious diseases, drug adverse reactions (non-steroidal anti-inflammatory
drugs, anticoagulation, anti-platelet drugs, chemotherapy, etc.), diverticulitis, radiation colitis,
and microscopic colitis. Performing invasive diagnostic investigations (like colonoscopy) can also
be challenging, since older age, other comorbidities and drugs used are risk factors for severe
complications [5,6,16,17].
The clinical course of elderly IBD seems to be less aggressive [6,8]. In CD, there is a higher
frequency of colonic location [16,18]. On the other hand, complications like strictures or perianal
involvement and extraintestinal manifestations are less common. As a result, the clinical presentation of
elderly CD can be similar to UC, with rectal bleeding as a main symptom. Abdominal pain, weight loss,
and diarrhea are less typical [16,18–20]. In the case of elderly UC, the predominant location is E2 or E3
according to the Montreal classification, whereas isolated proctitis is rare [20,21]. The disease is more
stable over time and there is a low frequency of proximal disease colonic extension [19,20]. The need
for a colectomy is also relatively low. A French population-based registry (EPIMAD) showed that only
16% of elderly onset UC patients underwent a colectomy in a ten-year follow-up period [6,8,22–24].
Despite a milder clinical course in long-term observation, the first IBD episode can be paradoxically
more severe than in younger patients [18]. Older age also seems to be related to a more frequent
hospitalization rate in IBD [18,20]. A study by Ananthakrishnan et al. revealed that hospitalized IBD
patients older than 65 are at a higher risk of significant malnutrition, anaemia, and hypovolemia [25].
The frequency of thromboembolic complications is increased due to hypercoagulability, dehydration,
prolonged bed rest, and immobilization. This is why the hospitalization of elderly IBD patients seems
to be connected with higher fatality [18,26–29].
Although there are no randomized, controlled trials assessing the therapeutic strategies
for IBD in the elderly, medical and surgical management is often different from patients of a
younger age [30–34]. The usage of many medications is limited due to their higher toxicity
(e.g., corticosteroids), the risk of interactions (e.g., thiopurines with allopurinol, mesalamine with
anticoagulants), contraindications (e.g., renal insufficiency in the case of mesalamine, severe congestive
heart failure in the case of anti-tumor necrosis factor alpha antibodies), and higher rates of adverse events
(e.g., serious infections, diabetes, arterial hypertension, mental disorders in the case of corticosteroids
or neoplastic complications in the case of thiopurines) [7,35–53]. The safety of newly registered
immunosuppressive molecules and biological agents (tofacitinib, anti-integrins–vedolizumab,
or anti-IL-12/23 antibodies–ustekinumab) in elderly IBD patients has not been studied at all [54].
General indications for surgery in IBD patients aged >60 are similar, when compared with the
younger subgroup, however, a decision to use surgical intervention should be taken with caution
since there is a higher risk of post-operative complications and mortality [5,11]. Nevertheless, in many
cases surgery is inevitable, which is why, in order to improve therapeutic outcomes, optimal treatment
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should be applied preoperatively, with minimization of corticosteroid use and extensive nutritional
support [5,11,55–57].
The rules for disease monitoring in elderly IBD patients should be also adjusted for age and
concomitant morbidities. Since repeated endoscopic assessment is often impossible, the importance of
non-invasive markers of inflammatory activity, like fecal calprotectin or C-reactive protein, is high [58,59].
In terms of cross-sectional imaging methods, repeated computed tomography or magnetic resonance (MR)
imaging can be difficult and, in many cases, contraindicated [60]. This is due to the fact that a significant
proportion of older patients suffer from renal insufficiency or are at a high risk of this complication,
which makes the administration of an intravenous contrast agent impossible. Another limitation for MR
imaging is the high frequency of metallic implants (e.g., after a total hip or knee replacement or after the
implantation of a cardiac rhythm control device) in elderly people. This is why more common use of an
abdominal ultrasound should be advised for the objective assessment of morphological abnormalities in
the gastrointestinal tract [60].
1.2. Ageing, IBD, and Malnutrition—What Are the Connections?
As discussed above, there are many limitations for the routine application of classical therapeutic
approaches in the case of IBD in elderly patients. Thus, non-pharmacological and non-surgical
interventions are of great importance. The role of dietary support is especially high, since ageing by itself
increases the risk of malnutrition. Epidemiological analyses show that 5%–20% of European citizens
aged 60 and older suffer from malnutrition, while for hospitalized patients or those in long-term
care, these numbers are even higher [61]. Thus, obligatory assessment of the nutritional status of all
older patients is recommended by both the American Society for Parenteral and Enteral Nutrition
(ASPEN) and the European Society for Parenteral and Enteral Nutrition (ESPEN). A Mini Nutritional
Assessment (MNA) is believed to be the most appropriate tool for this purpose [62–64].
The etiology of malnutrition in older people is multifactorial. There are multiple medical
conditions associated with a high risk of weight loss and nutritional deficiencies, like cancer,
pulmonary disorders (chronic obstructive pulmonary disease), diabetes, cerebrovascular and neurological
diseases, and gastrointestinal disorders. Many of those conditions are characterized by an increased
catabolism, loss of appetite, and dysphagia. Multimorbidity and polypharmacy—typical phenomena
among elderly people—are also connected with higher hospitalization rates, and increased probability
of significant drug interactions [65]. These factors can independently promote malnutrition [65–67].
Another important problem is poor oral health and dental status leading to chewing difficulties and
mouth dryness, which can cause lower food intake [68,69]. Depression, anxiety, dementia, and many other
neuropsychological factors can result in unintentional weight loss and nutritional deficiencies [70–72].
There are also many social determinants of malnutrition risk, like poverty, loneliness and isolation,
an inability to shop or cook, secondary to cognitive disorders and/or physical disability [73,74].
Interestingly, although ageing per se is not always associated with malnutrition, there are several
physiological phenomena increasing the risk of weight loss. Decreasing appetite among elderly and
otherwise healthy people can be explained by a reduction in stomach capacity and impairment of gastric
relaxation, accompanied by lower gastric emptying. One of the etiological hypotheses for these processes
in older people is fluctuation in the production and secretion of several enterohormones. There are data
suggesting that higher levels of cholecystokinin and lower concentration of ghrelin can contribute to
early satiation after food consumption. Moreover, degenerative processes in the gastrointestinal tract can
result in the reduction in the number of taste buds, which can be accompanied by a deterioration in the
sense of smell. These phenomena can additionally demotivate the patients to consume regularly [75–77].
Since the mechanisms underlying malnutrition in elderly people are complex, three types of
weight loss proposed by Roubenoff can coexist: wasting, cachexia, and sarcopenia [78,79]. Wasting is
associated with inadequate dietary intake and results in involuntary weight loss [80]. Cachexia is
caused by induced catabolic processes, with pro-inflammatory cytokines like interleukin-1 (IL-1),
tumor necrosis factor–alpha (TNF-alpha), IL-6, and others having a predominant role. The main
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consequence of cachexia is a decrease in fat-free mass and body cell mass [81]. Sarcopenia is defined
as a loss of muscle mass [78,79,82]. The etiology of this phenomenon is poorly understood, however,
a dominant role is hypothetically played by a lack of physical activity, induction of the pro-inflammatory
response, and dysregulation of anabolic hormones, like testosterone or growth hormone [83,84].
IBD is independently associated with an increased risk of malnutrition. Epidemiological data
shows that 65%–75% of CD patients and 18%–62% of UC patients have nutritional deficiencies [85].
The discrepancies in these numbers are a consequence of the different definitions of malnutrition.
Body mass index (BMI) is among the most frequently used criteria, but it has been widely criticized
recently, since it does not take into account several qualitative and quantitative parameters like the
relation between fat and muscle mass, the concentration of micro- and macronutrients, recent changes
in body mass or disease activity [86]. There are many data showing that low body mass is only one of
the dimensions reflecting malnutrition in IBD. Among other parameters, which have been frequently
reported, are deficiencies in iron, calcium, selenium, vitamin D and/or vitamin K [85].
The etiology of malnutrition in IBD is complex. It encompasses disease-related and
treatment-related factors [85]. In the first group, a decrease in food intake seems to be the most
important. This phenomenon can be related to IBD symptoms, like nausea, vomiting, abdominal
pain, diarrhea, fever or fatigue. Also, it has been shown that hospitalization is associated with
a higher risk of inappropriate food intake due to a frequent need to fast in preparation for
different investigations or due to an inadequate hospital diet [85,87]. Moreover, disease activity
by itself, with the production of multiple pro-inflammatory cytokines, induces catabolic processes,
and promotes increased energy expenditure, contributing to malnutrition. The absorptive functions of
the gastrointestinal tract are also impaired due to bowel wall damage with a loss of epithelial integrity,
bacterial overgrowth, and increased intestinal motility. The same factors contribute to enhanced
nutrient loss [85,88]. Considering the treatment-related causes of malnutrition, there are data on the
negative impact of steroids on body composition. Moreover, nitroimidazoles or immunosuppressive
drugs (thiopurines, methotrexate) can also alter the appetite, leading to reduced food intake [85].
On the other hand, multiple surgical resections limit the absorptive gastrointestinal surface, in spite of
the high compensatory potential of the remaining parts of the intestines [85].
Taking into consideration the complex etiology and high frequency of malnutrition among elderly
people and IBD patients analyzed separately, the significance of this phenomenon among CD and UC
patients aged 60 and older becomes especially challenging. In order to prevent and/or adequately treat
this unique subpopulation, proper dietary support is needed.
1.3. The Role of Diet in IBD and the Elderly
There are no strict dietitian recommendations for patients with IBD, since there are insufficient data
for promoting any special diet. The general rule is that patients should cover their energy demand by
eating well-balanced meals containing complex carbohydrates, proteins and fats, mainly of plant origin,
rich in vegetables and fruits, with the elimination of highly processed foods [89]. Special attention
should be paid to appropriate iron and vitamin D consumption. In each case, however, a highly
individualized recommendation should be defined in order to adjust the nutritional needs to a concrete,
clinical scenario, especially in older people.
According to current knowledge, in the case of physiological ageing special recommendations
should be given for protein, vitamin D, and water consumption. In order to maintain muscle mass,
the PROT-AGE study group defined the daily protein requirement, which is 1.0–1.2 g protein/kg
body weight [90]. Moreover, all individuals should supplement vitamin D3 in a dose of 800–2000 IU
per day [91]. Adults should drink 30–35 mL/kg body weight (at least 1500 mL/day or 1–1.5 mL/1 kcal) of
water (preferably medium-carbonized and still water). Since there is an increased risk of dehydration
among older people, the recommendations for daily water consumption in this subpopulation (similar to
the pediatric population) are more precisely defined as 100 mL of water for the first 10 kg, then 50 mL
for second 10 kg, and 15–20 mL for each additional kilogram of body weight [92,93]. In addition,
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older adults are in the groups at risk of vitamin B12 deficiency. The usual dietary sources of vitamin
B12 are animal products, including fish, meat, poultry, eggs, milk, and milk products. Vitamin B12
is generally not present in plant foods, but a lot of these products are fortified. The vitamin B12
recommended dietary allowance for older adults is 2.4 μg/day [94,95].
In the case of high IBD activity, especially in patients with severe diarrhea and abdominal pain
due to stricturing CD, it is advisable to avoid a high intake of fiber and lactose, in order to prevent
bacterial overgrowth and reduce the number of bowel movements [96]. The daily protein requirement
is 1.2–1.5 g protein/kg body weight [96]. Resting energy expenditure during a flare is 25–30 kcal/kg
standard body weight [96–98]. Moreover, according to the ESPEN recommendations, oral nutrition
supplements (ONS) should be considered in addition to a normal diet for the treatment of nutritional
deficiencies in the case of IBD exacerbation [96]. ONS contain high amounts of all (complete) or
selected (incomplete) macro- and microelements in relatively small volume products. ONS can be
also divided into two categories: standard ONS which contain different nutritional compounds in
proportions characteristic for a normal oral diet and specific ONS which is composed adequately for
some particular patient populations (e.g., Parkinson’s disease, Alzheimer’s disease, etc.). ONS can
be used together with meals; they contain no lactose, gluten, purines or cholesterol and should be
considered in each case of increased malnutrition risk or diagnosed malnutrition [96,99].
Recent years, however, have brought plenty of data about the crucial role of impaired microbiota
in the pathogenesis of intestinal inflammation. Moreover, there is a growing body of evidence that
also ageing is associated with changes in intestinal microbiota composition. In 2007 the ELDERMET
consortium was established to investigate this topic [100]. They found (by using the pyrosequencing
of 16S rRNA method) that there was an increase in Bacteroidetes and a concomitant decrease in
Firmicutes species among older people, however there was a significant inter-individual variability
in the composition of elderly gut microbiota [101]. One of the reasons was the health status of the
investigated subjects. The statistical analysis indicated a clear separation between community-dwelling
subjects and long-stay home residents [101]. Another observation was that health status and the
diversity of the intestinal microbiota in the ELDERMET study correlated with the patients’ nutritional
habits. It was shown that the diversity index of the fecal microbiota was significantly associated with a
low-fat and high-fiber diet [101]. It is, however, still not known whether changes in gut microbiota are
a result of dietary intervention or are more related to unhealthy ageing by itself.
Nevertheless, the possibility of shaping the intestinal microbiota by nutritional interventions
would be very attractive. The hypothetical promotion of a “healthy” in-vironment (microbiota) by
environmental factors (diet) seems to be an interesting concept for therapeutic intervention also in IBD.
This is why dietary intervention is currently considered not only in the context of sufficient nutritional
support, but also as a potential modulator of intestinal inflammation [102,103]. Our understanding of
the link between nutrition, intestinal microbiota, and inflammatory response is still poor, however,
due to the development of new technologies such as metabolic profiling and next-generation DNA
sequencing, we know that microbiota composition changes after exposure to different modifying
factors [104]. For example, there are data showing that a high-fat and low-fiber diet, as well as
an animal-based diet, increase the abundance of Bacteroidetes and Prevotella, which are believed to
participate in the development of chronic inflammation in the gastrointestinal tract [105]. On the other
hand, dietary fiber can promote short-chain fatty acids synthesis by colonic microbiota, which can lead
to the suppression of pro-inflammatory cytokines from dendritic cells and macrophages [104,106,107].
Another hypothetical association between the diet and inflammation is the epigenetic regulation of gene
expression by different nutritional components. There is some evidence that the typical Western diet,
deficient in micronutrients, like selenium and folate, can influence DNA methylation, which promotes
pro-inflammatory phenomena and seems to increase colorectal cancer susceptibility [104]. What is
more, in an experimental model of IBD it was shown that selenium supplementation prevented tissue
damage through interfering with the expression of the key genes responsible for inflammation [104,108].
Nevertheless, although these concepts of the associations between diet, microbiota, and inflammatory
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response are very promising, we are still not able to translate this knowledge into clinical practice.
We hope that it will be possible in the future to modulate our microbiota by changing the in-vironmental
milieu via nutritional intervention, but we still need more data.
Among different diets already studied in the context of IBD, main attention is being paid to
the low-fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) and
anti-inflammatory diet (IBD-AID), although supporting scientific evidence is relatively poor [104].
Recently, the advantages of the Mediterranean or the Dietary Approach to Stop Hypertension (DASH)
diets in the context of chronic inflammation have also been discussed [105,106].
The main rule of the low-FODMAP diet is to exclude highly fermentable and poorly absorbed
carbohydrates and polyols. In this diet, consumption of different food types is strongly discouraged,
such as many fruits (e.g., apple, blackberry, grapefruit, mango, nectarine, peach, plum, watermelon),
vegetables (e.g., artichoke, asparagus, avocado, onion, cabbage, garlic, leek, pea), dairy (e.g., cow, goat,
sheep, condensed and evaporated milk), beverages (e.g., green tea, soft drinks, white tea, coconut
water) and many nuts, seeds and legumes. Moreover, breaded meat or meat made with high fructose
corn syrup should be avoided. This is not a long-term diet and the dietary limitations should last for
only 6–8 weeks. Then patients should gradually restart foods high in FODMAPs in order to establish
an individual tolerance to specific oligosaccharides, disaccharides, monosaccharides, and polyols.
The utility of the low-FODMAP diet has been shown mainly for patients with irritable bowel syndrome
(IBS), since there is a hypothesis that high fermentation in the gastrointestinal lumen can lead to
increased intestinal permeability and provoke intestinal hypersensitivity in a genetically susceptible
host [107,108]. Data on the usefulness of this diet in IBD are limited and mainly come from retrospective
cohorts. It is advised that a low-FODMAP diet can be used in selected IBD patients with IBS-like
symptoms in addition to conventional therapy, but only under strict dietitian supervision [104–115].
IBD-AID is a multistep and highly individualized dietary intervention, limiting some specific
carbohydrates (e.g., refined sugar, gluten-based grains, certain starches). Olendzki et al., who developed
IBD-AID, hypothesized that this can decrease the growth of several pro-inflammatory bacteria in the
gastrointestinal tract, preventing dysbiosis [116]. In the next step, the patient should ingest prebiotics
and probiotics (e.g., leek, onion, fermented food) to promote restoration of the microbiota. Moreover,
the consumption of total and saturated fat, and hydrogenated oils should be avoided, together with
the individual identification of dietary intolerances and nutritional deficiencies. The rules of IBD-AID
were first published in 2017 and until now there were no randomized, controlled trials conducted in
order to confirm the initial, promising reports on the use of this diet as an adjunct therapy for the
treatment of IBD [104,116].
Lack of sufficient data for the usefulness of the low-FODMAP diet and IBD-AID in IBD result in a
high skepticism of clinicians to promote this kind of dietary intervention. In the case of elderly IBD
patients, another important limitation for the use of these diets is their complexity. Moreover, there is
a high risk of several nutritional deficiencies due to the restriction and avoidance of different foods,
especially when the dietary intervention is conducted without professional support. This can have
serious negative consequences, considering the general increased risk of malnutrition and the presence
of serious comorbidities in older people. This is why it seems to be more reasonable to promote safer
diets, with more robust data in the context of elderly patients.
Considering the nutritional requirements and characteristics of elderly patients with IBD discussed
above, as well as the most common disorders among older people (arterial hypertension and other
cardiovascular diseases, type 2 diabetes, hypercholesterolemia), the DASH or Mediterranean diet
could be recommended for this unique population. The main restrictions in the DASH diet concern
carbohydrates and fats, in particular by limiting simple carbohydrates (glucose, fructose, saccharose)
and reducing the intake of saturated fats. This means a significant reduction in the consumption
of sweets, sugar confectionery, sweeteners, fruit preservatives (less than five portions per week),
as well as red meat and highly processed food. Vegetables and fruits should be eaten 4–5 times/day,
and whole grain products 6–8 times/day. The DASH diet also includes medium-fat dairy products
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(2–3 portions/day), however, this needs to be accompanied with regular consumption of vegetable
oils (preferably raw, inter alia, to enable the absorption of fat-soluble vitamins). The recommended
frequency for eating fatty saltwater fish (herring, salmon, mackerel, halibut, sardine, codfish, flounder)
is 2–4 times/week. Different seeds, nuts, legumes are also an important part of the DASH diet, since they
contain (similar to vegetable oils—linseed, soybean or rapeseed oil— and fatty saltwater fish) high
amounts of omega-3 polyunsaturated fatty acids (PUFA). Another main rule of this type of diet is a
significant reduction in salt (sodium) consumption [117].
Although there are no data on the utility of the DASH diet in IBD, its beneficial effect on general
health status and cardiovascular risk is well known [118–121]. Moreover, Nilsson et al. showed that
adherence to a DASH-style diet was significantly associated with a lower clustered metabolic risk
among older women, and it promoted a systemic anti-inflammatory environment, independently of
physical activity [122]. The authors concluded that the DASH diet should be considered as a key target
for nutritional intervention among elderly people to prevent age-related metabolic abnormalities.
The general recommendations of the Mediterranean diet are very similar to DASH. It emphasizes
eating primarily plant-based foods (fruits, vegetables, whole grains, legumes, nuts, seeds, olive oil),
which should be consumed several times per day, together with dairy products (mainly different
types of cheese, yogurts). Low or moderate alcohol drinking (preferably red wine with a meal) is also
advised. Fish, eggs, and poultry can be consumed several times per week. In contrast, consumption
of sweets and red meat should be significantly reduced (a few times per month). The details of the
Mediterranean diet can vary depending on the region of the Mediterranean Basin; however, the general
rule is to eat foods coming from this geographic area [123,124].
In contrast to the DASH diet, there are some data on the usefulness of Mediterranean diet in IBD.
Marlow et al. demonstrated that even a short-term (six weeks) nutritional intervention is beneficial
for patients with CD, decreasing the concentration of several pro-inflammatory markers with a trend
to normalize the composition of intestinal microbiota. Transcriptomics analyses confirmed small
changes in many genes, providing a cumulative anti-inflammatory effect of the diet [125]. In another
study, Godny and colleagues showed that the Mediterranean diet is associated with decreased fecal
calprotectin in patients after pouch surgery in UC, which is accompanied by an improvement in gut
microbiota composition [126]. Moreover, Molendijk et al. demonstrated a beneficial effect of long-term
nutritional intervention in IBD. In this study, six months of the Mediterranean diet improved the
quality of life and reduced CRP levels. The level of improvement was associated with adherence to the
rules of this type of diet [127].
The question remains, which hypothetical mechanisms could be related to the anti-inflammatory
properties of the Mediterranean diet in IBD. As discussed above, this diet is characterized by a
low intake of omega-6 PUFA, high intake of omega-3 PUFA, and dietary fiber, which seems to be
important in the context of IBD. In line with that, the most recent epidemiological data indicate
that a higher ratio of omega-6/omega-3 PUFA in the diet can be associated with an increased UC
incidence [128]. Moreover, Hou et al. noted that a high intake of omega-6 PUFA, saturated fats,
and meat is correlated with an increased risk of developing UC and CD [129]. It was also shown in a
murine dextran sulfate sodium (DSS)-induced colitis model that omega-6/omega-3 PUFA ratio in the
diet can influence the inflammatory processes in the gastrointestinal tract [130]. The authors observed
that an α-linolenic acid (ALA)-enriched diet with a decreased uptake of linoleic acid (LA) resulted in
less severe colitis in mice, with a markedly alleviated intestinal inflammation [130]. This was supported
by Pearl et al. who showed the association between severity of intestinal inflammation and increased
content of omega-6 PUFA in inflamed mucosa in UC patients [131]. Furthermore, Uchiyama et al.
investigated the influence of a diet therapy involving the use of an “omega-3 PUFA food exchange
table”. The authors showed that omega-3 PUFA significantly increased the erythrocyte membrane
omega-3/omega-6 PUFA ratio in IBD patients, what was associated with clinical remission of the
disease [132]. Recently, another experimental study on the protective role of omega-3 PUFA has been
published. Charpentier et al. showed that supplementation of omega-3 PUFA significantly decreased
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colon inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, as well as IL-6
and leukotriene B4 production in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis [133].
Dietary fiber is also believed to have a protective effect on the development of inflammation
in the gastrointestinal tract. Moreover, the short-chain fatty acids, regarded as one of the major
microbial metabolites of dietary fiber, have the potential to improve intestinal mucosal immunity
and maintain homeostasis [134]. There are several experimental and clinical data supporting these
hypotheses. Liu et al. showed in a murine DSS-induced colitis model that supplementation of
β-glucans at a dose of 500 mg/kg per day reduced the severity of clinical activity of the disease.
β-glucans-enriched diet resulted in a smaller weight loss, improvement in the number of bowel
movements, and amelioration of the inflammatory response assessed microscopically. It has been also
shown that β-glucans supplementation inhibited the expression of pro-inflammatory proteins, such as
TNF-α, IL-1, IL-6 or NOS [135]. On the other hand, based on the data from the Nurses’ Health Study,
it was suggested in a prospective study that a long-term intake of dietary fiber was associated with
lower risk of CD, but not UC [136]. A meta-analysis, performed by Liu and colleagues, indicated that
the intake of dietary fiber was related to a decreased risk of developing IBD [137]. In a recent study by
Andersen et al. an inverse association between the consumption of cereal fiber and CD in non-smokers
was confirmed [138].
The only theoretical limitation of the DASH or Mediterranean diet in IBD is the high amount
of whole grain cereal products, nuts, and seeds of leguminous plants which can stimulate intestinal
peristalsis and increase the frequency of bowel movements. This is why it is advised to reduce the
consumption of these particular foods during an IBD flare, whereas in patients in remission the
individually tolerated amount of these products should be established.
The main rules of DASH and the Mediterranean diet are presented in Tables 1 and 2.
Table 1. The rules of Dietary Approaches to Stop Hypertension (DASH) diet [117].





Cereal products 6–8/day whole grain refined
Vegetables 4–5/day all -
Fruits 4–5/day all -
Protein 6 or less/day fatty saltwater fish, lean meat,seeds of leguminous plants fatty, red meat
Nuts and seeds 4–5/week all -
Fats 2–3/day vegetable oils rich inunsaturated fatty acids animal fat, coconut oil, palm oil
Dairy products 2–3/day low-fat or fat-free full-fat
Drinks several times a day unspecified drinks containingsimple carbohydrates
Other
Sweets, confectionery
products 5 or less/week - -
Sodium Max. 2300 mg/day - -
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Cereal products several times a day whole grains refined
Vegetables several times a day all -
Fruits several times a day all -
Fish and seafood several times a week(at least 2 times a week)
fatty saltwater fish (tuna, salmon,
sardines, herring) and mussels,
oysters and shrimps
-
Poultry and eggs several times a week all -
Red meat a few times a month - -
Nuts and seeds of
leguminous plants several times a day all -
Fats several times a day olive oil
animal fats such as lard,
butter, fatty beef, fatty pork,
poultry with skin
Dairy products several times a day all -
Drinks several times a day still water sugary drinks
Sweets, confectionery
products few times a week - -
Red wine every day; women max. 1,men max. 2 glasses/day - -
2. Conclusions
The ageing of the human population has become a big challenge for health care systems worldwide.
The increasing proportion of elderly people is a result of significant improvements in medical care,
successful prophylaxis of infectious diseases, and declining birth rates in developed countries. On the
other hand, the number of elderly IBD patients is also increasing and we have to face the problem
of managing this unique population. Since there are several important differences in the clinical
characteristics of older IBD patients, appropriate nutritional intervention and counseling should become
a crucial element of the therapy. Although there are no data on the definite therapeutic influence of
any diet on the course of IBD, it seems to be reasonable, considering data presented in this paper,
to actively promote a healthy diet among elderly patients with IBD with special emphasis on the DASH
or Mediterranean-style diet. Patients with IBD aged >60 are also at increased risk of cardiovascular
diseases, type 2 diabetes, and arterial hypertension. This is why these two similar types of nutrition
can cover not only the dietary requirements characteristic of a chronic inflammatory condition, but also
due to its anti-inflammatory properties, they can improve the metabolic abnormalities typical in older
age. Of course, it seems rational to advocate these types of diets only in parallel with classical treatment
of IBD and even regardless of subsequent gastrointestinal disorders or any other disease. Nevertheless,
since application of the current, aggressive therapeutic approaches in a significant proportion of elderly
IBD patients is limited, the use of the Mediterranean and DASH diets is reasonable, especially in this
unique population.
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Abstract: Epidemiological and experimental studies have suggested that diet is one of the
environmental factors that contributes to the onset and pathophysiology of ulcerative colitis. Although
many patients suffering from ulcerative colitis attribute their symptoms or disease relapse to dietary
factors, only a few well-designed randomized controlled trials have been done to investigate the
role of diet in the management of ulcerative colitis. Here, we review the potential mechanisms of
the relationship between diet and pathogenesis of ulcerative colitis and summarize randomized
controlled dietary interventions that have been conducted in ulcerative colitis patients.
Keywords: diet; inflammatory bowel disease; ulcerative colitis
1. Introduction
Ulcerative colitis (UC)—a subtype of inflammatory bowel disease (IBD)—is a chronic, idiopathic
inflammatory disease that affects the colon and is characterized by relapsing and remitting mucosal
inflammation [1]. UC patients mostly present blood in the stool and diarrhea [1]. UC is associated
with major morbidity in Western countries, and its incidence is increasing in developing countries [2].
The multifactorial pathophysiology of UC includes genetic predisposition, epithelial barrier defects,
dysregulated immune responses, microbial dysbiosis, and environmental factors [1,2].
It has been suggested that environmental factors play a major role in the pathogenesis of IBD.
Early-life events such as mode of birth, breastfeeding, and exposure to antibiotics and other factors such
as air pollution, smoking, psychological state, exercise, and diet are among the potential environmental
contributors of IBD development or disease activity [3].
Significant changes in dietary intake during the past decades have been associated with the
increase in incidence of UC. The relationship between diet and UC development has been indicated
in several epidemiological studies [4]. Two recent meta-analysis studies showed that soft drink
consumption and sucrose intake were associated with 69% and 10% increased risk of UC development,
respectively [5,6]. Consumption of fruits (odds ratio: 0.57) and vegetables (odds ratio: 0.71) was related
to decreased odds of UC development in another meta-analysis study [7]. A significant association
between meat intake (red meat in particular) and UC risk was found in a meta-analysis of seven
epidemiological studies (summary relative risk: 1.47) [8]. Furthermore, whereas n-3 polyunsaturated
fatty acids (PUFAs) content of diet was related to decreased odds of UC development (odds ratio:
0.56) [9], dietary arachidonic acid (an n-6 PUFA) as measured in adipose tissue increased risk of
UC development (relative risk: 4.16) in a large prospective cohort study among Danish adults [10].
Although the exact pathophysiological mechanisms in which diet plays a role in IBD development
remain unknown, several plausible explanations including its effects on composition of gut microbiota,
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production of microbial metabolites, alterations in mucosal immunity, and mucosal barrier function
have been proposed [11] (Figure 1).
 
Figure 1. Although the exact mechanisms responsible for the association between diet and development
of inflammatory bowel disease is unknown, several mechanisms have been suggested. An unhealthy
dietary pattern such as a Western diet has been linked to changes in the gut microbiome and epithelial
barrier function and seems to have a direct influence on immune function, triggering a pro-inflammatory
environment characterized by an imbalance in the T helper 17 (TH17) cell to regulatory T (Treg) cell
ratio [Adapted with permission [11]].
Abnormalities in the intestinal microbiota have been reported in some, but not all UC patients [1,12–14].
In some studies, UC patients have been shown to have decreased bacterial diversity, characterized by a
decreased Firmicutes and increased Gammaproteobacteria and Enterobacteriaceae [15]. However, it is not clear
if bacterial dysbiosis is the cause or effect of mucosal inflammation in UC [1,13] (Figure 2).
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Figure 2. The relationship between gut microbiota and colonic inflammation in inflammatory bowel
disease. Inflammation in colon stimulates production of Interferon gamma (IFN-γ) that eventually
generates reactive oxygen species (ROS). ROS make products for anaerobic respiration. These products can
be used by facultative anaerobes to outgrow, which leads to decreased bacterial diversity. The dysbiotic
microbiota may further stimulate the growth of fungi that can worsen inflammation via chitin and β
-glucan antigen-presenting cell (APC) activation of the type 1 T helper (TH1) pathway. In addition,
the microbial dysbiosis is associated with increased bacteriophage richness and abundance, which can
affect the bacterial microbiota via gene transfer. DMSO, dimethyl sulfoxide; TMAO, trimethylamine
N-oxide. [Adapted with permission [13]].
Dietary factors can be related to UC pathogenesis or disease course through direct effects on
the host or indirect effects through modulations of composition or function of gut microbiota. Diet
has a major role in shaping gut microbial composition [16]. For instance, increased Bacteroidetes
and decreased Firmicutes and Enterobacteriaceae in rural African children in comparison to European
children were mainly attributed to differences in dietary patterns between the two populations [17].
Therefore, it has been suggested that diet-induced changes in microbiota may transform healthy gut
microbiota into a disease-inducing entity that could either initiate or perpetuate inflammation in
patients with IBD [16]. Agus et al. [18] indicated that a high fat/high sugar diet resulted in intestinal
mucosal dysbiosis characterized by an overgrowth of pro-inflammatory proteobacteria and a decrease
in protective bacteria. In addition, they showed that the transplantation of feces from high fat/high
sugar fed mice to germ-free mice increased susceptibility to adherent-invasive Escherichia coli infection.
In addition to their significant effects on microbial composition, dietary factors can also affect
the metabolic functions of gut microbiota. Short chain fatty acids (SCFA), which are defined as
the groups of fatty acids with fewer than six carbons including formic acid (C1), acetic acid (C2),
propionic acid (C3), butyric acid (C4), and valeric acid (C5), are derived from commensal bacterial
fermentation of indigestible dietary fibers in both the small and large intestines [19,20]. Acetate,
propionate and butyrate account for more than 95 % of all the SCFA content in the gut [19]. Acetate and
butyrate in particular have an essential role in maintaining mucosal barrier function and modulating
immune function [21,22] (Figure 3). SCFA regulate the functions of epithelial and/or immune cells
through altering gene expression, cellular differentiation, chemotaxis, proliferation, and apoptosis [19].
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The number of SCFA-producing bacteria such as Faecalibacterium prausnitzii is decreased in some
UC patients, and these are inversely correlated with disease activity [23]. Moreover, a western diet
characterized by high intake of sugar [18,24] and fat [18] and decreased amount of dietary fiber was
associated with decreased SCFAs and increased susceptibility to colitis in experimental studies.
Figure 3. The role of fiber-derived short chain fatty acids (SCFAs) in regulation of intestinal homeostasis.
SCFAs serve as energy substrates for colonocytes. In addition, SCFAs regulate intestinal barrier function
and immune system through G-protein-coupled receptors (GPRs) signaling. SCFAs promote the
differentiation of regulatory T (Treg) cells and the production of interleukin (IL)-10 through GPR43.
Furthermore, SCFA facilitate inflammasome activation in colonic epithelial cells through GPR43,
stimulating IL-18 production that is critical for anti-inflammation and epithelial repair. SCFAs also
regulate intestinal barrier function via enhancing the expression of tight junction proteins and the
synthesis of mucin (MUC)2. DC, dendritic cells; FOXP3, forkhead box P3; HDAC, histone deacetylases;
Mφ, macrophages; TJ, tight junctions. [Adapted with permission [22]].
The mucus layer and intestinal epithelium are the first physical and chemical barriers against
intestinal bacteria, pathogens, and food antigens. A dysregulated mucosal immune response
characterized by alterations in the innate immune system, activation of effector T-cells, increased
presence of B-cells and antibody production, and increased production of pro-inflammatory mediators
have a major role in the pathogenesis of IBD [1,25]. Dietary factors can have direct effects on host cells.
For instance, it was shown that luminal iron may directly affect function of intestinal epithelial cells
and T cells in addition to triggering epithelial cell stress-associated apoptosis [26]. Zinc is an important
cofactor for various intestinal metalloproteinases, and zinc deficiency has been associated with reduced
barrier integrity and increased permeability in IBD patients [27]. There is also increasing evidence
for a role of vitamin D in strengthening the innate immune system and reducing inflammation in
experimental and human IBD [28]. Relationships between PUFAs content of diet and inflammatory
processes in IBD have also been shown [29,30]. Eicosapentaenoic acid and docosahexaenoic acid that
are long chain dietary n-3 PUFAs inhibit genes that are involved in inflammatory process and alter
the composition of cell membranes by displacing n-6 PUFAs, influencing lipid raft formation in cell
signaling [30]. Dietary amino acids act as key regulatory factors in cellular and microbial metabolic
pathways and play important roles in gut homeostasis. Intestinal inflammation as seen in IBD affects
several metabolic pathways related to metabolism of amino acids [22]. It has been reported that
several food additives, such as maltodextrin, emulsifying agents, or thickeners such as carboxymethyl
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cellulose, carrageenan, and xanthan gum, may also have detrimental effects on intestinal homeostasis
as well [31]. A complete review of all dietary factors and host interactions is beyond the scope of
this review; however, those interactions have been described comprehensively in other recent review
articles [11,21,22,31–34].
Currently, dietary recommendations for management of IBD-related symptoms are scarce and
non-evidence-based, mainly due to the limited number of dietary interventions in this population.
In the present review article, we summarize findings from previously conducted dietary interventions
in UC patients.
2. Methods
An electronic search in MEDLINE (Ovid) from inception to April 1, 2019, was conducted in
order to identify any dietary intervention studies on UC subjects). Reference lists of included studies
were also checked to identify relevant studies that might have been missed during initial search in
MEDLINE. Studies that only focused on nutritional supplements, enteral or parenteral nutrition,
or were published in languages other than English were not included. A comprehensive full-text
review of identified studies was conducted after the title screening and abstract screening of potentially
relevant articles. Collected data included journal name, publication year, design of the study, age,
sex, sample size, disease condition, intervention and comparator(s) of interest, outcome(s), outcome
measures, and main findings. The MEDLINE search strategy was as follows:






7. 1 or 2 or 3 or 4 or 5 or 6
8. Inflammatory Bowel Diseases/








17. 14 or 15 or 16
18. 7 and 13 and 17
3. Results
Our primary electronic search yielded 424 unique references. After title and abstract screening,
nine studies were selected for full-text review. Following the full-text review, seven randomized
controlled trials that met the inclusion and exclusion criteria were selected for this review [35–41].
The general characteristics of the included studies are summarized in Table 1.
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Wright et al. [35] randomly allocated UC patients with disease relapse into a milk-free diet (n = 26)
(all milk and milk products, whether in the form of dairy products such as fresh milk and cheese
or as powdered milk, were excluded, and butter was permitted), a gluten-free plus milk-free diet
(n = 27), or a control group (n = 24). Patients were asked to follow the diets for one year after the
induction of remission, and they were followed monthly to assess if they experienced disease relapse,
which was defined as diarrhea with an average of four or more stools a day for at least a week and
with macroscopic blood present, together with sigmoidoscopic evidence of inflammation. Although
the relapse rate was higher in patients randomized to the control group in comparison to those on
a milk-free diet (79.2% vs. 61.5%), it did not reach statistical significance (p = 0.2). In addition, the
relapse rate in the gluten-free plus milk-free diet was 70.4%, which was comparable to that in the other
two groups.
In a small randomized controlled trial for 6 weeks [36], 18 adult UC patients with mild to moderate
disease activity were randomized to a symptoms-guided elimination diet (n = 11) or a control group
(n = 7). Patients in the control group were asked to document but not alter their dietary intake.
However, patients in the experimental group were instructed to exclude foods that appeared to provoke
their symptoms. Fried foods were prohibited. In addition, refined sugars, additives and preservatives,
all condiments and spices other than salt, and beverages other than boiled water were prohibited
during the 6-week trial for patients randomized to the elimination diet group. In the first week, dairy
products were excluded from the diet, but were introduced over the next weeks in the following
order: Skim milk, yogurt, skim-milk cheese, full-cream milk, cream, and full-cream cheese. Each week,
subjects in the intervention group were interviewed in person, and their symptoms were reviewed in
relation to the foods eaten during the previous week. The food menu was expanded over the 6-week
trial to include as more variety of foods that each participant could tolerate. The induction of clinical
remission rate (the passage of normal stools with absence of rectal bleeding) 6 weeks after the baseline
visit was significantly higher in patients who received the symptoms-guided diet (36.3% vs. 0.0%).
However, the endoscopic and histologic improvement was comparable between the two groups.
In another study [37], children with newly diagnosed UC were randomly assigned to a cow’s milk
protein (CMP) elimination diet (n = 14) or a normal diet as the control group (n = 15). The study aimed
to compare the clinical remission rate between the two groups following the IBD induction therapy
and the rate of clinical relapse (defined as the occurrence or worsening of symptoms accompanied by
an increase of Pediatric Ulcerative Colitis Activity Index > 10 points which required treatment with
corticosteroids, immunosuppressive agents, or surgery) between the two groups during the one-year
trial. The authors reported that the clinical response rate four weeks after the initiation of the induction
therapy was not different between the two groups (92.8% in CMP elimination diet vs. 80.0% in the
control group, p = 0.6). In addition, clinical relapse rate was comparable between the two groups (53.8%
in CMP elimination diet group vs. 53.3% in the control group). In addition, they found no significant
changes in serum C-reactive protein (CRP), erythrocyte sedimentation rate or fecal calprotectin (FCP)
in the two diet groups from baseline to the last visit.
Kyaw et al. [38] recruited 112 adult UC patients and randomly assigned them to a dietary
intervention and a control group. Patients in the intervention group were given an educational booklet
that contained dietary recommendations to eat little and often (four to six times a day), drink adequate
fluids, decrease excess intake of fat, decrease simple carbohydrates, and decrease high-fiber foods
during flare. Patients were also advised to increase intake of “good-quality protein” during flare and
eliminate dairy products if they were lactose intolerant. Patients randomized to the control group were
provided with a booklet that included general recommendations on healthy eating (e.g., to choose
higher fiber or whole grain carbohydrates, to eat lots of fruits and vegetables) and were assigned to
follow their usual diet. At 24 weeks, there was a significant reduction in the Simple Clinical Colitis
Activity Index (SCCAI) score in the intervention group compared with an increase in the score in the
control group. However, there was no statistically significant change in quality of life scores from
baseline to week 24 in the two groups.
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Bhattacharyya et al. [39] conducted a small, randomized, double-blind, placebo-controlled,
multicenter, clinical trial on UC patients to investigate the effect of the common food additive carrageenan
on clinical relapse rates. The authors recruited UC patients over the age of 18 in clinical remission (SCCAI
≤ 2). Patients randomized to the carrageenan group (n = 5) received the carrageenan-containing capsules
(200 mg/day). Patients randomized to the placebo group received similar-appearing dextrose-containing
capsules (n = 7). The study duration was 12 months, and participants were instructed to follow a
carrageenan-free diet during that period. The primary outcome measure was occurrence of clinical
relapse, which was defined as an increase of two (or more) points on the SCCAI in association with an
increase in treatment. The Short Inflammatory Bowel Disease Questionnaire was used to assess changes
in quality of life. In addition, blood and stool samples were collected to measure inflammatory markers.
They found that UC patients who were on a carrageenan-free diet plus placebo had a lower relapse rate in
comparison to patients who were on a similar diet plus two oral capsules of carrageenan per day (0.0% vs.
60.0%, p = 0.05). In addition, they reported that carrageenan consumption aggravated disease activity as
indicated by increase in FCP (p = 0.06) and interleukin-6 (p = 0.02). However, there was no statistically
significant difference between the two groups in terms of changes in quality of life scores.
Pedersen et al. [40] conducted an open-label trial of patients with IBD (61 UC and 28 CD) in remission
or with mild-to-moderate disease and coexisting IBS-like symptoms. Patients were randomly assigned
to a low Fermentable, Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP) diet
(n = 44) or a normal diet (n= 45) for 6 weeks. In UC patients, there was a significant decrease in severity of
IBS-related symptoms (assessed by IBS symptom Severity System) in both diet groups, and this response
was not different between the two groups. However, the authors reported a significant decrease in disease
activity assessed by SCCAI but only in patients randomized to the low-FODMAP diet. In addition,
low-FODMAP diet increased quality of life of IBD patients (assessed by SIBDQ). However, low-FODMAP
diet did not change CRP and FCP levels significantly.
In a recent open-label, stratified study, Jian et al. [41] randomly allocated 97 UC patients who were
in remission or had mild to moderate disease activity to a food exclusion group versus a sham diet group.
At baseline, the presence of blood IgG antibodies specific to egg, wheat, milk, corn, tomato, crab, rice,
soybean, cod, shrimp, mushrooms, beef, chicken, and pork antigens were tested. Based on IgG antibody
titers, patients randomized to the exclusion diet group were instructed to stop or reduce taking specific
food items. Patients in the control group were asked to follow their routine diet. The duration of the trial
was 6 months. They reported that in comparison to the control diet, following the exclusion diet was
associated with a significant decrease in Mayo scores and improvement in quality of life.
4. Discussion
It has been suggested that environmental factors including diet play an important role in the
pathophysiology of IBD and especially in UC, a chronic colonic inflammation. In the present article,
after a brief overview of potential mechanisms in which diet plays a role in the pathogenesis of IBD,
we then reviewed dietary intervention studies in UC patients.
The three randomized controlled trials that have been performed to assess the efficacy of dietary
interventions for maintenance of remission in UC [35,37,39] were all focused on complete exclusion of
one or more food items that were hypothesized to trigger IBD symptoms. Two of these studies [35,37]
aimed to eliminate milk or dairy products; however, they failed to show a significant decrease in
relapse rate in patients randomized to the elimination diet group in comparison to those randomized
to the control diet. This finding is important as unnecessary dietary restrictions that lack supporting
scientific evidence may result in several nutritional deficiencies (e.g., calcium due to exclusion of milk
and dairy products) in IBD patients [42]. Therefore, patients should be informed by their health care
team about the possible harmful effects of food elimination diets.
In the present review, the only elimination diet that was associated with a reduction in clinical
relapse rate in UC patients who were in remission at baseline was a carrageenan-free diet [39].
Carrageenan belongs to a family of sulfated polysaccharides and are extracted from seaweeds. It is
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approved as “generally recognized as safe” by the United States Food and Drug Administration and is
used in the food industry for its gelling, thickening, and stabilizing properties. It has been suggested
that carrageenan may reduce protein and peptide bioaccessibility, disrupt normal epithelial function,
and promote intestinal inflammation [43]. However, others have been skeptical about these findings,
which are mainly derived from experimental animal studies [44]. The results from the randomized
clinical trial in which a carrageenan-free diet was found to be related to lower relapse rate and decreased
inflammation (as assessed by decreased serum interleukin-6 and FCP) should be interpreted with
caution as the sample size of this multi-center trial was very small (n = 12) and the reported p-values
obtained from parametric tests were marginally significant. Therefore, these interesting findings need
to be confirmed in future well-powered randomized controlled studies.
We identified only two studies [36,37] that tested the efficacy of diet for induction of remission in
UC patients. In the first study, exclusion of food items that were found to trigger UC-related symptoms
was associated with higher clinical remission rate in comparison to a normal diet [36]. Although
the elimination of foods was based on each participant’s self-reported food intolerance, there were
some general recommendations regarding specific food groups/items such as dairy products, refined
sugar, and beverages. However, the study was performed on a small number of patients (n = 18),
and the duration of follow-up was short (6 weeks). In addition, the intervention did not result in
endoscopic or histologic improvement in that time period. Furthermore, patients in the intervention
group experienced a mean weight loss of 2.5 kg that was not explained in the study. The authors
also reported that there was no food that triggered symptoms in all patients. However, spicy and
curried foods and fruits (specially grapes, melon, and citruses) were commonly reported to provoke
symptoms. In the second study, which was performed in pediatric UC patients with active disease,
elimination of cow milk protein from diet was not beneficial neither for induction or for maintenance
of remission during a one-year follow-up in comparison to a control diet [37]. As mentioned by the
authors, the dietary restrictions that many IBD patients follow often are not supported by scientific
evidence. These inappropriate diets reduce caloric intake and may contribute to malnutrition and
micronutrient deficiencies, especially in pediatric patients. Whether a subgroup of patients with UC
(e.g., patients with lactose intolerance or atopy) will benefit from elimination diets or not needs to be
explored in future clinical trials.
In this review, we also included three other studies that recruited patients with active disease and
UC remission concurrently. They reported the effectiveness of comprehensive dietary advices [38],
low FODMAP [40] or IgG-guided exclusion diets [41] in reduction of disease activity in UC patients.
Although these findings are encouraging, one of the major limitations of these studies is that they did
not report their findings for patients with active disease versus patients in UC remission separately
to allow meaningful interpretations [45]. Therefore, we suggest that in future studies the dietary
interventions be focused on clearly specified groups of patients (e.g., active disease or in remission) or
study outcomes to be reported for different groups of participants separately.
Diet is of major interest for IBD patients, and they use a variety of dietary strategies to manage their
underlying disease and related symptoms [34]. Despite the significant role of diet in the development
of IBD or management of gastrointestinal symptoms in these patients, we could identify only a few
randomized controlled trials that assessed the efficacy of diet for induction of remission, maintenance
of remission, or improvement of gastrointestinal symptoms in UC patients. In addition, in the previous
studies, the underlying mechanisms in which diet may prevent increases in colonic or systemic
inflammation and ultimately help patients to maintain remission have not been investigated. There
are many omics fields involved in the study of pathogenesis of IBD such as genomics, metagenomics,
transcriptomics, proteomics, and metabolomics [32]. As dietary factors have a significant impact
on some of these key players of IBD development, investigating the changes in this multi-omic
network of IBD during a controlled dietary intervention has the potential to elucidate the underlying
mechanisms of diet-IBD interactions. High quality, well-powered human dietary intervention studies
for management of IBD may include the following: Quantification of baseline habitual diet using
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appropriate tools such as food frequency questionnaires, monitoring of adherence to the diet using
food recalls/records, large long-term controlled trials, use of a control diet to determine the specificity
of observed effects to the intervention, use of a variety of subjective and objective endpoints (e.g.,
symptoms, quality of life, clinical biomarkers, endoscopic and histological evaluations) to monitor
response to dietary interventions [34], and consider the use of omic-based assessments of serum, urine,
stool, and/or intestinal biopsies to investigate underlying protective mechanisms. Considering findings
from previous observational studies and clinical trials, investigating the potential benefits of following
a healthy dietary pattern, such as experimental anti-inflammatory diets that incorporate several dietary
recommendations, is of great value in the management of UC-related symptoms and inflammation.
Furthermore, as indicated in elimination diet studies, food intolerances are individual-based, and not
all patients will benefit from excluding certain food items/groups. Therefore, personalized dietary
recommendations that take into account each patient’s food intolerances and food preferences should
be the subject of future well-designed dietary trials in IBD patients.
5. Conclusions
In conclusion, we found that there have been few well-designed and/or adequately powered
randomized clinical trials to investigate the role of diet in maintenance of remission in UC patients.
As suggested in a recent Cochrane systematic review [45], consensus on the composition of
evidence-based dietary interventions in IBD patients is required and there is a need for more high-quality,
well-powered, randomized, controlled trials to assess the efficacy of these interventions.
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Abstract: This review discusses the personalised dietary approach with respect to inflammatory bowel
disease (IBD). It identifies gene–nutrient interactions associated with the nutritional deficiencies that
people with IBD commonly experience, and the role of the Western diet in influencing these. It also
discusses food intolerances and how particular genotypes can affect these. It is well established that
with respect to food there is no “one size fits all” diet for those with IBD. Gene–nutrient interactions
may help explain this variability in response to food that is associated with IBD. Nutrigenomic
research, which examines the effects of food and its constituents on gene expression, shows that—like
a number of pharmaceutical products—food can have beneficial effects or have adverse (side) effects
depending on a person’s genotype. Pharmacogenetic research is identifying gene variants with
adverse reactions to drugs, and this is modifying clinical practice and allowing individualised
treatment. Nutrigenomic research could enable individualised treatment in persons with IBD and
enable more accurate tailoring of food intake, to avoid exacerbating malnutrition and to counter some
of the adverse effects of the Western diet. It may also help to establish the dietary pattern that is most
protective against IBD.
Keywords: inflammatory bowel disease; Westernisation; genotypes; nutrient deficiency; food
intolerance; FODMAPs; gluten; fructose; lactose; brassica; mushrooms
1. Introduction
The personalised dietary approach in combination with the knowledge of the genotype and genetic
variants of an individual who has nutrient deficiencies, follows the Western diet, or may have food
intolerances may be helpful for people who have inflammatory bowel disease (IBD). Gene–nutrient
interactions could help explain the variability in response to food that is associated with IBD, and
using this knowledge with a personalised dietary approach may offer a way forward. Identification of
individuals’ genotypes is a first step to building up data sets which combine this information with data
on individuals and their gut microbiome, dietary patterns, exercise routines, blood parameters and
anthropometric measurements. This information can be used to build machine-learning algorithms
to predict what foods/meals reduce inflammation and abdominal symptoms and maintain a healthy
gut flora. Zeevi et al. have pioneered this approach in their work with diabetes [1]. They used this
combination of information to successfully predict which foods/meals lowered postprandial blood
glucose. Identifying genotypes associated with nutrient deficiencies or low nutrient absorption, the
negative effects of the Western diet and the tolerance or intolerance of particular foods may also advise
people on how to eat a greater variety of food. A wider range of food available to the gut microbiota
enables their greater diversity, and this is associated with a healthy gut [2].
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Pharmacogenetic research (the study of the variability in drug response due to genotype) is
identifying gene variants with adverse reactions to drugs, and this is modifying clinical practice and
allowing individualised treatment. The aim is to provide the right drug, at the right dose, at the right
time, to the right patient [3]. Individual responses can be dependent on an individual’s genotype.
Genetic variants can alter the metabolism of drugs as well as responsiveness, and this may necessitate
changes to standardised drug regimes. The standard dose may not maintain the required therapeutic
level if individuals metabolise the drug more quickly; conversely, if they are slow metabolisers the
standard dose maybe toxic. Knowledge of pharmacogenetics and its application to precision medicine
to enhance treatment responses and minimize drug-related adverse events is one approach that
has been suggested as the way forward for IBD [4]. Pharmacogenetics information facilitates the
identification of responders and non-responders to drugs and guides the decision about optimal
treatment [5]. Similarly, further nutrigenomic research could identify nutrient–gene interactions in
people with IBD. This would enable the more accurate tailoring of food intake and could suggest
dietary patterns which avoid exacerbating malnutrition, curtail the adverse effects of the Western
diet and explain intolerance to particular foods. This could lead to the minimization of abdominal
symptoms and disease activity in those who experience IBD.
In an extensive study of 366,351 European individuals in 2016 aiming to identify dietary patterns
and risk of IBD, no dietary pattern was identified with the risk of either of the two main expressions of
IBD (i.e., ulcerative colitis (UC) or Crohn’s disease (CD)) [6]. However, when cases occurring within the
first two years after dietary assessment were excluded, there was a positive association between a “high
sugar and soft drinks” pattern and UC risk if they also had a low vegetable intake [6]. This study shows
there are many challenges in determining the best dietary pattern for individuals with a particular
chronic disease like IBD, given the genetic differences between people and their environments [7].
The current consensus is that no single nutrition recommendation can be made to modify this situation
with respect to IBD—that is, there is no “one size fits all” solution for people with IBD [8]. However,
using the personalised dietary approach combined with information on people’s genotypes may offer
a way to resolve this conundrum.
The aim of this narrative review (based on searching two data bases, PubMed and Google Scholar)
is to discuss the personalised dietary approach with respect to IBD. First it will identify nutritional
deficiencies which individuals with IBD commonly experience, and give an example of a key nutrient
whose absorption is affected by genotype. Secondly it will review the role of the Western diet in
contributing to nutrient deficiencies and IBD, and give examples of some of the genes involved. Thirdly
it will review the various food intolerances and food avoidances associated with IBD which may also
contribute to nutrient deficiencies, and how particular genotypes can contribute to these.
2. Nutrient Deficiencies Associated with IBD
2.1. Nutritional Status of People with Inflammatory Bowel Disease
Three studies which have assessed the nutritional status of people with IBD are illustrated in
Table 1. Assessment of people with IBD often shows they are under weight, with specific vitamin
and mineral imbalances, and this contributes to their ill health [9–14]. The three studies in this table
illustrate the common nutritional findings. Vagianos and colleagues collected dietary information
by questionnaires (including dietary supplements) and observed multiple and clinically significant
vitamin and mineral deficiencies in adults with CD who attended a gastroenterology outpatient
clinic [9]. Inadequate reported intake was defined as <66% of the dietary reference intake (RFI) for each
micronutrient. These authors reported that when comparisons were made by disease type or disease
activity, there were no significant differences in the percentage of subjects consuming inadequate
amounts of micronutrients. Stein and Bott (2008) reported on nutrient deficiencies in hospitalised
adults with CD [10]. Hartman et al. in 2016 [15] investigated the nutritional status of children and
adolescents who were ambulatory outpatients at a gastroenterology clinic. They reported on the
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percentage median nutrient intake compared with the required daily allowance (RDA) and dietary
intake of healthy children. The intake was considered low if it was less than 80% of the RDA. During
this study, two thirds of participants had active disease. However, there was no significant difference
in nutrient intake between those with active disease and those in remission, and no association of
nutrient levels with disease activity.
Table 1. Nutrient deficiencies in adults and adolescents with inflammatory bowel disease (IBD).
Reference
Vagianos et al. [9] Stein and Bott [10] Hartman et al. [15]
Outpatient Inpatient Outpatient
Year of Investigation 2007 2008 2016
Number of Participants 71 na 68
Gender (Male, Female) 32, 52 na na
Age (years) 37.6 ± 14.3 Adult 13.9 ± 3.2






Laboratory Measurement Biomarkers for nutrients (CD) na Biomarkers for nutrients
Dietary Deficiency
Measures % <66% RFI % Inadequate Intake % <80% of RDA
Vitamin B6 4.2 na 10
Vitamin B12 5.6 48 12
Folate 20 56–62 34
Vitamin C 9.9 na 31
Vitamin A 30 11–50 57
Vitamin D 38 23–75 25
Vitamin E 59 na 65
Calcium 25 13 79
Iron 14 25–50 22
Magnesium na 14–33 69
Zinc 8.5 40 28
CD: Crohn’s disease; FFQ: food frequency questionnaire; na: not available; RFI: dietary reference intake; RDA:
required daily allowance.
All three studies showed low levels of vitamin A and D and folate in people with CD. Stein and
Bott [10] and Hartman et al. [15] both found substantial risk for deficiencies of magnesium, zinc and
iron (Table 1). Stein and Bott [10] also showed lower B12 concentrations for inpatients and Vagianos et al.
commented that in those with CD (compared to those with UC, the other main expression of IBD)
had lower B12 concentrations with their serum biomarkers. Also, among men with CD there was a
significantly higher proportion who had haemoglobin below the normal range compared to men with
UC. Hartman et al. reported that anaemia was the most common sign of nutrient deficiency in their
adolescents (51%). These studies illustrate that people with different expressions of IBD (i.e., CD or UC)
have different nutrient needs. It also illustrates that it is important to assess nutritional status (through
laboratory measurement of nutrient biomarkers) to avoid exacerbating malnutrition if particular foods
are removed from the diet.
For people with CD in particular, malnutrition may also occur because of the severity of oral
lesions experienced, which results in difficulties with tasting, chewing and swallowing. This means
that some foods are avoided (e.g., tomatoes because of their perceived acidity). Oral involvement in
CD has been identified in 8%–29% of people, irrespective of disease activity [16]. Examples of oral
symptoms include labial swelling (which also may include gingiva and mucosa), mucosal polyps,
cracking at the edges of the lips (angular cheilitis), ulcers, fissures and granulomas [17,18]. The mucous
membranes in the mouth normally have a rapid cell turnover of 3–7 days, in contrast to the skin which
is up to 28 days [19]. Loss of cells without replacement can lead to the mouth showing early signs of
systemic disease and early predisposition to nutritional deficiency. This is another reason why optimal
nutrition is important for people with IBD.
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Many vitamins and minerals are considered necessary for healthy mucous membranes (Table 2) [20].
A number of these essential nutrients are low in people with people with IBD (Table 1 [9,10,15]). These
nutrient deficiencies, and a higher presence of bacteria associated with dental caries, undoubtedly
contribute to the oral symptoms experienced by people with CD. Sufficient levels of these nutrients
would need to be included in any food regime suggested for IBD.
Table 2. Nutrients associated with healthy mucous membranes [20].
Water Soluble Vitamins Fat-Soluble Vitamins Minerals
Vitamin B2 (riboflavin) A Calcium
Vitamin B3 (niacin) D Fluoride
Vitamin B6 family E Zinc
Vitamin B12 (cobalamin) Iron
Folic acid (folate)
Vitamin C (ascorbic acid)
2.2. Nutrient Absorption Impacted by Genotype
One example of a nutrient whose absorption can be impacted by genotype is beta-carotene.
The gene that affects its absorption is the beta-carotene 15,15′-monooxygenase gene (BCMO1). This
gene encodes a protein which is an important enzyme in the metabolism of the nutrient beta-carotene
to vitamin A [21]. It is expressed in a number of tissues (e.g., liver, lungs, skin, small intestine). Within
the enterocytes of the mucous membranes, the enzyme cleaves beta-carotene into two retinal molecules.
These are packaged with other dietary lipids into chylomicrons and then secreted into the lymphatic
system. Fat in the diet enables optimal chylomicron formation [21,22]. According to the study by
Leung et al., carrying one of the two polymorphisms (R267S: rs12934922 or A379V: rs7501331) of the
BCMO1 gene impedes the conversion of beta-carotene to retinol [23]. This study was based on a healthy
population from the UK. Up to 45% of people in this study carried one of these two polymorphisms.
Having one of the two polymorphisms of the BCMO1 gene in conjunction with IBD could thus have an
impact on the health status of the carrier. New Zealand (NZ) is a country with a high incidence of IBD
(26/100,000 in 2016) [24], and in their most recent National Nutrition Survey (2008/9) reported that
the NZ population sourced 58% of their vitamin A intake from carotenoids. The NZ population as a
whole was also recorded as 22.7% and 12.1% deficient in vitamin A for males and females, respectively.
For those aged 15-18 years, these percentages increased to 27.4% and 37.5% [25].
Adequate vitamin A intake is necessary for optimal activity of the innate and adaptive immune
systems. Vitamin A is needed for the appropriate innate immune defence response. It affects neutrophil
reactions to microbes, macrophage phagocytosis, and natural killer cell activity. Cultured human
macrophages enriched with retinoic acid have been shown to have increased resistance to M. tuberculosis
by down-regulating tryptophan–aspartate-containing coat protein (TACO) [26]. Vitamin A is also
needed for the optimal formation of T and B cells in the adaptive immune system and the balanced
type 1 and type 2 cytokine responses. Impairment of these functions through vitamin A deficiency
leads to epithelial barrier dysfunction and inflammation—hallmarks of IBD [27]. Vitamin A deficiency
in children increases the risk of signs and symptoms often associated with CD (i.e., impairment of iron
use that aggravates anaemia, respiratory infections and diminished growth rates) [28]. If individuals
with IBD also carry one of these at-risk alleles, they are at risk of being vitamin A deficient.
This may be a contributing factor to this nutrient deficiency reported in people with IBD. Using the
personalised dietary approach and identifying if a person with IBD carries these variants linked to poor
absorption of vitamin A would enable the tailoring of nutrient advice to ameliorate this. The Western
diet may also contribute to nutrient deficiencies.
333
Nutrients 2019, 11, 1532
3. The Western Diet
The incidence of gastro-intestinal disorders like CD and UC has been increasing [29–32]. This
has often been related to the current Western diet, which has changed substantially in the past seven
decades [33–39]. This is because of changes in food production and technology, which provides easy
access of urban based populations to cheap ultra-processed foods and foods high in refined grains, oil
and sugar [40]. In Bangladesh, for example, the incidence of diagnosed IBD is very low. However,
when Bangladeshis move to the United Kingdom where they are more highly exposed to Western
culture and food choices, the incidence of IBD increases substantially within a generation [41]. This may
also be associated with autoimmune disease developing as a result of increasing latitude, decreased
exposure to sunlight and lower vitamin D intake [42]. They may also receive better health care which
identifies their disease pathology more accurately. However, modern Western food is also becoming
more available in the developing world. In the review of the global epidemiology of IBD by M’Koma,
it was noted that there has been an increase in the incidence and prevalence of IBD in parts of Asia
and Africa—particularly in urban areas and in higher socio-economic classes [43]. This Westernisation
of the diet has resulted in lower intakes of dietary fibre, increased consumption of saturated fatty
acids, and sugar. Westernisation has also introduced other factors such as changes in birthing methods,
increased use of artificial formula instead of breast feeding, and the use of sugar substitutes, food
additives and antibiotics. Many of these changes have been associated with a reduction in gut microbial
diversity, which is a feature of IBD [44,45].
3.1. Lower Intakes of Dietary Fibre
As the diet becomes more Westernised and processed, “Western” food often contains less fibre.
Current intakes of fibre associated with the Western diet are assessed to be about 20 g/day, compared
to a fibre content of 70–120 g/day when diets rich in fruit, vegetables and grains are consumed, as is
estimated for hunter-gathers and agriculturalists in human history [46]. The low consumption of
fruit, vegetables and dietary fibre and the increased intake of animal fat and refined sugars have been
observed in people with disorders like IBD [47], as are exclusion diets for IBD that are made popular in
the media [48].
The risk of IBD has been negatively associated with the intake of fibre [34,49,50]. Fibre can be
defined in a number of ways, as illustrated by the different definitions by the American Association of
Cereal Chemists (AACC) [51] and The Codex Alimentarius Commission [52]. A recent AACC definition
describes fibre as being a component of “edible plants or analogous carbohydrates that are resistant to
digestion and absorption in the human small intestine, with complete or partial fermentation in the
large intestine” [53]. They include in their definition polysaccharides, oligosaccharides, lignin and
associated plant substances. Fibre has been further subdivided into rapidly digested starch, slowly
digested starch and resistant starch (RS), and the latter is classified into five categories (RS1–RS5).
High levels of resistant starch are found in unripe bananas, raw potatoes, maize, pulse grains and
legumes. However, depending on their processing, the RS content can vary, and in legumes this
can range from a few percent to 80% [54]. The RS3 category (retrograded starch) has been shown
in wild type interleukin-10-deficient IBD murine studies to decrease ileal and colonic inflammatory
lesions compared to a low-fat diet [55,56]. The authors suggested that soluble fibre and resistant starch
suppress gut inflammation. The inclusion of soluble fibre and resistant starch in the diet of individuals
with IBD may be helpful for this reason.
Fibre can also be described as soluble and insoluble [57]. The removal of insoluble fibre,
a component of the skins of fruit, vegetables, whole grains, and seeds, is a current recommendation by
the Crohn’s and Colitis Foundation of America [58]. When people are experiencing disease activity
(sometimes described as a flare or relapse), insoluble fibre may intensify bloating, pain, diarrhoea and
gas. However, the consumption of soluble fibre in vegetables (e.g., the brassica family, dried peas and
beans, parsnips, carrots, potatoes, spinach, squash, zucchini) and fruit (e.g., pip and stone fruit, berries,
bananas, dates, cantaloupe, grapes and pineapple), oat cereals and barley is recommended. Soluble
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fibre promotes water absorption, enabling the gut contents to form a gel-like consistency, which delays
emptying of the gut and reduces diarrhoea [58]. Soluble fibre also provides a substrate for bacterial
fermentation in the colon [59]. The soluble plant fibres in plantain and broccoli reduce the movement
of E. coli across M cells in Peyer’s patches in CD patients [60]. In CD, E. coli is found in increased
numbers in the mucosa [61,62]. This means it is important that appropriate fibre types are chosen if
people with IBD are removing food or food groups (e.g., selecting gluten-free diets or foods low in
FODMAPs (fermentable oligo-, di- and mono-saccharides and polyols)) so they do not inadvertently
contribute to an increase in disease activity later in their health journey [63].
There are also identified gene–nutrient interactions associated with the role of fibre. One of
these is the free fatty acid receptor 2 gene (FFAR2; previously known as G protein-coupled receptor
43—GPR43). This gene is a member of the largest gene family—the seven-transmembrane receptor
group known as G-protein-coupled receptors (GPCRs) [64]. These are involved as mediators of cellular
responses to many neurotransmitters and hormones [65]. FFAR2 is highly expressed in neutrophils [66].
One pathological marker of CD is the migration of neutrophilic granulocytes into the mucosa of the
intestine [67]. FFAR2 also activates pathways involved in intracellular Ca2+ release and inhibits the
build-up of cAMP [68].
The FFAR2 receptors are present in fat tissues, inflammatory cells and the large intestine [69]. In the
large intestine, the receptors are stimulated by short-chain fatty acids (SCFAs), which are produced
by bacteria fermenting dietary fibre [21,70]. Lower intakes of dietary fibre decrease the production
of SCFAs, which stimulates FFAR2 signalling. The study by Sivaprakasam et al. showed the critical
role of FFAR2 in the maintenance of healthy gut microbiota, leading to the suppression of intestinal
carcinogenesis [71].
The interaction of SCFAs and FFAR2 greatly affects inflammatory processes. SCFAs play an
important role in colon homeostasis, as they promote pathways involved in cell differentiation, growth
regulation, immune regulation and apoptosis [72]. SCFAs and butyrate in particular seem to be the
favoured fuel source of the bacteria in the colon as well as of colonocytes, which are required for the
functional integrity of the epithelium [73–76]. The source of SCFAs is the intake of highly fermentable
fibres, the residues of which are converted by anaerobic bacteria into SCFAs upon reaching the large
bowel [77]. SCFAs have been observed to increase the beneficial populations of Bifidobacterium and
Lactobacillus, which have a role in anti-inflammatory outcomes and immune functions [38,78,79]. SCFAs
appear to be important in epithelial barrier maintenance and immune system regulation. Maslowski
and Mackay consider the SCFAs produced in the colon to be very important for immunoregulation.
They propose that the lower dietary fibre intake associated with the modern Western diet is the driver
behind the increased incidence of inflammatory diseases associated with this lifestyle factor [70].
However, there is currently no published literature about the significance of this gene with respect
to people with IBD and their intake of fibre. People with IBD (whether with disease activity or in
remission) have been observed to have a low intake of fruit, vegetables and dietary fibre [49,80].
Perhaps particular variants in the FFAR2 gene may affect a person’s response to fibre, and this in turn
contributes to changes in microbiota composition. This may explain how those who follow a strict
FODMAP diet experience a reduction in beneficial bacteria [81,82].
3.2. Increased Consumption of Saturated Fatty Acids
Some authors believe that the Western diet has also become pro-inflammatory as a result of the
increased consumption of saturated fatty acids and decreased consumption of polyunsaturated fatty
acids (PUFAs), especially long-chain PUFAs (LC-PUFAs) [83–87]. There has also been a decrease in the
ratio of the omega-3 and omega-6 PUFAs ingested, partly because of a lower consumption of fish. Fish
intolerance and allergy is well-recognised in childhood, being the third most frequent allergen after
cow’s milk and egg in European children [88–90]. There is less evidence implicating fish intolerance or
allergy in CD. Untersmayr et al. observed that antacid medication plus fish consumption impeded the
digestion of dietary proteins in their BALB/c mouse fish allergy model [91].
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In earlier times, people consumed only small amounts of these PUFAs, and in about the same
proportion. Today it is estimated that this ratio is now about 1:10–1:20–25 omega-3:omega-6. This has
occurred from the increased intake of vegetable oils (e.g., soy, safflower, corn and sunflower) [83,92,93].
The genes and their variants linked to differences in fatty acid absorption include fatty acid desaturase
genes (FADS1, FADS2), the peroxisome proliferator-activated receptor genes (PPARA, PPARG), the X-ray
repair cross-complementing protein 1 gene (XRCC1) and stearoyl-CoA desaturase (SCD1). A number
of studies have discussed the role that these genes play in the serum levels of LC-PUFA-omega-3
and omega-6 fatty acids, as well as the effects of various variants on metabolic pathways and how
this impacts inflammation and cancer risk [94–104]. These studies show that the impact of these
fatty acids—especially on inflammation—is also influenced by the person’s genotype. This may have
deleterious effects on individuals with IBD who exclude fish and fish oils from their diet and have a
high omega-3:omega-6 PUFA ratio.
3.3. Fructose and Sugar Consumption
There is much debate in the literature about the effects of fructose consumption [105–116].
The rise in obesity, diabetes, metabolic syndrome, IBD, coronary heart disease, and whether the
increased consumption of fructose or fructans has contributed to these disorders, has been widely
discussed [105–116]. Over recent decades, increasing amounts of fructose have been consumed as part
of the Western diet. This has been particularly associated with the addition of sugars to processed
foods, particularly high-fructose corn syrup (HFCS, comprising ~60% fructose) in the USA or with
cane sugar (50% fructose) in NZ. Both are cheap and ubiquitous sweeteners, especially in soft drinks
and cereal products [117]. The effect of fructose in infant formulas on vascular inflammation has
also been investigated in full-term babies. The study found that the fructose formula had a higher
inflammatory response than the fructose-free formula, but the difference was not significant [118].
The authors commented that the result may become significant in a preterm infant [118]. According to
recent USDA figures, the estimated calories of HFCS consumed daily has risen from 0.4 g/day in 1970,
peaked at 44.3 g/day in 1997, and has gradually declined (31.0 g/day in 2015) [25,119,120]. However,
total “sweetener” consumption has increased compared to the 1970 figures (from 87.3 g/day in 1970
to 94.1 g/day in 2015) [119]. In NZ, the Adult Nutrition surveys of 1997 and 2008–2009 report that
the mean fructose intake and the mean total sugar consumption for European males and females
has declined from 1997 (26 g/day and 139 g/day, respectively), to 2008 (23.4 g/day and 100.3 g/day
respectively) [121]. Unfortunately, there are no recent national consumption figures to see whether
that national trend has continued. A small regional study (n = 227) in 2014 on a Canterbury (NZ)
population aged 50 years reported that the mean intake for fructose for men was 25.5 g and 20.6 g for
females [122]. This suggests that the downward trend has not continued.
Once ingested, fructose is transported into the blood stream through sugar-transporting proteins
GLUT2 and GLUT5, via the small intestine in limited amounts to the liver. The liver removes some
of the fructose from circulation to maintain the correct proportion of glucose to fructose (10 times
lower) [123–126], and converts fructose into other metabolites including triglycerides and uric acid.
This latter function is thought to be a contributor to the rise in obesity, metabolic syndrome and
diabetes [106,110,127,128]. Fructose intake also stimulates the thioredoxin-interacting protein gene
(TXNIP), which can lead to higher fructose intake [129]. The TXNIP gene has been associated
with promoting inflammation in endothelial cells, mediating hepatic inflammation, and regulating
NF-κB [130–134]. TXNIP has been shown to be involved in the differentiation of epithelial cells in
the intestine [135]. TXNIP mRNA, which negatively regulates the TXNIP gene, shows decreased
expression in the inflamed mucosa of the colon in people with UC [136]. Interestingly, thioredoxin-1
produced by the gene TXNIP is also inhibited by the production of vitamin D3 up-regulated protein 1
(VDUP1) when vitamin D3 is given [137,138].
The relationship between fructose uptake and the TXNIP gene may explain why fructose intake
has been increasingly linked to intestinal symptoms of bloating, abdominal pain, diarrhoea and fructose
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intolerance in individuals with IBD [126,139–142]. This underlies the need to consider fructose intake
when managing these symptoms. A recent NZ study by Spencer et al. on people with irritable bowel
syndrome (IBS) (n = 277) based in Canterbury, NZ found that the participants’ IBS score, constipation
and diarrhoea were not associated with fructose intake. However, they found that greater mean daily
fructose intakes (p = 0.05) were associated with a lower prevalence of IBS pain [122].
In adults, fructose intolerance is most commonly assessed by breath testing after swallowing 25 g
of fructose dissolved in water. Breath measurements are made on a 30-min schedule for up to three
hours. A value of ≥20 ppm H2, accompanied by symptoms (e.g., bloating, diarrhoea), is an affirmation
of fructose intolerance [139,143]. This is because the hydrogen produced by gut bacteria is reacting
with the fructose which has not been absorbed in the small intestine. Breath testing is a common
method of testing for fructose, and there are a variety of methodologies in its application, as well as
questions about its reliability [144]. A North American consensus statement has been drawn up for
hydrogen and methane-based breath testing in gastrointestinal disorders to address these issues [145].
When it is suggested that high-fructose-containing foods be eliminated in the diet, care must be
taken in deciding which foods are excluded, as the assessment of what constitutes a high-fructose
food varies [146]. If people stay on a low-fructose diet for too long, they may be in danger of nutrient
deficiencies due to lack of fruit and vegetables in the diet. It also needs to be remembered that fructose
taken as a bolus (e.g., after swallowing 25 g of fructose in a fructose intolerance test) is metabolized
differently to when it is ingested in the presence of glucose. Many people absorb fructose easily along
with sucrose or with glucose that is at similar levels [147].
3.4. Other Western Diet Factors
Westernisation has also introduced other factors into the diet, such as changes in birthing methods,
using artificial infant formula instead of breast feeding, and the use of sugar substitutes, food additives
and antibiotics (Table 3). Many of these changes have been associated with a reduction in gut microbial
diversity as well as dysbiosis (i.e., microbial imbalances in the gut)—a feature of IBD [44,45]. This
path to dysbiosis may start early, with lack of exposure to appropriate gut microbiota as an infant.
The composition of an infant’s gut bacteria is affected by the delivery method (i.e., whether infants are
born by caesarean (C-section) or vaginally, and whether breast-fed or given infant formula. C-section
babies have microbiota that resembles that on the mother’s skin, and those born vaginally are seeded
by the microbiota in the mother’s vagina [148,149]. The microbiota seeded from the mother’s vagina is
thought to contribute to a normal infant microbiome, whereas having a C-section and all the factors
associated with the reason for having a C-section does not [150].
The type of first foods also contributes to the composition of the microbiota. Breast feeding
promotes immune development and protects against many diseases. In a small study on 3-month-old
babies 1214 probe sets for epithelial cells were significantly differently expressed in exclusively
breast-fed (n = 12) and formula-fed babies (n = 10) [151]. This may explain some of the differences that
have been noted in clinical and epidemiological observations of these two groups. The two groups
have different gut development, with the breast-fed babies being described as being “less leaky”.
Bacteroidetes species, which are important players in the commensal bacteria, were not found in the
stools of the formula-fed infants [151]. Breast milk also contains human milk oligosaccharides (HMOs)
which stimulate the growth of the intestinal flora, acting as prebiotics for beneficial bacteria [152].
Human bioactive milk proteins modulate the immune system, and this too would contribute to the
enhancement of gut barrier function [153,154]. Formula feeding is becoming an increasingly common
pattern of infant feeding in Western culture.
The increasing use of artificial sweeteners (ASs) may also contribute to dysbiosis [155]. A number
of studies have been conducted on the effects of ASs on the gut. These have looked at their effects on
secretion, absorption, gut motility, the microbiome and gastrointestinal symptoms [156–160]. Some
studies imply that ASs have measurable effects on the oral/gut microbiota [155,161,162]. In one
example, male rats were randomised into control and AS groups and were exposed to doses ranging
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from 1.1 to 11 mg/kg/day for 12 weeks (the USA Federal Drug Administration (FDA) acceptable daily
intake for humans is 5 mg/kg/day). At the low dose of 1.1 mg/kg, the researchers reported that total
anaerobes were reduced by approximately 50% in all sucralose plus maltodextrin groups. However,
when this study was reviewed by an expert panel [163], it was criticised for not having an isocaloric
carbohydrate control, and not correcting for the water content of the stools. Both these factors can
affect the interpretation of the bacterial concentrations. This report also commented that the difference
between control and treatment groups for bacterial counts given were also less than 10-fold. They
concluded that this meant that the results could not be interpreted as indicative of adverse change,
but reflected the normal range of variation in bacteria over this period of time. However, further
research in healthy human subjects continues to suggest that microbiota are adversely affected by
ASs. Suez and colleagues showed that with 11 weeks of exposure to three common ASs, saccharin
altered gut microbiota and induced glucose intolerance [161]. This indicates the need for more
studies—particularly in humans—to elucidate the effects of ASs on microbiota [164–166].
Table 3. Western diet food factors, effects related to IBD and associated genes. LC-PUFA: long-chain
polyunsaturated fatty acid; SCFA: short-chain fatty acid.
Western Diet Food Factors Effects Related to IBD Associated Genes
Foods low in resistant starch and
soluble dietary fibre [47]
• Increased risk of IBD [34,36,49,50]
• Increased risk of E. coli in the
mucosa [60]
• Decreased production of SCFAs
(important in epithelial barrier
maintenance and immune system
regulation) [69]
FFAR2




saturated fatty acids with
decreased consumption of
LC-PUFAs from the increased
intake of soy, safflower, corn and
sunflower oils and reduced
consumption of fish [83,92,93]
• Inflammation and cancer risk







• Associated with the rise in obesity,
diabetes, metabolic syndrome, IBD,
coronary heart disease [105–116]
• Linked to intestinal symptoms of
bloating, abdominal pain, diarrhoea
and fructose intolerance in IBD [112]
• Possible effect on vascular




inflammation in endothelial cells,
mediating hepatic inflammation,
and regulating NF-κB) [129–133]




• Reduction in gut microbiotal
diversity [44,45]
• Increase in antibiotic resistance [168]
Genes in the microbiome [168]
Two other recent additions to the Western diet are emulsifiers in food to improve mouth feel in
low-fat products, and antibiotics in animal feed [167,168]. Emulsifiers have been shown in murine
studies to have an impact on the mouse gut microbiota that promotes colitis and decrease in (alpha)
diversity [167]. Antibiotics are used to reduce disease in livestock kept in confined quarters. Repeated
courses of antibiotics can lead to the development of what is termed “the resistome”—the collection of
genes in bacteria that confers resistance to antibiotics [169]. Increased antibiotic exposure in humans
through food sourced from animals that have had antibiotics may affect the human biome. When these
products from these animals are consumed, they contribute to antibiotic resistance. The US Food and
Drug Administration (2009) indicated that 80% of antimicrobial products in the USA were used in
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animal feed as growth stimulants, not for veterinary use [170]. In the highly pastoral country New
Zealand it is reported that about 60% of antibiotics are administered to animals [171]. The Ministry
for Primary Industries (NZ) states the use of antibiotics in cattle and sheep is low compared to the
intensive rearing pig and poultry industries [172].
The issue for people with IBD is its effect on the genetics of their microbiome when they incorporate
these products into their diet. For example, with antibiotics, antibiotic resistance genes are built up
in the microbial community both in pathogenic and non-pathogenic bacteria, and this builds the
resistome [169]. Genes in the resistome are readily transferred not only from one bacterial cell to
another, but also by cassettes of multiple genes [173,174]. This has been shown to result in a build-up
of multidrug resistance to E. coli in domestic animals [175,176]. These bacteria have also been identified
as being in increased numbers in those with CD [177–179]. Collectively, all these Western diet factors
impinge on the genetics of the biome and reduce microbiota diversity. Personalising the dietary
approach for people with IBD and identifying the effects of genes associated with these changes
(Table 3) would help reduce this adverse impact on the genes of the microbiome. It would help
maintain microbiotal diversity and positively modulate disease activity.
4. Food Intolerances
IBD has been linked with a number of food intolerances, especially with foods containing gluten,
dairy products/lactose or fructose (discussed earlier), or food high in FODMAPs. Many of these
intolerances can also be linked to specific genes or genotypes. Other food intolerances linked with
genotypes and IBD are brassica vegetables, mustard, wasabi, raw and cooked tomatoes, sweet potatoes,
mushrooms, sulphur dioxide, sulphites and sulphur compounds. The specific genes or genotypes
associated with these intolerances will be discussed further. This section begins with a discussion of
the FODMAP approach, as this is the newest dietary strategy suggested as being helpful for IBD. It
also links to a number of food intolerances associated with particular genotypes and/or gene variants.
4.1. FODMAPs
FODMAPs are fermentable oligo-, di- and mono-saccharides and polyols which, if lowered in the
diet, have been shown to be effective in decreasing the abdominal symptoms associated with IBS. This
approach is being proposed as being helpful also for people with IBD [2]. Foods that are identified as
FODMAPs have been discussed extensively in the literature [111,180–184]. Table 4 gives examples of
food sources of FODMAPs [185–191] and genes that are associated with them.
Table 4. Sources of foods high in fermentable oligo-, di- and mono-saccharides and polyols
(FODMAPs) [185–191].
FODMAPs Examples of Food Sources Examples of Associated Genes
Fructose
Honey, mangoes, watermelon,
grapes, fruit juices, high-fructose
corn syrup
TXNIP with fructose that is linked
to intestinal symptoms of bloating,
abdominal pain, diarrhoea in IBD
[125,138–141]
Lactose Dairy products (e.g., milk,ice-cream, yoghurt, soft cheeses)
Lactose intolerance associated




Brussels sprouts, broccoli, cabbage,
peas, beetroot, garlic, leeks, onions,
wheat or rye bread, pasta,
couscous, chickpeas, lentils
GSTMl and GSTTl, and DIO1
variants, with tolerance of brassica
vegetables [193–196]; HLA-DQA1
and HLA-DQB1 variants with
gluten intolerance [197]
Polyols




OCTN1 with mushrooms [198]
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Foods high in FODMAPs have been characterized in a healthy population (i.e., those who do
not experience inflammation) as not being well absorbed in the small intestine, having a laxative
effect if taken in higher doses and fermented rapidly by bacteria [2]. Inflammation of the gut wall—a
characteristic of IBD—also interrupts enzyme production by the brush border cells, and this also
contributes to the sugars not being absorbed. Unabsorbed sugars go to the large intestine, where
bacteria interact with them. When some metabolites (e.g., butan 2,3 diol, ketones, acids, aldehydes) are
formed, they can result in an alteration of the signalling mechanisms of the bacteria and this causes
gas, pain and diarrhoea [192]. Diarrhoea has a negative impact on water and electrolyte balance, and
may lead to dehydration. Gas, pain and diarrhoea commonly occur in non-IBD gastro-intestinal tracts
(i.e., healthy populations) if doses of oral fructose or polyols over 50 g are taken [113,193,194].
This physiological reaction is the rationale for using the FODMAP dietary regime in gastrointestinal
disorders like IBD [111,195]. This is based on studies with irritable bowel syndrome (IBS), where
the decreased consumption of these fermentable carbohydrates has decreased abdominal symptoms
(i.e., pain, flatulence, bloating, constipation, diarrhoea). There is no question that the by-products
of FODMAP digestion and absorption may be especially unpleasant, exacerbating the symptoms
of individuals with gastrointestinal disorders. Thus, it might appear as self-evident that avoidance
of this group of compounds could be therapeutic for individuals with IBD—especially if they also
have IBS [111,195]. A number of trials with IBS have suggested that this approach shows potential
for improving symptoms in IBD. However, to avoid compromising people’s nutritional status, care
must be taken so that any changes instigated in sources of fruits and vegetables do not reduce the total
recommended intake of fruits, vegetables or fibres [196].
How does the FODMAP approach relate to genotypes? As will be discussed further on, intolerance
to some vegetables (e.g., brassica, mushrooms, cooked tomatoes) whole grains and dairy products
may be linked to specific genotypes and gene variants (Table 5). Recent research has also indicated
that following a strict FODMAP diet can also have an effect on the genome of the microbiome and
encourage harmful gut microbiota and a decrease in Bifidobacterium [183,184]. In people with disorders
like IBD, their microbiotal composition is different from those found in healthy people [197–199].
Individuals with IBD have reduced numbers of microbiota, fewer divergent species with lower numbers
of Firmicutes, and increased number of Proteobacteria species compared to healthy people [200–203].
This means that strict adherence to a low-FODMAP diet could contribute to this dysbiosis.
In addition, people with IBD may have a loss of function of the fucosyltransferase 2 (FUT2)
gene, which identifies them as a “non-secretor”. A non-secretor has a significant reduction in
microbiotal diversity, richness and abundance [204]. The FUT2 gene has been identified as increasing
the susceptibility to CD [205–207]. Non-secretor individuals are also infrequently colonised by
Bifidobacterium bifidum (important in the infant flora), B. adolescentis and B. catenulatum/pseudocatenulatum
(important in adult intestinal flora) [204]. Bifidobacteria are an important part of the human intestinal
microbiome. They are crucial to the development of a healthy infant microbiota, encouraging
appropriate gut maturity and gut integrity, modulating immunity and negating the effects of
pathogens [208,209]. This would suggest that people with IBD who are non-secretors have an
increased risk of having a less-effective defence against a number of pathogens and are consequently
more vulnerable to having an inflamed gut. Following a low-FODMAP diet may exacerbate this.
Further research is needed on those who are a non-secretors, using the low-FODMAP approach to see
how this affects their microbiota.
4.2. Gluten
Intolerance to foods containing gluten is associated with the autoimmune disease coeliac disease
and with non-coeliac gluten sensitivity. These two have symptoms in common (e.g., bloating,
diarrhoea, constipation, abdominal pain and weight loss). Unlike coeliac disease, gluten sensitivity
is not associated with antibody formation and damage to the epithelium of the gut. Coeliac disease
has genetic links. Gluten intolerance is associated with gene variants of the major histocompatibility
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complex, class II, DQ alpha 1 (HLA-DQA1) gene and the major histocompatibility complex, class II,
DQ beta 1 (HLA-DQB1) gene [210]. Festen and colleagues in their meta-analysis of two genome-wide
association studies GWAS also identified the genes interleukin 18 receptor accessory protein (IL18RAP);
phosphatase, non-receptor type 2 (PTPN2); T cell activation RhoGTPase activating protein (TAGAP)
and pseudouridine synthase 10 (PUS10) as having shared risk loci for CD and coeliac disease [211].
The gene PTPN2 is involved in the regulation of the epithelial barrier function and is modulated by the
vitamin D receptor gene (VDR) [212]. Current nutrition advice for people with IBD includes checking
whether they have the autoimmune coeliac disease or if they have non-coeliac gluten sensitivity.
The blood test to detect the presence of anti-tissue transglutaminase (tTG) antibodies can be taken.
These antibodies are produced in the small intestine when inflammation occurs in response to gluten.
Another test that has a high specificity for coeliac disease is the anti-endomysial antibody (EMA)
test which detects villus atrophy—a feature of coeliac disease [213]. If IBD patients prove to have
an adverse response to gluten from these tests, then avoiding these foods and products containing
them is advised. These foods include wheat, oats, barley (which includes malt and malt vinegar) and
rye. There is no definitive test for non-coeliac gluten sensitivity except for eliminating gluten from
the diet to see if symptoms subside. The role of non-coeliac gluten or wheat sensitivity in the general
population as well as in IBD has been debated extensively. A review of the topic suggests that it may
be linked in IBD with those who also have IBS.
4.3. Dairy Products and Lactose
The sensitivity to dairy foods in people with IBD is about 10%–20% [214–216]. Some studies
have also linked increased incidence of IBD with the increased intake of dairy foods [217], particularly
cheese [218]. This may be because of the fat content of cheese [219]. Nolan-Clark and associates noted
that in their study on CD, sensitivity to dairy products was not related to disease activity status [219].
In a year-long trial on UC conducted by Wright et al. it was noted that patients had fewer relapses on a
milk-free diet [216].
This sensitivity to dairy products is often associated with the reduction of lactase enzyme in
adulthood. Lactase is an enzyme located in the villus enterocytes that is required for the digestion
of lactose in milk. Lactase catalyses lactose, the disaccharide in milk, to galactose and glucose (i.e.,
monosaccharides which can be absorbed into the blood stream). In most mammals, its activity declines
shortly after weaning. In humans, the enzyme may persist with its activity into adulthood. This is
known as lactase persistence, and it is a genetically determined trait. In Europe, a single allele—T-13910
of the lactase phlorizin hydrolase (LCT) gene—is the main one. However, in Africa and the Middle
East many more mutations are associated with lactase persistence [220,221].
This lactase persistence has associations with CD. In an NZ-based study [222], lactase persistence
in the Caucasian population was associated with an increased risk of CD for those with the lactase
(LCT) gene who were homozygous for the T allele of rs4988235 as compared with those homozygous
for the C allele (OR = 1.61, 95% CI: 1.03–2.51). Increasing lactase non-persistence in populations
has also been linked to a decreased risk of CD [223]. In a study encompassing populations from 26
countries around the world, CD decreased as lactase non-persistence increased (p < 0.01), [223].
Not consuming dairy products raises the risk of having insufficient intakes of calcium in the diet,
especially if few other sources of calcium are consumed. Calcium is not only essential for bone health,
but Ca2+ is extensively used in biological messenger systems and cell functions [224]. Low calcium
intake of people with Crohn’s disease increases their risk of bone demineralisation and osteoporosis.
These are well-known complications of this condition. Bernstein reported for people with IBD that
“The overall relative risk of fractures is 40% greater than that in the general population and increases
with age” [225]. Osteoporosis can also be exacerbated by the use of steroid medications (a common
treatment in IBD), as they have a detrimental effect on calcium and phosphate metabolism [226].
Calcium intake is important with respect to IBD because, as discussed earlier, Vagianos et al. observed
that 25% of their adult outpatients consumed less than the recommended intake of calcium. Further,
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the study of Hartman et al. showed that 79% of the adolescent outpatients consumed less than 80% of
RDA [9,15]. If people are not tolerant to dairy foods, non-dairy sources of calcium are available, such
as fortified soy, almond and rice milks, tofu, sardines, almonds, sesame seeds, broccoli and fortified
breakfast cereals and juices [227].
4.4. Brassica
Vegetables such as broccoli, cabbage, Brussels sprouts and cauliflower are members of the brassica
family of vegetables. These are known to be a good source of various micronutrients (e.g., selenium,
iodine) [228] and various phytochemicals (e.g., glucosinolates and quercetin) [229]. Common members
from this group of plants are recommended to be excluded from the low-FODMAP diet (Brussels
sprouts, broccoli and cabbage) [195]. However, two randomized controlled diet studies conducted by
Brauer et al. found different responses in individuals depending on their glutathione S-transferase Mu 1
(GSTMl) genotype with supplements of specific brassica vegetables (broccoli, cabbage, cauliflower
and radish sprouts) [230]. Their study found that this combination of brassicas altered the circulating
peptides transthyretin (TTR) and zinc alpha 2-glycoprotein (ZAG) fragments in a sensitive and
identifiable manner. TTR declines in serum with early signs of inflammation. ZAG (an adipokine) is
mainly involved in lipid mobilisation. In GSTMl+ individuals, ZAG and TTR declined with brassica
intake. However, this did not occur in those with the GSTMl-nul1 genotype.
GSTMl and genotypes of GSTTl are also significant with respect to individuals and their intakes
of brassica. There have been over 500 studies on GST enzymes showing that genotypes of these GSTMl
and GSTTl have an influence on cancer outcomes, contingent on the expression or non-expression of
these genes [231]. GSTT1 and GSTMl belong to the GST gene super family, which is an extensive group
of enzymes. The GST family contains several classes (e.g., alpha, kappa, mu, omega, pi, sigma, theta
and zeta) [232,233]. GST enzymes have significant roles in the metabolism of electrophilic compounds
(e.g., drugs and carcinogens) [234].
At the GSTMl locus, four allelic variants have been discovered in humans, and the null allele is
present in about 50% of individuals [235]. Where the GSTMl gene deletions or the null genotype exist,
there is a total lack of the protein encoded by the gene [236]. People with deletions are thought to
be more vulnerable to toxic xenobiotics (e.g., antibiotics and drugs) [237]. There is also a variation
between different cultural groups in the frequency of the GSTMl deletion. In Caucasian and Asian
populations, the frequency of the GSTMl null genotype genetic polymorphism is estimated to be about
53%. However, the frequency is lower in African- American populations, at 27% [231].
GST enzymes can also be acted on by isothiocyanates (found in brassicas) either as inducers or as
substrates in liver detoxification pathways, so a deletion or lowered activity of a GST gene can result in
a persistent or elevated level of isothiocyanates in the body [238]. Studies based in Asia suggest that
the null or less-active genotypes for GSTT1 and GSTM1 are protective and lower the risk of colorectal
cancer [239]. However, the opposite occurred in the USA-based studies. The active or expressed
genotypes, not the null genotypes, were associated with higher risk reduction [240]. The disparity of
these results may reflect the different glucosinolate content of the brassica consumed. In Asia, Chinese
cabbage (bok choy) is the predominately eaten brassica, and its main glucosinolate is glucobrassicin,
whereas in the USA where raw broccoli is the more favoured brassica, the glucosinolate contents
differ [241]. The main glucosinolate in this vegetable is glucoraphanin [241]. Glucobrassicin is an
indole, whereas glucoraphanin is a sulforaphane. Their distinct chemical structures as shown in Table 5
(adapted from Higdon et al.) may mean that they are metabolised differently as they pass through the
intestine, and this would suggest that their influence on the GST genes could also be dissimilar.
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Table 5. Differences in glucosinolate structures.
Glucobrassicin (in bok choy) Glucoraphanin (in broccoli)
Indole-3- Sulforaphane
A pilot study by Campbell et al. [242] was conducted on the GSTT1 (-/-) deletion in people with
CD, in a New Zealand cohort from the Auckland IBD study [243]. This also showed those consuming
broccoli, cauliflower and Chinese greens were more likely to report experiencing a beneficial effect if
they had the GSTT1 deletion. This may well apply to people with other gastrointestinal disorders such
as IBS [244]. Responses to another brassica, rocket (arugula), have also been found to be dependent
on a variant in the single-nucleotide polymorphism (SNP) rs9469220 of the human leucocyte antigen
gene (HLA) in people with CD [245]. An inflammatory colonic phenotype has also been associated
with variants in the HLA gene region [246–248]. This polymorphism has been linked to total IgE
levels, which have a key role in sensitivity type 1 reactions in allergies linked with rhinitis, dermatitis,
asthma and urticaria [249–251]. This adverse reaction to rocket in people with CD suggests that
consumption of this food initiates the immune response in a type I sensitivity reaction. Another variant
in the SNP rs7515322 in the iodothyronine deiodinase 1 gene (DIO1) has also been associated with
an adverse response to broccoli. DIO1 is part of the selenoenzyme family, which are important as
signalling molecules for thyroid hormones and pivotal to thyroid metabolism. Both selenium and
iodine deficiencies exist in NZ, and this may heighten individuals’ adverse response to broccoli if they
have this variant [245]. This influence of micronutrients may also explain inter-country variation in
responses to broccoli.
4.5. Mustard, Wasabi, Raw and Cooked Tomatoes and Sweet Potatoes
In another study by Marlow et al. [252], tolerance of mustard, wasabi, raw and cooked tomatoes
and sweet potatoes was dependent on the G variant of the SNP rs12212067 in the FOX03 gene.
Seventeen foods were identified with beneficial effects, and four foods with detrimental effects. Sweet
potatoes had the highest reported frequency of beneficial effects, and mustard, wasabi, raw and cooked
tomatoes were detrimental for over 25% of the study population with the G allele (SNP rs12212067)
associated with the FOX03 gene. FODMAP guidelines suggest that tomato products such as canned
tomatoes are not appropriate in the low-FODMAP diet, although plum tomatoes are [139]. This
guidance could perhaps be tailored more for people using the low-FODMAP diet if their gene variants
in the FOX03 gene were identified.
4.6. Mushrooms
In a study on CD in an NZ population, a statistically significant association with a variant (the T
allele) of the SNP rs1050152 of the organic cation transporter gene OCTN1 was found. This variant is
related to mushroom intolerance in those with CD, when compared with the general population. This
indicates that NZ people with CD who have this variant have an increased risk of adverse symptoms
associated with the intake of mushrooms [244].
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4.7. Sulphur Dioxide, Sulphites and Sulphur Compounds
Sulphur dioxide and sulphites (at concentrations greater than 10 mg/kg or 10 mg/L) are now listed
by the EU as a common cause of food intolerances and allergens [253]. Additive sulphites are often
used in the food industry, as they have multiple functions. They are used as food preservatives, as
they stop microbial growth and reduce the spoilage of food. They can act as antioxidants, inhibiting
browning actions. They can modify texture in doughs. They are found in wine, soft drinks, sausages
and burgers [254]. There is some evidence that they may aggravate IBD symptoms. Magee et al. report
in their novel method of diet analysis that in UC, sulphites adversely affect symptoms through their
anti-thiamine activity. Thiamine has a critical role in energy metabolism and cell function [255]. Low
levels have been implicated in fatigue and IBD in those in remission (UC) or quiescent (CD) [256].
Those with very active disease who ate large quantities of food containing sulphites also had high food
sigmoidoscopy scores [257].
Earlier studies linking sulphur compounds with IBD have described hydrogen sulphide as a
bacterial toxin in people with UC [258]. This description was based on the experimental work where
sulphated polysaccharides were ingested by guinea pigs and rabbits [259,260]. These sulphur products
impaired butyrate oxidation—a characteristic of UC [261]. Butyrate, as a SCFA (as mentioned earlier),
plays an important part in colon homeostasis by promoting the development of the intestinal barrier
through enhancing tight-junction formation, which is impaired in people with IBD [262]. More recent
work by Carbonero et al. has summarised the significance of microbiota in colonic sulphur metabolism
and identified a number of gut microbiota taxa that participate in it [263]. These authors suggest
that common variants in host genes involved in the sulphide oxidation pathways may be implicated
in ineffective epithelial sulphide detoxification. This makes people with these variants predisposed
to sulphide intolerance and consequent inflammation. The literature suggests that sulphur dioxide
sulphites, and other ingested sulphur-containing products, are another example of where nutrient–gene
interaction occurs. Particular variants are associated with their intolerance. Using the personalised
nutrition approach and identifying these gene variants in people with IBD would identify those who
are intolerant to sulphur dioxide, sulphites and sulphur compounds, and so remove foods containing
these substances and reduce inflammation.
5. Ethical Issues
The willingness of individuals to engage in genetic testing that would enable a personalised
diet/nutrition approach will depend on how they understand the benefits this would bring compared
to their perceived privacy risk [264]. Genetic testing for individuals can now be readily accessed with
a number of commercial applications available (e.g., Fitgenes, 23andMe) [265,266]. The availability of
genetic testing also raises a number of questions: Who should hold and have access to this information?
How safely is the information kept? How informed is the consent for consumers? [266]. The protection
of an individual’s genetic information and the validation of genetic tests needs to be guaranteed to
ensure consumer safety. Health practitioners also need to be able to understand the role of genetic
testing in their clinical practice so that they can integrate this information appropriately and offer a
personalised nutrition approach.
6. Conclusions
This review gives examples of genotypes and genetic variants that have been associated with
nutrient deficiencies, the Western diet, and food intolerances. Variation in genotypes could help
explain the variability in response to food that is associated with IBD. We need to identify the variants
associated with adverse reactions to food, as is currently being done in pharmacogenetic research
with respect to drugs. Identification of gene variants would allow more precise tailoring of diets to
avoid exacerbating malnutrition in vulnerable IBD groups. Use of the personalised nutrition approach
can also more accurately identify individual food intolerances, help ameliorate abdominal symptoms
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and improve the quality of life for people with IBD. Further nutrigenomic research can continue to
inform and improve the personalised nutrition approach in IBD. In the future, this information could
be combined with data on individuals such as their gut microbiome, dietary patterns, exercise routines,
blood parameters and anthropometric measurements. This combination of information could be
used to build machine-learning algorithms to predict which foods/meals reduce inflammation and
abdominal symptoms. This may also help to establish the dietary patterns and lifestyles that are most
protective against IBD in those genetically susceptible to IBD. This combination of data may also help
individuals with established IBD to tailor their diet and lifestyle to avoid exacerbating their signs
and symptoms, and promote longer periods of remission. The protection of an individual’s genetic
information and the validation of genetic tests needs to be guaranteed to ensure consumers’ safety
when using this information with a personalised nutrition approach.
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